Annual ReportMarch 2021
To Our Shareholders
At the start of 2020, no one could have imagined
just how dramatically our world was about to change
due to a virus that has impacted billions of people
in every nation. By any measure, it was a year
dominated by uncertainty—yet the pandemic helped
to clarify our priorities and reinforce our values.
And while the familiar yard signs may be faded now,
their message is more resonant than ever:
We’re all in this together.
Because of COVID-19, we all have a profound new
appreciation and gratitude for the doctors, nurses,
and hospital staff serving on the front lines of
care, and for the everyday heroism of the essential
workers who show up 24/7 to keep the world’s
critical healthcare infrastructure up and running.
Expectations that companies must drive positive
change on behalf of everyone—no matter who you
are, or where you live—are higher than ever. And
Alex Gorsky
we were all served an important reminder about
Chairman and Chief Executive Officer
just how central good health is to our collective
prosperity, our security, and our society at the most
fundamental level.
As the world’s largest and most
Nothing is more essential to every person, every
broadly-based healthcare company,
family, every town, and every nation on earth than
health. Whether COVID-19 touched you directly or we have both a unique perspective
indirectly, no individual’s life was left unchanged by on global health and a profound
the pandemic—and together we gained a shared
responsibility to lead when called.
understanding of a universal truth: No one is safe
untileveryone is safe. As soon as the DNA sequencing
of the COVID-19 virus was made
We Were Built for Times Like These
available, our role was clear even
In early January 2020, it was impossible to guess
exactly how the nascent pandemic would unfold. though success was anything but
But Johnson & Johnson has been investing in and guaranteed: We at Johnson &
applying the best science to take on the most
Johnson would do everything in our
serious public health threats for more than a
century—and there was never any question that power to develop a safe, effective,
we would contribute the full breadth and depth of and efficient vaccine for the largest
our company’s expertise to global efforts to
number of people around the world.
combat COVID-19.
Chairman’s Letter 1With this ambitious, urgent goal driving us forward, Excellence in Execution
we set out to follow the science and to make our The confidence placed in us by patients, physicians,
potential vaccine available on a not-for-profit basis customers, and consumers today is the result of
for pandemic emergency use. superb, sustained delivery on the commitments we
make—and 2020 was no exception.
This work was done around the clock, through
innovative models of public–private partnerships (cid:374)(cid:3)(cid:3)While the development of our COVID-19 vaccine
and new heights of purpose-driven collaboration. in just 12 months is an incredible triumph of
In the face of both successes and challenges, we science, it was not our only significant
continually affirmed our commitment to safety, achievement. Our Pharmaceutical business
scientific integrity, and transparency. And exactly continued to outperform the industry across
one year after we officially began the development therapeutic areas and regions. And 2020
process, we were able to share positive top-line marked the 9th consecutive year of above-
results from our Phase 3 ENSEMBLE clinical trial market adjusted operational growth—all while
for our company’s single-dose COVID-19 vaccine. keeping our pipeline submissions and approvals
Shortly after, based on the totality of scientific on track, as well as achieving greater patient
evidence, we received Emergency Use Authorization enrollment in clinical trials compared to 2019.
from the U.S. Food and Drug Administration for our We received approval for a subcutaneous
single-dose COVID-19 vaccine and immediately formulation of multiple myeloma drug DARZALEX®
began shipping doses in the U.S. (daratumumab) in 2020—ahead of our scheduled
U.S. PDUFA date. This new formulation took
This monumental achievement will be an enduring a multi-hour intravenous treatment down to a
point of pride for us for decades to come. Perhaps subcutaneous delivery that is executed in just
most remarkable of all: The successful development minutes. We focused on educating healthcare
of our COVID-19 vaccine was only one of the many practitioners and successfully launched the
incredible accomplishments that made 2020 a year product in a virtual environment—reaffirming
like no other for our company. our strong commercial capabilities.
Thanks to the resilience, dedication, (cid:374) Our Consumer Health business didn’t just meet
but exceeded goals for the year, being agile
and resourcefulness of my colleagues
enough to recognize and quickly adapt to fulfilling
all around the world, Johnson & increased demand for products likeTYLENOL®
Johnson didn’t just survive 2020—
and LISTERINE® in millions of homes worldwide
and recording approximately 55% year-over-year
our company pivoted with great
growth in e-commerce. Our Consumer Health
agility and delivered notable team also refused to let the challenges of 2020
deter them from launching their ambitious Healthy
financial performance during a
Lives Mission. This holistic approach to health
tumultuous year while continuing to
and wellness—advancing sustainable innovation
invest in sustainable, transformative and packaging, providing enhanced transparency
to the ingredients used in our products,
innovation for the long-term.
supporting proactive self-care, and encouraging
new consumer behavior—has been a welcome
As we have during so many periods of upheaval since reminder of what our company can accomplish
our founding in 1886, our broad base of diversified when we tackle the widest range of unmet
healthcare solutions created stability for investors as health needs.
we increased the shareholder dividend for the 58th
consecutive year. (cid:374) Perhaps the most striking testament to the power
of world-class execution can be seen in the
The core strengths that powered our performance rebound across our Medical Devices business
last year are the same ones that have served our after the COVID-19 pandemic caused many
stakeholders well in every market environment: individuals to delay healthcare treatment—from
an unwavering focus on execution, innovation, routine exams to important elective surgeries
and people. to emergency room visits. Our Medical Devices
business continued prioritizing patient and
customer needs, maintaining product reliability,
2 Chairman’s Letterand advancing innovation. We quickly identified (selexipag) injection for intravenous use to treat
urgent needs and focused efforts on supporting pulmonary arterial hypertension and DARZALEX
patients by training more than 6 million healthcare FASPRO™ for the treatment of newly diagnosed
professionals on our virtual platforms, conducting patients with light chain for amyloidosis. We also
live and remote case support, securing and hope to receive approval this year for ponesimod
providing personal protective equipment (PPE), for multiple sclerosis, and PP6M for the treatment
bringing together industry partners, and of schizophrenia. These developments will
expanding coverage to emerging sites of care. potentially change the lives of patients and their
Through these efforts we’ve developed new families in the years to come.
capabilities that strengthened our customer
relationships and set us up for even greater (cid:374)(cid:3)(cid:3)Our Medical Devices business made strong
performance in 2021 and beyond. progress achieving, and even accelerating,
key pipeline milestones throughout the year.
(cid:374) We focus our sustainability efforts in areas where We continued to invest in innovation and
we believe we can make the greatest impact to advance critical programs across each franchise
advance health for humanity. As a healthcare throughout 2020, including: further expansion
company, Johnson & Johnson understands that of our Hip and Knee portfolios into high-growth
climate health can affect human health. This is market segments, enhancements to our industry-
why we have a long-standing commitment to leadingTECNIS™ family of intraocular lenses,
environmental health and set new climate goals the introduction ofECHELON ENDOPATH™
in 2020 that we will track over the next 10 years. Staple Line Reinforcement, and the launch of
To this end, we are honored to have, once again, CERENOVUS STROKE SOLUTIONS™. We remain
been recognized as a global corporate leader in incredibly excited about the great potential of
climate action and water security and awarded the end-to-end digital surgery ecosystem and are
two ‘A-List’ ratings from the Carbon Disclosure simultaneously developing three differentiated
Project—the third year in a row for tackling robotic programs and recently achieved a
climate change and the second year in a row for significant milestone with theFDA clearance for
our work on water security. our VELYS™ Robotic-Assisted Solution designed
for use with the ATTUNE® Total Knee System.
Life-Enhancing Innovation Our industry is just starting to unlock the full
One thing that I think speaks volumes about both potential and benefits of these robotic and digital
our performance and our prospects as a company technologies—and it seems only fitting that
was our 2020 investment in innovation. In the midst the same company that helped pioneer sterile
of all the year’s uncertainty, Johnson & Johnson surgery 135 years ago is now poised to lead the
invested an all-time high of $12.2 billion in research way in bringing differentiated, cutting-edge new
and development (up $800 million from 2019) and solutions to the 21st-century operating room.
more than $7 billion in acquisitions, as we continued
to fortify our pipeline and ensure we will be able to (cid:374)(cid:3)(cid:3)In Consumer Health, we displayed great agility
continue changing the trajectory of human health in finding ways to ensure we could supply
long after this pandemic is over. Among the year’s families worldwide with essential products
highlights in science and innovation: throughout the pandemic. The innovation didn’t
stop there: Our brands launched nearly 200 new
(cid:374)(cid:3)(cid:3)Vaccine development was just one area where products in 2020 and deepened our commitment
our world-class scientists utilized their expertise to creating inclusive and sustainable health
for our Pharmaceutical business. We initiated solutions that meet the needs of consumers. One
the U.S. FDA filing for ourBCMA CAR-T therapy timely example was the launch of NICORETTE®
ciltacabtagene autoleucel (cilta-cel) for the Quickmist SmartTrack in the United Kingdom.
treatment of relapsed or refractory multiple The world’s first digitally connected smoking
myeloma patients who have received three cessation option, this tool was developed with
prior classes of therapies. We filed for approval top behavioral scientists to connect smokers
of amivantamab for the treatment of patients to a support app and help them track against
with metastatic non-small cell lung cancer personalized programs.
with epidermal growth factor receptor Exon 20
insertion mutations whose disease has progressed
on or after platinum-based chemotherapy.
Additionally, we filed for approval for UPTRAVI®
Chairman’s Letter 3(cid:374) Because innovation doesn’t just happen in (cid:374) No look back at 2020 could possibly ignore the
laboratories, I also want to recognize the events of the last summer that forced us—as
impactful work of our Supply Chain colleagues individuals, as a company, and as a country—
in driving improvements and efficiencies over the to confront the reality of systemic racism in
past year. Gartner Research honored Johnson & our society. The turmoil on the streets in cities
Johnson with a number three ranking across all across America and beyond brought to light
industries in its 2020 Supply Chain Top 25 Index, an overdue recognition of the inequalities that
up five spots from our 2019 ranking, and the top were simultaneously being exacerbated by
ranking on its 2020 Healthcare Supply Chain the disproportionate impact of COVID-19 on
Top 25, citing our commitment to continuous communities of color.
improvement while putting innovation into
practice, particularly in our response to the Real change doesn’t happen in one galvanizing
COVID-19 pandemic. moment, or through dialogue alone: It requires a
sustained, long-term commitment. Because we want
Powered by Our People and Our Purpose to make an impact that is meaningful and lasting, we
Meeting our commitments to all our stakeholders started from a place of recognition that racism is a
is a balancing act even in times of stability and public health crisis. This is why Johnson & Johnson
prosperity. While the fierce headwinds we faced chose to focus on eliminating health inequities
throughout 2020 sometimes put our most deeply for people of color with our $100 million Race to
held beliefs to the test—and dealing with constant Health Equity platform launched in November. The
disruption often felt like a full-time job—I’m dramatically higher mortality rate for communities
incredibly proud of our 135,000 employees for truly of color in the COVID-19 pandemic is just the
living into Our Credo values even in the face of the most recent example of the disparity in access to
most daunting challenges. After all, a once-in-a- quality healthcare and the resultant outcomes for
century pandemic could have been an excuse for patients and their families in these communities.
delay rather than a call to action. But that’s not what Our determination is to put better health within the
we do at Johnson & Johnson. reach of everyone. This work includes the use of data
to better understand the root causes of inequalities
(cid:374) Even during the pandemic’s toughest days, our and to encourage information sharing and effective
employees around the globe worked tirelessly to training methods for medical centers and clinics
provide uninterrupted access to our medicines on a local level. We are helping grassroots leaders
and products and use the full spectrum of our and frontline workers to be better prepared and
expertise to support healthcare systems at risk positioned to care for and lift up their
of being overwhelmed by surges in cases and own communities.
hospitalizations. For the billion lives we touch
every day, they delivered again and again and Achieving true diversity in clinical trials and hiring,
again—even as their own professional and in offices and boardrooms will take time, effort, and
personal lives changed in ways that demanded investment. But every day brings a new opportunity
unparalleled resilience and creativity. to be more inclusive, and we know from decades of
experience in science and technology that innovation
(cid:374) The Johnson & Johnson Family of Companies depends on collaboration driven by a diversity of
and the Johnson & Johnson Foundation rallied ideas, approaches, opinions, and individuals. This will
to support healthcare professionals, including make us a better company and better citizens in the
a $50 million initiative to provide doctors and world community.
nurses working on the front lines of the pandemic
with PPE, mental health resources, and other
critical forms of support. For a select number of
Johnson & Johnson employees, the call to serve
was even stronger: Nearly 40 licensed healthcare
professionals in our ranks took advantage of
the company’s newly announced benefit of 14
weeks of paid leave to volunteer in the hardest-hit
hospitals and community health centers.
4 Chairman’s LetterIn Closing Now is the time to shift the
There’s an old saying: “Adversity doesn’t build focus in healthcare away from
character, it reveals it.” Without question, the
just effectiveness and cost to
COVID-19 pandemic has shown us just how much
we can accomplish by following the moral compass sustainability, resiliency, and value.
of Our Credo. We have witnessed unprecedented
levels of collaboration and public–
The idea that companies could do right by their
customers, patients, healthcare professionals, private partnerships over the past 15
employees, and shareholders while also doing good months—let’s use these new models
in the world was a pretty revolutionary concept when
to supercharge efforts to combat
General Robert Wood Johnson first put our values
into words in 1943. But I have no doubt that the idea other urgent public health challenges.
that we are all in this fight for the health of humanity And we must do the hard work that’s
together would be as resonant to him as it has been
required to turn our collective desire
for all of us.
to address disparities in care that
Since 1886, we’ve been showing the world what plague underserved communities into
it looks like to lead with purpose—especially
measurable, meaningful action.
in moments of great crisis. And despite all the
disruption that we’ve had to navigate over the last
year, I have never been more confident about the As we forge onward, I’m filled with optimism that the
future of our industry and our company. lessons we’ve learned from COVID-19 will ultimately
accelerate our progress to a healthier and more
equitable future for all—and that Johnson & Johnson
In this moment, we must ensure
will continue to play a pivotal role in achieving it. And
that the COVID-19 pandemic isn’t
during this consequential moment in world history,
just a wake-up call about the critical I am profoundly grateful to have had the opportunity
to lead this company and our exceptional employees.
importance of public health to our
national, economic, and societal
Sincerely,
security: It must be a call to action.
As we consider our post-pandemic
future, we have the opportunity to
decide what to bring with us into Alex Gorsky
Chairman and Chief Executive Officer
this new world, and what we should
Johnson & Johnson
leave behind. We owe it to those
whose lives and livelihoods have
been ravaged by this virus, and those
who have made enormous personal
sacrifices for the greater good, to
choose wisely.
Note Regarding Forward-Looking Statements
This letter contains forward-looking statements relating to, among other things, future operating and financial performance,
product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are
based on current expectations of future events. For important information about these statements, including the risks, uncertainties
and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed
in any forward-looking statements, the reader should review the enclosed Annual Report on Form 10-K for the fiscal year ended
January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward Looking Statements” and “Item 1A. Risk
Factors.” Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future
events or developments.
Chairman’s Letter 5UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
Í ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES
EXCHANGE ACT OF 1934
ForthefiscalyearendedJanuary3,2021
or
‘ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934 for the transition period from to
Commissionfilenumber1-3215
JOHNSON & JOHNSON
(Exactnameofregistrantasspecifiedinitscharter)
NewJersey 22-1024240
(Stateofincorporation) (I.R.S.EmployerIdentificationNo.)
OneJohnson&JohnsonPlaza
NewBrunswick,NewJersey 08933
(Addressofprincipalexecutiveoffices) (ZipCode)
OneJohnson&JohnsonPlaza
NewBrunswick,NewJersey08933
(Addressofprincipalexecutiveoffices)
Registrant’stelephonenumber,includingareacode:(732)524-0400
SECURITIESREGISTEREDPURSUANTTOSECTION12(b)OFTHEACT
Titleofeachclass TradingSymbol Nameofeachexchangeonwhichregistered
CommonStock,ParValue$1.00 JNJ NewYorkStockExchange
0.250%NotesDueJanuary2022 JNJ22 NewYorkStockExchange
0.650%NotesDueMay2024 JNJ24C NewYorkStockExchange
5.50%NotesDueNovember2024 JNJ24BP NewYorkStockExchange
1.150%NotesDueNovember2028 JNJ28 NewYorkStockExchange
1.650%NotesDueMay2035 JNJ35 NewYorkStockExchange
Indicatebycheckmarkiftheregistrantisawell-knownseasonedissuer,asdefinedinRule405oftheSecurities
Act. Yes Í No ‘
IndicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttoSection13orSection15(d)oftheExchange
Act. Yes ‘ No Í
Indicatebycheckmarkwhethertheregistrant(1)hasfiledallreportsrequiredtobefiledbySection13or15(d)oftheExchange
Actduringthepreceding12months(orforsuchshorterperiodthattheregistrantwasrequiredtofilesuchreports),and(2)has
beensubjecttosuchfilingrequirementsforthepast90days. Yes Í No ‘
IndicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryInteractiveDataFilerequiredtobesubmitted
pursuanttoRule405ofRegulationS-Tduringthepreceding12months(orforsuchshorterperiodthattheregistrantwas
requiredtosubmitsuchfiles). Yes Í No ‘
Indicatebycheckmarkwhethertheregistrantisalargeacceleratedfiler,anacceleratedfiler,anon-acceleratedfiler,asmaller
reportingcompany,oremerginggrowthcompany.Seethedefinitionsof“largeacceleratedfiler,”“acceleratedfiler”,“smaller
reportingcompany,”and“emerginggrowthcompany”inRule12b-2oftheExchangeAct.
Largeacceleratedfiler Í Acceleratedfiler ‘
Non-acceleratedfiler ‘ Smallerreportingcompany ‘
Emerginggrowthcompany ‘
Ifanemerginggrowthcompany,indicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiod
forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttoSection13(a)oftheExchange
Act. ‘
Indicatebycheckmarkwhethertheregistranthasfiledareportonandattestationtoitsmanagement’sassessmentofthe
effectivenessofitsinternalcontroloverfinancialreportingunderSection404(b)oftheSarbanes-OxleyAct(15U.S.C.
7262(b))bytheregisteredpublicaccountingfirmthatpreparedorissueditsauditreport. Yes Í No ‘
Indicatebycheckmarkwhethertheregistrantisashellcompany(asdefinedinRule12b-2oftheExchange
Act). Yes ‘ No Í
TheaggregatemarketvalueoftheCommonStockheldbynon-affiliatescomputedbyreferencetothepriceatwhichthe
CommonStockwaslastsoldasofthelastbusinessdayoftheregistrant’smostrecentlycompletedsecondfiscalquarter
wasapproximately$363billion.
OnFebruary16,2021,therewere2,628,679,824sharesofCommonStockoutstanding.
DOCUMENTSINCORPORATEDBYREFERENCE
PartsIandIII: Portionsofregistrant’sproxystatementforits2021annualmeetingofshareholdersfiledwithin
120daysafterthecloseoftheregistrant’sfiscalyear(the“ProxyStatement”),areincorporatedby
referencetothisreportonForm10-K(this“Report”).Item Page
PARTI
1 Business 1
General 1
SegmentsofBusiness 1
GeographicAreas 2
RawMaterials 3
Patents 3
Trademarks 3
Seasonality 3
Competition 3
Environment 4
Regulation 4
EmployeesandHumanCapitalManagement 5
AvailableInformation 7
1A. RiskFactors 7
1B. UnresolvedStaffComments 14
2 Properties 14
3 LegalProceedings 15
4 MineSafetyDisclosures 15
ExecutiveOfficersoftheRegistrant 16
PARTII
5 MarketforRegistrant’sCommonEquity,RelatedStockholderMattersandIssuerPurchasesof
EquitySecurities 18
6 (Reserved) 18
7 Management’sDiscussionandAnalysisofResultsofOperationsandFinancialCondition 19
7A. QuantitativeandQualitativeDisclosuresAboutMarketRisk 40
8 FinancialStatementsandSupplementaryData 40
9 ChangesinandDisagreementsWithAccountantsonAccountingandFinancialDisclosure 109
9A. ControlsandProcedures 109
9B. OtherInformation 109
PARTIII
10 Directors,ExecutiveOfficersandCorporateGovernance 110
11 ExecutiveCompensation 110
12 SecurityOwnershipofCertainBeneficialOwnersandManagementandRelatedStockholder
Matters 110
13 CertainRelationshipsandRelatedTransactions,andDirectorIndependence 111
14 PrincipalAccountantFeesandServices 111
PARTIV
15 ExhibitsandFinancialStatementSchedules 112
16 Form10-KSummary 112
Signatures 113
ExhibitIndex 115CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
ThisAnnualReportonForm10-KandJohnson&Johnson’sotherpubliclyavailabledocumentscontain“forward-looking
statements”withinthemeaningofthesafeharborprovisionsoftheU.S.PrivateSecuritiesLitigationReformActof
1995.ManagementandrepresentativesofJohnson&Johnsonanditssubsidiaries(the“Company”)alsomayfromtimeto
timemakeforward-lookingstatements.Forward-lookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsand
reflectmanagement’sassumptions,views,plans,objectivesandprojectionsaboutthefuture.Forward-lookingstatements
maybeidentifiedbytheuseofwordssuchas“plans,”“expects,”“will,”“anticipates,”“estimates”andotherwordsof
similarmeaninginconjunctionwith,amongotherthings:discussionsoffutureoperations;expectedoperatingresultsand
financialperformance;impactofplannedacquisitionsanddispositions;theCompany’sstrategyforgrowth;product
development;regulatoryapprovals;marketpositionandexpenditures.
Becauseforward-lookingstatementsarebasedoncurrentbeliefs,expectationsandassumptionsregardingfutureevents,
theyaresubjecttouncertainties,risksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe
Company’scontrol.Investorsshouldrealizethatifunderlyingassumptionsproveinaccurate,orknownorunknownrisksor
uncertaintiesmaterialize,theCompany’sactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand
projectionsexpressedorimpliedinitsforward-lookingstatements.Investorsarethereforecautionednottorelyonthese
forward-lookingstatements.Risksanduncertaintiesinclude,butarenotlimitedto:
RisksRelatedtoProductDevelopment,MarketSuccessandCompetition
• Challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologies
onwhichtheCompany’scontinuedgrowthandsuccessdepend,includinguncertaintyofclinicaloutcomes,additional
analysisofexistingclinicaldata,obtainingregulatoryapprovals,healthplancoverageandcustomeraccess,andinitial
andcontinuedcommercialsuccess;
• ChallengestotheCompany’sabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew
andexistingproductsandtechnologiesintheUnitedStatesandotherimportantmarkets;
• Theimpactofpatentexpirations,typicallyfollowedbytheintroductionofcompetingbiosimilarsandgenericsand
resultingrevenueandmarketsharelosses;
• IncreasinglyaggressiveandfrequentchallengestotheCompany’spatentsbycompetitorsandothersseekingtolaunch
competinggeneric,biosimilarorotherproductsandincreasedreceptivityofcourts,theUnitedStatesPatentand
TrademarkOfficeandotherdecisionmakerstosuchchallenges,potentiallyresultinginlossofmarketexclusivityand
rapiddeclineinsalesfortherelevantproductsoonerthanexpected;
• Competitioninresearchanddevelopmentofnewandimprovedproducts,processesandtechnologies,whichcanresult
inproductandprocessobsolescence;
• Competitiontoreachagreementwiththirdpartiesforcollaboration,licensing,developmentandmarketingagreements
forproductsandtechnologies;
• Competitionbasedoncost-effectiveness,productperformance,technologicaladvancesandpatentsattainedby
competitors;and
• AllegationsthattheCompany’sproductsinfringethepatentsandotherintellectualpropertyrightsofthirdparties,which
couldadverselyaffecttheCompany’sabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamages
andfutureroyalties.
RisksRelatedtoProductLiability,LitigationandRegulatoryActivity
• Productefficacyorsafetyconcerns,whetherornotbasedonscientificevidence,potentiallyresultinginproduct
withdrawals,recalls,regulatoryactiononthepartoftheUnitedStatesFoodandDrugAdministration(orinternational
counterparts),decliningsales,reputationaldamage,increasedlitigationexpenseandsharepriceimpact;
• Impact,includingdecliningsalesandreputationaldamage,ofsignificantlitigationorgovernmentactionadversetothe
Company,includingproductliabilityclaimsandallegationsrelatedtopharmaceuticalmarketingpracticesand
contractingstrategies;
• Impactofanadversejudgmentorsettlementandtheadequacyofreservesrelatedtolegalproceedings,including
patentlitigation,productliability,personalinjuryclaims,securitiesclassactions,governmentinvestigations,employment
andotherlegalproceedings;
• Increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin
investigationsandprosecutions,whichcarrytheriskofsignificantcivilandcriminalpenalties,including,butnotlimited
to,debarmentfromgovernmentbusiness;
Johnson&Johnson2020AnnualReport •• FailuretomeetcomplianceobligationsintheMcNEIL-PPC,Inc.ConsentDecreeoranyothercomplianceagreements
withgovernmentsorgovernmentagencies,whichcouldresultinsignificantsanctions;
• PotentialchangestoapplicablelawsandregulationsaffectingUnitedStatesandinternationaloperations,including
relatingto:approvalofnewproducts;licensingandpatentrights;salesandpromotionofhealthcareproducts;access
to,andreimbursementandpricingfor,healthcareproductsandservices;environmentalprotectionandsourcingofraw
materials;
• CompliancewithlocalregulationsandlawsthatmayrestricttheCompany’sabilitytomanufactureorsellitsproductsin
relevantmarkets,includingrequirementstocomplywithmedicaldevicereportingregulationsandotherrequirements
suchastheEuropeanUnion’sMedicalDevicesRegulation;
• Changesindomesticandinternationaltaxlawsandregulations,includingchangesrelatedtotheTaxCutsandJobsAct
intheUnitedStates,increasingauditscrutinybytaxauthoritiesaroundtheworldandexposurestoadditionaltax
liabilitiespotentiallyinexcessofexistingreserves;and
• IssuanceofneworrevisedaccountingstandardsbytheFinancialAccountingStandardsBoardandregulationsbythe
SecuritiesandExchangeCommission.
RisksRelatedtotheCompany’sStrategicInitiativesandHealthcareMarketTrends
• Pricingpressuresresultingfromtrendstowardhealthcarecostcontainment,includingthecontinuedconsolidation
amonghealthcareprovidersandothermarketparticipants,trendstowardmanagedcare,theshifttowardgovernments
increasinglybecomingtheprimarypayersofhealthcareexpenses,significantnewentrantstothehealthcaremarkets
seekingtoreducecostsandgovernmentpressureoncompaniestovoluntarilyreducecostsandpriceincreases;
• Restrictedspendingpatternsofindividual,institutionalandgovernmentalpurchasersofhealthcareproductsand
servicesduetoeconomichardshipandbudgetaryconstraints;
• ChallengestotheCompany’sabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovations,
suchasdevelopmentcollaborations,strategicacquisitions,licensingandmarketingagreements,andthepotential
heightenedcostsofanysuchexternalarrangementsduetocompetitivepressures;
• Thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor
divestiturebytheCompanymaynotberealizedormaytakelongertorealizethanexpected;and
• Thepotentialthattheexpectedbenefitsandopportunitiesrelatedtopastandongoingrestructuringactionsmaynotbe
realizedormaytakelongertorealizethanexpected.
RisksRelatedtoEconomicConditions,FinancialMarketsandOperatingInternationally
• TherisksassociatedwithglobaloperationsontheCompanyanditscustomersandsuppliers,includingforeign
governmentsincountriesinwhichtheCompanyoperates.
• Impactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch
fluctuationsonrevenues,expensesandresultingmargins;
• Potentialchangesinexport/importandtradelaws,regulationsandpoliciesoftheUnitedStatesandothercountries,
includinganyincreasedtraderestrictionsortariffsandpotentialdrugreimportationlegislation;
• Theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomies,sovereignrisk,possible
impositionofgovernmentalcontrolsandrestrictiveeconomicpolicies,andunstableinternationalgovernmentsandlegal
systems;
• Theimpactofglobalpublichealthcrisesandpandemics,includingtheoutbreakofthenovelcoronavirus(COVID-19)
pandemic;
• Changestoglobalclimate,extremeweatherandnaturaldisastersthatcouldaffectdemandfortheCompany’sproducts
andservices,causedisruptionsinmanufacturinganddistributionnetworks,altertheavailabilityofgoodsandservices
withinthesupplychain,andaffecttheoveralldesignandintegrityoftheCompany’sproductsandoperations;and
• TheimpactofarmedconflictsandterroristattacksintheUnitedStatesandotherpartsoftheworldincludingsocialand
economicdisruptionsandinstabilityoffinancialandothermarkets.
RisksRelatedtoSupplyChainandOperations
• Difficultiesanddelaysinmanufacturing,internally,throughthirdpartyprovidersorotherwisewithinthesupplychain,that
mayleadtovoluntaryorinvoluntarybusinessinterruptionsorshutdowns,productshortages,withdrawalsor
suspensionsofproductsfromthemarket,andpotentialregulatoryaction;
• InterruptionsandbreachesoftheCompany’sinformationtechnologysystemsorthoseoftheCompany’svendors,
whichcouldresultinreputational,competitive,operationalorotherbusinessharmaswellasfinancialcostsand
regulatoryaction;
• Johnson&Johnson2020AnnualReport• Relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing
regulatoryrequirementsthatmayadverselyaffectsupply,sourcingandpricingofmaterialsusedintheCompany’s
products;and
• Thepotentialthattheexpectedbenefitsandopportunitiesrelatedtorestructuringactionscontemplatedfortheglobal
supplychain,includingtheCompany’stransactionwithJabil,maynotberealizedormaytakelongertorealizethan
expected,includingduetoanyrequiredapprovalsfromapplicableregulatoryauthorities.Disruptionsassociatedwiththe
announcedglobalsupplychainactionsmayadverselyaffectsupplyandsourcingofmaterialsusedintheCompany’s
products.
InvestorsalsoshouldcarefullyreadtheRiskFactorsdescribedinItem1AofthisAnnualReportonForm10-Kfora
descriptionofcertainrisksthatcould,amongotherthings,causetheCompany’sactualresultstodiffermateriallyfrom
thoseexpressedinitsforward-lookingstatements.Investorsshouldunderstandthatitisnotpossibletopredictoridentify
allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinItem1Atobeacompletestatementofall
potentialrisksanduncertainties.TheCompanydoesnotundertaketopubliclyupdateanyforward-lookingstatementthat
maybemadefromtimetotime,whetherasaresultofnewinformationorfutureeventsordevelopments.
Johnson&Johnson2020AnnualReport •PART I
Item 1. BUSINESS
General
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately134,500employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.Johnson&Johnson
isaholdingcompany,withoperatingcompaniesconductingbusinessinvirtuallyallcountriesoftheworld.TheCompany’s
primaryfocusisproductsrelatedtohumanhealthandwell-being.Johnson&JohnsonwasincorporatedintheStateof
NewJerseyin1887.
TheExecutiveCommitteeofJohnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategic
operationsandallocationoftheresourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesofthe
Company’sthreebusinesssegments:ConsumerHealth(previouslyreferredtoasConsumer),Pharmaceuticaland
MedicalDevices.WithinthestrategicparametersprovidedbytheCommittee,seniormanagementgroupsatU.S.and
internationaloperatingcompaniesareeachresponsiblefortheirownstrategicplansandtheday-to-dayoperationsof
thosecompanies.Eachsubsidiarywithinthebusinesssegmentsis,withlimitedexceptions,managedbyresidentsofthe
countrywherelocated.
Segments of Business
TheCompanyisorganizedintothreebusinesssegments:ConsumerHealth,PharmaceuticalandMedicalDevices.
Additionalinformationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsof
segmentsandoperatingresultsunder:“Item7.Management’sDiscussionandAnalysisofResultsofOperationsand
FinancialCondition”ofthisReport;andNote17“SegmentsofBusinessandGeographicAreas”oftheNotesto
ConsolidatedFinancialStatementsincludedinItem8ofthisReport.
ConsumerHealth
TheConsumerHealthsegmentincludesabroadrangeofproductsfocusedonpersonalhealthcareusedintheskin
health/beauty,over-the-countermedicines,babycare,oralcare,women’shealthandwoundcaremarkets.Majorbrandsin
skinhealth/beautyincludetheAVEENO®;CLEAN&CLEAR®;DR.CI:LABO®;NEUTROGENA®andOGX®product
lines.Over-the-counter(OTC)medicinesincludethebroadfamilyofTYLENOL®acetaminophenproducts;SUDAFED®
cold,fluandallergyproducts;BENADRYL®andZYRTEC®allergyproducts;MOTRIN®IBibuprofenproducts;
NICORETTE®smokingcessationproductsoutsidetheU.S.;ZARBEE’SNATURALS®andthePEPCID®lineofacidreflux
products.BabyCareincludestheJOHNSON’S®andAVEENOBaby®lineofproducts.OralCareincludesthe
LISTERINE®productline.MajorbrandsinWomen’sHealthoutsideofNorthAmericaareSTAYFREE®andCAREFREE®
sanitarypadsando.b.®tamponbrands.WoundCarebrandsincludetheBAND-AID®BrandAdhesiveBandagesand
NEOSPORIN®FirstAidproductlines.Theseproductsaremarketedtothegeneralpublicandsoldonline(eCommerce)
andtoretailoutletsanddistributorsthroughouttheworld.
Pharmaceutical
ThePharmaceuticalsegmentisfocusedonsixtherapeuticareas:Immunology(e.g.,rheumatoidarthritis,inflammatory
boweldiseaseandpsoriasis),InfectiousDiseases(e.g.,HIV/AIDS),Neuroscience(e.g.,mooddisorders,
neurodegenerativedisordersandschizophrenia),Oncology(e.g.,prostatecancerandhematologicmalignancies),
CardiovascularandMetabolism(e.g.,thrombosisanddiabetes)andPulmonaryHypertension(e.g.,PulmonaryArterial
Hypertension).Medicinesinthissegmentaredistributeddirectlytoretailers,wholesalers,hospitalsandhealthcare
professionalsforprescriptionuse.KeyproductsinthePharmaceuticalsegmentinclude:REMICADE®(infliximab),a
treatmentforanumberofimmune-mediatedinflammatorydiseases;SIMPONI®(golimumab),asubcutaneoustreatment
foradultswithmoderatetosevererheumatoidarthritis,activepsoriaticarthritis,activeankylosingspondylitisand
moderatelyactivetoseverelyactiveulcerativecolitis;SIMPONIARIA®(golimumab),anintravenoustreatmentforadults
withmoderatetosevererheumatoidarthritis,activepsoriaticarthritisandactiveankylosingspondylitis;STELARA®
(ustekinumab),atreatmentforadultsandchildrenwithmoderatetosevereplaquepsoriasis,foradultswithactivepsoriatic
arthritis,foradultswithmoderatelytoseverelyactiveCrohn’sdiseaseandtreatmentofmoderatelytoseverelyactive
Johnson&Johnson2020AnnualReport • 1ulcerativecolitis;TREMFYA®(guselkumab),atreatmentforadultswithmoderatetosevereplaquepsoriasis;EDURANT®
(rilpivirine),PREZISTA®(darunavir)andPREZCOBIX®/REZOLSTA®(darunavir/cobicistat),antiretroviralmedicinesforthe
treatmentofhumanimmunodeficiencyvirus(HIV-1)incombinationwithotherantiretroviralproductsandSYMTUZA®
(darunavir/cobicistat/emtricitabine/tenofoviralafenamide),aonce-dailysingletabletregimenforthetreatmentofHIV;
CONCERTA®(methylphenidateHCl)extended-releasetabletsCII,atreatmentforattentiondeficithyperactivitydisorder;
INVEGASUSTENNA®/XEPLION®(paliperidonepalmitate),forthetreatmentofschizophreniaandschizoaffectivedisorder
inadults;INVEGATRINZA®/TREVICTA®(paliperidonepalmitate),forthetreatmentofschizophreniainpatientsafterthey
havebeenadequatelytreatedwithINVEGASUSTENNA®foratleastfourmonths;RISPERDALCONSTA®(risperidone
long-actinginjection),forthetreatmentofschizophreniaandthemaintenancetreatmentofBipolar1Disorderinadults;
ZYTIGA®(abirateroneacetate),atreatmentformetastaticcastration-resistantprostatecancer(CRPC)andmetastatic
high-riskcastration-sensitiveprostatecancer;IMBRUVICA®(ibrutinib),atreatmentforcertainB-cellmalignancies,or
bloodcancers,chronicgraftversushostdiseaseandWaldenström’sMacroglobulinemia;DARZALEX®(daratumumab),a
treatmentforrelapsed/refractorymultiplemyeloma;ERLEADA®(apalutamide),anext-generationandrogenreceptor
inhibitorforthetreatmentofpatientswithprostatecancer;VELCADE®(bortezomib),atreatmentformultiplemyeloma
mantlecelllymphoma;PROCRIT®/EPREX®(epoetinalfa),atreatmentforchemotherapy-inducedanemiaandpatients
withchronickidneydisease;XARELTO®(rivaroxaban),anoralanticoagulantforthepreventionofdeepveinthrombosis
(DVT),whichmayleadtopulmonaryembolism(PE)inpatientsundergoinghiporkneereplacementsurgery,toreducethe
riskofstrokeandsystemicembolisminpatientswithnonvalvularatrialfibrillation,andforthetreatmentandreductionof
riskofrecurrenceofDVTandPE;INVOKANA®(canagliflozin),forthetreatmentofadultswithtype2diabetes;
INVOKAMET®/VOKANAMET®(canagliflozin/metforminHCl),acombinationtherapyoffixeddosesofcanagliflozinand
metforminhydrochlorideforthetreatmentofadultswithtype2diabetes;andINVOKAMET®XR(canagliflozin/metformin
hydrochlorideextended-release),aonce-daily,fixed-dosecombinationtherapyofcanagliflozinandmetformin
hydrochlorideextended-release,forthetreatmentofadultswithtype2diabetes;OPSUMIT®(macitentan)asmonotherapy
orincombination,indicatedforthelong-termtreatmentofpulmonaryarterialhypertension(PAH);UPTRAVI®(selexipag),
theonlyapprovedoral,selectiveIPreceptoragonisttargetingaprostacyclinpathwayinPAH.Manyofthesemedicines
weredevelopedincollaborationwithstrategicpartnersorarelicensedfromothercompaniesandmaintainactivelifecycle
developmentprograms.
MedicalDevices
TheMedicalDevicessegmentincludesabroadrangeofproductsusedintheInterventionalSolutions,Orthopaedics,
Surgery,andVisionfields.MedicalDevicesinInterventionalSolutionsincludeElectrophysiologyproducts(Biosense
Webster)totreatcardiovasculardiseases,Neurovascularcare(Cerenovus)thattreatshemorrhagicandischemicstroke;
theOrthopaedicsportfolio(DePuySynthes)iscomprisedofproductsinsupportofHips,Knees,Trauma,andSpine,
Sports&Other;theSurgeryportfolios(Ethicon)includeadvancedandgeneralsurgeryofferings,solutionsthatfocuson
BreastAesthetics(Mentor)andEar,NoseandThroat(Acclarent)procedures;andJohnson&JohnsonVisionproducts
suchasACUVUE®Branddisposablecontactlensesandophthalmicproductsrelatedtocataractandlaserrefractive
surgery.Theseproductsaredistributedtowholesalers,hospitalsandretailers,andusedpredominantlyintheprofessional
fieldsbyphysicians,nurses,hospitals,eyecareprofessionalsandclinics.
Geographic Areas
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately134,500employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.TheCompany
conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand
well-being.
Theproductsmadeandsoldintheinternationalbusinessincludemanyofthosedescribedaboveunder“—Segmentsof
Business—ConsumerHealth,”“—Pharmaceutical”and“—MedicalDevices.”However,theprincipalmarkets,products
andmethodsofdistributionintheinternationalbusinessvarywiththecountryandtheculture.Theproductssoldin
internationalbusinessincludethosedevelopedintheU.S.andbysubsidiariesabroad.
InvestmentsandactivitiesinsomecountriesoutsidetheU.S.aresubjecttohigherrisksthancomparableU.S.activities
becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomies,
restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertainties.
2 • Johnson&Johnson2020AnnualReportRaw Materials
RawmaterialsessentialtotheCompany’sbusinessaregenerallyreadilyavailablefrommultiplesources.Wherethereare
exceptions,thetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe
financialresultsoftheCompany.
Patents
TheCompany’ssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere
possible.Theyown,orarelicensedunder,asignificantnumberofpatentsintheU.S.andothercountriesrelatingtotheir
products,productuses,formulationsandmanufacturingprocesses,whichintheaggregatearebelievedtobeofmaterial
importancetotheCompanyintheoperationofitsbusinesses.TheCompany’ssubsidiariesfacepatentchallengesfrom
thirdparties,includingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsoftheCompany’s
keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproducts.Significantlegal
proceedingsandclaimsinvolvingtheCompany’spatentandotherintellectualpropertyaredescribedinNote19,“Legal
Proceedings—IntellectualProperty”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
SalesoftheCompany’slargestproduct,STELARA®(ustekinumab),accountedforapproximately9.3%oftheCompany’s
totalrevenuesforfiscal2020.Accordingly,thepatentsrelatedtothisproductarebelievedtobematerialtotheCompany.
JanssenBiotech,Inc.,awholly-ownedsubsidiaryofJohnson&Johnson,ownspatentsspecificallyrelatedtoSTELARA®.
ThelatestexpiringUnitedStatespatentexpiresin2023.ThelatestexpiringEuropeanpatentexpiresin2024.
SalesoftheCompany’ssecondlargestproduct,DARZALEX®(daratumumab)andDARZALEXFASPRO™(daratumumab
andhyaluronidase-fihj),accountedforapproximately5.1%oftheCompany’stotalrevenuesforfiscal2020.
Accordingly,thepatentsrelatedtothisproductarebelievedtobematerialtotheCompany.GenmabA/Sownspatents
relatedtoDARZALEX®,andJanssenBiotech,Inc.hasanexclusivelicensetothosepatents.Thelatestexpiringlicensed
UnitedStatespatentexpiresin2029.ThelatestexpiringlicensedEuropeanpatentexpiresin2031.JanssenBiotech,Inc.
ownsaseparatepatentportfoliorelatedtoDARZALEXFASPRO™.
SalesoftheCompany’sthirdlargestproduct,IMBRUVICA®(ibrutinib),accountedforapproximately5.0%ofthe
Company’stotalrevenuesforfiscal2020.Accordingly,patentsrelatedtothisproductarebelievedtobematerialtothe
Company.PharmacyclicsLLC(anAbbViecompany)ownsthepatentsrelatedtoIMBRUVICA®,andJanssenBiotech,Inc.
hasanexclusivelicensetothosepatents.ThePharmacyclicspatentsandtheirexpirationdatesarelistedintheApproved
DrugProductswithTherapeuticEquivalenceEvaluations(OrangeBook).PharmacyclicsLLCandJanssenBiotech,Inc.
haveenteredintoconfidentialsettlementagreementswithcertaingenericcompaniesgrantinglicensestomarkettheir
genericibrutinibproductsintheUnitedStatesbeforetheexpirationofcertainpatents.
Trademarks
TheCompany’ssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection
forthesetrademarksbyallavailablemeans.ThesetrademarksareprotectedbyregistrationintheU.S.andothercountries
wheresuchproductsaremarketed.TheCompanyconsidersthesetrademarksintheaggregatetobeofmaterial
importanceintheoperationofitsbusinesses.
Seasonality
Worldwidesalesdonotreflectanysignificantdegreeofseasonality;however,spendinghasbeenheavierinthefourth
quarterofeachyearthaninotherquarters.Thisreflectsincreasedspendingdecisions,principallyforadvertisingand
researchanddevelopmentactivity.
Competition
Inalloftheirproductlines,theCompany’ssubsidiariescompetewithcompaniesbothlocallyandglobally.Competition
existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.Competitionin
research,bothinternallyandexternallysourced,involvingthedevelopmentandtheimprovementofnewandexisting
productsandprocesses,isparticularlysignificant.Thedevelopmentofnewandinnovativeproducts,aswellasprotecting
theunderlyingintellectualpropertyoftheCompany’sproductportfolio,isimportanttotheCompany’ssuccessinallareas
ofitsbusiness.Thecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearch.Inaddition,the
developmentandmaintenanceofcustomerdemandfortheCompany’sconsumerproductsinvolvesignificant
expendituresforadvertisingandpromotion.
Johnson&Johnson2020AnnualReport • 3Environment
TheCompanyissubjecttoavarietyofU.S.andinternationalenvironmentalprotectionmeasures.TheCompanybelieves
thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulations.TheCompany’s
compliancewiththeserequirementsdidnotchangeduringthepastyear,andisnotexpectedtohaveamaterialeffect
uponitscapitalexpenditures,cashflows,earningsorcompetitiveposition.
Regulation
TheCompany’sbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperations
areconducted,andthegeneraltrendistowardincreasinglystringentregulationandenforcement.TheCompanyissubject
tocostlyandcomplexU.S.andforeignlawsandgovernmentalregulationsandanyadverseregulatoryactionmay
materiallyadverselyaffecttheCompany’sfinancialconditionandbusinessoperations.IntheU.S.,thedrug,deviceand
cosmeticindustrieshavelongbeensubjecttoregulationbyvariousfederalandstateagencies,primarilyastoproduct
safety,efficacy,manufacturing,advertising,labelingandsafetyreporting.Theexerciseofbroadregulatorypowersbythe
U.S.FoodandDrugAdministration(theU.S.FDA)continuestoresultinincreasesintheamountsoftestingand
documentationrequiredforU.S.FDAapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseof
productintroduction.SimilartrendsarealsoevidentinmajormarketsoutsideoftheU.S.Thenewmedicaldevice
regulatoryframeworkandthenewprivacyregulationsinEuropeandinothercountriesareexamplesofsuchincreased
regulation.
TheregulatoryagenciesunderwhosepurviewtheCompanyoperateshaveadministrativepowersthatmaysubjectitto
actionssuchasproductwithdrawals,recalls,seizureofproductsandothercivilandcriminalsanctions.Insomecases,the
Company’ssubsidiariesmaydeemitadvisabletoinitiateproductrecalls.
TheU.S.FDAandregulatoryagenciesaroundtheglobearealsoincreasingtheirenforcementactivities.IftheU.S.FDA
weretoconcludethatwearenotincompliancewithapplicablelawsorregulations,orthatanyofourdrugsormedical
devicesareineffectiveorposeanunreasonablehealthrisk,theU.S.FDAcouldbansuchproducts,detainorseize
adulteratedormisbrandedproducts,orderarecall,repair,replacement,orrefundofsuchproducts,refusetogrant
pendingapplicationsformarketingauthorizationorrequirecertificatesofforeigngovernmentsforexports,and/orrequire
ustonotifyhealthprofessionalsandothersthattheproductspresentunreasonablerisksofsubstantialharmtothepublic
health.TheU.S.FDAmayalsoassesscivilorcriminalpenaltiesagainstus,ourofficersoremployeesandimpose
operatingrestrictionsonacompany-widebasis,orenjoinand/orrestraincertainconductresultinginviolationsof
applicablelaw.TheU.S.FDAmayalsorecommendprosecutiontotheUSDepartmentofJustice.Anyadverseregulatory
action,dependingonitsmagnitude,mayrestrictusfromeffectivelymarketingandsellingourproductsandlimitourability
toobtainfutureclearancesorapprovals,andcouldresultinasubstantialmodificationtoourbusinesspracticesand
operations.Equivalentenforcementmechanismsexistindifferentcountriesinwhichweconductbusiness.
Thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudy,investigationandregulationby
governmentalagenciesandlegislativebodiesaroundtheworld.IntheU.S.,attentionhasbeenfocusedbystates,
regulatoryagenciesandcongressondrugpricesandprofitsandprogramsthatencouragedoctorstowriteprescriptions
forparticulardrugs,ortorecommend,useorpurchaseparticularmedicaldevices.Lawsandregulationshavebeen
enactedtorequireadherencetostrictcompliancestandardsandpreventfraudandabuseinthehealthcareindustry.There
isincreasedfocusoninteractionsandfinancialrelationshipsbetweenhealthcarecompaniesandhealthcareproviders.
Varioustransparencylawsandregulationsrequiredisclosuresofpaymentsandothertransfersofvaluemadetophysicians
andteachinghospitalsand,beginningwithdisclosuresin2022,tocertainnon-physicianpractitioners.Federalandforeign
lawsgoverninginternationalbusinesspracticesrequirestrictcompliancewithanti-briberystandardsandcertain
prohibitionswithrespecttopaymentstoanyforeigngovernmentofficial.Payershavebecomeamorepotentforceinthe
marketplaceandincreasedattentionisbeingpaidtodrugandmedicaldevicepricing,appropriatedrugandmedical
deviceutilizationandthequalityandcostsofhealthcaregenerally.
U.S.governmentagenciescontinueeffortstorepeal,modify,orinvalidateprovisionsofthePatientProtectionand
AffordableCareAct(theACA)whichpassedin2010.Forexample,federallegislationrepealedtheACA’sindividual
mandatetaxpenaltyaswellasthetaxongenerousemployer-sponsoredhealthcareplans;theCenterforMedicare&
MedicaidServices(CMS)beganpermittingstatestoimposeworkrequirementsonpersonscoveredbyMedicaid
expansionplans;certainfederalsubsidiestoinsurershaveended;andcertainshort-terminsuranceplansnotofferingthe
fullarrayofACAbenefitshavebeenallowedtoextendinduration.SomeofthesechangesarebeingchallengedinU.S.
courtsandsotheirlong-termimpactremainsuncertain.TheACAhasalsobeensubjecttojudicialchallenge.InNovember
2020,theU.S.SupremeCourtheardargumentinTexasv.Azar,whichchallengestheconstitutionalityoftheACA.
Pendingresolutionofthelitigation,alloftheACAbuttheindividualmandatetobuyhealthinsuranceremainsineffect.The
4 • Johnson&Johnson2020AnnualReportU.S.governmentalsocontinuestoproposeandimplementchangestotheMedicarePartDbenefitincludingthesizeof
manufacturerdiscountsinthecoveragegapandcatastrophicphasesofthebenefit.Thereareanumberofadditionalbills
pendinginCongressandhealthcarereformproposalsatthestatelevelthatwouldaffectdrugpricingintheMedicareand
Medicaidprograms.ThischangingfederallandscapehasbothpositiveandnegativeimpactsontheU.S.healthcare
industrywithmuchremaininguncertainastohowvariousprovisionsoffederallaw,andpotentialmodificationorrepealof
theselaws,willultimatelyaffecttheindustry.
Inaddition,businesspracticesinthehealthcareindustryhavecomeunderincreasedscrutiny,particularlyintheU.S.,by
governmentagenciesandstateattorneysgeneral,andresultinginvestigationsandprosecutionscarrytheriskofsignificant
civilandcriminalpenalties.
Further,theCompanyreliesonglobalsupplychains,andproductionanddistributionprocesses,thatarecomplex,are
subjecttoincreasingregulatoryrequirements,andmaybefacedwithunexpectedchangessuchasthoseresultingfrom
theCOVID-19pandemicandBrexit,thatmayaffectsourcing,supplyandpricingofmaterialsusedintheCompany’s
products.Theseprocessesalsoaresubjecttocomplexandlengthyregulatoryapprovals.
TheglobalregulatorylandscapeisalsosubjecttochangeastheCOVID-19pandemiccontinuestoaffecttheU.S.and
globaleconomies.TheU.S.FDAandotherhealthauthoritieshaveshiftedresourcesandprioritiestomeetthemany
challengespresentedbythepandemic.Pandemic-relateddisruptionscouldnegativelyimpacttheprocessingofregulatory
submissionsandslowagencyreviewtimesnecessaryfortheapprovalorclearanceofnewdrugsanddevices.The
durationandseverityoftheCOVID-19pandemicisunpredictableanddifficulttoassess.
Employees and Human Capital Management
AsofJanuary3,2021andDecember29,2019,thenumberofemployeeswereapproximately:
2020 2019
Employees1 136,400 133,200
Full-timeequivalent(FTE)positions2 134,500 132,200
1 “Employee”isdefinedasanindividualworkingfull-timeorpart-time,excludingfixedtermemployees,internsandco-opemployees.
Employeedatamaynotincludefullpopulationfrommorerecentlyacquiredcompaniesandindividualsonlong-termdisabilityare
excluded.Contingentworkers,contractorsandsubcontractorsarealsoexcluded.
2 FTErepresentsthetotalnumberoffull-timeequivalentpositionsanddoesnotreflectthetotalnumberofindividualemployeesas
someworkpart-time.
Employees by region (in percentages)
14.9%
34.4%
30.2%
20.5%
Asia-Pacific EMEA
Latin America North America
Strategy
TheCompanybelievesthatitsemployeesarecriticaltoitscontinuedsuccessandareanessentialelementofitslong-
termstrategy.ManagementisresponsibleforensuringthatitspoliciesandprocessesreflectandreinforcetheCompany’s
desiredcorporateculture,includingpoliciesandprocessesrelatedtostrategy,riskmanagement,andethicsand
compliance.TheCompany’shumancapitalmanagementstrategyisbuiltonthreefundamentalfocusareas:
• Attractingandrecruitingthebesttalent
Johnson&Johnson2020AnnualReport • 5• Developingandretainingtalent
• Empoweringandinspiringtalent
Underpinningthesefocusareasareongoingeffortstocultivateandfosteraculturebuiltondiversity,equityandinclusion
(DEI),innovation,health,well-beingandsafety,wheretheCompany’semployeesareencouragedtosucceedboth
professionallyandpersonallywhilehelpingtheCompanyachieveitsbusinessgoals.
CultureandEmployeeEngagement
AtJohnson&Johnson,employeesareguidedbyOurCredowhichsetsforththeCompany’sresponsibilitiestopatients,
consumers,customers,healthcareprofessionals,employees,communitiesandshareholders.Employeesworldwideare
furtherguidedbytheCompany’sCodeofBusinessConductwhichsetsbasicrequirementsforbusinessconductand
servesasafoundationfortheCompanypolicies,proceduresandguidelines,allofwhichprovideadditionalguidanceon
expectedemployeebehaviorsineverymarketwhereitoperates.TheCompanyconductsglobalsurveysthatofferits
employeestheabilitytoprovidefeedbackandvaluableinsighttohelpaddresspotentialhumanresourcesrisksandidentify
opportunitiestoimprove.In2020,93%ofglobalemployeesacross78countriesparticipatedinOurCredoSurveywhich
isofferedin36languages.
GrowthandDevelopment
Tocontinuetoleadinthechanginghealthcarelandscape,itiscrucialthattheCompanycontinuetoattractandretaintop
talent.TheCompanybelievesthatitsemployeesmustbeequippedwiththerightknowledgeandskillsandbeprovided
withopportunitiestogrowanddevelopintheircareers.Accordingly,professionaldevelopmentprogramsandeducational
resourcesareavailabletoallemployees.TheCompany’sobjectiveistofosteralearningculturethathelpsshapeeach
person’suniquecareerpathwhilecreatingarobustpipelineoftalenttodeliverontheCompany’slong-termstrategies.In
furtheranceofthisobjective,theCompanydeploysaglobalapproachtoensuredevelopmentisforeveryone,regardlessof
wheretheyareontheircareerjourney.In2020,44.6%ofemployeesinManagerandabovejobcategoriestookadvantage
ofcareeropportunitiesbymovingacrossfunctions,countryorbusinesssegmentlines(includingupwardpromotionor
lateraltransferandexcludingemployeesintheresearchanddevelopmentorganizations).TheCompany’svoluntary
turnoverratewas5.2%.
Diversity,Equity,andInclusion(DEI)
TheCompanyiscommittedtoworkplacediversityandtocultivating,fostering,andadvancingacultureofequityand
inclusion.EnablingemployeestoperformattheirbestwhilebeingthemselvesisfundamentaltotheCompany’scontinued
success.TheCompany’sDEIvisionis:Beyourself,changetheworld.TheCompany’sDEIstrategyfocusesonthreepillars
thatreflectthestrategicprioritiesidentifiedtoenabletheCompanytoaddressthechallengesandopportunitiespresented
bythisevolvingunderstandingofdiversity:
• AcceleratetheCompany’seffortstoadvanceacultureofinclusionandinnovation
• Buildadiverseworkforceforthefuture
• Enhancebusinessresultsandreputation
TheCompany’sDEIstrategyisguidedbyinternalandexternalinsights,globalbestpracticesandcontinualemployee
feedbackwhichremindtheCompanythatwhilediversitychangesbylocation,inclusionisthesameeverywhere.
CompensationandBenefits
AspartoftheCompany’stotalrewardsphilosophy,theCompanyofferscompetitivecompensationandbenefitstoattract
andretaintoptalent.TheCompanyiscommittedtofairnessandequitabletreatmentinitscompensationandbenefitsfor
employeesatalllevels.TheCompanyobserveslegalminimumwageprovisionsandexceedsthemwherepossible.The
Company’stotalrewardsofferingsincludeanarrayofprogramstosupportitsemployees’financial,physical,andmental
well-being,includingannualperformanceincentiveopportunities,pensionandretirementsavingsprograms,healthand
welfarebenefits,paidtimeoff,leaveprograms,flexibleworkschedulesandemployeeassistanceprograms.
Health,WellnessandSafety
TheCompany’sinvestmentinemployeehealth,well-beingandsafetyisbuiltonitsconvictionthatadvancinghealthfor
humanitystartswithadvancingthehealthofitsemployees.Withtherightawareness,focus,practicesandtools,the
6 • Johnson&Johnson2020AnnualReportCompanyensuresthatallitsemployeesaroundtheworld,aswellastemporarycontractorsandvisitorstotheCompany’s
sites,canworksafely.TheCompanyhascontinuouslyexpandedhealthandwell-beingprogramsthroughouttheCompany
andacrosstheglobe,incorporatingnewthinkingandtechnologiestokeepitsofferingsbest-in-classandtohelp
employeesachievetheirpersonalmindandbodyhealthgoals.TheprogramsandpracticestheCompanyadvancescovers
threecoredimensions:HealthyEating,HealthyMovementandHealthyMind.
Available Information
TheCompany’smaincorporatewebsiteaddressiswww.jnj.com.AlloftheCompany’sSECfilingsarealsoavailableonthe
Company’swebsiteatwww.investor.jnj.com/sec.cfm,assoonasreasonablypracticableafterhavingbeenelectronically
filedorfurnishedtotheSEC.AllSECfilingsarealsoavailableattheSEC’swebsiteatwww.sec.gov.
InvestorsandthepublicshouldnotethattheCompanyalsoannouncesinformationat
www.factsaboutourprescriptionopioids.comandwww.factsabouttalc.com.Weusethesewebsitestocommunicatewith
investorsandthepublicaboutourproducts,litigationandothermatters.Itispossiblethattheinformationweposttothese
websitescouldbedeemedtobematerialinformation.Therefore,weencourageinvestorsandothersinterestedinthe
Companytoreviewtheinformationpostedtothesewebsitesinconjunctionwithwww.jnj.com,theCompany’sSECfilings,
pressreleases,publicconferencecallsandwebcasts.
Inaddition,theAmendedandRestatedCertificateofIncorporation,By-Laws,thewrittenchartersoftheAuditCommittee,
theCompensation&BenefitsCommittee,theNominating&CorporateGovernanceCommittee,theRegulatory
ComplianceCommitteeandtheScience,Technology&SustainabilityCommitteeoftheBoardofDirectorsandthe
Company’sPrinciplesofCorporateGovernance,CodeofBusinessConduct(foremployees),CodeofBusiness
Conduct&EthicsforMembersoftheBoardofDirectorsandExecutiveOfficers,andothercorporategovernance
materials,areavailableatwww.investor.jnj.com/gov.cfmontheCompany’swebsiteandwillbeprovidedwithoutchargeto
anyshareholdersubmittingawrittenrequest,asprovidedabove.Theinformationonwww.jnj.com,
www.factsaboutourprescriptionopioids.comandwww.factsabouttalc.comisnot,andwillnotbedeemed,apartofthisReport
orincorporatedintoanyotherfilingstheCompanymakeswiththeSEC.
Item 1A. RISK FACTORS
AninvestmentintheCompany’scommonstockordebtsecuritiesinvolvesrisksanduncertainties.TheCompanyseeksto
identify,manageandmitigateriskstoourbusiness,butuncertaintiesandrisksaredifficulttopredictandmanyareoutside
oftheCompany’scontrolandcannotthereforebeeliminated.Inadditiontotheotherinformationinthisreportandthe
Company’sotherfilingswiththeSEC,investorsshouldconsidercarefullythefactorssetforthbelow.Investorsshouldbe
awarethatitisnotpossibletopredictoridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacomplete
discussionofallpotentialrisksoruncertainties.Ifknownorunknownrisksoruncertaintiesmaterialize,theCompany’s
business,resultsofoperationsorfinancialconditioncouldbeadverselyaffected,potentiallyinamaterialway.
Risks Related to Our Business, Industry and Operations
TheCompany’sbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould
adverselyaffecttheCompany’searnings.
TheCompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarkets.TheCompany’s
businessescompetewithcompaniesofallsizesonthebasisofcost-effectiveness,technologicalinnovations,intellectual
propertyrights,productperformance,realorperceivedproductadvantages,pricingandavailabilityandrateof
reimbursement.TheCompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisitions,
collaborationsandlicensingagreementswiththirdparties.Competitionforrightstoproductcandidatesandtechnologies
mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsfortheCompany.Competitors’
developmentofmoreeffectiveorlesscostlyproducts,and/ortheirabilitytosecurepatentandotherintellectualproperty
rightsandsuccessfullymarketproductsaheadoftheCompany,couldnegativelyimpactsalesoftheCompany’sexisting
productsaswellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproduct
development.
FortheCompany’spharmaceuticalbusinesses,lossofpatentexclusivityforaproductoftenisfollowedbyasubstantial
reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket.
Similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproduct.FortheCompany’smedicaldevice
businesses,technologicalinnovation,productquality,reputationandcustomerserviceareespeciallyimportantto
Johnson&Johnson2020AnnualReport • 7competitiveness.Developmentbyothercompaniesofneworimprovedproducts,processesandtechnologiescould
threatentomaketheCompany’sproductsortechnologieslessdesirable,lesseconomicalorobsolete.TheCompany’s
consumerhealthbusinessesfaceintensecompetitionfromotherbrandedproductsandretailers’private-labelbrands.Ifthe
Companyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproducts,thiscouldadverselyaffect
revenuesandprofitabilityofthoseproducts.
InterruptionsanddelaysinmanufacturingoperationscouldadverselyaffecttheCompany’sbusiness,sales
andreputation.
TheCompany’smanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplex,high-quality
componentsandmaterials.TheCompany’ssubsidiariesoperate90manufacturingfacilitiesaswellassourcingfrom
hundredsofsuppliersaroundtheworld.TheCompanyhasinthepast,andmayinthefuture,faceunanticipated
interruptionsanddelaysinmanufacturingthroughitsinternalorexternalsupplychain.Manufacturingdisruptionscanoccur
formanyreasonsincludingregulatoryaction,productionqualitydeviationsorsafetyissues,labordisputes,site-specific
incidents(suchasfires),naturaldisasterssuchashurricanesandothersevereweatherevents,rawmaterialshortages,
politicalunrest,terroristattacksandepidemicsorpandemics.Suchdelaysanddifficultiesinmanufacturingcanresultin
productshortages,declinesinsalesandreputationalimpactaswellassignificantremediationandrelatedcostsassociated
withaddressingtheshortage.
TheCompanyreliesonthirdpartiestomanufacturecertainofourproducts.Anyfailurebyorlossofathird-
partymanufacturercouldresultindelaysandincreasedcosts,whichmayadverselyaffectourbusiness.
TheCompanyreliesonthirdpartiestomanufacturecertainofourproducts.Wedependonthesethirdparty
manufacturerstoallocatetousaportionoftheirmanufacturingcapacitysufficienttomeetourneeds,toproduceproducts
ofacceptablequalityandatacceptablemanufacturingyieldsandtodeliverthoseproductstousonatimelybasisandat
acceptableprices.However,wecannotguaranteethatthesethird-partymanufacturerswillbeabletomeetournear-term
orlong-termmanufacturingrequirements,whichcouldresultinlostsalesandhaveanadverseeffectonourbusiness.
Otherrisksassociatedwithourrelianceonthirdparties,includingtheCompany’sstrategicpartnershipwithJabilinthe
MedicalDevicessegment,tomanufacturetheseproductsincluderelianceonthethirdpartyforregulatorycomplianceand
qualityassurance,misappropriationoftheCompany’sintellectualproperty,limitedabilitytomanageourinventory,possible
breachofthemanufacturingagreementbythethirdpartyandthepossibleterminationornonrenewalofthemanufacturing
agreementbythethirdpartyatatimethatiscostlyorinconvenientforus.Moreover,ifanyofourthirdpartymanufacturers
sufferanydamagetofacilities,losebenefitsundermaterialagreements,experiencepoweroutages,encounterfinancial
difficulties,areunabletosecurenecessaryrawmaterialsfromtheirsuppliersorsufferanyotherreductioninefficiency,the
Companymayexperiencesignificantbusinessdisruption.Intheeventofanysuchdisruption,theCompanywouldneedto
seekandsourceotherqualifiedthird-partymanufacturers,likelyresultinginfurtherdelaysandincreasedcostswhichcould
affectourbusinessadversely.
Counterfeitversionsofourproductscouldharmourpatientsandhaveanegativeimpactonourrevenues,
earnings,reputationandbusiness.
Ourindustrycontinuestobechallengedbythevulnerabilityofdistributionchannelstoillegalcounterfeitingandthe
presenceofcounterfeitproductsinagrowingnumberofmarketsandovertheInternet.Thirdpartiesmayillegallydistribute
andsellcounterfeitversionsofourproducts,whichdonotmeetourrigorousmanufacturingandtestingstandards.To
distributorsandpatients,counterfeitproductsmaybevisuallyindistinguishablefromtheauthenticversion.Counterfeit
medicinesposearisktopatienthealthandsafetybecauseoftheconditionsunderwhichtheyaremanufactured–oftenin
unregulated,unlicensed,uninspectedandunsanitarysites–aswellasthelackofregulationoftheircontents.
Theindustry’sfailuretomitigatethethreatofcounterfeitmedicinescouldadverselyimpactourbusinessandreputationby
impactingpatientconfidenceinourauthenticproducts,potentiallyresultinginlostsales,productrecalls,andanincreased
threatoflitigation.Inaddition,diversionofourproductsfromtheirauthorizedmarketintootherchannelsmayresultin
reducedrevenuesandnegativelyaffectourprofitability.
TheCOVID-19pandemichasadverselyimpactedcertainaspectsoftheCompany’sbusinessandcould
causedisruptionsorfutureimpacttotheCompany’sbusiness,resultsofoperationsandfinancial
condition.
Wearesubjecttorisksassociatedwithglobalhealthcrisesandpandemics,includingtheglobaloutbreakofthenovel
coronavirusanditsmutations(COVID-19).TheCOVID-19pandemichasadverselyimpacted,andisexpectedtocontinue
toadverselyimpact,certainaspectsoftheCompany’sbusiness,resultsofoperationsandfinancialcondition,including
8 • Johnson&Johnson2020AnnualReportlowersalesandreducedcustomerdemandandusageofcertainofourproducts.ThespreadofCOVID-19hascaused
theCompanytomodifyitsbusinesspractices(includinginstitutingremoteworkformanyoftheCompany’semployees),
andtheCompanymaytakefurtheractionsasmayberequiredbygovernmentauthoritiesorastheCompanydetermines
areinthebestinterestsofourpatients,customers,employeesandbusinesspartners.TheCompanycontinuestomonitor
thesituationandwhilewehaverobustbusinesscontinuityplansinplaceacrossourglobalsupplychainnetworktohelp
mitigatetheimpactofCOVID-19,theseeffortsmaynotcompletelypreventourbusinessfrombeingadverselyaffected
andfutureimpactsremainuncertain.
WhiletheU.S.andothercountrieshavebegunorwillbegintoreopentheireconomies,theextenttowhichCOVID-19will
impacttheCompany’sfutureoperationswilldependonmanyfactorswhichcannotbepredictedwithconfidence,
includingthedurationoftheoutbreak.AnyresurgenceinCOVID-19infectionscouldresultintheimpositionofnew
mandatesandprolongedrestrictivemeasuresimplementedinordertocontrolthespreadofthedisease.Thecontinued
globalspreadofCOVID-19couldadverselyimpacttheCompany’soperations,including,amongotherthings,our
manufacturingoperations,supplychain,includingthird-partysuppliers,salesandmarketingandclinicaltrialoperations.
AnyofthesefactorscouldadverselyaffecttheCompany’sbusiness,financialresults,andglobaleconomicconditions
generally.
WealsofaceuncertaintiesrelatedtooureffortstodevelopaCOVID-19vaccinecandidate,includinguncertaintiesrelated
totheriskthatourdevelopmentprogramsmaynotbesuccessful,commerciallyviableorreceiveapprovalorEmergency
UseAuthorizationfromregulatoryauthorities;risksassociatedwithclinicaltrialdata,includingfurtheranalysesofexisting
preclinicalorclinicaltrialdatathatmaybeinconsistentwiththedatausedforselectionoftheJNJ-78436735vaccine
candidateanddoselevelforthePhase3(ENSEMBLE)trial;theriskthatclinicaltrialdataaresubjecttodiffering
interpretationsandassessments,includingduringthepeerreview/publicationprocess,inthescientificcommunity
generally,andbyregulatoryauthorities;disruptionsintherelationshipsbetweenus,ourthird-partysuppliersandexternal
manufacturers;theriskthatothercompaniesmayproducesuperiororcompetitiveproducts;theriskthatdemandforany
productswemaydevelopmaynolongerexist;risksrelatedtotheavailabilityofrawmaterialstomanufactureanysuch
products;theriskthatwemaynotbeabletorecoupcostsassociatedwithourR&Dandmanufacturingeffortsandrisks
associatedwithanychangesinthewayweapproachorprovideadditionalresearchfundingforpotentialdrug
developmentrelatedtoCOVID-19;theriskthatwemaynotbeabletocreateorscaleupmanufacturingcapacityona
timelybasis,thatwemayexperiencemanufacturingdelaysonceamanufacturingsiteisactivated,orhaveaccessto
logisticsorsupplychannelscommensuratewithglobaldemandforanypotentialapprovedvaccineorproductcandidate,
whichwouldnegativelyimpactourabilitytosupplytheestimatednumbersofdosesofourvaccinecandidatewithinthe
projectedtimeperiodsindicated,andotherchallengesandrisksassociatedwiththepaceofourvaccinedevelopment
program;andpricingandaccesschallengesforsuchproducts,includingintheU.S.
Inaddition,totheextenttheCOVID-19pandemicadverselyaffectsourbusinessandfinancialresults,itmayalsohavethe
effectofheighteningmanyoftheotherrisksdescribedinthis“RiskFactors”sectionandthoseincorporatedbyreference
herein,includingrisksrelatingtotheCompany’seffectivetaxrateasaresultofchangesinconsumptionaswellas
changesinlawsrelatingtosupplyoftheCompany’sproducts.GiventhatdevelopmentsconcerningtheCOVID-19
pandemichavebeenconstantlyevolving,additionalimpactsandrisksmayarise,includinglitigation,thatarenotpresently
knowntotheCompany.
Risk Related to the Government Regulation and Legal Proceedings
GlobalsalesintheCompany’spharmaceuticalandmedicaldevicessegmentsmaybenegatively
impactedbyhealthcare reformsandincreasingpricingpressures.
SalesoftheCompany’spharmaceuticalandmedicaldeviceproductsaresignificantlyaffectedbyreimbursementsby
third-partypayerssuchasgovernmenthealthcareprograms,privateinsuranceplansandmanagedcareorganizations.As
partofvariouseffortstocontainhealthcarecosts,thesepayersareputtingdownwardpressureonpricesatwhich
productswillbereimbursed.IntheU.S.,increasedpurchasingpowerofentitiesthatnegotiateonbehalfofMedicare,
Medicaid,andprivatesectorbeneficiaries,inpartduetocontinuedconsolidationamonghealthcareproviders,could
resultinfurtherpricingpressures.Inaddition,increasedpoliticalscrutinycouldresultinadditionalpricingpressures.
OutsidetheU.S.,numerousmajormarkets,includingtheEU,UnitedKingdomandJapan,havepervasivegovernment
involvementinfundinghealthcareand,inthatregard,directlyorindirectlyimposepricecontrols,limitaccessto,or
reimbursementfor,theCompany’sproducts,orreducethevalueofitsintellectualpropertyprotection.
Johnson&Johnson2020AnnualReport • 9TheCompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpenses,
finesandreputationaldamage.
Intheordinarycourseofbusiness,Johnson&Johnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuits
involvingvariousissuessuchaspatentdisputes,productliabilityandclaimsthattheirproductsales,marketingandpricing
practicesviolatevariousantitrust,unfairtradepracticesand/orconsumerprotectionlaws.TheCompany’smoresignificant
legalproceedingsaredescribedinNote19,“LegalProceedings”underNotestotheConsolidatedFinancialStatements
includedinItem8ofthisReport.Litigation,ingeneral,andsecurities,derivativeaction,classactionandmulti-district
litigation,inparticular,canbeexpensiveanddisruptive.Someofthesemattersmayincludethousandsofplaintiffs,may
involvepartiesseekinglargeand/orindeterminateamounts,includingpunitiveorexemplarydamages,andmayremain
unresolvedforseveralyears.Forexample,theCompanyisadefendantinnumerouslawsuitsarisingoutoftheuseofbody
powderscontainingtalc,primarilyJOHNSONS®BabyPowder,andtheCompany’ssale,manufacturingandmarketingof
opioids.WhiletheCompanybelievesithassubstantialdefensesinthesematters,itisnotfeasibletopredicttheultimate
outcomeoflitigation.TheCompanycouldinthefutureberequiredtopaysignificantamountsasaresultofsettlementsor
judgmentsinthesematters,potentiallyinexcessofaccruals,includingmatterswheretheCompanycouldbeheldjointly
andseverallyliableamongotherdefendants.Theresolutionof,orincreaseinaccrualsfor,oneormoreofthesemattersin
anyreportingperiodcouldhaveamaterialadverseeffectontheCompany’sresultsofoperationsandcashflowsforthat
period.TheCompanydoesnotpurchasethird-partyproductliabilityinsurance;howevertheCompanyutilizesawholly-
ownedcaptiveinsurancecompanysubjecttocertainlimits.
Productreliability,safetyandeffectivenessconcernscanhavesignificantnegativeimpactson
salesandresultsofoperations,leadtolitigationandcausereputationaldamage.
Concernsaboutproductsafety,whetherraisedinternallyorbylitigants,regulatorsorconsumeradvocates,andwhetheror
notbasedonscientificevidence,canresultinsafetyalerts,productrecalls,governmentalinvestigations,regulatoryaction
onthepartoftheU.S.FoodandDrugAdministration(oritscounterpartinothercountries),privateclaimsandlawsuits,
paymentoffinesandsettlements,decliningsalesandreputationaldamage.Thesecircumstancescanalsoresultin
damagetobrandimage,brandequityandconsumertrustintheCompany’sproducts.Productrecallshaveinthepast,
andcouldinthefuture,promptgovernmentinvestigationsandinspections,theshutdownofmanufacturingfacilities,
continuedproductshortagesandrelatedsalesdeclines,significantremediationcosts,reputationaldamage,possiblecivil
penaltiesandcriminalprosecution.
TheCompanyfacessignificantregulatoryscrutinywhichimposessignificantcompliancecosts
andexposestheCompanytogovernmentinvestigations,legalactionsandpenalties.
Likeothercompaniesinthehealthcareindustry,theCompanyissubjecttoextensiveregulation,investigationsandlegal
action,bynational,stateandlocalgovernmentagenciesintheU.S.andothercountriesinwhichtheyoperate.Regulatory
issuesregardingcompliancewithcurrentGoodManufacturingPractices(cGMP)(andcomparablequalityregulationsin
foreigncountries)bymanufacturersofdrugs,devicesandconsumerproductscanleadtofinesandpenalties,product
recalls,productshortages,interruptionsinproduction,delaysinnewproductapprovalsandlitigation.Inaddition,the
marketing,pricingandsaleoftheCompany’sproductsaresubjecttoregulation,investigationsandlegalactionsincluding
undertheFederalFood,Drug,andCosmeticAct,theMedicaidRebateProgram,federalandstatefalseclaimsacts,state
unfairtradepracticesactsandconsumerprotectionlaws.Scrutinyofhealthcareindustrybusinesspracticesby
governmentagenciesandstateattorneysgeneralintheU.S.,andanyresultinginvestigationsandprosecutions,carryrisk
ofsignificantcivilandcriminalpenaltiesincluding,butnotlimitedto,debarmentfromparticipationingovernment
healthcareprograms.AnysuchdebarmentcouldhaveamaterialadverseeffectontheCompany’sbusinessandresultsof
operations.Themostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesaredescribedin
Note19,“LegalProceedings-GovernmentProceedings”underNotestotheConsolidatedFinancialStatementsincluded
inItem8ofthisReport.
ChangesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpacttheCompany’s
operatingresults.
ChangesintaxlawsorregulationsaroundtheworldcouldnegativelyimpacttheCompany’seffectivetaxrateandresults
ofoperations.AchangeinstatutorytaxrateinanycountrywouldresultintherevaluationoftheCompany’sdeferredtax
assetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawisenacted.Thischange
wouldresultinanexpenseorbenefitrecordedtotheCompany’sConsolidatedStatementofEarnings.TheCompany
closelymonitorstheseproposalsastheyariseinthecountrieswhereitoperates.Changestothestatutorytaxratemay
occuratanytime,andanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarterandyearinwhichthe
lawchangeisenacted.
10 • Johnson&Johnson2020AnnualReportSeeNote8onincometaxesforadditionalinformation.
TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandisaddressingtaxauditsanddisputes
withmanytaxauthorities.Inconnectionwiththe2015OrganizationforEconomicCooperationandDevelopmentBase
ErosionandProfitShifting(BEPS)project,companiesarerequiredtodisclosemoreinformationtotaxauthoritieson
operationsaroundtheworld,whichmayleadtogreaterauditscrutinyofprofitsearnedinothercountries.TheCompany
regularlyassessesthelikelyoutcomesofitstaxauditsanddisputestodeterminetheappropriatenessofitstaxreserves.
However,anytaxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytotheCompany’sexpectations,which
couldresultintaxliabilitiesinexcessofreserves.
Risks Related to Our Intellectual Property
TheCompanymaynotbeabletosuccessfullysecureanddefendintellectualpropertyrightsessentialto
theCompany’sbusinesses.
TheCompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrights,relatingtoitsproductsand
manufacturingprocesses.TheserightsareessentialtotheCompany’sbusinessesandmateriallyimportanttothe
Company’sresultsofoperations.Publicpolicy,bothwithinandoutsidetheU.S.,hasbecomeincreasinglyunfavorable
towardintellectualpropertyrights.TheCompanycannotbecertainthatitwillobtainadequatepatentprotectionfornew
productsandtechnologiesintheUnitedStatesandotherimportantmarketsorthatsuchprotections,oncegranted,will
lastaslongasoriginallyanticipated.
CompetitorsroutinelychallengethevalidityorextentoftheCompany’sownedorlicensedpatentsandproprietaryrights
throughlitigation,interferences,oppositionsandotherproceedings,suchasinterpartesreview(IPR)proceedingsbefore
theUnitedStatesPatent&TrademarkOffice(USPTO).Theseproceedingsabsorbresourcesandcanbeprotractedas
wellasunpredictable.Inaddition,challengesthattheCompany’sproductsinfringethepatentsofthirdpartiescouldresult
intheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionandsalesofthe
productsinquestion.
TheCompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand
biosimilarversionsoftheCompany’skeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering
thoseproducts.IntheU.S.,manufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay
challengethevalidity,orclaimnon-infringement,ofinnovatorproductsthroughtheAbbreviatedNewDrugApplication,or
ANDA,processwiththeFDAandrelatedANDAlitigation.TheBiologicsPriceCompetitionandInnovationAct(BPCIA),
enactedin2010,whichcreatedanewregulatorypathwayfortheapprovalbytheFDAofbiosimilaralternativesto
innovator-developedbiologicalproducts,alsocreatedmechanismsforbiosimilarapplicantstochallengethepatentson
theinnovatorbiologics.TheIPRprocesswiththeUSPTOisalsobeingusedbycompetitorstochallengepatentsasserted
inlitigation.
IntheeventtheCompanyisnotsuccessfulindefendingitspatentsagainstsuchchallenges,oruponthe“at-risk”launch
(despitependingpatentinfringementlitigation)bythegenericorbiosimilarfirmofitsproduct,theCompanycanlosea
majorportionofrevenuesforthereferencedproductinaveryshortperiodoftime.Currentlegalproceedingsinvolvingthe
Company’spatentsandotherintellectualpropertyrightsaredescribedinNote19,“LegalProceedings—Intellectual
Property”oftheNotestotheConsolidatedFinancialStatementsincludedinItem8ofthisReport.
RisksRelatedtoProductDevelopment,RegulatoryApprovalandCommercialization
SignificantchallengesordelaysintheCompany’sinnovationanddevelopmentofnewproducts,
technologiesandindicationscouldhaveanadverseimpactontheCompany’slong-termsuccess.
TheCompany’scontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiated
productsandservicesthataddresstheevolvinghealthcareneedsofpatients,providersandconsumers.Developmentof
successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhentheCompany’sexistingproducts
losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivity.Newproductsintroduced
withinthepastfiveyearsaccountedforapproximately25%of2020sales.TheCompanycannotbecertainwhenor
whetheritwillbeabletodevelop,licenseorotherwiseacquirecompanies,productsandtechnologies,whetherparticular
productcandidateswillbegrantedregulatoryapproval,and,ifapproved,whethertheproductswillbecommercially
successful.
Johnson&Johnson2020AnnualReport • 11TheCompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaborations,
acquisitions,jointventuresandlicensingorotherarrangementswiththirdparties.Inallofthesecontexts,developingnew
products,particularlypharmaceuticalandbiotechnologyproductsandmedicaldevices,requiressignificantinvestmentof
resourcesovermanyyears.Onlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially
viableproducts.Theprocessdependsonmanyfactorsincludingtheabilitytodiscernpatients’andhealthcareproviders’
futureneeds;developpromisingnewcompounds,strategiesandtechnologies;achievesuccessfulclinicaltrialresults;
secureeffectiveintellectualpropertyprotection;obtainregulatoryapprovalsonatimelybasis;and,ifandwhentheyreach
themarket,successfullydifferentiatetheCompany’sproductsfromcompetingproductsandapproachestotreatment.
Newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue
toproductandpricecompetition,changesincustomerpreferencesorhealthcarepurchasingpatterns,resistanceby
healthcareprovidersoruncertaintyoverthird-partyreimbursement.Evenfollowinginitialregulatoryapproval,thesuccess
ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerreal-worldpatientpopulations,aswellas
marketentryofcompetitiveproducts.
Risk Related to Financial and Economic Market Conditions
TheCompanyfacesavarietyofrisksassociatedwithconductingbusinessinternationally.
TheCompany’sextensiveoperationsandbusinessactivityoutsidetheU.S.areaccompaniedbycertainfinancial,
economicandpoliticalrisks,includingthoselistedbelow.
ForeignCurrencyExchange:Infiscal2020,approximately48%oftheCompany’ssalesoccurredoutsideoftheU.S.,with
approximately23%inEurope,7%intheWesternHemisphere,excludingtheU.S.,and18%intheAsia-PacificandAfrica
region.Changesinnon-U.S.currenciesrelativetotheU.S.dollarimpacttheCompany’srevenuesandexpenses.While
theCompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflows,
unhedgedexposurescontinuetobesubjecttocurrencyfluctuations.Inaddition,theweakeningorstrengtheningofthe
U.S.dollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe
Company’snon-U.S.businessactivityaretranslatedintoU.S.dollars.
InflationandCurrencyDevaluationRisks:TheCompanyfaceschallengesinmaintainingprofitabilityofoperationsin
economiesexperiencinghighinflationrates.TheCompanyhasaccountedforoperationsinArgentina(beginninginthe
fiscalthirdquarterof2018)andVenezuelaashighlyinflationary,asthepriorthree-yearcumulativeinflationratesurpassed
100%.WhiletheCompanystrivestomaintainprofitmarginsintheseareasthroughcostreductionprograms,productivity
improvementsandperiodicpriceincreases,itmightexperienceoperatinglossesasaresultofcontinuedinflation.In
addition,theimpactofcurrencydevaluationsincountriesexperiencinghighinflationratesorsignificantcurrencyexchange
fluctuationscouldnegativelyimpacttheCompany’soperatingresults.
IllegalImportationofPharmaceuticalProducts:Theillegalimportationofpharmaceuticalproductsfromcountrieswhere
governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffecttheCompany’ssalesand
profitabilityintheU.S.andothercountriesinwhichtheCompanyoperates.Withtheexceptionoflimitedquantitiesof
prescriptiondrugsforpersonaluse,foreignimportsofpharmaceuticalproductsareillegalundercurrentU.S.law.
However,thevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower-
pricedimportshasgrownsignificantly.
Anti-BriberyandOtherRegulations:TheCompanyissubjecttovariousfederalandforeignlawsthatgovernitsinternational
businesspracticeswithrespecttopaymentstogovernmentofficials.ThoselawsincludetheU.S.ForeignCorrupt
PracticesAct(FCPA),whichprohibitsU.S.publiclytradedcompaniesfrompromising,offering,orgivinganythingofvalue
toforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingtheCompanyobtain
orretainbusinessorgainanyimproperadvantage.TheCompany’sbusinessisheavilyregulatedandthereforeinvolves
significantinteractionwithforeignofficials.Also,inmanycountriesoutsidetheU.S.,thehealthcareproviderswho
prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare
governmententities;therefore,theCompany’sinteractionswiththeseprescribersandpurchasersaresubjecttoregulation
undertheFCPA.InadditiontotheU.S.applicationandenforcementoftheFCPA,variousjurisdictionsinwhichthe
Companyoperateshavelawsandregulations,includingtheU.KBriberyAct2010,aimedatpreventingandpenalizing
corruptandanticompetitivebehavior.EnforcementactivitiesundertheselawscouldsubjecttheCompanytoadditional
administrativeandlegalproceedingsandactions,whichcouldincludeclaimsforcivilpenalties,criminalsanctions,and
administrativeremedies,includingexclusionfromhealthcareprograms.
12 • Johnson&Johnson2020AnnualReportOtherLegal,SocialandPoliticalRisks.Otherrisksinherentinconductingbusinessgloballyinclude:
• protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimport/exportlicensing
requirements;
• compliancewithlocalregulationsandlawsincluding,insomecountries,regulatoryrequirementsrestrictingthe
Company’sabilitytomanufactureorsellitsproductsintherelevantmarket;
• diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdictions;
• potentialnationalizationorexpropriationoftheCompany’sforeignassets;
• politicalorsocialupheavals,economicinstability,repression,orhumanrightsissues;and
• geopoliticalevents,includingnaturaldisasters,disruptionstomarketsduetowar,armedconflict,terrorism,epidemicsor
pandemics.
Failuretomaintainasatisfactorycreditratingcouldadverselyaffectourliquidity,capitalposition,
borrowingcostsandaccesstocapitalmarkets.
WecurrentlymaintaininvestmentgradecreditratingswithMoody’sInvestorsServiceandStandard&Poor’sRatings
Services.Ratingagenciesroutinelyevaluateus,andtheirratingsofourlong-termandshort-termdebtarebasedona
numberoffactors.Anydowngradeofourcreditratingsbyacreditratingagency,whetherasaresultofouractionsor
factorswhicharebeyondourcontrol,canincreasethecostofborrowingunderanyindebtednesswemayincur,reduce
marketcapacityforourcommercialpaperorrequirethepostingofadditionalcollateralunderourderivativecontracts.
Therecanbenoassurancethatwewillbeabletomaintainourcreditratings,andanyadditionalactualoranticipated
changesordowngradesinourcreditratings,includinganyannouncementthatourratingsareunderreviewfora
downgrade,mayhaveanegativeimpactonourliquidity,capitalpositionandaccesstocapitalmarkets.
Other Risks
Ourbusinessdependsonourabilitytorecruitandretaintalented,highlyskilledemployeesandadiverse
workforce.
Ourcontinuedgrowthrequiresustorecruitandretaintalentedemployeesrepresentingdiversebackgrounds,experiences,
andskillsets.Themarketforhighlyskilledworkersandleadersinourindustryisextremelycompetitiveandourabilityto
competedependsonourabilitytohire,developandmotivatehighlyskilledpersonnelinallareasofourorganization.
Maintainingourbrandandreputation,aswellasadiverse,equitableandinclusiveworkenvironmentenablesustoattract
toptalent.Ifwearelesssuccessfulinourrecruitingefforts,orifwecannotretainhighlyskilledworkersandkeyleaders,
ourabilitytodevelopanddeliversuccessfulproductsandservicesmaybeadverselyaffected.Inaddition,effective
successionplanningisimportanttoourlong-termsuccess.Anyunsuccessfulimplementationofoursuccessionplansor
failuretoensureeffectivetransferofknowledgeandsmoothtransitionsinvolvingkeyemployeescouldadverselyaffectour
business,financialcondition,orresultsofoperations.
Aninformationsecurityincident,includingacybersecuritybreach,couldhaveanegativeimpacttothe
Company’sbusinessorreputation.
Tomeetbusinessobjectives,theCompanyreliesonbothinternaltechnology(IT)systemsandnetworks,andthoseof
thirdpartiesandtheirvendors,toprocessandstoresensitivedata,includingconfidentialresearch,businessplans,
financialinformation,intellectualproperty,andpersonaldatathatmaybesubjecttolegalprotection,andensurethe
continuityoftheCompany’ssupplychain.Theextensiveinformationsecurityandcybersecuritythreats,whichaffect
companiesglobally,posearisktothesecurityandavailabilityofthesesystemsandnetworks,andtheconfidentiality,
integrity,andavailabilityoftheCompany’ssensitivedata.TheCompanycontinuallyassessesthesethreatsandmakes
investmentstoincreaseinternalprotection,detection,andresponsecapabilities,aswellasensuretheCompany’sthird-
partyprovidershaverequiredcapabilitiesandcontrols,toaddressthisrisk.Todate,theCompanyhasnotexperiencedany
materialimpacttothebusinessoroperationsresultingfrominformationorcybersecurityattacks;however,becauseofthe
frequentlychangingattacktechniques,alongwiththeincreasedvolumeandsophisticationoftheattacks,thereisthe
potentialfortheCompanytobeadverselyimpacted.Thisimpactcouldresultinreputational,competitive,operationalor
otherbusinessharmaswellasfinancialcostsandregulatoryaction.TheCompanymaintainscybersecurityinsurancein
theeventofaninformationsecurityorcyberincident;however,thecoveragemaynotbesufficienttocoverallfinancial,
legal,businessorreputationallosses.
Johnson&Johnson2020AnnualReport • 13Climatechangeorlegal,regulatoryormarketmeasurestoaddressclimatechangemaynegativelyaffect
ourbusinessandresultsofoperations.
Climatechangeresultingfromincreasedconcentrationsofcarbondioxideandothergreenhousegasesintheatmosphere
couldpresentriskstoouroperations,includinganadverseimpactonglobaltemperatures,weatherpatternsandthe
frequencyandseverityofextremeweatherandnaturaldisasters.Naturaldisastersandextremeweatherconditions,such
asahurricane,tornado,earthquake,wildfireorflooding,mayposephysicalriskstoourfacilitiesanddisrupttheoperation
ofoursupplychain.Theimpactsofthechangingclimateonwaterresourcesmayresultinwaterscarcity,limitingourability
toaccesssufficienthigh-qualitywaterincertainlocations,whichmayincreaseoperationalcosts.
Concernoverclimatechangemayalsoresultinneworadditionallegalorregulatoryrequirementsdesignedtoreduce
greenhousegasemissionsand/ormitigatetheeffectsofclimatechangeontheenvironment.Ifsuchlawsorregulations
aremorestringentthancurrentlegalorregulatoryobligations,wemayexperiencedisruptionin,oranincreaseinthecosts
associatedwithsourcing,manufacturinganddistributionofourproducts,whichmayadverselyaffectourbusiness,results
ofoperationsorfinancialcondition
Item 1B. UNRESOLVED STAFF COMMENTS
Notapplicable.
Item 2. PROPERTIES
TheCompany’ssubsidiariesoperate90manufacturingfacilitiesoccupyingapproximately15.2millionsquarefeetoffloor
space.ThemanufacturingfacilitiesareusedbytheindustrysegmentsoftheCompany’sbusinessapproximatelyas
follows:
SquareFeet
Segment (inthousands)
ConsumerHealth 4,684
Pharmaceutical 5,559
MedicalDevices 4,951
WorldwideTotal 15,194
WithintheU.S.,fivefacilitiesareusedbytheConsumerHealthsegment,fivebythePharmaceuticalsegmentand19by
theMedicalDevicessegment.OutsideoftheU.S.,24facilitiesareusedbytheConsumerHealthsegment,14bythe
Pharmaceuticalsegmentand23bytheMedicalDevicessegment.
Thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollows:
SquareFeet
GeographicArea NumberofFacilities (inthousands)
UnitedStates 29 4,351
Europe 25 5,992
WesternHemisphere,excludingU.S. 10 1,777
Africa,AsiaandPacific 26 3,074
WorldwideTotal 90 15,194
Inadditiontothemanufacturingfacilitiesdiscussedabove,theCompanymaintainsnumerousofficeandwarehouse
facilitiesthroughouttheworld.ResearchfacilitiesarealsodiscussedinItem7.Management’sDiscussionandAnalysisof
ResultsofOperationsandFinancialConditionofthisReport.
TheCompany’ssubsidiariesgenerallyseektoown,ratherthanlease,theirmanufacturingfacilities,althoughsome,
principallyinnon-U.S.locations,areleased.Officeandwarehousefacilitiesareoftenleased.TheCompanyalsoengages
contractmanufacturers.
TheCompanyiscommittedtomaintainingallofitspropertiesingoodoperatingcondition.
McNEIL-PPC,Inc.(nowJohnson&JohnsonConsumerInc.)(McNEIL-PPC)continuestooperateunderaconsentdecree,
signedin2011withtheFDA,whichgovernscertainMcNeilConsumerHealthcaremanufacturingoperations,andrequires
McNEIL-PPCtoremediatethefacilitiesitoperatesinLancaster,Pennsylvania,FortWashington,Pennsylvania,andLas
14 • Johnson&Johnson2020AnnualReportPiedras,PuertoRico(the“ConsentDecree”).FollowingFDAinspectionsMcNEIL-PPCreceivednotificationsfromthe
FDAthatallthreemanufacturingfacilitiesareinconformitywithapplicablelawsandregulations,andcommercial
productionrestartedin2015.
UndertheConsentDecree,afterreceivingnoticefromtheFDAofbeingincompliancewithapplicablelawsand
regulations,eachofthethreefacilitiesissubjecttoafive-yearauditperiodbyathird-partycGMPexpert.Athird-party
expertcontinuedtoreassessthesitesatvarioustimesthrough2020.McNEIL-PPCisawaitingFDAinspectionsofthe
facilitieswhichhavebeendelayedduetoCOVID-19.
Segmentinformationonadditionstoproperty,plantandequipmentiscontainedinNote17“SegmentsofBusinessand
GeographicAreas”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Item 3. LEGAL PROCEEDINGS
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinNote19“Legal
Proceedings”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Inaddition,Johnson&Johnsonanditssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthe
ComprehensiveEnvironmentalResponse,Compensation,andLiabilityAct,commonlyknownasSuperfund,and
comparablestate,localorforeignlawsinwhichtheprimaryreliefsoughtisthecostofpastand/orfutureremediation.
Item 4. MINE SAFETY DISCLOSURES
Notapplicable.
Johnson&Johnson2020AnnualReport • 15EXECUTIVE OFFICERS OF THE REGISTRANT
ListedbelowaretheexecutiveofficersoftheCompany.Therearenofamilyrelationshipsbetweenanyoftheexecutive
officers,andthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto
whichtheexecutiveofficerwasselected.AttheannualmeetingoftheBoardofDirectors,theexecutiveofficersare
electedbytheBoardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualified,oruntil
earlierresignationorremoval.
InformationwithregardtothedirectorsoftheCompany,includinginformationforAlexGorsky,whoisalsoanexecutive
officer,isincorporatedhereinbyreferencetothematerialcaptioned“Item1.ElectionofDirectors”intheProxyStatement.
Name Age Position
JoaquinDuato 58 ViceChairman,ExecutiveCommittee(a)
Member,ExecutiveCommittee;ExecutiveVicePresident,ChiefHuman
PeterM.Fasolo,Ph.D. 58
ResourcesOfficer(b)
Chairman,BoardofDirectors;Chairman,ExecutiveCommittee;ChiefExecutive
AlexGorsky 60
Officer
Member,ExecutiveCommittee;ExecutiveVicePresident,WorldwideChairman,
AshleyMcEvoy 50
MedicalDevices(c)
Member,ExecutiveCommittee,ExecutiveVicePresident,WorldwideChairman,
ThibautMongon 51
ConsumerHealth(d)
Member,ExecutiveCommittee;ExecutiveVicePresident,GlobalCorporate
MichaelE.Sneed 61
AffairsandChiefCommunicationOfficer(e)
PaulusStoffels,M.D. 58 ViceChairman,ExecutiveCommittee;ChiefScientificOfficer(f)
Member,ExecutiveCommittee;ExecutiveVicePresident,WorldwideChairman,
JenniferL.Taubert 57
Pharmaceuticals(g)
MichaelH.Ullmann 62 Member,ExecutiveCommittee;ExecutiveVicePresident,GeneralCounsel(h)
Member,ExecutiveCommittee;ExecutiveVicePresident,ChiefGlobalSupply
KathrynE.Wengel 55
ChainOfficer(i)
Member,ExecutiveCommittee;ExecutiveVicePresident,ChiefFinancial
JosephJ.Wolk 54
Officer(j)
(a) Mr.J.DuatojoinedtheCompanyin1989withJanssen-FarmaceuticaS.A.(Spain),asubsidiaryoftheCompany,andheldexecutive
positionsofincreasingresponsibilityinthePharmaceuticalsector.In2009,hewasnamedCompanyGroupChairman,
Pharmaceuticals,andin2011,hewasnamedWorldwideChairman,Pharmaceuticals.In2016,Mr.Duatobecameamemberofthe
ExecutiveCommitteeandwasnamedExecutiveVicePresident,WorldwideChairman,Pharmaceuticals.InJuly2018,Mr.Duatowas
promotedtoViceChairmanoftheExecutiveCommittee,withresponsibilityforthecompany’sPharmaceuticalandConsumerHealth
sectors,supplychain,informationtechnology,globalservicesandtheHealth&Wellnessgroups.
(b) Dr.P.M.FasolojoinedtheCompanyin2004asVicePresident,WorldwideHumanResourcesforCordisCorporation,asubsidiary
oftheCompany,andwassubsequentlynamedVicePresident,GlobalTalentManagementfortheCompany.HeleftJohnson&
Johnsonin2007tojoinKohlbergKravisRoberts&Co.asChiefTalentOfficer.Dr.FasoloreturnedtotheCompanyin2010asthe
VicePresident,GlobalHumanResources,andin2011,hebecameamemberoftheExecutiveCommittee.InApril2016,hewas
namedExecutiveVicePresident,ChiefHumanResourcesOfficer.Dr.Fasolohasresponsibilityforglobaltalent,recruiting,diversity,
compensation,benefits,employeerelationsandallaspectsofthehumanresourcesagendafortheCompany.
(c) Ms.A.McEvoyjoinedtheCompanyin1996asAssistantBrandManagerofMcNeilConsumerHealth,asubsidiaryoftheCompany,
advancingthroughpositionsofincreasingresponsibilitiesuntilshewasappointedCompanyGroupChairman,VisionCarein2012,
followedbyCompanyGroupChairman,ConsumerMedicalDevicesin2014.InJuly2018,Ms.McEvoywaspromotedtoExecutive
VicePresident,WorldwideChairman,MedicalDevices,andbecameamemberoftheExecutiveCommittee.Ms.McEvoyhas
responsibilityforthesurgery,orthopaedics,interventionalsolutionsandeyehealthbusinessesacrossEthicon,DePuySynthes,
BiosenseWebsterandJohnson&JohnsonVision.
(d) Mr.T.MongonjoinedtheCompanyin2000asDirectorofMarketingfortheVisionCaregroupinFranceandsubsequentlyheld
generalmanagementpositionsasCountryManagerFrance,BelgiumandNorthAfrica,ManagingDirectorLatinAmerica,and
PresidentAsia-Pacific.Mr.MongontransitionedtothePharmaceuticalsectorin2012astheGlobalCommercialStrategyLeaderfor
theNeurosciencetherapeuticarea,beforejoiningtheConsumerHealthsectorasCompanyGroupChairmanAsia-Pacific.In2019,
hewaspromotedtoExecutiveVicePresidentandWorldwideChairman,ConsumerHealth,andbecameamemberoftheExecutive
Committee.Mr.MongonhasresponsibilityfortheglobaldevelopmentofJohnson&Johnson’shealthandwellnessproductsand
solutionsinbeauty,OTC,oralcare,babycare,women’shealth,andwoundcare.
16 • Johnson&Johnson2020AnnualReport(e) Mr.M.E.SneedjoinedtheCompanyin1983asMarketingAssistantforPersonalProductsCompany,asubsidiaryoftheCompany,
andgainedincreasedresponsibilitiesinexecutivepositionsacrosstheglobalenterprise.In2004,Mr.Sneedwasappointed
CompanyGroupChairman,ConsumerNorthAmerica,followedbyCompanyGroupChairman,VisionCareFranchisein2007.In
2012,hebecametheVicePresident,GlobalCorporateAffairsandChiefCommunicationsOfficer.Mr.Sneedwasappointed
ExecutiveVicePresident,GlobalCorporateAffairsandChiefCommunicationsOfficerinJanuary2018,andbecameamemberofthe
ExecutiveCommitteeinJuly2018,leadingtheCompany’sglobalmarketing,communication,designandphilanthropyfunctions.
(f) Dr.P.StoffelsrejoinedtheCompanyin2002withtheacquisitionofTibotecVircoNV,wherehewasChiefExecutiveOfficerofVirco
NVandChairmanofTibotecNV.In2005,hewasappointedCompanyGroupChairman,GlobalVirology.In2006,heassumedthe
roleofCompanyGroupChairman,Pharmaceuticals.Dr.StoffelswasappointedGlobalHead,Research&Development,
Pharmaceuticalsin2009,andin2011,becameWorldwideChairman,Pharmaceuticals.In2012,Dr.StoffelswasappointedChief
ScientificOfficer,andbecameamemberoftheExecutiveCommittee.In2016,Dr.StoffelswasnamedExecutiveVicePresident,
ChiefScientificOfficer.In2018,Dr.StoffelswaspromotedtoViceChairmanoftheExecutiveCommittee,ChiefScientificOfficer.He
isresponsiblefortheCompany’sinnovationagendaacrossthePharmaceutical,MedicalDevicesandConsumerHealthsectors,
productsafetystrategy,andtheCompany’sglobalpublichealthstrategy.
(g) Ms.J.L.TaubertjoinedtheCompanyin2005asWorldwideVicePresidentatJohnson&JohnsonPharmaceuticalServices,a
subsidiaryoftheCompany.SheheldseveralexecutivepositionsofincreasingresponsibilityinthePharmaceuticalsectoruntil2012
whenshewasappointedCompanyGroupChairman,NorthAmericaPharmaceuticals,andin2015becameCompanyGroup
Chairman,TheAmericas,Pharmaceuticals.InJuly2018,Ms.TaubertwaspromotedtoExecutiveVicePresident,Worldwide
Chairman,Pharmaceuticals,andbecameamemberoftheExecutiveCommittee.Ms.TauberthasresponsibilityfortheImmunology,
InfectiousDiseases,Neuroscience,Oncology,CardiovascularandMetabolism,andPulmonaryHypertensionbusinessesthroughout
Janssen.
(h) Mr.M.H.UllmannjoinedtheCompanyin1989asacorporateattorneyintheLawDepartment.HewasappointedCorporate
Secretaryin1999andservedinthatroleuntil2006.Duringthattime,healsoheldvariousmanagementpositionsintheLaw
Department.In2006,hewasnamedGeneralCounsel,MedicalDevicesandDiagnosticsandwasappointedVicePresident,General
CounselandbecameamemberoftheExecutiveCommitteein2012.InApril2016,Mr.UllmannwasnamedExecutiveVice
President,GeneralCounsel.Mr.Ullmannhasworldwideresponsibilityforlegal,governmentaffairs&policy,globalsecurity,aviation,
healthcarecompliance,globalbrandprotectionandprivacy.
(i) Ms.K.E.WengeljoinedtheCompanyin1988asProjectEngineerandEngineeringSupervisoratJanssen,asubsidiaryofthe
Company.DuringhertenurewiththeCompany,shehasheldavarietyofstrategicleadershipandexecutivepositionsacrossthe
globalenterprise,inroleswithinoperations,quality,engineering,newproducts,informationtechnology,andothertechnicaland
businessfunctions.In2010,Ms.WengelbecamethefirstChiefQualityOfficeroftheCompany.In2014,shewaspromotedtoVice
President,Johnson&JohnsonSupplyChain.InJuly2018,shewaspromotedtoExecutiveVicePresident,ChiefGlobalSupplyChain
Officer,andbecameamemberoftheExecutiveCommittee.
(j) Mr.J.J.WolkjoinedtheCompanyin1998asFinanceManager,BusinessDevelopmentforOrtho-McNeil,asubsidiaryofthe
Company,andthroughtheyearsheldavarietyofseniorleadershiprolesinseveralsegmentsandfunctionsacrosstheCompany’s
subsidiaries,inPharmaceuticals,MedicalDevicesandSupplyChain.From2014to2016,heservedasVicePresident,Financeand
ChiefFinancialOfficeroftheJanssenPharmaceuticalCompaniesofJohnson&Johnson.In2016,Mr.WolkbecametheVice
President,InvestorRelations.InJuly2018,hewasappointedExecutiveVicePresident,ChiefFinancialOfficerandbecameamember
oftheExecutiveCommittee.Mr.WolkplaysastrategicroleintheoverallmanagementoftheCompany,andleadsthedevelopment
andexecutionoftheCompany’sgloballong-termfinancialstrategy.
Johnson&Johnson2020AnnualReport • 17PART II
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES
AsofFebruary16,2021,therewere132,376recordholdersofcommonstockoftheCompany.Additionalinformation
calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisReport:Note16“Common
Stock,StockOptionPlansandStockCompensationAgreements”oftheNotestoConsolidatedFinancialStatements
includedinItem8;andItem12“SecurityOwnershipofCertainBeneficialOwnersandManagementandRelated
StockholderMatters–EquityCompensationPlanInformation.”
Issuer Purchases of Equity Securities
ThefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbytheCompanyduringthefiscalfourth
quarterof2020.Commonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneeds
oftheCompany’scompensationprograms.Therepurchasesbelowalsoincludethestock-for-stockoptionexercisesthat
settledinthefiscalfourthquarter.
TotalNumberof MaximumNumber(or
Shares(orUnits) ApproximateDollar
PurchasedasPart Value)ofShares(orUnits)
TotalNumber ofPublicly thatMayYetBe
ofShares Avg.Price AnnouncedPlans PurchasedUnderthe
FiscalPeriod Purchased(1) PaidPerShare orPrograms PlansorPrograms
September28,2020through
October25,2020 350,000 $145.57 — —
October26,2020through
November22,2020 369,000 148.53 — —
November23,2020throughJanuary3,
2021 1,432,333 150.50 — —
Total 2,151,333
(1) Duringthefiscalfourthquarterof2020,theCompanyrepurchasedanaggregateof2,151,333sharesofJohnson&Johnson
CommonStockinopen-markettransactions,allofwhichwerepurchasedinopen-markettransactionsaspartofasystematicplanto
meettheneedsoftheCompany’scompensationprograms.
Item 6. Reserved
18 • Johnson&Johnson2020AnnualReportItem 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF
OPERATIONS AND FINANCIAL CONDITION
Organization and Business Segments
Description of the Company and Business Segments
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately134,500employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.TheCompany
conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand
well-being.
TheCompanyisorganizedintothreebusinesssegments:ConsumerHealth(previouslyreferredtoasConsumer),
PharmaceuticalandMedicalDevices.TheConsumerHealthsegmentincludesabroadrangeofproductsusedinthebaby
care,oralcare,skinhealth/beauty,over-the-counterpharmaceutical,women’shealthandwoundcaremarkets.These
productsaremarketedtothegeneralpublicandsoldonline(eCommerce)andtoretailoutletsanddistributorsthroughout
theworld.ThePharmaceuticalsegmentisfocusedonsixtherapeuticareas,includingimmunology,infectiousdiseases,
neuroscience,oncology,pulmonaryhypertension,andcardiovascularandmetabolicdiseases.Productsinthissegment
aredistributeddirectlytoretailers,wholesalers,hospitalsandhealthcareprofessionalsforprescriptionuse.TheMedical
Devicessegmentincludesabroadrangeofproductsusedintheorthopaedic,surgery,interventionalsolutions
(cardiovascularandneurovascular)andeyehealthfields.Theseproductsaredistributedtowholesalers,hospitalsand
retailers,andusedprincipallyintheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsandclinics.
TheExecutiveCommitteeofJohnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategic
operationsandallocationoftheresourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesofthe
ConsumerHealth,PharmaceuticalandMedicalDevicesbusinesssegments.
Inallofitsproductlines,theCompanycompeteswithothercompaniesbothlocallyandglobally,throughouttheworld.
Competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.
Competitioninresearch,involvingthedevelopmentandtheimprovementofnewandexistingproductsandprocesses,is
particularlysignificant.Thedevelopmentofnewandinnovativeproducts,aswellasprotectingtheunderlyingintellectual
propertyoftheCompany’sproductportfolio,isimportanttotheCompany’ssuccessinallareasofitsbusiness.The
competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearch.Inaddition,thedevelopmentand
maintenanceofcustomerdemandfortheCompany’sconsumerproductsinvolvessignificantexpendituresforadvertising
andpromotion.
Management’sObjectives
With“OurCredo”asthefoundation,theCompany’spurposeistoblendheart,scienceandingenuitytoprofoundly
changethetrajectoryofhealthforhumanity.TheCompanyiscommittedtobringingitsfullbreadthanddepthtoensure
healthforpeopletodayandforfuturegenerations.Unitedaroundthiscommonambition,theCompanyispoisedtofulfillits
purposeandsuccessfullymeetthedemandsoftherapidlyevolvingmarketsinwhichitcompetes.
TheCompanyisbroadlybasedinhumanhealthcare,andiscommittedtocreatingvaluebydevelopingaccessible,high
quality,innovativeproductsandservices.Newproductsintroducedwithinthepastfiveyearsaccountedforapproximately
25%of2020sales.In2020,$12.2billionwasinvestedinresearchanddevelopmentand$7.3billionspenton
acquisitions,reflectingmanagement’scommitmenttocreatelife-enhancinginnovationsandtocreatevaluethrough
partnershipsthatwillprofoundlychangethetrajectoryofhealthforhumanity.
AcriticaldriveroftheCompany’ssuccessisthe134,500diverseemployeesworldwide.Employeesareempoweredand
inspiredtoleadwiththeCompany’sOurCredoandpurposeasguides.ThisallowseveryemployeetousetheCompany’s
reachandsizetoadvancetheCompany’spurpose,andtoalsoleadwithagilityandurgency.Leveragingtheextensive
resourcesacrosstheenterpriseenablestheCompanytoinnovateandexecutewithexcellence.Thisensuresthe
Companycanremainfocusedonaddressingtheunmetneedsofsocietyeverydayandinvestforanenduringimpact,
ultimatelydeliveringvaluetoitspatients,consumersandhealthcareprofessionals,employees,communitiesand
shareholders.
Johnson&Johnson2020AnnualReport • 1912.2
snoilliB
nI
$
snoilliB
nI
$
sralloD
nI
Research & Acquisi(cid:2)ons (net Dividends Paid
Development of cash acquired) Per Share
11.4 3.98 3.75
7.3
5.8
2020 2019 2020 2019 2020 2019
Results of Operations
AnalysisofConsolidatedSales
Fordiscussiononresultsofoperationsandfinancialconditionpertainingtothefiscalyears2019and2018seethe
Company’sAnnualReportonForm10-KforthefiscalyearendedDecember29,2019,Item7.Management’sDiscussion
andAnalysisofResultsofOperationsandFinancialCondition.
In2020,worldwidesalesincreased0.6%to$82.6billionascomparedtoanincreaseof0.6%in2019.Thesesales
changesconsistedofthefollowing:
Salesincrease/(decrease)dueto: 2020 2019
Volume 3.5% 3.7%
Price (2.3) (0.9)
Currency (0.6) (2.2)
Total 0.6% 0.6%
Thenetimpactofacquisitionsanddivestituresontheworldwidesalesgrowthwasanegativeimpactof0.3%in2020and
anegativeimpactof1.7%in2019.
SalesbyU.S.companieswere$43.1billionin2020and$42.1billionin2019.Thisrepresentsincreasesof2.5%in2020
and0.5%in2019.Salesbyinternationalcompanieswere$39.5billionin2020and$40.0billionin2019.Thisrepresents
adecreaseof1.3%in2020andanincreaseof0.7%in2019.
Thefive-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere3.3%,3.9%and2.8%,
respectively.Theten-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere3.0%,3.9%and
2.1%,respectively.
In2020,salesbycompaniesinEuropeachievedgrowthof2.8%ascomparedtotheprioryear,whichincluded
operationalgrowthof2.0%andapositivecurrencyimpactof0.8%.SalesbycompaniesintheWesternHemisphere
(excludingtheU.S.)experiencedasalesdeclineof10.2%ascomparedtotheprioryear,whichincludedoperational
growthof0.4%offsetbyanegativecurrencyimpactof10.6%.SalesbycompaniesintheAsia-Pacific,Africaregion
experiencedasalesdeclineof2.7%ascomparedtotheprioryear,includinganoperationaldeclineof3.1%partiallyoffset
byapositivecurrencyimpactof0.4%.
The2020resultsbenefitedfromtheinclusionofa53rdweek.(SeeNote1totheConsolidatedFinancialStatementsfor
AnnualClosingDatedetails).TheCompanyestimatedthatthefiscalyear2020salesgrowthratewasenhancedby
approximately1.0%.Whiletheadditionalweekaddedafewdaystosales,italsoaddedafullweek’sworthofoperating
costs;therefore,thenetearningsimpactwasnegligible.
In2020,theCompanyutilizedthreewholesalersdistributingproductsforallthreesegmentsthatrepresented
approximately16.0%,12.0%and12.0%ofthetotalconsolidatedrevenues.In2019,theCompanyhadthreewholesalers
distributingproductsforallthreesegmentsthatrepresentedapproximately15.0%,12.0%and11.0%ofthetotal
consolidatedrevenues.
20 • Johnson&Johnson2020AnnualReport2020 Sales by Geographic Region (in billions) 2020 Sales by Segment (in billions)
$15.1
$23.0
$5.3
$43.1
$45.6
$19.0 $14.1
Europe Western Hemisphere (ex. U.S.) Consumer Health Pharmaceutical
Asia-Pacific, Africa U.S. Medical Devices
Note:valuesmayhavebeenrounded
Analysis of Sales by Business Segments
ConsumerHealthSegment
ConsumerHealthsegmentsalesin2020were$14.1billion,anincreaseof1.1%from2019,whichincluded3.0%
operationalgrowthandanegativecurrencyimpactof1.9%.U.S.ConsumerHealthsegmentsaleswere$6.4billion,an
increaseof9.0%.Internationalsaleswere$7.7billion,adecreaseof4.6%,whichincludedanoperationaldeclineof1.3%
andanegativecurrencyimpactof3.3%.In2020,acquisitionsanddivestitureshadanetnegativeimpactof0.1%onthe
operationalsalesgrowthoftheworldwideConsumerHealthsegment.
MajorConsumerHealthFranchiseSales*:
%Change
(DollarsinMillions) 2020 2019 ’20vs.’19
OTC $4,824 4,444 8.5%
SkinHealth/Beauty** 4,450 4,593 (3.1)
OralCare 1,641 1,528 7.4
BabyCare 1,517 1,675 (9.4)
Women’sHealth 901 986 (8.6)
WoundCare/Other 720 671 7.2
TotalConsumerHealth*Sales $14,053 13,898 1.1%
* PreviouslyreferredtoasConsumer
** PreviouslyreferredtoasBeauty
Johnson&Johnson2020AnnualReport • 21TheOTCfranchisesalesof$4.8billionincreased8.5%ascomparedtotheprioryear.Growthwasprimarilyattributable
tosalesfromTYLENOL®drivenbyCOVID-19stockingdemand,ZYRTEC®duetocompetitorproductoutofstockand
PEPCID®duetocompetitiveproductwithdrawalbothintheU.S.,andincreasedconsumptioninanti-smokingaids.
InternationalsaleswerenegativelyimpactedbyCOVID-19andlowincidenceofcoughandflu.
TheSkinHealth/Beautyfranchisesaleswere$4.5billionin2020,adecreaseof3.1%ascomparedtotheprioryear.The
declinewasprimarilyduetonegativeCOVID-19relatedimpactsandSKUrationalizationpartiallyoffsetbygrowthin
eCommerceandnewproductinnovation.
TheOralCarefranchisesalesof$1.6billionincreased7.4%ascomparedtotheprioryearprimarilyattributabletosalesof
LISTERINE®mouthwashduetoU.S.eCommerceandclubchannelgrowth,increasedstockingdemandrelatedto
COVID-19andnewproductlaunchesinAsiaPacific.
TheBabyCarefranchisesaleswere$1.5billionin2020,adecreaseof9.4%comparedtotheprioryear.Thedeclinewas
primarilyduetoCOVID-19relatedimpacts,SKUrationalizationandtheBabyCenterdivestitureintheU.S.partiallyoffset
bystrengthinAVEENO®baby.
TheWomen’sHealthfranchisesaleswere$0.9billionin2020,adecreaseof8.6%ascomparedtotheprioryear.The
declinewasprimarilydrivenbyCOVID-19impacts.
TheWoundCare/Otherfranchisesaleswere$0.7billionin2020,anincreaseof7.2%ascomparedtotheprioryear.
GrowthwasduetostrongperformanceofNEOSPORIN®andBAND-AID®BrandAdhesiveBandagesandCOVID-19
relateddemandintheAsiaPacificregion.
22 • Johnson&Johnson2020AnnualReportPharmaceutical Segment
Pharmaceuticalsegmentsalesin2020were$45.6billion,anincreaseof8.0%from2019,whichincludedoperational
growthof8.2%andanegativecurrencyimpactof0.2%.U.S.saleswere$25.7billion,anincreaseof7.8%.International
saleswere$19.8billion,anincreaseof8.3%,whichincluded8.8%operationalgrowthandanegativecurrencyimpactof
0.5%.In2020,acquisitionsanddivestitureshadanetnegativeimpactof0.2%ontheoperationalsalesgrowthofthe
worldwidePharmaceuticalsegment.AdjustmentstopreviousreserveestimatespositivelyimpactedthePharmaceutical
segmentoperationalgrowthbyapproximately1.0%inbothfiscalyears2020and2019.
MajorPharmaceutical TherapeuticAreaSales*:
%Change
(DollarsinMillions) 2020 2019 ’20vs.’19
TotalImmunology $15,055 13,950 7.9%
REMICADE® 3,747 4,380 (14.4)
SIMPONI®/SIMPONIARIA® 2,243 2,188 2.6
STELARA® 7,707 6,361 21.1
TREMFYA® 1,347 1,012 33.2
OtherImmunology 11 10 6.4
TotalInfectiousDiseases 3,574 3,413 4.7
EDURANT®/rilpivirine 964 861 11.9
PREZISTA®/PREZCOBIX®/REZOLSTA®/SYMTUZA® 2,184 2,110 3.5
OtherInfectiousDiseases 427 441 (3.2)
TotalNeuroscience 6,548 6,328 3.5
CONCERTA®/methylphenidate 622 696 (10.6)
INVEGASUSTENNA®/XEPLION®/INVEGATRINZA®/TREVICTA® 3,653 3,330 9.7
RISPERDALCONSTA® 642 688 (6.8)
OtherNeuroscience 1,632 1,614 1.1
TotalOncology 12,367 10,692 15.7
DARZALEX® 4,190 2,998 39.8
ERLEADA®(1) 760 332 **
IMBRUVICA® 4,128 3,411 21.0
VELCADE® 408 751 (45.7)
ZYTIGA®/abirateroneacetate 2,470 2,795 (11.6)
OtherOncology 413 407 1.7
TotalPulmonaryHypertension 3,148 2,623 20.0
OPSUMIT® 1,639 1,327 23.5
UPTRAVI® 1,093 819 33.5
OtherPulmonaryHypertension(2) 416 476 (12.8)
TotalCardiovascular/Metabolism/Other 4,878 5,192 (6.0)
XARELTO® 2,345 2,313 1.4
INVOKANA®/INVOKAMET® 795 735 8.2
PROCRIT®/EPREX® 552 790 (30.2)
Other 1,186 1,353 (12.4)
TotalPharmaceuticalSales $45,572 42,198 8.0%
* Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
** Percentagegreaterthan100%ornotmeaningful
Johnson&Johnson2020AnnualReport • 23(1) PreviouslyincludedinOtherOncology
(2) InclusiveofTRACLEER®whichwaspreviouslydisclosedseparately
Immunologyproductssaleswere$15.1billionin2020,representinganincreaseof7.9%ascomparedtotheprioryear
drivenbystronguptakeofSTELARA®(ustekinumab)inCrohn’sdiseaseandUlcerativeColitisandstrengthinTREMFYA®
(guselkumab)inPsoriasis.ThiswaspartiallyoffsetbyCOVID-19relateddemandandlowersalesofREMICADE®
(infliximab)duetoincreaseddiscounts/rebatesandbiosimilarcompetition.
ThepatentsforREMICADE®(infliximab)incertaincountriesinEuropeexpiredinFebruary2015.Biosimilarversionsof
REMICADE®havebeenintroducedincertainmarketsoutsidetheUnitedStates,resultinginareductioninsalesof
REMICADE®inthosemarkets.Additionalbiosimilarcompetitionwilllikelyresultinafurtherreductioninsalesof
REMICADE®inmarketsoutsidetheUnitedStates.IntheUnitedStates,abiosimilarversionofREMICADE®was
introducedin2016,andadditionalcompetitorscontinuetoenterthemarket.Continuedinfliximabbiosimilarcompetitionin
theU.S.marketwillresultinafurtherreductioninU.S.salesofREMICADE®.
Infectiousdiseaseproductssaleswere$3.6billionin2020,representinganincreaseof4.7%ascomparedtotheprior
yearprimarilyduetostrongsalesofSYMTUZA®andJULUCA®.ThiswaspartiallyoffsetbylowersalesofPREZISTA®
andPREZCOBIX®/REZOLSTA®duetoincreasedcompetitionandlossofexclusivityofPREZISTA®incertaincountries
outsidetheU.S.
Neuroscienceproductssaleswere$6.5billion,representinganincreaseof3.5%ascomparedtotheprioryear.
Paliperidonelong-actinginjectablesgrowthdrivenbysalesofINVEGASUSTENNA®/XEPLION®(paliperidonepalmitate)
andINVEGATRINZA®/TREVICTA®fromnewpatientstartsandpersistence.Thegrowthwaspartiallyoffsetbymigration
fromRISPERDALCONSTA®(risperidone)anddeclinesinCONCERTA®(methylphenidate)duetocompetitiveentrants.
Oncologyproductsachievedsalesof$12.4billionin2020,representinganincreaseof15.7%ascomparedtotheprior
year.ContributorstothegrowthwerestrongsalesofDARZALEX®(daratumumab)drivenbypatientuptakeinalllinesof
therapyandthelaunchofasubcutaneousformulationintheU.S.andE.U.;IMBRUVICA®(ibrutinib)duetomarketgrowth
globallyandmaintainingstrongshareandthecontinuedgloballaunchuptakeandsharegainsofERLEADA®
(apalutamide).Additionally,thegrowthwasnegativelyimpactedbydecliningsalesofZYTIGA®(abirateroneacetate)and
VELCADE®(bortezomib)duetogenericcompetition.
PulmonaryHypertensionproductsachievedsalesof$3.1billion,representinganincreaseof20.0%ascomparedtothe
prioryear.SalesgrowthofOPSUMIT®(macitentan)andUPTRAVI®(selexipag)wereduetocontinuedsharegainsand
marketgrowth.Additionally,salesofTRACLEER®(bosentan)werenegativelyimpactedbygenericsandmigrationto
OPSUMIT®.
Cardiovascular/Metabolism/Otherproductssaleswere$4.9billion,adeclineof6.0%ascomparedtotheprioryear.Sales
growthofINVOKANA®/INVOKAMET®(canagliflozin)wereduetomarketgrowthandfavorablechannelmixdynamicsin
theU.S.andstrengthintheEuropeanregionpartiallyoffsetbyU.S.sharedeclinesduetocompetitivepressures.The
growthofXARELTO®(rivaroxaban)wasduetodemandgrowthpartiallyoffsetbyhigherrebates.Lowersalesof
PROCRIT®/EPREX®(epoetinalfa)wereduetobiosimilarcompetition.
24 • Johnson&Johnson2020AnnualReportDuring2020,theCompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand
additionalindicationsforexistingdrugsasfollows:
ProductName(Chemical US EU US EU
Name) Indication Approval Approval Filing Filing
Amivantamab TreatmentofPatientswithMetastaticNon-SmallCellLung
• •
CancerwithEGFRExon20InsertionMutations
DARZALEX®(daratumumab) CombinationRegimenforNewlyDiagnosed,Transplant- •
eligiblePatientswithMultipleMyeloma
DARZALEX®(daratumumab) CombinationwithCarfilzomibandDexamethasoneforpatients
•
withRelapsed/RefractoryMultipleMyeloma
DARZALEX®FASPRO SubcutaneousFormulationofDaratumumabintheTreatment
(daratumumaband ofPatientswithMultipleMyeloma • •
hyaluronidase)
ERLEADA®(apalutamide) TreatmentofMetastaticCastration-SensitiveProstateCancer •
IMBRUVICA®(ibrutinib) IncombinationwithRituximabfortreatmentofChronic •
LymphocyticLeukemia
INVOKANA®(canagliflozin) TreatmentofDiabeticKidneyDisease •
rilpivirineandcabotegravir ForMonthly,Injectable,TwoDrugRegimenforTreatmentof • •
HIV
PaliperidonePamitate6-month TreatmentofSchizophrenia • •
Ponesimod TreatmentofadultswithRelapsedMultipleSclerosis • •
SIMPONIARIA®(golimumab) TreatmentofPolyarticularJuvenileIdiopathicArthritisand
•
JuvenilePsoriaticArthritis
SIRTURO®(bedaquiline) CombinationTherapytoTreatChildrenwithPulmonary • •
Multidrug-ResistantTuberculosis
SPRAVATO®(esketamine) RapidReductionofDepressiveSymptomsinAdultswith
MajorDepressiveDisorderwhohaveActiveSuicidalIdeation •
withIntent
STELARA®(ustekinumab) TreatmentofPediatricPatientswithModeratetoSevere • •
PlaquePsoriasis
TREMFYA®(guselkumab) TreatmentofAdultswithActivePsoriaticArthritis • •
Uptravi®IV Pulmonaryarterialhypertension •
XARELTO®(rivaroxaban) NewIndicationtoExpandUseinPatientswithPeripheral
•
ArteryDisease
ZABDENO(Ad26.ZEBOV)and PreventiveEbolaVaccine •
MVABEA(MVA-BN-Filo)
Johnson&Johnson2020AnnualReport • 25MedicalDevicesSegment
TheMedicalDevicessegmentsalesin2020were$23.0billion,adecreaseof11.6%from2019,whichincludedan
operationaldecreaseof11.4%andanegativecurrencyimpactof0.2%.U.S.saleswere$11.0billion,adecreaseof
10.9%ascomparedtotheprioryear.Internationalsaleswere$11.9billion,adecreaseof12.2%ascomparedtotheprior
year,withanoperationaldecreaseof11.8%andanegativecurrencyimpactof0.4%.In2020,thenetimpactof
acquisitionsanddivestituresontheMedicalDevicessegmentworldwideoperationalsalesgrowthwasanegative0.9%of
which,thedivestitureofAdvancedSterilizationProducts(ASP)hadanimpactofapproximately0.8%.Growthwas
negativelyimpactedbyCOVID-19andassociateddeferralofmedicalprocedures.
MajorMedicalDevicesFranchiseSales*:
%Change
(DollarsinMillions) 2020 2019 ’20vs.’19
Surgery $8,232 9,501 (13.4)%
Advanced 3,839 4,095 (6.2)
General(1) 4,392 5,406 (18.8)
Orthopaedics 7,763 8,839 (12.2)
Hips 1,280 1,438 (11.0)
Knees 1,170 1,480 (21.0)
Trauma 2,614 2,720 (3.9)
Spine,Sports&Other(2) 2,699 3,201 (15.7)
Vision 3,919 4,624 (15.2)
ContactLenses/Other 2,994 3,392 (11.7)
Surgical 925 1,232 (24.9)
InterventionalSolutions 3,046 2,997 1.6
TotalMedicalDevicesSales $22,959 25,963 (11.6)%
* Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
(1) IncludesSpecialtySurgerywhichwaspreviouslydisclosedseparately
(2) PreviouslyreferredtoasSpine&Other
TheSurgeryfranchisesaleswere$8.2billionin2020,adecreaseof13.4%from2019.ThedeclineinAdvancedSurgery
wasprimarilydrivenbythenegativeimpactofCOVID-19andcompetitivepressuresintheU.S.Thiswaspartiallyoffsetby
thesuccessofnewproductsoutsidetheU.S.andtherecoveryofanisolatedsupplydisruptionintheprioryearrelatedto
SURGIFLO®.ThedeclineinGeneralSurgerywasprimarilydrivenbythenegativeimpactofCOVID-19andtheASP
divestiture.
TheOrthopaedicsfranchisesaleswere$7.8billionin2020,adecreaseof12.2%from2019.Thedeclineinhipswas
drivenbythenegativeimpactofCOVID-19partiallyoffsetbyaleadershippositionintheAnteriorapproach,strongmarket
demandfortheACTIS®stemandenablingtechnologies–KINCISE™andVELYS™HipNavigation.Thedeclineinknees
wasdrivenbythenegativeimpactofCOVID-19.ThedeclineinTraumawasdrivenbythenegativeimpactofCOVID-19
partiallyoffsetbystrengthfromnewproducts.ThedeclineinSpine,Sports&Otherwasdrivenbythenegativeimpactof
COVID-19partiallyoffsetbytheuptakeofnewproducts.
TheVisionfranchisesaleswereof$3.9billionin2020,adecreaseof15.2%from2019.TheContactLenses/Other
operationaldeclinewasduetothenegativeimpactofCOVID-19.TheSurgicaloperationaldeclinewasprimarilydrivenby
thenegativeimpactofCOVID-19andcompetitivepressuresintheU.S.
TheInterventionalSolutionsfranchiseachievedsalesof$3.0billionin2020,anincreaseof1.6%from2019.Growthin
theelectrophysiologybusinesswasdrivenbyAtrialFibrillationproceduregrowthcoupledwithstrengthfromnewproducts
andmarketrecoveryoffsettingnegativeimpactsfromCOVID-19.
26 • Johnson&Johnson2020AnnualReportAnalysisofConsolidatedEarningsBeforeProvisionforTaxesonIncome
Consolidatedearningsbeforeprovisionfortaxesonincomewas$16.5billionand$17.3billionfortheyears2020and
2019,respectively.Asapercenttosales,consolidatedearningsbeforeprovisionfortaxesonincomewas20.0%and
21.1%,in2020and2019,respectively.
Earnings Before Provision for Taxes
$17.3
$16.5
21.1%
20.0%
2020 2019
(Dollars in billions. Percentages in chart are as a percent to total sales)
CostofProductsSoldandSelling,MarketingandAdministrativeExpenses:
Cost of Products Sold Selling, Marke(cid:2)ng & Administra(cid:2)ve
$28.4 $27.6 $22.1 $22.2
34.4% 33.6%
26.8% 27.0%
2020 2019 2020 2019
(Dollars in billions. Percentages in chart are as a percent to total sales)
Costofproductssoldincreasedasapercenttosalesdrivenby:
• MedicalDeviceidlecapacitycostsassociatedwithCOVID-19relatedproductionslowdowns
• EstablishmentofobsolescencereservesandfixedcostdeleveragingassociatedwiththeimpactofCOVID-19inthe
MedicalDevicesbusiness
• SupplychaincostsassociatedwiththedevelopmentoftheCOVID-19vaccineinthePharmaceuticalbusiness
Partiallyoffsetby:
• FavorablemixwithinthePharmaceuticalbusiness
• FavorableproductmixwithahigherpercentageofsalescomingfromthePharmaceuticalbusiness
Johnson&Johnson2020AnnualReport • 27Theintangibleassetamortizationexpenseincludedincostofproductssoldwas$4.7billionand$4.5billion,fortheyears
2020and2019,respectively.
Selling,MarketingandAdministrativeExpensesdecreasedasapercenttosalesdrivenby:
• LeveraginginthePharmaceuticalandConsumerHealthbusinesses
• PortfolioandinvestmentoptimizationincludingexecutionoftheongoingSKUrationalizationprogramintheConsumer
Healthbusiness
• FavorablesegmentmixwithahigherpercentageofsalescomingfromthePharmaceuticalbusiness
Partiallyoffsetby:
• ThenegativeimpactonsalesresultingfromCOVID-19intheMedicalDevicesbusiness
ResearchandDevelopmentExpense:
Researchanddevelopmentexpensebysegmentofbusinesswasasfollows:
2020 2019
(DollarsinMillions) Amount %ofSales* Amount %ofSales*
ConsumerHealth $422 3.0% $493 3.5%
Pharmaceutical 9,563 21.0 8,834 20.9
MedicalDevices 2,174 9.5 2,028 7.8
Totalresearchanddevelopmentexpense $12,159 14.7% $11,355 13.8%
Percentincrease/(decrease)overtheprioryear 7.1% 5.4%
* Asapercenttosegmentsales
ResearchanddevelopmentactivitiesrepresentasignificantpartoftheCompany’sbusiness.Theseexpendituresrelateto
theprocessesofdiscovering,testinganddevelopingnewproducts,upfrontpaymentsanddevelopmentalmilestones,
improvingexistingproducts,aswellasensuringproductefficacyandregulatorycompliancepriortolaunch.TheCompany
remainscommittedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovative
products.
ResearchandDevelopmentincreasedasapercenttosalesprimarilydrivenby:
• SegmentmixdrivenbyahigherpercentageofsalesgeneratedbythePharmaceuticalbusinessversustheprioryear
• ThenegativeCOVID-19impactonMedicalDevicessales
• IncreasedinvestmentintheMedicalDevicesbusinessrelatedtoroboticsanddigitalprograms
• PortfolioprogressionincludingtheCOVID-19vaccineinthePharmaceuticalbusiness,netofgovernmental
reimbursements
ResearchfacilitiesarelocatedintheU.S.,Belgium,Brazil,China,France,Germany,India,Israel,theNetherlands,Poland,
Singapore,Sweden,SwitzerlandandtheUnitedKingdomwithadditionalR&Dsupportinover30othercountries.
In-ProcessResearchandDevelopment(IPR&D):Infiscalyear2020,theCompanyrecordedanIPR&Dchargeof
$0.2billionprimarilyrelatedtoapartialimpairmentduetotimingandprogressionofoneofthedigitalsurgeryplatforms
acquiredwiththeAurisHealthacquisition.Inthefiscalyear2019,theCompanyrecordedanIPR&Dchargeof$0.9billion
fortheremainingintangibleassetvaluerelatedtothedevelopmentprogramofAL-8176,aninvestigationaldrugforthe
treatmentofRespiratorySyncytialVirus(RSV)andhumanmetapneumovirus(hMPV)acquiredwiththe2014acquisitionof
AliosBiopharmaInc.Theimpairmentchargewasbasedonadditionalinformation,includingclinicaldata,whichbecame
availableandledtotheCompany’sdecisiontoabandonthedevelopmentofAL-8176.
Other(Income)Expense,Net:Other(income)expense,netistheaccountwheretheCompanyrecordsgainsand
lossesrelatedtothesaleandwrite-downofcertaininvestmentsinequitysecuritiesheldbyJohnson&JohnsonInnovation
—JJDC,Inc.(JJDC),unrealizedgainsandlossesoninvestments,gainsandlossesondivestitures,certaintransactional
currencygainsandlosses,acquisition-relatedcosts,litigationaccrualsandsettlements,aswellasroyaltyincome.
28 • Johnson&Johnson2020AnnualReportOther(income)expense,netforthefiscalyear2020wasunfavorableby$0.4billionascomparedtotheprioryear
primarilyduetothefollowing:
(DollarsinBillions)(Income)/Expense 2020 2019 Change
Litigationexpense(1) $5.1 5.1 —
AcquisitionandIntegrationrelated(2) (1.1) 0.3 (1.4)
Unrealized(gains)/lossesonsecurities (0.5) (0.6) 0.1
Equitystep-upgainrelatedtoDR.CI:LABO 0.0 (0.3) 0.3
DivestitureGains(3) (0.2) (2.2) 2.0
Restructuringrelated 0.1 0.2 (0.1)
Other (0.5) 0.0 (0.5)
TotalOther(Income)Expense,Net $2.9 2.5 0.4
(1) 2020litigationexpenseprimarilyassociatedwithTalcrelatedreservesandcertainsettlements($4.0billion).2019litigationexpense
primarilyrelatedtotheagreementinprincipletosettleopioidlitigation($4.0billion).
(2) 2020isprimarilydrivenbyacontingentconsiderationreversalofapproximately$1.1billionrelatedtothetimingofcertain
developmentalmilestonesassociatedwiththeAurisHealthacquisition.
(3) 2019includedthedivestitureofASP
Interest(Income)Expense:Thefiscalyear2020includednetinterestexpenseof$90millionascomparedtoincomeof
$39millioninthefiscalyear2019.Thiswasprimarilyduetoreducedinterestincomeresultingfromlowerratesofinterest
earnedoncashbalancesandahigheraveragedebtbalance.Thiswaspartiallyoffsetbyaloweraveragedebtinterestrate
andahigheraveragecashbalance.Cash,cashequivalentsandmarketablesecuritiestotaled$25.2billionattheendof
2020,andaveraged$22.2billionascomparedtothecash,cashequivalentsandmarketablesecuritiestotalof
$19.3billionand$19.5billionaveragecashbalancein2019.Thetotaldebtbalanceattheendof2020was$35.3billion
withanaveragedebtbalanceof$31.5billionascomparedto$27.7billionattheendof2019andanaveragedebt
balanceof$29.1billion.Inthefiscalthirdquarterof2020,theCompanyissuedapproximately$5.0billionofcommercial
paper,withapproximately$0.8billionoutstandingatyearend.Inthefiscalthirdquarterof2020,theCompanyissued
seniorunsecurednotesforatotalof$7.5billion.
IncomeBeforeTaxbySegment
Income(loss)beforetaxbysegmentofbusinesswereasfollows:
Percentof
IncomeBeforeTax SegmentSales SegmentSales
(DollarsinMillions) 2020 2019 2020 2019 2020 2019
ConsumerHealth $(1,064) 2,061 14,053 13,898 (7.6)% 14.8
Pharmaceutical 15,462 8,816 45,572 42,198 33.9 20.9
MedicalDevices 3,044 7,286 22,959 25,963 13.3 28.1
Total(1) 17,442 18,163 82,584 82,059 21.1 22.1
Less:Netexpensenotallocatedtosegments(2) 945 835
Earningsbeforeprovisionfortaxesonincome $16,497 17,328 82,584 82,059 20.0% 21.1
(1) SeeNote17totheConsolidatedFinancialStatementsformoredetails.
(2) Amountsnotallocatedtosegmentsincludeinterest(income)expenseandgeneralcorporate(income)expense.
ConsumerHealthSegment:In2020,theConsumerHealthsegmentlossbeforetaxasapercentofsaleswas(7.6)%
versusincomebeforetaxof14.8%in2019.Thedecreaseintheincomebeforetaxasapercentofsaleswasprimarily
drivenbythefollowing:
• Higherlitigationexpenseof$3.9billionin2020vs.$0.4billionin2019(primarilyassociatedwithtalcrelatedreserves
andcertainsettlements)
Johnson&Johnson2020AnnualReport • 29• Thefiscalyear2019includedagainof$0.3billionrelatedtotheCompany’spreviouslyheldequityinvestmentinDR.
CI:LABO
Partiallyoffsetby:
• PortfolioandinvestmentoptimizationincludingexecutionoftheongoingSKUrationalizationprogram
PharmaceuticalSegment:In2020,thePharmaceuticalsegmentincomebeforetaxasapercenttosaleswas33.9%
versus20.9%in2019.Theincreaseintheincomebeforetaxasapercentofsaleswasprimarilydrivenbythefollowing:
• Lowerlitigationexpenseof$0.8billionin2020vs.$4.3billionin2019(primarilyrelatedtotheagreementinprincipleto
settleopioidlitigation,ofwhich$1.0billionisin2020and$4.0billionisin2019)
• Anin-processresearchanddevelopmentchargeof$0.9billioninfiscal2019relatedtoAlios
• Loweracquisitionandintegrationrelatedcostsinfiscal2020
• Leveraginginselling,marketingandadministrativeexpense
MedicalDevicesSegment:In2020,theMedicalDevicessegmentincomebeforetaxasapercenttosaleswas13.3%
versus28.1%in2019.Thedecreaseintheincomebeforetaxasapercenttosaleswasprimarilydrivenbythefollowing:
• Againof$2.0billionrelatedtotheASPdivestiturerecordedinthefiscal2019
• IdlecapacitycostsassociatedwithCOVID-19relatedproductionslowdownsinfiscal2020
• EstablishmentofobsolescencereservesandfixedcostdeleveragingassociatedwiththeimpactofCOVID-19infiscal
2020
• ThenegativeimpactofCOVID-19onsalesinfiscal2020
• Anin-processresearchanddevelopmentchargeof$0.2billioninfiscal2020primarilyrelatedtotheAurisHealth
acquisition
Partiallyoffsetby:
• Acontingentconsiderationreversalofapproximately$1.1billioninfiscal2020relatedtothetimingofcertain
developmentalmilestonesassociatedwiththeAurisHealthacquisition
• Litigationexpensewas$0.3billionin2020vs.$0.4billionin2019
Restructuring:Inthefiscalsecondquarterof2018,theCompanyannouncedplanstoimplementactionsacrossits
globalsupplychainthatareintendedtoenabletheCompanytofocusresourcesandincreaseinvestmentsincritical
capabilities,technologiesandsolutionsnecessarytomanufactureandsupplyitsproductportfolioofthefuture,enhance
agilityanddrivegrowth.TheCompanyexpectsthesesupplychainactionswillincludeexpandingitsuseofstrategic
collaborations,andbolsteringitsinitiativestoreducecomplexity,improvingcost-competitiveness,enhancingcapabilities
andoptimizingitsnetwork.Discussionsregardingspecificfutureactionsareongoingandaresubjecttoallrelevant
consultationrequirementsbeforetheyarefinalized.Intotal,theCompanyexpectstheseactionstogenerateapproximately
$0.6to$0.8billioninannualpre-taxcostsavingsthatwillbesubstantiallydeliveredby2022.TheCompanyexpectsto
recordpre-taxrestructuringchargesofapproximately$1.9to$2.3billion.TheCompanyestimatesthatapproximately
70%ofthecumulativepre-taxcostswillresultincashoutlays.In2020,theCompanyrecordedapre-taxchargeof
$0.4billion,whichisincludedonthefollowinglinesoftheConsolidatedStatementofEarnings,$0.2billionin
restructuring,$0.1billioninother(income)expenseand$0.1billionincostofproductssold.Totalprojectcostsof
approximately$1.3billionhavebeenrecordedsincetherestructuringwasannounced.
SeeNote20totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtotherestructuringprograms.
ProvisionforTaxesonIncome:Theworldwideeffectiveincometaxratewas10.8%in2020and12.7%in2019.
Duringthefiscalfirstquarterof2021,theInternalRevenueServicepublishedfinalregulationsaddressingthe
requirementsfortaxdeductibilityofsettlementpayments.TheCompanyrecordedapre-taxreservefor$4.0billioninthe
fiscalyear2019basedontheagreementinprincipletosettleopioidlitigationandrecordedanadditionalpre-tax
$1.0billioninthefiscalthirdquarterof2020uponwhichaneffectiverateof21.4%hasbeenapplied.
Fordiscussionrelatedtothefiscal2020provisionfortaxesrefertoNote8totheConsolidatedFinancialStatements.
30 • Johnson&Johnson2020AnnualReportLiquidity and Capital Resources
Liquidity&CashFlows
Cashandcashequivalentswere$14.0billionattheendof2020ascomparedto$17.3billionattheendof2019.
Theprimarysourcesandusesofcashthatcontributedtothe$3.3billiondecreasewere:
(DollarsInBillions)
$17.3 Q42019Cashandcashequivalentsbalance
23.5 cashgeneratedfromoperatingactivities
(20.8) netcashusedbyinvestingactivities
(6.1) netcashusedbyfinancingactivities
0.1 effectofexchangerateandrounding
$14.0 Q42020Cashandcashequivalentsbalance
Inaddition,theCompanyhad$11.2billioninmarketablesecuritiesattheendoffiscalyear2020and$2.0billionatthe
endoffiscalyear2019.SeeNote1totheConsolidatedFinancialStatementsforadditionaldetailsoncash,cash
equivalentsandmarketablesecurities.
Cashflowfromoperationsof$23.5billionwastheresultof:
(DollarsInBillions)
$14.7 NetEarnings
non-cashexpensesandotheradjustmentsprimarilyfordepreciationandamortization,stock-based
compensation,assetwrite-downsandcreditlossesandaccountsreceivableallowancespartiallyoffsetbythe
7.3 deferredtaxprovisionandnetgainonsaleofassets/businesses
0.8 decreaseinaccountsreceivable
5.9 anincreaseinaccountspayableandaccruedliabilitiesandothercurrentandnon-currentliabilities
(4.0) anincreaseininventoriesandothercurrentandnon-currentassets
contingentconsiderationreversal(relatedtothetimingofcertaindevelopmentalmilestonesassociatedwiththe
(1.2) AurisHealthacquisition)androunding
$23.5 CashFlowfromoperations
Investingactivitiesuseof$20.8billionofcashwasprimarilyusedfor:
(DollarsInBillions)
primarilyrelatedtotheacquisitionsofMomenta,bermekimabandrelatedassetsfromXBiotechInc.aswellasthe
$(7.3) acquisitionofalloutstandingsharesinVerbSurgicalInc.
(3.3) additionstoproperty,plantandequipment
(9.0) netpurchasesofinvestments
(1.0) Creditsupportagreementsactivity,net
0.3 proceedsfromthedisposalofassets/businesses,net
(0.5) other(primarilylicensesandmilestones)
$(20.8) Netcashusedforinvestingactivities
Financingactivitiesuseof$6.1billionofcashwasprimarilyusedfor:
(DollarsInBillions)
$(10.5) dividendstoshareholders
(3.2) repurchaseofcommonstock
7.1 netproceedsfromshortandlongtermdebt
1.1 proceedsfromstockoptionsexercised/employeewithholdingtaxonstockawards,net
(0.3) Creditsupportagreementsactivity,net
(0.3) other
$(6.1) Netcashusedforfinancingactivities
AsofJanuary3,2021,theCompany’snotespayableandlong-termdebtwasinexcessofcash,cashequivalentsand
marketablesecurities.AsofJanuary3,2021,thenetdebtpositionwas$10.1billionascomparedtotheprioryearof
$8.4billion.Therewasanincreaseinthenetdebtpositionduetoincreasedborrowingsinthefiscalthirdquarterof2020.
Johnson&Johnson2020AnnualReport • 31Thedebtbalanceattheendof2020was$35.3billionascomparedto$27.7billionin2019.Consideringrecentmarket
conditionsandtheon-goingCOVID-19crisis,theCompanyhasevaluateditsoperatingcashflowsandliquidityprofile
anddoesnotforeseeanysignificantincrementalrisk.TheCompanyanticipatesthatoperatingcashflows,theabilityto
raisefundsfromexternalsources,borrowingcapacityfromexistingcommittedcreditfacilitiesandaccesstothe
commercialpapermarketswillcontinuetoprovidesufficientresourcestofundoperatingneeds,includingthetalclitigation
andagreementinprincipletosettleopioidlitigationofwhichthemajoritymaybepaidoverthenexttwotothreeyears.In
addition,theCompanymonitorstheglobalcapitalmarketsonanongoingbasisandfromtimetotimemayraisecapital
whenmarketconditionsarefavorable.Inthefiscalthirdquarterof2020,theCompanyissuedapproximately$5.0billionof
commercialpaper,withapproximately$0.8billionoutstandingatyearend.Inthefiscalthirdquarterof2020,theCompany
issuedseniorunsecurednotesforatotalof$7.5billion.Foradditionaldetailsonborrowings,seeNote7tothe
ConsolidatedFinancialStatements.ThenetproceedsfromthisofferingwereusedtofundtheMomentaPharmaceuticals,
Inc.acquisitionwhichclosedonOctober1,2020andforgeneralcorporatepurposes.Additionally,asaresultoftheTax
CutsandJobsAct(TCJA),theCompanyhasaccesstoitscashoutsidetheU.S.atasignificantlyreducedcost.
ThefollowingtablesummarizestheCompany’smaterialcontractualobligationsandtheiraggregatematuritiesasof
January3,2021:Tosatisfytheseobligations,theCompanyintendstousecashfromoperations.
Tax Intereston
Legislation Debt Debt
(DollarsinMillions) (TCJA) Obligations Obligations Total
2021 $812 1,799 949 3,560
2022 812 2,226 908 3,946
2023 1,522 1,552 880 3,954
2024 2,029 1,598 842 4,469
2025 2,536 1,744 789 5,069
After2025 — 25,515 9,503 35,018
Total $7,711 34,434 13,871 56,016
Fortaxmatters,seeNote8totheConsolidatedFinancialStatements.Thetabledoesnotincludeactivityrelatedto
businesscombinationsortheCompany’sapproximate$0.9billionincontractualsupplycommitmentsassociatedwithits
developmentofaCOVID-19vaccine.
FinancingandMarketRisk
TheCompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows.
Accordingly,theCompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency
assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcosts.Gainsorlosses
onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactions.A10%appreciationoftheU.S.Dollar
fromtheJanuary3,2021marketrateswouldincreasetheunrealizedvalueoftheCompany’sforwardcontractsby
$121million.Conversely,a10%depreciationoftheU.S.DollarfromtheJanuary3,2021marketrateswoulddecrease
theunrealizedvalueoftheCompany’sforwardcontractsby$148million.Ineitherscenario,thegainorlossontheforward
contractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhavenoimpactonfuture
anticipatedearningsandcashflows.
TheCompanyhedgestheexposuretofluctuationsincurrencyexchangerates,andtheeffectoncertainassetsand
liabilitiesinforeigncurrency,byenteringintocurrencyswapcontracts.A1%changeinthespreadbetweenU.S.and
foreigninterestratesontheCompany’sinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe
unrealizedvalueoftheCompany’sswapcontractsbyapproximately$1,667million.Ineitherscenario,atmaturity,thegain
orlossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhave
noimpactonfutureanticipatedcashflows.
TheCompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposes.Further,theCompanyhasa
policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditrating.Thecounterpartiesto
thesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone
counterparty.Managementbelievestheriskoflossisremote.TheCompanyenteredintocreditsupportagreements
(CSA)withcertainderivativecounterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsand
nettingagreements.SeeNote6totheConsolidatedFinancialStatementsforadditionaldetailsoncreditsupport
agreements.
TheCompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate
risk.Thefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrates,whilefloating
32 • Johnson&Johnson2020AnnualReportratesecuritiesmayproducelessincomethanpredictedifinterestratesfall.A1%(100basispoints)changeinspreadon
theCompany’sinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash
equivalentsandcurrentmarketablesecuritiesbyapproximately$36million.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2020,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember9,2021.Interestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids
providedbybanks,LondonInterbankOfferedRates(LIBOR),SecuredOvernightFinancingRate(SOFR)SwapCurveor
otherapplicablemarketrateasallowedplusapplicablemargins.Commitmentfeesundertheagreementarenotmaterial.
Totalborrowingsattheendof2020and2019were$35.3billionand$27.7billion,respectively.Theincreasein
borrowingswastheissuanceofnotesin2020whenmarketconditionswerefavorable.In2020,netdebt(cashand
currentmarketablesecurities,netofdebt)was$10.1billioncomparedtonetdebtof$8.4billionin2019.Totaldebt
represented35.8%oftotalcapital(shareholders’equityandtotaldebt)in2020and31.8%oftotalcapitalin2019.
Shareholders’equitypershareattheendof2020was$24.04comparedto$22.59atyear-end2019.
AsummaryofborrowingscanbefoundinNote7totheConsolidatedFinancialStatements.
Dividends
TheCompanyincreaseditsdividendin2020forthe58thconsecutiveyear.Cashdividendspaidwere$3.98persharein
2020and$3.75persharein2019.
OnJanuary4,2021,theBoardofDirectorsdeclaredaregularcashdividendof$1.01pershare,payableonMarch9,
2021toshareholdersofrecordasofFebruary23,2021.
Other Information
CriticalAccountingPoliciesandEstimates
Management’sdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedontheCompany’s
consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin
theU.S.(GAAP).Thepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand
assumptionsthataffecttheamountsreportedforrevenues,expenses,assets,liabilitiesandotherrelateddisclosures.
Actualresultsmayormaynotdifferfromtheseestimates.TheCompanybelievesthattheunderstandingofcertainkey
accountingpoliciesandestimatesareessentialinachievingmoreinsightintotheCompany’soperatingresultsand
financialcondition.Thesekeyaccountingpoliciesincluderevenuerecognition,incometaxes,legalandself-insurance
contingencies,valuationoflong-livedassets,assumptionsusedtodeterminetheamountsrecordedforpensionsandother
employeebenefitplansandaccountingforstockbasedawards.
TheextenttowhichCOVID-19impactstheCompany’sbusinessandfinancialresultswilldependonnumerousevolving
factorsincluding,butnotlimitedto,themagnitudeanddurationofCOVID-19,theextenttowhichitwillimpactworldwide
macroeconomicconditionsincludinginterestrates,employmentratesandhealthinsurancecoverage,thespeedofthe
anticipatedrecovery,andgovernmentalandbusinessreactionstothepandemic.TheCompanyassessedcertain
accountingmattersthatgenerallyrequireconsiderationofforecastedfinancialinformationincontextwiththeinformation
reasonablyavailabletotheCompanyandtheunknownfutureimpactsofCOVID-19asofJanuary3,2021andthroughthe
dateofthisreport.Theaccountingmattersassessedincluded,butwerenotlimitedto,theCompany’sallowancefor
doubtfulaccountsandcreditlosses,inventoryandrelatedreserves,accruedrebatesandassociatedreserves,andthe
carryingvalueofthegoodwillandotherlong-livedassets.WhiletherewasnotamaterialimpacttotheCompany’s
consolidatedfinancialstatementsasofandfortheyearendedJanuary3,2021,theCompany’sfutureassessmentofthe
magnitudeanddurationofCOVID-19,aswellasotherfactors,couldresultinmaterialimpactstotheCompany’s
consolidatedfinancialstatementsinfuturereportingperiods.
RevenueRecognition:TheCompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofa
contractwiththecustomeraresatisfied;generally,thisoccurswiththetransferofcontrolofthegoodstocustomers.The
Company’sglobalpaymenttermsaretypicallybetween30to90days.Provisionsforcertainrebates,salesincentives,
tradepromotions,coupons,productreturnsanddiscountstocustomersareaccountedforasvariableconsiderationand
recordedasareductioninsales.
Johnson&Johnson2020AnnualReport • 33Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingconsiderationofcompetitorpricing.Rebatesareestimatedbasedoncontractual
terms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarketconditionsinthevariousmarkets
served.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof
wholesalerandotherthird-partysell-throughandmarketresearchdata,aswellasinternallygeneratedinformation.
Salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibitunusual
salesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas
partoftheaccountingforsalesreturnaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket
asapercenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescredit
tocustomersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewiththe
U.S.GAAPguidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsales
value.SalesreturnsintheConsumerHealthandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Sales
returnsforcertainfranchisesintheMedicalDevicessegmentaretypicallyresalablebutarenotmaterial.TheCompany
infrequentlyexchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhas
beenapproximately1.0%ofannualnettradesalesduringthefiscalyears2020and2019.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
sameperiodasrelatedsales.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentive
programs.Theredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.
Volume-basedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas
productsaresold.Thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas
areductionofrevenue.TheCompanyalsoearnsprofit-sharepaymentsthroughcollaborativearrangementsofcertain
products,whichareincludedinsalestocustomers.Forallyearspresented,profit-sharepaymentswerelessthan3.0%of
thetotalrevenuesandareincludedinsalestocustomers.
Inaddition,theCompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities.
Amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered,
basedontherelativesellingprice.Upfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover
theperformanceperiod.SeeNote1totheConsolidatedFinancialStatementsforadditionaldisclosuresoncollaborations.
Reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebates,returnsandpromotionsarenot
anticipatedtohaveamaterialeffectonthefinancialstatements.TheCompanycurrentlydisclosestheimpactofchanges
toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact.
Belowaretablesthatshowtheprogressionofaccruedrebates,returns,promotions,reservefordoubtfulaccountsand
reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedJanuary3,2021andDecember29,2019.
34 • Johnson&Johnson2020AnnualReportConsumerHealthSegment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits Period
2020
Accruedrebates(1) $284 793 (788) 289
Accruedreturns 63 138 (125) 76
Accruedpromotions 487 1,988 (2,047) 428
Subtotal $834 2,919 (2,960) 793
Reservefordoubtfulaccounts 35 7 (3) 39
Reserveforcashdiscounts 17 201 (206) 12
Total $886 3,127 (3,169) 844
2019
Accruedrebates(1) $271 841 (828) 284
Accruedreturns 57 128 (122) 63
Accruedpromotions 497 2,119 (2,129) 487
Subtotal $825 3,088 (3,079) 834
Reservefordoubtfulaccounts 32 21 (18) 35
Reserveforcashdiscounts 23 198 (204) 17
Total $880 3,307 (3,301) 886
(1) Includesreserveforcustomerrebatesof$66millionatJanuary3,2021and$54millionatDecember29,2019,recordedasacontra
asset.
Pharmaceutical Segment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits(2) Period
2020
Accruedrebates(1) $9,013 32,415 (31,591) 9,837
Accruedreturns 500 233 (273) 460
Accruedpromotions 5 10 (9) 6
Subtotal $9,518 32,658 (31,873) 10,303
Reservefordoubtfulaccounts 36 24 (8) 52
Reserveforcashdiscounts 65 1,034 (1,029) 70
Total $9,619 33,716 (32,910) 10,425
2019
Accruedrebates(1) $7,510 26,868 (25,365) 9,013
Accruedreturns 436 354 (290) 500
Accruedpromotions 13 17 (25) 5
Subtotal $7,959 27,239 (25,680) 9,518
Reservefordoubtfulaccounts 47 2 (13) 36
Reserveforcashdiscounts 53 936 (924) 65
Total $8,059 28,177 (26,617) 9,619
(1) Includesreserveforcustomerrebatesof$174millionatJanuary3,2021and$93millionatDecember29,2019,recordedasa
contraasset.
(2) Includesadjustments
Johnson&Johnson2020AnnualReport • 35MedicalDevicesSegment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits Period
2020
Accruedrebates(1) $1,013 5,144 (4,983) 1,174
Accruedreturns 118 578 (558) 138
Accruedpromotions 46 118 (112) 52
Subtotal $1,177 5,840 (5,653) 1,364
Reservefordoubtfulaccounts 155 95 (48) 202
Reserveforcashdiscounts 10 88 (89) 9
Total $1,342 6,023 (5,790) 1,575
2019
Accruedrebates(1) $1,218 5,487 (5,692) 1,013
Accruedreturns 114 673 (669) 118
Accruedpromotions 42 106 (102) 46
Subtotal $1,374 6,266 (6,463) 1,177
Reservefordoubtfulaccounts 169 30 (44) 155
Reserveforcashdiscounts — 106 (96) 10
Total $1,543 6,402 (6,603) 1,342
(1) Includesreserveforcustomerrebatesof$707millionatJanuary3,2021and$499millionatDecember29,2019,recordedasa
contraasset.
IncomeTaxes:Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe
resultsofanydifferencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.
TheCompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesin
taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAP,which
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
TheCompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortoDecember31,2017fromits
internationalsubsidiaries.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto
January1,2018fromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvested.The
Companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperations.IftheCompanydecidesata
laterdatetorepatriatetheseearningstotheU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectson
theseamounts.TheCompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximately$0.7billion
undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates.
Duringthefiscalfirstquarterof2021,theInternalRevenueServicepublishedfinalregulationsaddressingthe
requirementsfortaxdeductibilityofsettlementpayments.TheCompanyrecordedapre-taxreservefor$4.0billioninfiscal
2019basedontheagreementinprincipletosettleopioidlitigationandrecordedanadditionalpre-tax$1.0billioninthe
fiscalthirdquarterof2020uponwhichaneffectiverateof21.4%hasbeenapplied.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
LegalandSelfInsuranceContingencies:TheCompanyrecordsaccrualsforvariouscontingencies,includinglegal
proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusiness.Theaccrualsarebasedon
management’sjudgmentastotheprobabilityoflossesand,whereapplicable,actuariallydeterminedestimates.The
Companyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.Inadditiontoaccrualsintheself
insuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe
reasonablyestimated.
36 • Johnson&Johnson2020AnnualReportTheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.
SeeNotes1and19totheConsolidatedFinancialStatementsforfurtherinformationregardingproductliabilityandlegal
proceedings.
Long-LivedandIntangibleAssets:TheCompanyassesseschanges,bothqualitativelyandquantitatively,ineconomic
conditionsandmakesassumptionsregardingestimatedfuturecashflowsinevaluatingthevalueoftheCompany’s
property,plantandequipment,goodwillandintangibleassets.Astheseassumptionsandestimatesmaychangeovertime,
itmayormaynotbenecessaryfortheCompanytorecordimpairmentcharges.
EmployeeBenefitPlans:TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,
definedcontributionandterminationindemnityplans,whichcovermostemployeesworldwide.Theseplansarebasedon
assumptionsforthediscountrate,expectedreturnonplanassets,mortalityrates,expectedsalaryincreases,healthcare
costtrendratesandattritionrates.SeeNote10totheConsolidatedFinancialStatementsforfurtherdetailsonthese
rates.
StockBasedCompensation:TheCompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity
instrumentstoemployeesfortheirservices.Basedonthetypeofequityinstrument,thefairvalueisestimatedonthedate
ofgrantusingeithertheBlack-ScholesoptionvaluationmodeloracombinationofboththeBlack-Scholesoption
valuationmodelandMonteCarlovaluationmodel,andisexpensedinthefinancialstatementsovertheserviceperiod.The
inputassumptionsusedindeterminingfairvaluearetheexpectedlife,expectedvolatility,risk-freerateandexpected
dividendyield.Priortofiscal2020,forperformanceshareunits,thefairmarketvaluewascalculatedforeachofthethree
componentgoalsatthedateofgrant:operationalsales,adjustedoperationalearningspershareandrelativetotal
shareholderreturn.Beginninginfiscal2020,forperformanceshareunits,thefairmarketvalueiscalculatedforthetwo
componentgoalsatthedateofgrant:adjustedoperationalearningspershareandrelativetotalshareholderreturn.Thefair
valuesfortheearningspersharegoalofeachperformanceshareunitwasestimatedonthedateofgrantusingthefair
marketvalueofthesharesatthetimeoftheaward,discountedfordividends,whicharenotpaidontheperformanceshare
unitsduringthevestingperiod.Thefairvaluefortherelativetotalshareholderreturngoalofeachperformanceshareunit
wasestimatedonthedateofgrantusingtheMonteCarlovaluationmodel.SeeNote16totheConsolidatedFinancial
Statementsforadditionalinformation.
NewAccountingPronouncements
RefertoNote1totheConsolidatedFinancialStatementsforrecentlyadoptedaccountingpronouncementsandrecently
issuedaccountingpronouncementsnotyetadoptedasofJanuary3,2021.
EconomicandMarketFactors
COVID-19considerationsandbusinesscontinuity
TheCompanyhasconsideredvariousinternalandexternalfactorsinassessingthepotentialimpactofCOVID-19onits
businessandfinancialresultsbaseduponinformationavailableatthistime,asfollows:
• OperatingModel:TheCompanyhasadiversifiedbusinessmodelacrossthehealthcareindustrywithflexibilitydesigned
intoitsmanufacturing,researchanddevelopmentclinicaloperationsandcommercialcapabilities.
• SupplyChain:TheCompanycontinuestoleverageitsglobalmanufacturingfootprintanddual-sourcecapabilitieswhile
closelymonitoringandmaintainingcriticalinventoryatmajordistributioncentersawayfromhigh-riskareastoensure
adequateandeffectivedistribution.
• BusinessContinuity:Therobust,activebusinesscontinuityplansacrosstheCompany’snetworkhavebeeninstrumental
inpreparingtheCompanyforeventslikeCOVID-19andtheabilitytomeetthemajorityofpatientandconsumerneeds
remainsuninterrupted.
• Workforce:TheCompanyhasputproceduresinplacetoprotectitsessentialworkforceinmanufacturing,distribution,
commercialandresearchoperationswhileensuringappropriateremoteworkingprotocolshavebeenestablishedfor
otheremployees.
• Liquidity:TheCompany’shigh-qualitycreditratingallowstheCompanysuperioraccesstothefinancialcapitalmarkets
fortheforeseeablefuture.Inthefiscalthirdquarterof2020,theCompanyissuedapproximately$5.0billionof
commercialpaper,withapproximately$0.8billionoutstandingatyearend,foradditionalliquidity.Additionally,inthe
fiscalthirdquarterof2020,theCompanyissuedseniorunsecurednotesforatotalof$7.5billion.Thenetproceeds
fromthisofferingwereusedtofundtheMomentaPharmaceuticals,Inc.acquisitiononOctober1,2020andforgeneral
corporatepurposes.
Johnson&Johnson2020AnnualReport • 37• DomesticandForeignLegislation:TheCompanywillcontinuetoassessandevaluatetheon-goinggloballegislative
effortstocombattheCOVID-19impactoneconomiesandthesectorsinwhichitparticipates.Currently,therecent
legislativeactsputinplacearenotexpectedtohaveamaterialimpactontheCompany’soperations.
Infiscal2020,theCompanyenteredintoaseriesofcontractmanufacturingarrangementsforvaccineproductionwith
thirdpartycontractmanufacturingorganizations.ThesearrangementsprovidetheCompanywithfuturesupplemental
commercialcapacityforvaccineproductionandpotentiallytransferablerightstosuchproductionifcapacityisnot
required.Amountspaidandcontractuallyobligatedtobepaidtothesecontractmanufacturingorganizationsof
approximately$0.9billionarereflectedintheprepaidexpensesandother,otherassets,accruedliabilitiesandother
liabilitiesaccountsintheCompany’sconsolidatedbalancesheetuponexecutionofeachagreement.Additionally,the
Companyhasenteredintocertainvaccinedevelopmentcostsharingarrangementswithgovernmentrelatedorganizations.
TheCompanyisawarethatitsproductsareusedinanenvironmentwhere,formorethanadecade,policymakers,
consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcare.Inresponsetotheseconcerns,
theCompanyhasalong-standingpolicyofpricingproductsresponsibly.Fortheperiod2010-2020,intheU.S.,the
weightedaveragecompoundannualgrowthrateoftheCompany’snetpriceincreasesforhealthcareproducts
(prescriptionandover-the-counterdrugs,hospitalandprofessionalproducts)wasbelowtheU.S.ConsumerPriceIndex
(CPI).
TheCompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallenges.The
Companycontinuestomonitorthesesituationsandtakeappropriateactions.Inflationratescontinuetohaveaneffecton
worldwideeconomiesand,consequently,onthewaycompaniesoperate.TheCompanyhasaccountedforoperationsin
Argentina(beginninginthefiscalthirdquarterof2018)andVenezuelaashighlyinflationary,asthepriorthree-year
cumulativeinflationratesurpassed100%.ThisdidnothaveamaterialimpacttotheCompany’sresultsintheperiod.In
thefaceofincreasingcosts,theCompanystrivestomaintainitsprofitmarginsthroughcostreductionprograms,
productivityimprovementsandperiodicpriceincreases.
InJune2016,theUnitedKingdom(U.K.)heldareferenduminwhichvotersapprovedanexitfromtheEuropeanUnion
(E.U.),commonlyreferredtoas“Brexit”.TheU.K.officiallyexitedtheE.U.onJanuary31,2020,however,therewasa
transitionperiodtoallowtimetoagreethetermsofanewtradedeal.OnDecember30,2020,theU.K.,E.U.andthe
EuropeanAtomicEnergyCommunity(Euratom)signedtheEU–UKTradeandCooperationAgreement(TCA).Overthe
lastfewyears,Brexithascreatedglobalpoliticalandeconomicuncertaintyandhasledtovolatilityinexchangeratesand
interestrates,additionalcostcontainmentbythird-partypayorsandchangesinregulations.WhiletheUKandEUhave
nowagreedonafuturetradeandcooperationagreement,itisstillunclearwhattheultimatefinancial,trade,regulatoryand
legalimplicationsthewithdrawaloftheU.K.fromtheE.U.willhave.However,theCompanycurrentlydoesnotbelievethat
theseandotherrelatedeffectswillhaveamaterialimpactontheCompany’sconsolidatedfinancialpositionoroperating
results.AsofJanuary3,2021,thebusinessoftheCompany’sU.K.subsidiariesrepresentedlessthan6%ofthe
Company’sconsolidatedassetsandlessthan3%oftheCompany’sfiscaltwelvemonthsrevenues.
TheCompanyisexposedtofluctuationsincurrencyexchangerates.A1%changeinthevalueoftheU.S.Dollaras
comparedtoallforeigncurrenciesinwhichtheCompanyhadsales,incomeorexpensein2020wouldhaveincreasedor
decreasedthetranslationofforeignsalesbyapproximately$384millionandnetincomebyapproximately$115million.
Governmentsaroundtheworldconsidervariousproposalstomakechangestotaxlaws,whichmayincludeincreasingor
decreasingexistingstatutorytaxrates.Achangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthe
Company’sdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawis
enacted.ThischangewouldresultinanexpenseorbenefitrecordedtotheCompany’sConsolidatedStatementof
Earnings.TheCompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperates.Changestothe
statutorytaxratemayoccuratanytime,andanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarter
andyearinwhichthelawchangeisenacted.
TheCompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude
healthcarecostcontainmentandgovernmentlegislationrelatingtosales,promotionsandreimbursementofhealthcare
products.
Changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservices,includingdelaying
medicalprocedures,rationingprescriptionmedications,reducingthefrequencyofphysicianvisitsandforegoinghealth
careinsurancecoverage,asaresultofthecurrentglobaleconomicdownturn,maycontinuetoimpacttheCompany’s
businesses.
38 • Johnson&Johnson2020AnnualReportTheCompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrights.Firmshavefiled
AbbreviatedNewDrugApplicationsorBiosimilarBiologicalProductApplicationswiththeFDAorotherwisechallenged
thecoverageand/orvalidityoftheCompany’spatents,seekingtomarketgenericorbiosimilarformsofmanyofthe
Company’skeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproducts.Intheevent
theCompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuits,genericorbiosimilar
versionsoftheproductsatissuewillbeintroducedtothemarket,resultinginthepotentialforsubstantialmarketshareand
revenuelossesforthoseproducts,andwhichmayresultinanon-cashimpairmentchargeinanyassociatedintangible
asset.Thereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionoftheproductatissue
followingregulatoryapprovaleventhoughoneormorevalidpatentsareinplace.
LegalProceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercialandothermatters;governmentalinvestigations;andotherlegalproceedingsthatarise
fromtimetotimeintheordinarycourseofbusiness.
TheCompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata
liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimated.AsofJanuary3,2021,theCompanyhas
determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimated.The
Companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight
bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithASC450-20-25.Fortheseand
otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossible,theCompany
isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccrued.Amountsaccruedforlegal
contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon
estimatesandassumptionsincludingtimingofrelatedpayments.Theabilitytomakesuchestimatesandjudgmentscanbe
affectedbyvariousfactorsincluding,amongotherthings,whetherdamagessoughtintheproceedingsare
unsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnotcommencedorisnotcomplete;proceedingsarein
earlystages;matterspresentlegaluncertainties;therearesignificantfactsindispute;proceduralorjurisdictionalissues;
theuncertaintyandunpredictabilityofthenumberofpotentialclaims;abilitytoachievecomprehensivemulti-party
settlements;complexityofrelatedcross-claimsandcounterclaims;and/ortherearenumerouspartiesinvolved.Tothe
extentadverseverdictshavebeenrenderedagainsttheCompany,theCompanydoesnotrecordanaccrualuntilalossis
determinedtobeprobableandcanbereasonablyestimated.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutionof,orincreaseinaccrualsfor,
oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
SeeNote19totheConsolidatedFinancialStatementsforfurtherinformationregardinglegalproceedings.
CommonStock
TheCompany’sCommonStockislistedontheNewYorkStockExchangeunderthesymbolJNJ.AsofFebruary16,
2021,therewere132,376recordholdersofCommonStockoftheCompany.
Johnson&Johnson2020AnnualReport • 39Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK
Theinformationcalledforbythisitemisincorporatedhereinbyreferenceto“Item7.Management’sDiscussionand
AnalysisofResultsofOperationsandFinancialCondition-LiquidityandCapitalResources—FinancingandMarketRisk”
ofthisReport;andNote1“SummaryofSignificantAccountingPolicies-FinancialInstruments”oftheNotesto
ConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
IndextoAuditedConsolidatedFinancialStatements
41 ConsolidatedBalanceSheets
42 ConsolidatedStatementsofEarnings
43 ConsolidatedStatementsofComprehensiveIncome
44 ConsolidatedStatementsofEquity
45 ConsolidatedStatementsofCashFlows
46 NotestoConsolidatedFinancialStatements
103 ReportofIndependentRegisteredPublicAccountingFirm
107 Management’sReportonInternalControlOverFinancialReporting
40 • Johnson&Johnson2020AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AtJanuary3,2021andDecember29,2019
(DollarsinMillionsExceptShareandPerShareAmounts)(Note1)
2020 2019
Assets
Currentassets
Cashandcashequivalents(Notes1and2) $13,985 17,305
Marketablesecurities(Notes1and2) 11,200 1,982
Accountsreceivabletrade,lessallowancesfordoubtfulaccounts$293(2019,$226) 13,576 14,481
Inventories(Notes1and3) 9,344 9,020
Prepaidexpensesandotherreceivables 3,132 2,392
Assetsheldforsale(Note18) — 94
Totalcurrentassets 51,237 45,274
Property,plantandequipment,net(Notes1and4) 18,766 17,658
Intangibleassets,net(Notes1and5) 53,402 47,643
Goodwill(Notes1and5) 36,393 33,639
Deferredtaxesonincome(Note8) 8,534 7,819
Otherassets 6,562 5,695
Totalassets $174,894 157,728
LiabilitiesandShareholders’Equity
Currentliabilities
Loansandnotespayable(Note7) $2,631 1,202
Accountspayable 9,505 8,544
Accruedliabilities 13,968 9,715
Accruedrebates,returnsandpromotions 11,513 10,883
Accruedcompensationandemployeerelatedobligations 3,484 3,354
Accruedtaxesonincome(Note8) 1,392 2,266
Totalcurrentliabilities 42,493 35,964
Long-termdebt(Note7) 32,635 26,494
Deferredtaxesonincome(Note8) 7,214 5,958
Employeerelatedobligations(Notes9and10) 10,771 10,663
Long-termtaxespayable(Note1) 6,559 7,444
Otherliabilities 11,944 11,734
Totalliabilities 111,616 98,257
CommitmentsandContingencies(Note19)
Shareholders’equity
Preferredstock—withoutparvalue(authorizedandunissued2,000,000shares) — —
Commonstock—parvalue$1.00pershare(Note12)(authorized4,320,000,000shares;issued
3,119,843,000shares) 3,120 3,120
Accumulatedothercomprehensiveincome(loss)(Note13) (15,242) (15,891)
Retainedearnings 113,890 110,659
101,768 97,888
Less:commonstockheldintreasury,atcost(Note12)(487,331,000sharesand487,336,000shares) 38,490 38,417
Totalshareholders’equity 63,278 59,471
Totalliabilitiesandshareholders’equity $174,894 157,728
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2020AnnualReport • 41JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(DollarsandSharesinMillionsExceptPerShareAmounts)(Note1)
2020 2019 2018
Salestocustomers $82,584 82,059 81,581
Costofproductssold 28,427 27,556 27,091
Grossprofit 54,157 54,503 54,490
Selling,marketingandadministrativeexpenses 22,084 22,178 22,540
Researchanddevelopmentexpense 12,159 11,355 10,775
In-processresearchanddevelopment(Note5) 181 890 1,126
Interestincome (111) (357) (611)
Interestexpense,netofportioncapitalized(Note4) 201 318 1,005
Other(income)expense,net 2,899 2,525 1,405
Restructuring(Note20) 247 266 251
Earningsbeforeprovisionfortaxesonincome 16,497 17,328 17,999
Provisionfortaxesonincome(Note8) 1,783 2,209 2,702
Netearnings $14,714 15,119 15,297
Netearningspershare(Notes1and15)
Basic $5.59 5.72 5.70
Diluted $5.51 5.63 5.61
Averagesharesoutstanding(Notes1and15)
Basic 2,632.8 2,645.1 2,681.5
Diluted 2,670.7 2,684.3 2,728.7
SeeNotestoConsolidatedFinancialStatements
42 • Johnson&Johnson2020AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(DollarsinMillions)(Note1)
2020 2019 2018
Netearnings $14,714 15,119 15,297
Othercomprehensiveincome(loss),netoftax
Foreigncurrencytranslation (233) 164 (1,518)
Securities:
Unrealizedholdinggain(loss)arisingduringperiod 1 — (1)
Reclassificationstoearnings — — 1
Netchange 1 — —
Employeebenefitplans:
Priorservicecredit(cost),netofamortization 1,298 (18) (44)
Gain(loss),netofamortization (1,135) (714) (56)
Effectofexchangerates (229) (1) 92
Netchange (66) (733) (8)
Derivatives&hedges:
Unrealizedgain(loss)arisingduringperiod 1,000 (107) (73)
Reclassificationstoearnings (53) 7 (192)
Netchange 947 (100) (265)
Othercomprehensiveincome(loss) 649 (669) (1,791)
Comprehensiveincome $15,363 14,450 13,506
Thetaxeffectsinothercomprehensiveincomeforthefiscalyears2020,2019and2018respectively:ForeignCurrency
Translation;$536million,$19millionand$236million;EmployeeBenefitPlans:$21million,$222millionand$4million,
Derivatives&Hedges:$252million,$27millionand$70million.
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2020AnnualReport • 43JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(DollarsinMillions)(Note1)
Accumulated Common
Other Stock Treasury
Retained Comprehensive Issued Stock
Total Earnings Income(Loss) Amount Amount
Balance,December31,2017 $60,160 101,793 (13,199) 3,120 (31,554)
Cumulativeadjustment(1) (486) (254) (232)
Netearnings 15,297 15,297
Cashdividendspaid($3.54pershare) (9,494) (9,494)
Employeecompensationandstockoptionplans 1,949 (1,111) 3,060
Repurchaseofcommonstock (5,868) (5,868)
Other (15) (15)
Othercomprehensiveincome(loss),netoftax (1,791) (1,791)
Balance,December30,2018 59,752 106,216 (15,222) 3,120 (34,362)
Netearnings 15,119 15,119
Cashdividendspaid($3.75pershare) (9,917) (9,917)
Employeecompensationandstockoptionplans 1,933 (758) 2,691
Repurchaseofcommonstock (6,746) (6,746)
Other (1) (1)
Othercomprehensiveincome(loss),netoftax (669) (669)
Balance,December29,2019 59,471 110,659 (15,891) 3,120 (38,417)
Netearnings 14,714 14,714
Cashdividendspaid($3.98pershare) (10,481) (10,481)
Employeecompensationandstockoptionplans 2,217 (931) 3,148
Repurchaseofcommonstock (3,221) (3,221)
Other (71) (71)
Othercomprehensiveincome(loss),netoftax 649 649
Balance,January3,2021 $63,278 113,890 (15,242) 3,120 (38,490)
(1) SeeNote1toConsolidatedFinancialStatementsforadditionaldetailsontheeffectofcumulativeadjustmentstoretainedearnings.
SeeNotestoConsolidatedFinancialStatements
44 • Johnson&Johnson2020AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(DollarsinMillions)(Note1)
2020 2019 2018
Cashflowsfromoperatingactivities
Netearnings $14,714 15,119 15,297
Adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities:
Depreciationandamortizationofpropertyandintangibles 7,231 7,009 6,929
Stockbasedcompensation 1,005 977 978
Assetwrite-downs 233 1,096 1,258
Contingentconsiderationreversal (1,148) — —
Netgainonsaleofassets/businesses (111) (2,154) (1,217)
Deferredtaxprovision (1,141) (2,476) (1,016)
Creditlossesandaccountsreceivableallowances 63 (20) (31)
Changesinassetsandliabilities,netofeffectsfromacquisitionsanddivestitures:
Decrease/(Increase)inaccountsreceivable 774 (289) (1,185)
Increaseininventories (265) (277) (644)
Increaseinaccountspayableandaccruedliabilities 5,141 4,060 3,951
Increaseinothercurrentandnon-currentassets (3,704) (1,054) (275)
Increase/(Decrease)inothercurrentandnon-currentliabilities 744 1,425 (1,844)
Netcashflowsfromoperatingactivities 23,536 23,416 22,201
Cashflowsfrominvestingactivities
Additionstoproperty,plantandequipment (3,347) (3,498) (3,670)
Proceedsfromthedisposalofassets/businesses,net 305 3,265 3,203
Acquisitions,netofcashacquired(Note18) (7,323) (5,810) (899)
Purchasesofinvestments (21,089) (3,920) (5,626)
Salesofinvestments 12,137 3,387 4,289
Creditsupportagreementsactivity,net (987) 338 —
Other(primarilylicensesandmilestones) (521) 44 (464)
Netcashusedbyinvestingactivities (20,825) (6,194) (3,167)
Cashflowsfromfinancingactivities
Dividendstoshareholders (10,481) (9,917) (9,494)
Repurchaseofcommonstock (3,221) (6,746) (5,868)
Proceedsfromshort-termdebt 3,391 39 80
Repaymentofshort-termdebt (2,663) (100) (2,479)
Proceedsfromlong-termdebt,netofissuancecosts 7,431 3 5
Repaymentoflong-termdebt (1,064) (2,823) (1,555)
Proceedsfromtheexerciseofstockoptions/employeewithholdingtaxonstockawards,net 1,114 954 949
Creditsupportagreementsactivity,net (333) 100 25
Other (294) 475 (173)
Netcashusedbyfinancingactivities (6,120) (18,015) (18,510)
Effectofexchangeratechangesoncashandcashequivalents 89 (9) (241)
(Decrease)/Increaseincashandcashequivalents (3,320) (802) 283
Cashandcashequivalents,beginningofyear(Note1) 17,305 18,107 17,824
Cashandcashequivalents,endofyear(Note1) $13,985 17,305 18,107
Supplementalcashflowdata
Cashpaidduringtheyearfor:
Interest $904 995 1,049
Interest,netofamountcapitalized 841 925 963
Incometaxes 4,619 4,191 4,570
Supplementalscheduleofnon-cashinvestingandfinancingactivities
Treasurystockissuedforemployeecompensationandstockoptionplans,netofcashproceeds/employee
withholdingtaxonstockawards $1,937 1,736 2,095
Conversionofdebt 27 1 6
Acquisitions
Fairvalueofassetsacquired $7,755 7,228 1,047
Fairvalueofliabilitiesassumedandnoncontrollinginterests (432) (1,418) (148)
Netcashpaidforacquisitions(Note18) $7,323 5,810 899
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2020AnnualReport • 45NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies
PrinciplesofConsolidation
TheconsolidatedfinancialstatementsincludetheaccountsofJohnson&Johnsonanditssubsidiaries(theCompany).
Intercompanyaccountsandtransactionsareeliminated.Columnsandrowswithintablesmaynotaddduetorounding.
Percentageshavebeencalculatedusingactual,non-roundedfigures.
DescriptionoftheCompanyandBusinessSegments
TheCompanyhasapproximately134,500employeesworldwideengagedintheresearchanddevelopment,manufacture
andsaleofabroadrangeofproductsinthehealthcarefield.TheCompanyconductsbusinessinvirtuallyallcountriesof
theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwell-being.
TheCompanyisorganizedintothreebusinesssegments:ConsumerHealth(previouslyreferredtoasConsumer),
PharmaceuticalandMedicalDevices.TheConsumerHealthsegmentincludesabroadrangeofproductsusedinthebaby
care,oralcare,skinhealth/beauty,over-the-counterpharmaceutical,women’shealthandwoundcaremarkets.These
productsaremarketedtothegeneralpublicandsoldonline(eCommerce)andtoretailoutletsanddistributorsthroughout
theworld.ThePharmaceuticalsegmentisfocusedonsixtherapeuticareas,includingimmunology,infectiousdiseases,
neuroscience,oncology,pulmonaryhypertension,andcardiovascularandmetabolicdiseases.Productsinthissegment
aredistributeddirectlytoretailers,wholesalers,hospitalsandhealthcareprofessionalsforprescriptionuse.TheMedical
Devicessegmentincludesabroadrangeofproductsusedintheorthopaedic,surgery,interventionalsolutions
(cardiovascularandneurovascular)andeyehealthfields,whicharedistributedtowholesalers,hospitalsandretailers,and
usedprincipallyintheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsandclinics.
NewAccountingStandards
RecentlyAdoptedAccountingStandards
ASU2018-18:CollaborativeArrangements
TheCompanyadoptedthisstandardasofthebeginningofthefiscalyear2020.Thisupdateclarifiestheinteraction
betweenASC808,CollaborativeArrangementsandASC606,RevenuefromContractswithCustomers.Theupdate
clarifiesthatcertaintransactionsbetweenparticipantsinacollaborativearrangementshouldbeaccountedforunderASC
606whenthecounterpartyisacustomer.Inaddition,theupdateprecludesanentityfrompresentingconsiderationfroma
transactioninacollaborativearrangementasrevenueifthecounterpartyisnotacustomerforthattransaction.The
adoptionofthisstandarddidnothaveamaterialimpactontheCompany’sconsolidatedfinancialstatements.
ASU2016-13:FinancialInstruments—CreditLosses
TheCompanyadoptedthisstandardasofthebeginningofthefiscalyear2020.Thisupdateintroducesthecurrent
expectedcreditloss(CECL)model,whichrequiresanentitytomeasurecreditlossesforcertainfinancialinstrumentsand
financialassets,includingtradereceivables.Underthisupdate,oninitialrecognitionandateachreportingperiod,anentity
isrequiredtorecognizeanallowancethatreflectstheentity’scurrentestimateofcreditlossesexpectedtobeincurred
overthelifeofthefinancialinstrument.TheadoptionofthisstandarddidnothaveamaterialimpactontheCompany’s
consolidatedfinancialstatements.
ASU2018-14:Compensation—DefinedBenefitPlans
TheCompanyadoptedthisstandardinthefiscalyearended2020.Thisstandardrevisedthefinancialstatementnote
disclosurerequirementsofASC715-20fordefinedbenefitplansponsors.Theadoptionofthisstandardhadnoimpact
ontheCompany’sconsolidatedfinancialstatements.SeeNote10totheConsolidatedFinancialStatementsfordefined
benefitplandisclosures.
46 • Johnson&Johnson2020AnnualReportAccountingStandardsadoptedinthefiscal2018withacumulativeeffecttothe2018opening
balanceofRetainedEarnings
Thefollowingtablesummarizesthecumulativeeffectadjustmentsmadetothe2018openingbalanceofretainedearnings
uponadoptionoftheseaccountingstandardsin2018:
CumulativeEffect
AdjustmentIncrease
(Decrease)to
(DollarsinMillions) RetainedEarnings
ASU2014-09—RevenuefromContractswithCustomers $(47)
ASU2016-01—FinancialInstruments 232
ASU2016-16—IncomeTaxes:Intra-EntityTransfers (439)
Total $(254)
RecentlyIssuedAccountingStandards
NotAdoptedasofJanuary3,2021
TheCompanyassessestheadoptionimpactsofrecentlyissuedaccountingstandardsbytheFinancialAccounting
StandardsBoardontheCompany’sfinancialstatementsaswellasmaterialupdatestopreviousassessments,ifany,from
theCompany’sAnnualReportonForm10-KforthefiscalyearendedDecember29,2019.Therewerenonewmaterial
accountingstandardsissuedinfiscal2020thatimpactedtheCompany.
CashEquivalents
TheCompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase
ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof
purchaseascurrentmarketablesecurities.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercial
institutionsthathaveatleastaninvestmentgradecreditrating.TheCompanyinvestsitscashprimarilyingovernment
securitiesandobligations,corporatedebtsecurities,moneymarketfundsandreverserepurchaseagreements(RRAs).
RRAsarecollateralizedbydepositsintheformofGovernmentSecuritiesandObligationsforanamountnotlessthan
102%oftheirvalue.TheCompanydoesnotrecordanassetorliabilityastheCompanyisnotpermittedtosellor
repledgetheassociatedcollateral.TheCompanyhasapolicythatthecollateralhasatleastanA(orequivalent)credit
rating.TheCompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis
maintainedat102%ofthevalueoftheRRAsonadailybasis.RRAswithstatedmaturitiesofgreaterthanthreemonths
fromthedateofpurchaseareclassifiedasmarketablesecurities.
Investments
Investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare
reportedinearnings.Investmentsclassifiedasavailable-for-saledebtsecuritiesarecarriedatestimatedfairvaluewith
unrealizedgainsandlossesrecordedasacomponentofaccumulatedothercomprehensiveincome.Available-for-sale
securitiesavailableforcurrentoperationsareclassifiedascurrentassetsotherwise,theyareclassifiedaslongterm.
Managementdeterminestheappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeof
purchaseandre-evaluatessuchdeterminationateachbalancesheetdate.TheCompanyreviewsitsinvestmentsfor
impairmentandadjuststheseinvestmentstofairvaluethroughearnings,asrequired.
Property,PlantandEquipmentandDepreciation
Property,plantandequipmentarestatedatcost.TheCompanyutilizesthestraight-linemethodofdepreciationoverthe
estimatedusefullivesoftheassets:
Buildingandbuildingequipment 20-30years
Landandleaseholdimprovements 10-20years
Machineryandequipment 2-13years
Johnson&Johnson2020AnnualReport • 47TheCompanycapitalizescertaincomputersoftwareanddevelopmentcosts,includedinmachineryandequipment,when
incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternaluse.Capitalizedsoftwarecostsare
amortizedovertheestimatedusefullivesofthesoftware,whichgenerallyrangefrom3to8years.
TheCompanyreviewslong-livedassetstoassessrecoverabilityusingundiscountedcashflows.Whencertaineventsor
changesinoperatingoreconomicconditionsoccur,animpairmentassessmentmaybeperformedontherecoverabilityof
thecarryingvalueoftheseassets.Iftheassetisdeterminedtobeimpaired,thelossismeasuredbasedonthedifference
betweentheasset’sfairvalueanditscarryingvalue.Ifquotedmarketpricesarenotavailable,theCompanywillestimate
fairvalueusingadiscountedvalueofestimatedfuturecashflows.
Revenue Recognition
TheCompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofacontractwiththecustomer
aresatisfied;generally,thisoccurswiththetransferofcontrolofthegoodstocustomers.TheCompany’sglobalpayment
termsaretypicallybetween30to90days.Provisionsforcertainrebates,salesincentives,tradepromotions,coupons,
productreturnsanddiscountstocustomersareaccountedforasvariableconsiderationandrecordedasareductionin
sales.TheliabilityisrecognizedwithinAccruedRebates,Returns,andPromotionsontheconsolidatedbalancesheet.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingconsiderationofcompetitorpricing.Rebatesareestimatedbasedoncontractual
terms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarketconditionsinthevariousmarkets
served.AsignificantportionoftheliabilityrelatedtorebatesisfromthesaleoftheCompany’spharmaceuticalproducts
withintheU.S.,primarilytheManagedCare,MedicareandMedicaidprograms,whichamountedto$7.2billionand
$7.0billionasofJanuary3,2021andDecember29,2019,respectively.TheCompanyevaluatesmarketconditionsfor
productsorgroupsofproductsprimarilythroughtheanalysisofwholesalerandotherthird-partysell-throughandmarket
researchdata,aswellasinternallygeneratedinformation.
Salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibitunusual
salesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas
partoftheaccountingforsalesreturnaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket
asapercenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescredit
tocustomersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewiththe
U.S.GAAPguidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsales
value.SalesreturnsintheConsumerHealthandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Sales
returnsforcertainfranchisesintheMedicalDevicessegmentaretypicallyresalablebutarenotmaterial.TheCompany
infrequentlyexchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhas
beenapproximately1.0%ofannualnettradesalesduringeachofthefiscalyears2020,2019and2018.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
sameperiodasrelatedsales.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentive
programs.Theredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.
Volume-basedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas
productsaresold.Thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas
areductionofrevenue.TheCompanyalsoearnsprofit-sharepaymentsthroughcollaborativearrangementsforcertain
products,whichareincludedinsalestocustomers.Forallyearspresented,profit-sharepaymentswerelessthan3.0%of
thetotalrevenuesandareincludedinsalestocustomers.
SeeNote17totheConsolidatedFinancialStatementsforfurtherdisaggregationofrevenue.
ShippingandHandling
Shippingandhandlingcostsincurredwere$1.0billion,$1.0billionand$1.1billioninfiscalyears2020,2019and2018,
respectively,andareincludedinselling,marketingandadministrativeexpense.Theamountofrevenuereceivedfor
shippingandhandlingislessthan0.5%ofsalestocustomersforallperiodspresented.
48 • Johnson&Johnson2020AnnualReportInventories
Inventoriesarestatedatthelowerofcostornetrealizablevaluedeterminedbythefirst-in,first-outmethod.
IntangibleAssetsandGoodwill
TheauthoritativeliteratureonU.S.GAAPrequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed
annuallyforimpairment.TheCompanycompleteditsannualimpairmenttestfor2020inthefiscalfourthquarter.Future
impairmenttestswillbeperformedannuallyinthefiscalfourthquarter,orsoonerifwarranted.Purchasedin-process
researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted,
atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleasset,orabandoned,atwhichpoint
theintangibleassetwillbewrittenofforpartiallyimpaired.
Intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullives,andarereviewedfor
impairmentwhenwarrantedbyeconomicconditions.SeeNote5forfurtherdetailsonIntangibleAssetsandGoodwill.
FinancialInstruments
AsrequiredbyU.S.GAAP,allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Fairvalueistheexit
pricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-basedmeasurement
determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.Theauthoritativeliterature
establishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue,withLevel1havingthehighest
priorityandLevel3havingthelowest.Changesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings
orothercomprehensiveincome,dependingonwhetherthederivativeisdesignatedaspartofahedgetransaction,andif
so,thetypeofhedgetransaction.
TheCompanydocumentsallrelationshipsbetweenhedgeditemsandderivatives.Theoverallriskmanagementstrategy
includesreasonsforundertakinghedgetransactionsandenteringintoderivatives.Theobjectivesofthisstrategyare:
(1)minimizeforeigncurrencyexposure’simpactontheCompany’sfinancialperformance;(2)protecttheCompany’scash
flowfromadversemovementsinforeignexchangerates;(3)ensuretheappropriatenessoffinancialinstruments;and
(4)managetheenterpriseriskassociatedwithfinancialinstitutions.SeeNote6foradditionalinformationonFinancial
Instruments.
Leases
TheCompanydetermineswhetheranarrangementisaleaseatcontractinceptionbyestablishingifthecontractconveys
therighttocontroltheuseofidentifiedproperty,plant,orequipmentforaperiodoftimeinexchangeforconsideration.
RightofUse(ROU)AssetsandLeaseLiabilitiesforoperatingleasesareincludedinOtherassets,Accruedliabilities,and
Otherliabilitiesontheconsolidatedbalancesheet.TheROUAssetsrepresenttherighttouseanunderlyingassetforthe
leasetermandleaseliabilitiesrepresentanobligationtomakeleasepaymentsarisingfromthelease.Commitmentsunder
financeleasesarenotsignificant,andareincludedinProperty,plantandequipment,Loansandnotespayable,andLong-
termdebtontheconsolidatedbalancesheet.
ROUAssetsandLeaseLiabilitiesarerecognizedattheleasecommencementdatebasedonthepresentvalueofall
minimumleasepaymentsovertheleaseterm.TheCompanyusesitsincrementalborrowingratebasedontheinformation
availableatcommencementdateindeterminingthepresentvalueofleasepayments,whentheimplicitrateisnotreadily
determinable.Leasetermsmayincludeoptionstoextendorterminatethelease.Theseoptionsareincludedinthelease
termwhenitisreasonablycertainthattheCompanywillexercisethatoption.Operatingleaseexpenseisrecognizedona
straight-linebasisovertheleaseterm.TheCompanyhaselectedthefollowingpolicyelectionsonadoption:useof
portfolioapproachonleasesofassetsundermasterserviceagreements,exclusionofshorttermleasesonthebalance
sheet,andnotseparatingleaseandnon-leasecomponents.
TheCompanyprimarilyhasoperatingleaseforspace,vehicles,manufacturingequipmentanddataprocessingequipment.
TheROUassetpertainingtooperatingleaseswas$1.0billionand$1.0billionin2020and2019,respectively.Thelease
liabilitywas$1.1billionand$1.0billionin2020and2019,respectively.Theoperatingleasecostswere$0.3billion,
$0.3billionand$0.3billionin2020,2019and2018,respectively.Cashpaidforamountsincludedinthemeasurementof
leaseliabilitieswere$0.3billionand$0.3billionin2020and2019,respectively.
ProductLiability
Accrualsforproductliabilityclaimsarerecorded,onanundiscountedbasis,whenitisprobablethataliabilityhasbeen
incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially
Johnson&Johnson2020AnnualReport • 49determinedestimateswhereapplicable.Theaccrualsareadjustedperiodicallyasadditionalinformationbecomes
available.TheCompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecosts
areprobableandcanbereasonablyestimated.TotheextentadverseverdictshavebeenrenderedagainsttheCompany,
theCompanydoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated.
TheCompanyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.Inadditiontoaccrualsintheself
insuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe
reasonablyestimated.
ResearchandDevelopment
ResearchanddevelopmentexpensesareexpensedasincurredinaccordancewithASC730,Researchand
Development.Upfrontandmilestonepaymentsmadetothirdpartiesinconnectionwithresearchanddevelopment
collaborationsareexpensedasincurreduptothepointofregulatoryapproval.Paymentsmadetothirdpartiessubsequent
toregulatoryapprovalarecapitalizedandamortizedovertheremainingusefullifeoftherelatedproduct.Amounts
capitalizedforsuchpaymentsareincludedinotherintangibles,netofaccumulatedamortization.
TheCompanyentersintocollaborativearrangements,typicallywithotherpharmaceuticalorbiotechnologycompanies,to
developandcommercializedrugcandidatesorintellectualproperty.Thesearrangementstypicallyinvolvetwo(ormore)
partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe
commercialsuccessoftheactivities.Thesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties,
includingresearchanddevelopment,marketingandsellinganddistribution.Often,thesecollaborationsrequireupfront,
milestoneandroyaltyorprofitsharepayments,contingentupontheoccurrenceofcertainfutureeventslinkedtothe
successoftheassetindevelopment.
Amountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesaregenerallyreflectedasareductionof
researchanddevelopmentexpensebecausetheperformanceofcontractdevelopmentservicesisnotcentraltothe
Company’soperations.Ingeneral,theincomestatementpresentationforthesecollaborationsisasfollows:
Nature/TypeofCollaboration StatementofEarningsPresentation
Third-partysaleofproduct&profitsharepaymentsreceived Salestocustomers
Royalties/milestonespaidtocollaborativepartner(post- Costofproductssold
regulatoryapproval)*
Royaltiesreceivedfromcollaborativepartner Otherincome(expense),net
Upfrontpayments&milestonespaidtocollaborativepartner Researchanddevelopmentexpense
(pre-regulatoryapproval)
Researchanddevelopmentpaymentstocollaborative Researchanddevelopmentexpense
partner
Researchanddevelopmentpaymentsreceivedfrom ReductionofResearchanddevelopmentexpense
collaborativepartnerorgovernmententity
* Milestonesarecapitalizedasintangibleassetsandamortizedtocostofproductssoldovertheusefullife.
Forallyearspresented,therewasnoindividualprojectthatrepresentedgreaterthan5%ofthetotalannualconsolidated
researchanddevelopmentexpense.
TheCompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding
XARELTO®,co-developedwithBayerHealthCareAGandIMBRUVICA®,developedincollaborationandco-marketed
withPharmacyclicsLLC,anAbbViecompany.
Separately,theCompanyhasanumberoflicensingarrangementsforproductsandcompoundsincludingDARZALEX®,
licensedfromGenmabA/S.
Advertising
Costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinselling,marketingand
administrativeexpenses.Advertisingexpensesworldwide,whichcomprisedtelevision,radio,printmediaandInternet
advertising,were$2.1billion,$2.2billionand$2.6billioninfiscalyears2020,2019and2018,respectively.
50 • Johnson&Johnson2020AnnualReportIncomeTaxes
Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany
differencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.TheCompany
estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesintaxlawsand
ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAPwhich
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
In2017,theUnitedStatesenactedintolawnewU.S.taxlegislation,theU.S.TaxCutsandJobsAct(TCJA).Thislaw
includedprovisionsforacomprehensiveoverhaulofthecorporateincometaxcode,includingareductionofthestatutory
corporatetaxratefrom35%to21%,effectiveonJanuary1,2018.TheTCJAincludedaprovisionforataxonall
previouslyundistributedearningsofU.S.companieslocatedinforeignjurisdictions.Undistributedearningsintheformof
cashandcashequivalentsweretaxedatarateof15.5%andallotherearningsweretaxedatarateof8.0%.Thistaxis
payableover8yearsandwillnotaccrueinterest.Thesepaymentsbeganin2018andwillcontinuethrough2025.The
remainingbalanceattheendofthe2020wasapproximately$7.7billion,ofwhich$6.9billionisclassifiedasnoncurrent
andreflectedas“Long-termtaxespayable”ontheCompany’sbalancesheet.Thebalanceofthisaccountisrelatedto
receivablesfromtaxauthoritiesnotexpectedtobereceivedinthenext12months.
TheTCJAalsoincludesprovisionsforataxonglobalintangiblelow-taxedincome(GILTI).GILTIisdescribedasthe
excessofaU.S.shareholder’stotalnetforeignincomeoveradeemedreturnontangibleassets,asprovidedbytheTCJA.
InJanuary2018,theFASBissuedguidancethatallowscompaniestoelectasanaccountingpolicywhethertorecordthe
taxeffectsofGILTIintheperiodthetaxliabilityisgenerated(i.e.,“periodcost”)orprovidefordeferredtaxassetsand
liabilitiesrelatedtobasisdifferencesthatexistandareexpectedtoeffecttheamountofGILTIinclusioninfutureyears
uponreversal(i.e.,“deferredmethod”).In2018,theCompanyelectedtoaccountforGILTIunderthedeferredmethod.
Thedeferredtaxamountsrecordedarebasedontheevaluationoftemporarydifferencesthatareexpectedtoreverseas
GILTIisincurredinfutureperiods.
TheCompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortoDecember31,2017fromits
internationalsubsidiaries.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto
January1,2018fromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvested.The
Companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperations.IftheCompanydecidesata
laterdatetorepatriatetheseearningstotheU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectson
theseamounts.TheCompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximately$0.7billion
undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
NetEarningsPerShare
Basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage
numberofcommonsharesoutstandingfortheperiod.Dilutedearningspersharereflectsthepotentialdilutionthatcould
occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod.
UseofEstimates
Thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe
U.S.requiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreported.Estimatesareusedwhen
accountingforsalesdiscounts,rebates,allowancesandincentives,productliabilities,incometaxes,withholdingtaxes,
depreciation,amortization,employeebenefits,contingenciesandintangibleassetandliabilityvaluations.Actualresults
mayormaynotdifferfromthoseestimates.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
TheextenttowhichCOVID-19impactstheCompany’sbusinessandfinancialresultswilldependonnumerousevolving
factorsincluding,butnotlimitedto:themagnitudeanddurationofCOVID-19,theextenttowhichitwillimpactworldwide
Johnson&Johnson2020AnnualReport • 51macroeconomicconditionsincludinginterestrates,employmentratesandhealthinsurancecoverage,thespeedofthe
anticipatedrecovery,andgovernmentalandbusinessreactionstothepandemic.TheCompanyassessedcertain
accountingmattersthatgenerallyrequireconsiderationofforecastedfinancialinformationincontextwiththeinformation
reasonablyavailabletotheCompanyandtheunknownfutureimpactsofCOVID-19asofJanuary3,2021andthroughthe
dateofthisreport.Theaccountingmattersassessedincluded,butwerenotlimitedto,theCompany’sallowancefor
doubtfulaccountsandcreditlosses,inventoryandrelatedreserves,accruedrebatesandassociatedreserves,andthe
carryingvalueofthegoodwillandotherlong-livedassets.WhiletherewasnotamaterialimpacttotheCompany’s
consolidatedfinancialstatementsasofandforthefiscalyearendedJanuary3,2021,theCompany’sfutureassessmentof
themagnitudeanddurationofCOVID-19,aswellasotherfactors,couldresultinmaterialimpactstotheCompany’s
consolidatedfinancialstatementsinfuturereportingperiods.
AnnualClosingDate
TheCompanyfollowstheconceptofafiscalyear,whichendsontheSundaynearesttotheendofthemonthof
December.Normallyeachfiscalyearconsistsof52weeks,buteveryfiveorsixyearsthefiscalyearconsistsof53weeks,
andthereforeincludesadditionalshippingdays,aswasthecaseinfiscalyear2020,andwillbethecaseagaininfiscal
year2026.
Reclassification
Certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
2. Cash, Cash Equivalents and Current Marketable Securities
Attheendofthefiscalyear2020and2019,cash,cashequivalentsandcurrentmarketablesecuritieswerecomprisedof:
2020
Estimated Cash& Current
Carrying Unrecognized Fair Cash Marketable
(DollarsinMillions) Amount Gain Value Equivalents Securities
Cash $2,863 — 2,863 2,863 —
Non-U.S.SovereignSecurities(1) 690 — 690 — 690
U.S.Reverserepurchaseagreements 1,937 — 1,937 1,937 —
Corporatedebtsecurities(1) 2,674 — 2,674 1,451 1,223
Moneymarketfunds 2,102 — 2,102 2,102 —
Timedeposits(1) 877 — 877 877 —
Subtotal $11,143 — 11,143 9,230 1,913
U.S.Gov’tSecurities $13,777 1 13,778 4,731 9,047
OtherSovereignSecurities 14 — 14 — 14
Corporatedebtsecurities 250 — 250 24 226
Subtotalavailableforsale(2) $14,041 1 14,042 4,755 9,287
Totalcash,cashequivalentsandcurrentmarketable
securities $13,985 11,200
52 • Johnson&Johnson2020AnnualReport2019
Cash& Current
Carrying Cash Marketable
(DollarsinMillions) Amount Equivalents Securities
Cash $2,637 2,637 —
Non-U.S.SovereignSecurities(1) 439 149 290
U.S.Reverserepurchaseagreements 6,375 6,375 —
OtherReverserepurchaseagreements 375 375 —
Corporatedebtsecurities(1) 1,323 889 434
Moneymarketfunds 2,864 2,864 —
Timedeposits(1) 906 906 —
Subtotal $14,919 14,195 724
Gov’tSecurities $4,102 3,095 1,007
Corporatedebtsecurities 266 15 251
Subtotalavailableforsale(2) $4,368 3,110 1,258
Totalcash,cashequivalentsandcurrentmarketablesecurities $17,305 1,982
(1) Heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearnings.
(2) Availableforsaledebtsecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinother
comprehensiveincome.
Attheendoffiscalyear2019,thecarryingamountwasthesameastheestimatedfairvalue.
Fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker
pricesandsignificantotherobservableinputs.
ThecontractualmaturitiesoftheavailableforsaledebtsecuritiesatJanuary3,2021areasfollows:
Cost Fair
(DollarsinMillions) Basis Value
Duewithinoneyear $14,026 14,027
Dueafteroneyearthroughfiveyears 15 15
Dueafterfiveyearsthroughtenyears — —
Totaldebtsecurities $14,041 14,042
TheCompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhigh-quality
moneymarketinstruments.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat
leastaninvestmentgradecreditrating.
3. Inventories
Attheendoffiscalyears2020and2019,inventorieswerecomprisedof:
(DollarsinMillions) 2020 2019
Rawmaterialsandsupplies $1,410 1,117
Goodsinprocess 2,040 1,832
Finishedgoods 5,894 6,071
Totalinventories(1) $9,344 9,020
(1) SeeNote18totheConsolidatedFinancialStatementsfordetailsonassetsheldforsaleandtherelateddivestituresforthefiscal
yearendedDecember29,2019.TherewerenoassetsheldforsaleatJanuary3,2021.
Johnson&Johnson2020AnnualReport • 534. Property, Plant and Equipment
Attheendoffiscalyears2020and2019,property,plantandequipmentatcostandaccumulateddepreciationwere:
(DollarsinMillions) 2020 2019
Landandlandimprovements $882 854
Buildingsandbuildingequipment 12,502 11,877
Machineryandequipment 29,104 26,964
Constructioninprogress 4,316 3,637
Totalproperty,plantandequipment,gross $46,804 43,332
Lessaccumulateddepreciation 28,038 25,674
Totalproperty,plantandequipment,net(1) $18,766 17,658
(1) SeeNote18totheConsolidatedFinancialStatementsfordetailsonassetsheldforsaleandtherelateddivestituresforthefiscal
yearendedDecember29,2019.TherewerenoassetsheldforsaleatJanuary3,2021.
TheCompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipment.Interestexpense
capitalizedinfiscalyears2020,2019and2018was$63million,$70millionand$86million,respectively.
Depreciationexpense,includingtheamortizationofcapitalizedinterestinfiscalyears2020,2019and2018was
$2.6billion,$2.5billionand$2.6billion,respectively.
Uponretirementorotherdisposalofproperty,plantandequipment,thecostsandrelatedamountsofaccumulated
depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccounts,respectively.The
difference,ifany,betweenthenetassetvalueandtheproceedsarerecordedinearnings.
5. Intangible Assets and Goodwill
Attheendoffiscalyears2020and2019,thegrossandnetamountsofintangibleassetswere:
(DollarsinMillions) 2020 2019
Intangibleassetswithdefinitelives:
Patentsandtrademarks—gross $39,990 36,634
Lessaccumulatedamortization 17,618 13,154
Patentsandtrademarks—net $22,372 23,480
Customerrelationshipsandotherintangibles—gross $22,898 22,056
Lessaccumulatedamortization 10,912 9,462
Customerrelationshipsandotherintangibles—net* $11,986 12,594
Intangibleassetswithindefinitelives:
Trademarks $7,195 6,922
Purchasedin-processresearchanddevelopment(1) 11,849 4,647
Totalintangibleassetswithindefinitelives $19,044 11,569
Totalintangibleassets—net $53,402 47,643
* Themajorityiscomprisedofcustomerrelationships
(1) Infiscalyear2020,theCompanycompletedmultipleacquisitionsandrecordedin-processresearchanddevelopmentintangible
assetsof$6.0billionfromMomentaPharmaceuticals,Inc.,$0.8billionforbermekimabandcertainrelatedassetsfromXBiotech,Inc.,
and$0.4billionfromtheacquisitionofalloutstandingsharesinVerbSurgical,Inc.
54 • Johnson&Johnson2020AnnualReportGoodwillasofJanuary3,2021andDecember29,2019,asallocatedbysegmentofbusiness,wasasfollows:
(DollarsinMillions) ConsumerHealth Pharmaceutical MedicalDevices Total
GoodwillatDecember30,2018 $8,670 9,063 12,720 30,453
Goodwill,relatedtoacquisitions 1,188 75 2,018 3,281
Currencytranslation/other (122) 31 (4) (95)
GoodwillatDecember29,2019 $9,736 9,169 14,734 33,639
Goodwill,relatedtoacquisitions — 1,222 238 1,460
Currencytranslation/other 600 618 76 1,294
GoodwillatJanuary3,2021 $10,336 11,009 15,048 36,393
Theweightedaverageamortizationperiodforpatentsandtrademarksis12years.Theweightedaverageamortization
periodforcustomerrelationshipsandotherintangibleassetsis21years.Theamortizationexpenseofamortizableassets
includedincostofproductssoldwas$4.7billion,$4.5billionand$4.4billionbeforetax,forthefiscalyearsended
January3,2021,December29,2019andDecember30,2018,respectively.Intangibleassetwrite-downsareincludedin
Other(income)expense,net.
Theestimatedamortizationexpenseforapprovedproducts,beforetax,forthefivesucceedingyearsisapproximately:
(DollarsinMillions)
2021 2022 2023 2024 2025
$4,600 4,200 4,100 3,900 3,200
SeeNote18totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures.
6. Fair Value Measurements
TheCompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflows,primarily
relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthird-partypurchasesofmaterials
denominatedinaforeigncurrency.TheCompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk
primarilyrelatedtoborrowings.Bothtypesofderivativesaredesignatedascashflowhedges.
Additionally,theCompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate
borrowings.Thesederivativesaredesignatedasfairvaluehedges.TheCompanyusescrosscurrencyinterestrateswaps
andforwardforeignexchangecontractsdesignatedasnetinvestmenthedges.Additionally,theCompanyusesforward
foreignexchangecontractstooffsetitsexposuretocertainforeigncurrencyassetsandliabilities.Theseforwardforeign
exchangecontractsarenotdesignatedashedgesandtherefore,changesinthefairvaluesofthesederivativesare
recognizedinearnings,therebyoffsettingthecurrentearningseffectoftherelatedforeigncurrencyassetsandliabilities.
TheCompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposes,orthatcontaincredit
riskrelatedcontingentfeatures.TheCompanymaintainscreditsupportagreements(CSA)withcertainderivative
counterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsandnettingagreements.Asof
January3,2021,thetotalamountofcashcollateralpaidbytheCompanyundertheCSAamountedto$1.1billionnet,
relatedtonetinvestmentandcashflowhedges.Onanongoingbasis,theCompanymonitorscounter-partycreditratings.
TheCompanyconsiderscreditnon-performancerisktobelow,becausetheCompanyprimarilyentersintoagreements
withcommercialinstitutionsthathaveatleastaninvestmentgradecreditrating.Refertothetableonsignificantfinancial
assetsandliabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswiththesecommercial
institutions.AsofJanuary3,2021,theCompanyhadnotionalamountsoutstandingforforwardforeignexchange
contracts,andcrosscurrencyinterestrateswapsof$37.8billionand$30.6billion,respectively.AsofDecember29,
2019,theCompanyhadnotionalamountsoutstandingforforwardforeignexchangecontractsandcrosscurrencyinterest
rateswapsof$45.3billionand$20.1billion,respectively.
Allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Changesinthefairvalueofderivativesare
recordedeachperiodincurrentearningsorothercomprehensiveincome,dependingonwhetherthederivativeis
designatedaspartofahedgetransaction,andifso,thetypeofhedgetransaction.
Johnson&Johnson2020AnnualReport • 55Thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontract.Atinception,allderivatives
areexpectedtobehighlyeffective.Foreignexchangecontractsdesignatedascashflowhedgesareaccountedforunder
theforwardmethodandallgains/lossesassociatedwiththesecontractswillberecognizedintheincomestatementwhen
thehedgeditemimpactsearnings.Changesinthefairvalueofthesederivativesarerecordedinaccumulatedother
comprehensiveincomeuntiltheunderlyingtransactionaffectsearnings,andarethenreclassifiedtoearningsinthesame
accountasthehedgedtransaction.
Gainsandlossesassociatedwithinterestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesin
interestratesarerecordedtointerestexpenseintheperiodinwhichtheyoccur.Theeffectofwhichareimmaterialforthe
fiscalyearsendedJanuary3,2021andDecember29,2019.Gainsandlossesonnetinvestmenthedgeareaccounted
throughthecurrencytranslationaccountwithinaccumulatedothercomprehensiveincome.Theportionexcludedfrom
effectivenesstestingisrecordedthroughinterest(income)expenseusingthespotmethod.Onanongoingbasis,the
Companyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesofhedgeditems.Ifand
whenaderivativeisnolongerexpectedtobehighlyeffective,hedgeaccountingisdiscontinued.
TheCompanydesignateditsEurodenominatednotesissuedinMay2016withduedatesrangingfrom2022to2035as
anetinvestmenthedgeoftheCompany’sinvestmentsincertainofitsinternationalsubsidiariesthatusetheEuroastheir
functionalcurrencyinordertoreducethevolatilitycausedbychangesinexchangerates.
AsofJanuary3,2021,thebalanceofdeferrednetgainonderivativesincludedinaccumulatedothercomprehensive
incomewas$652millionafter-tax.Foradditionalinformation,seetheConsolidatedStatementsofComprehensiveIncome
andNote13.TheCompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill
bereclassifiedintoearningsoverthenext12monthsasaresultoftransactionsthatareexpectedtooccuroverthat
period.ThemaximumlengthoftimeoverwhichtheCompanyishedgingtransactionexposureis18months,excluding
interestratecontracts,netinvestmenthedges.Theamountultimatelyrealizedinearningsmaydifferasforeignexchange
rateschange.Realizedgainsandlossesareultimatelydeterminedbyactualexchangeratesatmaturityofthederivative.
ThefollowingtableisasummaryoftheactivityrelatedtoderivativesandhedgesforthefiscalyearsendedJanuary3,
2021andDecember29,2019,netoftax:
January3,2021 December29,2019
Costof Interest Other Costof Interest Other
Products R&D (Income) (Income) Products R&D (Income) (Income)
(DollarsinMillions) Sales Sold Expense Expense Expense Sales Sold Expense Expense Expense
Theeffectsoffairvalue,netinvestment
andcashflowhedging:
Gain(Loss)onnetinvestment
hedgingrelationship:
Crosscurrencyinterestrateswaps
contracts:
Amountofgainor(loss)recognizedin
incomeonderivativeamount
excludedfromeffectivenesstesting $— — — 153 — — — — 159 —
Amountofgainor(loss)recognizedin
AOCI — — — 153 — — — — 159 —
Gain(Loss)oncashflowhedging
relationship:
Forwardforeignexchange
contracts:
Amountofgainor(loss)reclassified
fromAOCIintoincome 12 (329) (137) — (16) (54) (321) (105) — 22
Amountofgainor(loss)recognizedin
AOCI 44 298 (191) — (52) (20) (606) (94) — 39
Crosscurrencyinterestrateswaps
contracts:
Amountofgainor(loss)reclassified
fromAOCIintoincome — — — 370 — — — — 292 —
Amountofgainor(loss)recognizedin
AOCI $— — — 748 — — — — 417 —
56 • Johnson&Johnson2020AnnualReportThefollowingtableistheeffectofderivativesnotdesignatedashedginginstrumentforthefiscalyearsendedJanuary3,
2021andDecember29,2019:
LocationofGain/(Loss) Gain/(Loss)
RecognizedinIncomeon RecognizedIn
(DollarsinMillions) Derivative IncomeonDerivative
DerivativesNotDesignatedasHedgingInstruments January3,2021 December29,2019
ForeignExchangeContracts Other(income)expense $24 (144)
ThefollowingtableistheeffectofnetinvestmenthedgesforthefiscalyearsendedJanuary3,2021andDecember29,
2019:
Gain/(Loss)
Gain/(Loss) LocationofGainor(Loss)Reclassified ReclassifiedFrom
RecognizedIn fromAccumulatedOtherComprehensive AccumulatedOCI
AccumulatedOCI IncomeIntoIncome IntoIncome
January3, December29, January3, December29,
(DollarsinMillions) 2021 2019 2021 2019
Debt $(473) 121 Interest(income)expense — —
CrossCurrencyinterestrateswaps $ 65 488 Interest(income)expense — —
TheCompanyholdsequityinvestmentswithreadilydeterminablefairvaluesandequityinvestmentswithoutreadily
determinablefairvalues.TheCompanymeasuresequityinvestmentsthatdonothavereadilydeterminablefairvaluesat
costminusimpairment,ifany,plusorminuschangesresultingfromobservablepricechangesinorderlytransactionsfor
theidenticalorasimilarinvestmentofthesameissuer.
ThefollowingtableisasummaryoftheactivityrelatedtoequityinvestmentsforthefiscalyearsendedJanuary3,2021
andDecember29,2019:
January3,2021
ChangesinFairValue
December29,2019
ReflectedinNet Sales/ NonCurrentOther
(DollarsinMillions) CarryingValue Income(1) Purchases/Other(2) CarryingValue Assets
EquityInvestmentswithreadily
determinablevalue $1,148 527 (194) 1,481 1,481
EquityInvestmentswithoutreadily
determinablevalue $712 (55) 81 738 738
December29,2019
ChangesinFairValue
December30,2018
ReflectedinNet Sales/ NonCurrentOther
(DollarsinMillions) CarryingValue Income(1) Purchases/Other(2) CarryingValue Assets
EquityInvestmentswithreadily
determinablevalue $511 533 104 1,148 1,148
EquityInvestmentswithoutreadily
determinablevalue $681 (38) 69 712 712
(1) RecordedinOtherIncome/Expense
(2) Otherincludesimpactofcurrency
ForthefiscalyearsendedJanuary3,2021andDecember29,2019forequityinvestmentswithoutreadilydeterminable
marketvalues,$76millionand$57million,respectively,ofthechangesinfairvaluereflectedinnetincomeweretheresult
ofimpairments.Therewere$21millionand$19million,respectively,ofchangesinfairvaluereflectedinnetincomedue
tochangesinobservableprices.
Fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-based
measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.In
accordancewithASC820,athree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevelswithinthe
hierarchyaredescribedbelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Thefairvalueofaderivativefinancialinstrument(i.e.,forwardforeignexchangecontracts,interestratecontracts)isthe
aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand
Johnson&Johnson2020AnnualReport • 57subsequentlyconvertedtotheU.S.Dollaratthecurrentspotforeignexchangerate.TheCompanydoesnotbelievethat
fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor
maturity,orthatthechangesinfairvaluewillhaveamaterialeffectontheCompany’sresultsofoperations,cashflowsor
financialposition.TheCompanyalsoholdsequityinvestmentswhichareclassifiedasLevel1anddebtsecuritieswhich
areclassifiedasLevel2.TheCompanyholdsacquisitionrelatedcontingentliabilitiesbaseduponcertainregulatoryand
commercialevents,whichareclassifiedasLevel3,whosevaluesaredeterminedusingdiscountedcashflow
methodologiesorsimilartechniquesforwhichthedeterminationoffairvaluerequiressignificantjudgmentorestimations.
Thefollowingthreelevelsofinputsareusedtomeasurefairvalue:
Level1—Quotedpricesinactivemarketsforidenticalassetsandliabilities.
Level2—Significantotherobservableinputs.
Level3—Significantunobservableinputs.
TheCompany’ssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofthefiscalyearendedJanuary3,2021
andDecember29,2019wereasfollows:
2020 2019
(DollarsinMillions) Level1 Level2 Level3 Total Total(1)
Derivativesdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts $ — 849 — 849 209
Interestratecontracts(2)(3) — 240 — 240 693
Total $ — 1,089 — 1,089 902
Liabilities:
Forwardforeignexchangecontracts — 702 — 702 426
Interestratecontracts(3) — 1,569 — 1,569 193
Total $ — 2,271 — 2,271 619
Derivativesnotdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts $ — 49 — 49 23
Liabilities:
Forwardforeignexchangecontracts — 38 — 38 33
AvailableForSaleOtherInvestments:
Equityinvestments(4) 1,481 — — 1,481 1,148
Debtsecurities(5) — 14,042 — 14,042 4,368
OtherLiabilities
ContingentConsideration(6) $ 633 633 1,715
GrosstoNetDerivativeReconciliation 2020 2019
(DollarsinMillions)
TotalGrossAssets $1,138 925
CreditSupportAgreement(CSA) (1,107) (841)
TotalNetAsset 31 84
TotalGrossLiabilities 2,309 652
CreditSupportAgreement(CSA) (2,172) (586)
TotalNetLiabilities $137 66
58 • Johnson&Johnson2020AnnualReportSummarizedinformationaboutchangesinliabilitiesforcontingentconsiderationisasfollows:
2020 2019 2018
(DollarsinMillions)
BeginningBalance $1,715 397 600
Changesinestimatedfairvalue(7) (1,089) 151 (156)
Additions 106 1,246 125
Payments (99) (79) (172)
EndingBalance $633 1,715 397
(1) 2019assetsandliabilitiesareallclassifiedasLevel2withtheexceptionofequityinvestmentsof$1,148million,whichareclassified
asLevel1andcontingentconsiderationof$1,715million,classifiedasLevel3.
(2) Includes$1millionofnon-currentassetsasofDecember29,2019.
(3) Includescrosscurrencyinterestrateswapsandinterestrateswaps.
(4) Classifiedasnon-currentotherassets.
(5) Classifiedascashequivalentsandcurrentmarketablesecurities.
(6) Includes$594million,$1,631million(primarilyrelatedtoAurisHealth)and$397million,classifiedasnon-currentotherliabilitiesas
ofJanuary3,2021,December29,2019andDecember30,2018,respectively.Includes$39millionand$84millionclassifiedas
currentliabilitiesasofJanuary3,2021andDecember29,2019,respectively.
(7) OngoingfairvalueadjustmentamountsarerecordedprimarilyinResearchandDevelopmentexpense.TheCompanyrecordeda
contingentconsiderationreversalof$1,148millionin2020relatedtothetimingofcertaindevelopmentalmilestonesassociatedwith
theAurisHealthacquisition.ThereversalofthecontingentconsiderationwasrecordedinOtherincomeandexpense
SeeNotes2and7forfinancialassetsandliabilitiesheldatcarryingamountontheConsolidatedBalanceSheet.
Johnson&Johnson2020AnnualReport • 597. Borrowings
Thecomponentsoflong-termdebtareasfollows:
Effective Effective
(DollarsinMillions) 2020 Rate% 2019 Rate%
3%ZeroCouponConvertibleSubordinatedDebenturesdue2020 $ — — 51 3.00
2.95%Debenturesdue2020 — — 549 3.15
1.950%Notesdue2020 — — 500 1.99
3.55%Notesdue2021 450 3.67 449 3.67
2.45%Notesdue2021 350 2.48 349 2.48
1.65%Notesdue2021 999 1.65 999 1.65
0.250%Notesdue2022(1BEuro1.2281)(2)/(1BEuro1.1096)(3) 1,227(2) 0.26 1,108(3) 0.26
2.25%Notesdue2022 999 2.31 998 2.31
6.73%Debenturesdue2023 250 6.73 250 6.73
3.375%Notesdue2023 803 3.17 804 3.17
2.05%Notesdue2023 499 2.09 498 2.09
0.650%Notesdue2024(750MMEuro1.2281)(2)/(750MMEuro1.1096)(3) 919(2) 0.68 829(3) 0.68
5.50%Notesdue2024
(500MM1.3654GBP)(2)/(500MMGBP1.2987)(3) 679(2) 6.75 645(3) 6.75
2.625%Notesdue2025 748 2.63 748 2.63
0.55%Notesdue2025(5) 996 0.57 — —
2.45%Notesdue2026 1,994 2.47 1,993 2.47
2.95%Notesdue2027 997 2.96 996 2.96
0.95%Notesdue2027(5) 1,494 0.96 — —
1.150%Notesdue2028(750MMEuro1.2281)(2)/(750MMEuro1.1096)(3) 915(2) 1.21 825(3) 1.21
2.90%Notesdue2028 1,495 2.91 1,494 2.91
6.95%Notesdue2029 297 7.14 297 7.14
1.30%Notesdue2030(5) 1,743 1.30 — —
4.95%Debenturesdue2033 498 4.95 498 4.95
4.375%Notesdue2033 855 4.24 855 4.24
1.650%Notesdue2035(1.5BEuro1.2281)(2)/(1.5BEuro1.1096)(3) 1,827(2) 1.68 1,649(3) 1.68
3.55%Notesdue2036 989 3.59 989 3.59
5.95%Notesdue2037 992 5.99 992 5.99
3.625%Notesdue2037 1,488 3.64 1,487 3.64
5.85%Debenturesdue2038 696 5.85 696 5.85
3.400%Notesdue2038 991 3.42 991 3.42
4.50%Debenturesdue2040 539 4.63 539 4.63
2.10%Notesdue2040(5) 986 2.14 — —
4.85%Notesdue2041 297 4.89 297 4.89
4.50%Notesdue2043 496 4.52 495 4.52
3.70%Notesdue2046 1,974 3.74 1,973 3.74
3.75%Notesdue2047 991 3.76 991 3.76
3.500%Notesdue2048 742 3.52 742 3.52
2.250%Notesdue2050(5) 984 2.29 — —
2.450%Notesdue2060(5) 1,228 2.49 — —
Other 7 — 18 —
Subtotal 34,434(4) 2.85%(1) 27,594(4) 3.19(1)
Lesscurrentportion 1,799 1,100
Totallong-termdebt $32,635 26,494
60 • Johnson&Johnson2020AnnualReport(1) Weightedaverageeffectiverate.
(2) TranslationrateatJanuary3,2021.
(3) TranslationrateatDecember29,2019.
(4) Theexcessofthefairvalueoverthecarryingvalueofdebtwas$5.4billionattheendoffiscalyear2020and$3.0billionattheend
offiscalyear2019.
(5) Inthefiscalthirdquarterof2020,theCompanyissuedseniorunsecurednotesforatotalof$7.5billion.
Fairvalueofthelong-termdebtwasestimatedusingmarketprices,whichwerecorroboratedbyquotedbrokerpricesand
significantotherobservableinputs.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2020,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember9,2021.Interestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids
providedbybanks,LondonInterbankOfferedRates(LIBOR),SecuredOvernightFinancingRate(SOFR)SwapCurveor
otherapplicablemarketrateasallowedplusapplicablemargins.Commitmentfeesundertheagreementsarenotmaterial.
Throughoutfiscalyear2020,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.
Short-termborrowingsandthecurrentportionoflong-termdebtamountedtoapproximately$2.6billionattheendof
fiscalyear2020,ofwhich$1.8billionisthecurrentportionofthelong-termdebt,andtheremainderiscommercialpaper
andlocalborrowingsbyinternationalsubsidiaries.
Throughoutfiscalyear2019,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.
Short-termborrowingsandthecurrentportionoflong-termdebtamountedtoapproximately$1.2billionattheendof
fiscalyear2019,ofwhich$1.1billionisthecurrentportionofthelongtermdebt,andtheremainderprincipallyrepresents
localborrowingbyinternationalsubsidiaries.
Aggregatematuritiesoflong-termdebtobligationscommencingin2021are:
(DollarsinMillions)
2021 2022 2023 2024 2025 After2025
$1,799 2,226 1,552 1,598 1,744 25,515
8. Income Taxes
Theprovisionfortaxesonincomeconsistsof:
(DollarsinMillions) 2020 2019 2018
Currentlypayable:
U.S.taxes $1,026 1,941 1,284
Internationaltaxes 1,898 2,744 2,434
Totalcurrentlypayable 2,924 4,685 3,718
Deferred:
U.S.taxes (76) (814) 1,210(1)
Internationaltaxes (1,065) (1,662) (2,226)
Totaldeferred (1,141) (2,476) (1,016)
Provisionfortaxesonincome $1,783 2,209 2,702
(1) Includes$1.4billionofdeferredtaxexpensefortheadoptionofthedeferredmethodtoaccountforGILTI.
Johnson&Johnson2020AnnualReport • 61AcomparisonofincometaxexpenseattheU.S.statutoryrateof21%infiscalyears2020,2019and2018,tothe
Company’seffectivetaxrateisasfollows:
(DollarsinMillions) 2020 2019 2018
U.S. $4,312 3,543 5,575
International 12,185 13,785 12,424
Earningsbeforetaxesonincome: $16,497 17,328 17,999
Taxrates:
U.S.statutoryrate 21.0% 21.0 21.0
Internationaloperations(1) (9.9) (5.9) (3.7)
U.S.taxesoninternationalincome(2) 2.7 1.8 1.4
TaxbenefitsonCapitalLoss (1.2) (0.3)(4) —
Taxbenefitsonshare-basedcompensation (1.5) (0.5) (1.5)
TCJAandrelatedimpacts 0.7 (3.9)(3) (1.9)(3)
Allother (1.0) 0.5(4) (0.3)
EffectiveRate 10.8% 12.7 15.0
(1) ForallperiodspresentedtheCompanyhassubsidiariesoperatinginPuertoRicoundervarioustaxincentives.International
operationsreflectstheimpactsofoperationsinjurisdictionswithstatutorytaxratesdifferentthantheU.S.,particularlyIreland,
SwitzerlandandPuertoRico,whichisafavorableimpactontheeffectivetaxrateascomparedwiththeU.S.statutoryrate.The2020
and2019amountsincludetheimpactofthenewtaxlegislationenactmentinSwitzerland,whichisfurtherdescribedbelow.
(2) IncludestheimpactoftheGILTItax,theForeign-DerivedIntangibleIncomedeductionandotherforeignincomethatistaxableunder
theU.S.taxcode.
(3) Representsimpactofadjustmentstobalancesoriginallyrecordedaspartofthe2017TCJAprovisionaltaxcharge.Further
informationprovidedbelow.
(4) Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
Thefiscalyear2020taxratedecreasedby1.9%comparedtothefiscalyear2019taxrate,whichwasprimarilydrivenby
thefollowingitems.Infiscalyear2019,SwitzerlandenactedtheFederalActonTaxReformandAHVFinancing(TRAF)
whichbecameeffectiveonJanuary1,2020.TheFederaltransitionalprovisionsofTRAFallowcompanies,undercertain
conditions,toadjustthetaxbasisincertainassetstofairvalue(i.e.,“step-up”)tobedepreciatedandamortizedresulting
inanincrementalSwisstaxdeductionoverthetransitionalperiod.
TRAFalsoprovidesforparameterswhichenabletheSwisscantonstoestablishlocalizedtaxratesandregulationsfor
companies.Thenewcantonaltaxparametersincludefavorabletaxbenefitsforpatentsandadditionalresearchand
developmenttaxdeductions.ThecantonaltransitionalprovisionsofTRAFallowedcompaniestoelecteither1)taxbasis
step-upsimilartotheFederaltransitionbenefitor2)alternativestatutorytaxrateforaperiodnottoexceed5years.The
CompanycurrentlyhasoperationslocatedinvariousSwisscantons.Duringthefiscalyear2019,asdescribedinfurther
detailbelow,theCompanyrecordedtheimpactsoftheTRAFthatwereenactedinthatperiod.
Duringthefiscalyear2020,thefinalcantonwheretheCompanymaintainssignificantoperationsenactedTRAF
legislation.Additionally,theCompanyreceivedrulingsfromtheSwissFederalandcantonaltaxauthoritiesintheremaining
jurisdictionswhereithassignificantoperations.TheserulingsresultedintheCompanyrevisingitsestimateonthetax
basisadjustment(i.e.,“step-up”)foritsassetsandasaresult,theCompanyrecordedadditionaldeferredtaxbenefitsin
2020.TheCompanyrecognizedanetbenefitinthefiscalyear2020forSwissTaxReformofapproximately$0.4billionor
2.6%benefittotheCompany’sannualeffectivetaxrate,comprisedofthefollowingitems:
• approximately$0.3billiontaxbenefitrelatingtotheremeasurementofSwissdeferredtaxassetsandliabilitiesforthe
changeintheFederalandcantonaltaxrates,whereenactmentoccurredinthefiscalyear2020;thisbenefithasbeen
reflectedas“InternationalOperations”ontheCompany’seffectivetaxratereconciliation.
• a$450milliondeferredtaxassetrelatedtotheestimatedvalueofaFederaltaxbasisstep-upoftheCompany’sSwiss
subsidiaries’assetsasdescribedabove;thisbenefithasbeenreflectedas“InternationalOperations”ontheCompany’s
effectivetaxratereconciliation.
62 • Johnson&Johnson2020AnnualReport• approximately$0.3billionofU.S.deferredtaxexpenserelatingtotheGILTIdeferredtaxliabilityresultingfromthe
remeasurementoftheSwissdeferredtaxassetsandliabilitiesinthefiscalyear2020.Thisbenefithasbeenreflectedas
“U.S.taxoninternationalincome”ontheCompany’seffectivetaxratereconciliation.
TheCompanydoesnotexpecttoreceivefuturerulingsregardingthetransitionalprovisionsofTRAF.
Also,inthefiscalfourthquarterof2020,theCompanyrecognizedacapitallossoncertainU.S.affiliatesrelatedtothe
previouslyimpairedbookvalueofcertainintangibles,whichreducedthe2020taxratebyapproximately1.2%whichis
reflectedasa“TaxBenefitsonCapitalLoss”ontheeffectivetaxratereconciliation.Inadditioninthefiscalyear2020,the
Companyhadlowerincomeinhighertaxjurisdictions,primarilydrivenby:
• theimpactoftheaccrualoflitigationcostsrelatedtoTalcfor$4.0billionwhichreducedtheU.S.earningsbefore
taxesataneffectivetaxrateof23.5%;
• theaccrualofadditionallegalcosts,includinganadditional$1.0billionassociatedwitharevisedagreementin
principletosettleopioidlitigationataneffectivetaxrateof21.4%
TheCompanyalsogeneratedadditionaltaxbenefitsfromstock-basedcompensationthatwereeitherexercisedorvested;
reducedthecontingentconsiderationliabilityrelatedtotheAurisHealthacquisition(seeNote18);andreversalofsomeof
itsunrecognizedtaxbenefitsduetothecompletionofseveralyearsoftaxexaminationsincertainjurisdictionsduringthe
fiscalyear2020.
Thefiscalyear2019taxratedecreasedby2.3%comparedtothefiscalyear2018taxrate.Inadditiontotheimpactof
TRAFdiscussedinmoredetailbelow,theprimarydriversofthenetdecreasewereasfollows:
• TheCompanyreorganizedtheownershipstructureofcertainwholly-ownedinternationalsubsidiariesinthefiscal
fourthquarterof2019,whichresultedinareductionofcertainwithholdingandlocaltaxesthatithadpreviously
recognizedaspartoftheprovisionalTaxCutsandJobsAct(TCJA)taxchargeinthefiscalyear2017andfinalizedin
thefiscalyear2018.Followingthecompletionofthisrestructuringandapprovalbytheapplicablelocalauthorities,
theCompanyreversedadeferredtaxliabilityof$0.6billionandarelateddeferredtaxassetof$0.2billionforU.S.
foreigntaxcredits,foranetdeferredtaxbenefitof$0.4billiondecreasingtheannualeffectivetaxrateby2.2%.This
benefithasbeenreflectedas“TCJAandrelatedimpacts”ontheCompany’seffectivetaxratereconciliation.
• Theimpactoftheagreementinprincipletosettleopioidlitigationfor$4billion(seeNote19totheConsolidated
FinancialStatements)whichreducedtheU.S.earningsbeforetaxesataneffectivetaxrateof23.5%anddecreased
theCompany’sannualeffectivetaxratebyapproximately2.1%.
• InDecemberoffiscalyear2019,theU.S.Treasuryissuedfinalforeigntaxcreditregulations,whichresultedinthe
Companyrevisingtheamountofforeigntaxcreditsthatwereinitiallyrecordedinthefiscalyear2017aspartofthe
provisionalTCJAtaxcharge.Asaresult,theCompanyrecordedanincreaseddeferredtaxassetrelatedtothese
foreigntaxcreditsofapproximately$0.3billionor1.7%totheannualeffectivetaxrate.Thisbenefithasbeen
reflectedas“TCJAandrelatedimpacts”ontheCompany’seffectivetaxratereconciliation.
• TheCompanyreassesseditsuncertaintaxpositionsrelatedtothecurrentIRSauditandincreaseditsunrecognized
taxbenefitby$0.3billionliabilitywhichincreasedtheannualeffectivetaxratebyapproximately1.5%(seesectionon
UnrecognizedTaxBenefitsforadditionalinformation).Asthesepositionswererelatedtouncertaintaxregarding
internationaltransferpricing,thisexpensehasbeenclassifiedas“InternationalOperations”ontheCompany’s
effectivetaxratereconciliation.SubsequenttoDecember29,2019,theCompanyreceivedandagreedtoNoticesof
ProposedAdjustments(NOPAs)fromtheIRS.TheCompanybelievesitisadequatelyreservedforpotential
exposures.
• Therewereseveralone-timetaximpactsthatresultedinacumulativenettaxbenefittothe2018annualeffectivetax
rateof1.2%.TheseitemsincludedtheLifeScandivestiture,theadjustmenttothe2017provisionalTCJAtaxcharge
andtheaccelerationofcertaintaxdeductionsaspartofthe2017taxreturn.
• Moreincomeinhighertaxjurisdictionsrelativetolowertaxjurisdictionsascomparedto2018.
AsdescribedabovefortheSwisstaxlegislation,inthefiscalyear2019,theCompanyrecordedanettaxexpenseof
$0.1billionwhichincreasedtheeffectivetaxrateforthefiscalyear2019byapproximately0.6%.Thisnettaxexpense
relatedtofederalandcertaincantonalenactmentsinthefiscalyear2019consistingofthefollowingprovisions:
• approximately$0.6billiontaxexpenserelatingtotheremeasurementofSwissdeferredtaxassetsandliabilitiesfor
thechangeintheFederalandcantonaltaxrates,whereenactmentoccurredbyDecember29,2019;thisexpense
hasbeenreflectedas“InternationalOperations”ontheCompany’seffectivetaxratereconciliation.
Johnson&Johnson2020AnnualReport • 63• a$0.9billiondeferredtaxassetrelatedtotheestimatedvalueofaFederaltaxbasisstep-upoftheCompany’sSwiss
subsidiaries’assets;thisbenefithasbeenreflectedas“InternationalOperations”ontheCompany’seffectivetaxrate
reconciliation.
• approximately$450millionofU.S.deferredtaxexpenserelatingtotheGILTIdeferredtaxliabilityresultingfromthe
remeasurementoftheSwissdeferredtaxassetsandliabilitiesandthenewdeferredtaxassetfortheFederalstep-up.
Thisbenefithasbeenreflectedas“U.S.taxoninternationalincome”ontheCompany’seffectivetaxrate
reconciliation.
Inthefiscalyear2018,theCompanycompleteditsfullassessmentandfinalizedtheaccountingfortheimpactofthe
TCJA.TheCompanyrecordednetadjustmentstotheabovecomponentsoftheprovisionalchargeofapproximately
$0.2billion.Theserevisionswerebasedonupdatedestimatesandadditionalanalysisbymanagementaswellasapplying
interpretativeguidanceissuedbytheU.S.DepartmentofTreasurytothefactsandcircumstancesthatexistedasofthe
TCJAenactmentdate.Thischargewasprimarilyrelatedtoadditionaldeferredtaxliabilitiesforforeignlocaland
withholdingtaxesfortheremainingbalanceofundistributedforeignearningsasofDecember31,2017thatwerenot
providedforinthe2017provisionalcharge.
AsdescribedinNote1,inthefiscalyear2018,theCompanyelectedtotreatGILTIasaperiodexpenseunderthe
deferredmethodandrecordedadeferredtaxcostofapproximately$1.4billioninthefiscalyear2018relatedtofactsand
circumstancesthatexistedonthedateofTCJAenactment.During2018,theCompanyreorganizedtheownership
structureofcertainforeignsubsidiarieswhichresultedinareductionofcertainforeignwithholdingtaxesthatithad
recognizedaspartoftheprovisionalTCJAtaxchargeinthefourthquarterof2017.Followingthecompletionofthis
restructuringandasaresultofclarificationbySwisstaxauthoritiesregardingtheapplicabilityofwithholdingtaxto
repatriationofcertainearnings,theCompanyreversedadeferredtaxliabilityof$2.8billionandarelateddeferredtax
assetof$0.9billionforU.S.foreigntaxcredits,foranetdeferredtaxbenefitof$1.9billion.Thisbenefithasbeenreflected
as“TCJAandrelatedimpacts”ontheCompany’seffectivetaxratereconciliation.
Temporarydifferencesandcarryforwardsattheendoffiscalyears2020and2019wereasfollows:
2020 2019
DeferredTax DeferredTax*
(DollarsinMillions) Asset Liability Asset Liability
Employeerelatedobligations $2,434 2,473
Stockbasedcompensation 627 595
Depreciation&amortization 721 1,122
Non-deductibleintangibles (6,567) (5,835)
InternationalR&Dcapitalizedfortax 1,517 1,189
Reserves&liabilities 3,466 2,337
Incomereportedfortaxpurposes 1,705 1,605
Netoperatinglosscarryforwardinternational 990 838
Undistributedforeignearnings 812 (1,435) 765 (1,289)
Globalintangiblelow-taxedincome (3,606) (2,965)
Miscellaneousinternational 854 (211) 696 (81)
MiscellaneousU.S. 12 411
Totaldeferredincometaxes $13,138 (11,819) 12,031 (10,170)
*Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
TheCompanyhaswholly-ownedinternationalsubsidiariesthathavecumulativenetlosses.TheCompanybelievesthatitis
morelikelythannotthatthesesubsidiarieswillgeneratefuturetaxableincomesufficienttoutilizethesedeferredtaxassets.
64 • Johnson&Johnson2020AnnualReportThefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits:
(DollarsinMillions) 2020 2019 2018
Beginningofyear $3,853 3,326 3,151
Increasesrelatedtocurrentyeartaxpositions 265 249 242
Increasesrelatedtopriorperiodtaxpositions 668 408 145
Decreasesrelatedtopriorperiodtaxpositions (551) (105) (137)
Settlements (839) (9) (40)
Lapseofstatuteoflimitations (23) (16) (35)
Endofyear $3,373 3,853 3,326
Theunrecognizedtaxbenefitsof$3.4billionatJanuary3,2021,ifrecognized,wouldaffecttheCompany’sannual
effectivetaxrate.TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits
inprogresswithanumberoftaxauthorities.WithrespecttotheUnitedStates,theInternalRevenueService(IRS)has
completeditsauditforthetaxyearsthrough2012.AsofDecember29,2019,theCompanyclassifiedunrecognizedtax
benefitsandrelatedinterestofapproximately$0.9billionasacurrentliabilityonthe“AccruedtaxesonIncome”lineofthe
ConsolidatedBalanceSheet.Inthefiscalyear2020,theCompanymadeitsfinalpaymentsforapproximately$0.7billion
totheU.S.Treasuryrelatedtothefinalsettlementof2010-2012taxauditliability.
InothermajorjurisdictionswheretheCompanyconductsbusiness,theyearsthatremainopentotaxauditgobacktothe
year2006.TheCompanybelievesitispossiblethattaxauditsmaybecompletedoverthenexttwelvemonthsbytaxing
authoritiesinsomejurisdictionsoutsideoftheUnitedStates.However,theCompanyisnotabletoprovideareasonably
reliableestimateofthetimingofanyotherfuturetaxpaymentsrelatingtouncertaintaxpositions.
TheCompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslong-termliabilities,
exceptaspreviouslynotedonamountsrelatedtothecurrentUnitedStatesIRSaudit.Interestexpenseandpenalties
relatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpense.TheCompanyrecognizedaftertaxinterest
expenseof$32million,$50millionand$53millioninfiscalyears2020,2019and2018,respectively.Thetotalamountof
accruedinterestwas$468millionand$559millioninfiscalyears2020and2019,respectively.
9. Employee Related Obligations
Attheendoffiscal2020andfiscal2019,employeerelatedobligationsrecordedontheConsolidatedBalanceSheets
were:
(DollarsinMillions) 2020 2019
Pensionbenefits $5,761 5,538
Postretirementbenefits 2,229 2,297
Postemploymentbenefits 3,078 3,004
Deferredcompensation 250 338
Totalemployeeobligations 11,318 11,177
Lesscurrentbenefitspayable 547 514
Employeerelatedobligations—non-current $10,771 10,663
Prepaidemployeerelatedobligationsof$656millionand$551millionfor2020and2019,respectively,areincludedin
OtherassetsontheConsolidatedBalanceSheets.
Johnson&Johnson2020AnnualReport • 6510. Pensions and Other Benefit Plans
TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,definedcontributionand
terminationindemnityplans,whichcovermostemployeesworldwide.TheCompanyalsoprovidespost-retirement
benefits,primarilyhealthcare,toalleligibleU.S.retiredemployeesandtheirdependents.
Manyinternationalemployeesarecoveredbygovernment-sponsoredprogramsandthecosttotheCompanyisnot
significant.
IntheU.S,non-unionpensionbenefitsforemployeeshiredbeforeJanuary1,2015areprimarilybasedontheemployee’s
compensationduringthelastfiveyearsbeforeretirementandthenumberofyearsofservice(theFinalAveragePay
formula).U.S.pensionbenefitsforemployeeshiredafter2014,arecalculatedusingadifferentformulabasedonemployee
compensationovertotalyearsofservice(theRetirementValueformula).
InJanuary2021,theCompanyannouncedthat,effectiveonJanuary1,2026,alleligibleU.S.non-unionemployees,
regardlessofhiredate,willearnbenefitsundertheRetirementValueformula.Thisamendmentdoesnotaffectthebenefits
accruedundertheFinalAveragePayformulaforservicebeforeJanuary1,2026.Theimpactofthischangedecreasesthe
PBOasofJanuary3,2021byapproximately$1.8billionandisincludedinthe“Amendments”lineintheChangein
BenefitObligation.
Internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrustees,annuitiesarepurchasedundergroup
contracts,orreservesareprovided.
TheCompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture.
In2020and2019theCompanyusedDecember31,2020andDecember31,2019,respectively,asthemeasurement
dateforallU.S.andinternationalretirementandotherbenefitplans.
NetperiodicbenefitcostsfortheCompany’sdefinedbenefitretirementplansandotherbenefitplansfor2020,2019and
2018includethefollowingcomponents:
RetirementPlans OtherBenefitPlans
(DollarsinMillions) 2020 2019 2018 2020 2019 2018
Servicecost $1,380 1,163 1,283 287 274 269
Interestcost 955 1,096 996 133 185 148
Expectedreturnonplanassets (2,461) (2,322) (2,212) (7) (6) (7)
Amortizationofpriorservicecost 2 4 3 (31) (31) (31)
Recognizedactuariallosses(gains) 891 579 852 142 129 123
Curtailmentsandsettlements 23 73 1 — — —
Netperiodicbenefitcost $790 593 923 524 551 502
UnrecognizedgainsandlossesfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceforeach
plan.Forplanswithnoactiveemployees,theyareamortizedovertheaveragelifeexpectancy.Theamortizationofgains
andlossesfortheotherU.S.benefitplansisdeterminedbyusinga10%corridorofthegreaterofthemarketvalueof
assetsortheaccumulatedpostretirementbenefitobligation.Totalunamortizedgainsandlossesinexcessofthecorridor
areamortizedovertheaverageremainingfutureservice.
Priorservicecosts/benefitsfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceofplan
participantsatthetimeoftheplanamendment.Priorservicecost/benefitfortheotherU.S.benefitplansisamortizedover
theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment.
66 • Johnson&Johnson2020AnnualReportThefollowingtablerepresentstheweighted-averageactuarialassumptions:
RetirementPlans OtherBenefitPlans
WorldwideBenefitPlans 2020 2019 2018 2020 2019 2018
NetPeriodicBenefitCost
Servicecostdiscountrate 2.82% 3.63 3.20 3.04 4.45 3.85
Interestcostdiscountrate 3.13% 4.13 3.60 3.08 4.25 3.62
Rateofincreaseincompensationlevels 4.00% 3.99 3.98 4.25 4.29 4.29
Expectedlong-termrateofreturnonplanassets 8.12% 8.31 8.46
BenefitObligation
Discountrate 2.14% 2.91 3.76 2.23 3.39 4.40
Rateofincreaseincompensationlevels 4.00% 4.01 3.97 4.27 4.29 4.29
TheCompany’sdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighquality,long-term
fixedincomeinstruments.Theresultingdiscountratesareconsistentwiththedurationofplanliabilities.TheCompany’s
methodologyindeterminingserviceandinterestcostusesdurationspecificspotratesalongthatyieldcurvetotheplans’
liabilitycashflows.
TheexpectedratesofreturnonplanassetassumptionsrepresenttheCompany’sassessmentoflong-termreturnson
diversifiedinvestmentportfoliosglobally.Theassessmentisdeterminedusingprojectionsfromexternalfinancialsources,
long-termhistoricalaverages,actualreturnsbyassetclassandthevariousassetclassallocationsbymarket.
Thefollowingtabledisplaystheassumedhealthcarecosttrendrates,forallindividuals:
HealthCarePlans 2020 2019
Healthcarecosttrendrateassumedfornextyear 5.68% 5.87%
Ratetowhichthecosttrendrateisassumedtodecline(ultimatetrend) 4.49% 4.50%
Yeartheratereachestheultimatetrendrate 2040 2040
Johnson&Johnson2020AnnualReport • 67Thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatfiscalyear-end
2020and2019fortheCompany’sdefinedbenefitretirementplansandotherpost-retirementplans:
OtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2020 2019 2020 2019
ChangeinBenefitObligation
Projectedbenefitobligation—beginningofyear $37,188 31,670 5,076 4,480
Servicecost 1,380 1,163 287 274
Interestcost 955 1,096 133 185
Planparticipantcontributions 61 63 — —
Amendments(1) (1,780) — — —
Actuarial(gains)losses(2) 5,716 5,178 (75) 562
Divestitures&acquisitions (88) (278) — —
Curtailments,settlements&restructuring (24) (172) — —
Benefitspaidfromplan (1,111) (1,555)(3) (396) (431)
Effectofexchangerates 1,003 23 3 6
Projectedbenefitobligation—endofyear $43,300 37,188 5,028 5,076
ChangeinPlanAssets
Planassetsatfairvalue—beginningofyear $32,201 26,818 115 180
Actualreturnonplanassets 5,524 6,185 14 19
Companycontributions 870 908 357 347
Planparticipantcontributions 61 63 — —
Settlements (13) (16) — —
Divestitures&acquisitions (84) (274) — —
Benefitspaidfromplanassets (1,111) (1,555)(3) (396) (431)
Effectofexchangerates 747 72 — —
Planassetsatfairvalue—endofyear $38,195 32,201 90 115
Fundedstatus—endofyear $(5,105) (4,987) (4,938) (4,961)
AmountsRecognizedintheCompany’sBalanceSheetconsistofthefollowing:
Non-currentassets $656 551 — —
Currentliabilities (125) (113) (418) (397)
Non-currentliabilities (5,636) (5,425) (4,520) (4,564)
Totalrecognizedintheconsolidatedbalancesheet—endofyear $(5,105) (4,987) (4,938) (4,961)
AmountsRecognizedinAccumulatedOtherComprehensiveIncomeconsistof
thefollowing:
Netactuarialloss $10,860 8,835 1,463 1,685
Priorservicecost(credit)(1) (1,797) (8) (44) (75)
Unrecognizednettransitionobligation — — — —
Totalbeforetaxeffects $9,063 8,827 1,419 1,610
AccumulatedBenefitObligations—endofyear $40,356 33,416
(1) InJanuary2021,theCompanyannouncedthat,effectiveonJanuary1,2026,alleligibleU.S.non-unionemployees,regardlessofhire
date,willearnbenefitsundertheRetirementValueformula.ThisamendmentdoesnotaffectthebenefitsaccruedundertheFinal
AveragePayformulaforservicebeforeJanuary1,2026.
(2) Theactuariallossesforretirementplansin2020and2019wasprimarilyrelatedtodecreasesindiscountrates.
(3) In2019,theCompanyofferedavoluntarylump-sumpaymentoptionforcertaineligibleformeremployeeswhoarevestedparticipants
oftheU.S.QualifiedDefinedBenefitPensionPlan.Thedistributionofthelump-sumswascompletedbytheendoffiscal2019.The
amountdistributedin2019wasapproximately$514million.
68 • Johnson&Johnson2020AnnualReportOtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2020 2019 2020 2019
AmountsRecognizedinNetPeriodicBenefitCostandOtherComprehensive
Income
Netperiodicbenefitcost $790 593 524 551
Netactuarial(gain)loss 2,616 1,084 (81) 550
Amortizationofnetactuarialloss (891) (579) (142) (129)
Priorservicecost(credit) (1,780) — — —
Amortizationofpriorservice(cost)credit (2) (4) 31 31
Effectofexchangerates 293 1 1 1
Totalloss/(income)recognizedinothercomprehensiveincome,beforetax $236 502 (191) 453
Totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome $1,026 1,095 333 1,004
TheCompanyplanstocontinuetofunditsU.S.QualifiedPlanstocomplywiththePensionProtectionActof2006.
InternationalPlansarefundedinaccordancewithlocalregulations.Additionaldiscretionarycontributionsaremadewhen
deemedappropriatetomeetthelong-termobligationsoftheplans.Forcertainplans,fundingisnotacommonpractice,as
fundingprovidesnoeconomicbenefit.Consequently,theCompanyhasseveralpensionplansthatarenotfunded.
In2020,theCompanycontributed$441millionand$429milliontoitsU.S.andinternationalpensionplans,respectively.
ThefollowingtabledisplaysthefundedstatusoftheCompany’sU.S.Qualified&Non-Qualifiedpensionplansand
internationalfundedandunfundedpensionplansatDecember31,2020andDecember31,2019,respectively:
U.S.Plans InternationalPlans
QualifiedPlans Non-QualifiedPlans FundedPlans UnfundedPlans
(DollarsinMillions) 2020 2019 2020 2019 2020 2019 2020 2019
PlanAssets $25,554 21,398 — — 12,641 10,803 — —
ProjectedBenefitObligation 25,466 22,034 2,748 2,544 14,541 12,132 545 478
AccumulatedBenefitObligation 24,158 19,831 2,495 2,115 13,210 11,040 493 430
Over(Under)FundedStatus
ProjectedBenefitObligation $88 (636) (2,748) (2,544) (1,900) (1,329) (545) (478)
AccumulatedBenefitObligation 1,396 1,567 (2,495) (2,115) (569) (237) (493) (430)
Planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligation,projected
benefitobligationandplanassetsof$8.8billion,$9.8billionand$4.4billion,respectively,attheendof2020,and
$4.3billion,$5.2billionand$0.9billion,respectively,attheendof2019.
ThefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromtheCompany’sretirementandotherbenefitplans:
(DollarsinMillions) 2021 2022 2023 2024 2025 2026-2030
Projectedfuturebenefitpayments
Retirementplans $1,257 1,292 1,388 1,424 1,494 8,795
Otherbenefitplans $427 440 453 465 417 2,273
Thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplans.Theseamounts
donotincludeanydiscretionarycontributionsthattheCompanymayelecttomakeinthefuture.
(DollarsinMillions) 2021 2022 2023 2024 2025 2026-2030
Projectedfuturecontributions $110 116 121 130 136 787
Eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand
investmentofthepensionplans.Indetermininginvestmentpolicies,strategiesandgoals,eachcommitteeorboard
considersfactorsincluding,localpensionrulesandregulations;localtaxregulations;availabilityofinvestmentvehicles
Johnson&Johnson2020AnnualReport • 69(separateaccounts,commingledaccounts,insurancefunds,etc.);fundedstatusoftheplans;ratioofactivestoretirees;
durationofliabilities;andotherrelevantfactorsincluding:diversification,liquidityoflocalmarketsandliquidityofbase
currency.AmajorityoftheCompany’spensionfundsareopentonewentrantsandareexpectedtobeon-goingplans.
Permittedinvestmentsareprimarilyliquidand/orlisted,withlittlerelianceonilliquidandnon-traditionalinvestmentssuch
ashedgefunds.
TheCompany’sretirementplanassetallocationattheendof2020and2019andtargetallocationsfor2021areasfollows:
Percentof Target
PlanAssets Allocation
2020 2019 2021
WorldwideRetirementPlans
Equitysecurities 66% 74% 67%
Debtsecurities 34 26 33
Totalplanassets 100% 100% 100%
DeterminationofFairValueofPlanAssets
ThePlanhasanestablishedandwell-documentedprocessfordeterminingfairvalues.Fairvalueisbaseduponquoted
marketprices,whereavailable.Iflistedpricesorquotesarenotavailable,fairvalueisbaseduponmodelsthatprimarily
use,asinputs,market-basedorindependentlysourcedmarketparameters,includingyieldcurves,interestrates,volatilities,
equityordebtprices,foreignexchangeratesandcreditcurves.
WhilethePlanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipants,theuseof
differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent
estimateoffairvalueatthereportingdate.
ValuationHierarchy
Theauthoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedinthetablebelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
TheNetAssetValue(NAV)isbasedonthevalueoftheunderlyingassetsownedbythefund,minusitsliabilities,andthen
dividedbythenumberofsharesoutstanding.
Afinancialinstrument’scategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis
significanttothefairvaluemeasurement.
Followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue.
• Short-terminvestmentfunds—Cashandquotedshort-terminstrumentsarevaluedattheclosingpriceortheamountheld
ondepositbythecustodianbank.OtherinvestmentsarethroughinvestmentvehiclesvaluedusingtheNAVprovidedby
theadministratorofthefund.TheNAVisaquotedpriceinamarketthatisnotactiveandclassifiedasLevel2.
• Governmentandagencysecurities—Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon
themajormarketonwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,
theinvestmentsareclassifiedwithinLevel1ofthevaluationhierarchy.Ifquotedmarketpricesarenotavailableforthe
specificsecurity,thenfairvaluesareestimatedbyusingpricingmodels,quotedpricesofsecuritieswithsimilar
characteristicsordiscountedcashflows.Whenquotedmarketpricesforasecurityarenotavailableinanactivemarket,
theyareclassifiedasLevel2.
• Debtinstruments—Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarketon
whichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,theinvestmentsare
classifiedasLevel1.Ifquotedmarketpricesarenotavailableforthespecificsecurity,thenfairvaluesareestimatedby
usingpricingmodels,quotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified
asLevel2.Level3debtinstrumentsarepricedbasedonunobservableinputs.
• Equitysecurities—Equitysecuritiesarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual
securitiesaretraded.SubstantiallyallequitysecuritiesareclassifiedwithinLevel1ofthevaluationhierarchy.
• Commingledfunds—TheseinvestmentvehiclesarevaluedusingtheNAVprovidedbythefundadministrator.Assetsin
theLevel2categoryhaveaquotedmarketprice.
70 • Johnson&Johnson2020AnnualReport• Otherassets—Otherassetsarerepresentedprimarilybylimitedpartnerships.Theseinvestmentvehiclesarevalued
usingtheNAVprovidedbythefundadministrator.Otherassetsthatareexchangelistedandactivelytradedare
classifiedasLevel1,whileinactivelytradedassetsareclassifiedasLevel2.
ThefollowingtablesetsforththeRetirementPlans’investmentsmeasuredatfairvalueasofDecember31,2020and
December31,2019:
QuotedPrices Significant
inActive Other Significant Investments
Marketsfor Observable Unobservable Measuredat
IdenticalAssets Inputs Inputs(1) NetAsset
(Level1) (Level2) (Level3) Value TotalAssets
(DollarsinMillions) 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019
Short-terminvestmentfunds $127 119 763 405 — — — — 890 524
Governmentandagencysecurities — — 5,023 4,140 — — — — 5,023 4,140
Debtinstruments — — 3,931 3,452 — — — — 3,931 3,452
Equitysecurities 14,375 12,483 2 2 — — — — 14,377 12,485
Commingledfunds — — 4,690 3,338 160 181 8,236 7,580 13,086 11,099
Otherassets — — 11 9 21 19 856 473 888 501
Investmentsatfairvalue $14,502 12,602 14,420 11,346 181 200 9,092 8,053 38,195 32,201
(1) TheactivityfortheLevel3assetsisnotsignificantforallyearspresented.
TheCompany’sOtherBenefitPlansareunfundedexceptforU.S.commingledfunds(Level2)of$90millionand
$84millionatDecember31,2020andDecember31,2019,respectivelyandU.S.short-terminvestmentfunds(Level2)
of$31millionatDecember31,2019.
ThefairvalueofJohnson&JohnsonCommonStockdirectlyheldinplanassetswas$946million(2.5%oftotalplan
assets)atDecember31,2020and$984million(3.1%oftotalplanassets)atDecember31,2019.
11. Savings Plan
TheCompanyhasvoluntary401(k)savingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible
employees.TheCompanymatchesapercentageofeachemployee’scontributionsconsistentwiththeprovisionsofthe
planforwhichhe/sheiseligible.TotalCompanymatchingcontributionstotheplanswere$243million,$235millionand
$242millioninfiscalyears2020,2019and2018,respectively.
12. Capital and Treasury Stock
Changesintreasurystockwere:
TreasuryStock
(AmountsinMillionsExceptTreasuryStockSharesinThousands) Shares Amount
BalanceatDecember31,2017 437,318 $31,554
Employeecompensationandstockoptionplans (22,082) (3,060)
Repurchaseofcommonstock 42,283 5,868
BalanceatDecember30,2018 457,519 34,362
Employeecompensationandstockoptionplans (20,053) (2,691)
Repurchaseofcommonstock 49,870 6,746
BalanceatDecember29,2019 487,336 38,417
Employeecompensationandstockoptionplans (21,765) (3,148)
Repurchaseofcommonstock 21,760 3,221
BalanceatJanuary3,2021 487,331 $38,490
Aggregatesharesofcommonstockissuedwereapproximately3,119,843,000sharesattheendoffiscalyears2020,
2019and2018.
Johnson&Johnson2020AnnualReport • 71Cashdividendspaidwere$3.98pershareinfiscalyear2020,comparedwithdividendsof$3.75pershareinfiscalyear
2019,and$3.54pershareinfiscalyear2018.
OnJanuary4,2021,theBoardofDirectorsdeclaredaregularcashdividendof$1.01pershare,payableonMarch9,
2021toshareholdersofrecordasofFebruary23,2021.
OnDecember17,2018,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$5.0billionoftheCompany’ssharesofcommonstock.Thissharerepurchase
programwascompletedasofSeptember29,2019.
13. Accumulated Other Comprehensive Income (Loss)
Componentsofothercomprehensiveincome(loss)consistofthefollowing:
Total
Gain/(Loss) Accumulated
Foreign Gain/(Loss) Employee On Other
Currency On Benefit Derivatives Comprehensive
(DollarsinMillions) Translation Securities Plans &Hedges Income(Loss)
December31,2017 $(7,351) 232 (6,150) 70 (13,199)
Cumulativeadjustmenttoretainedearnings (232)(1) (232)
Net2018changes (1,518) — (8) (265) (1,791)
December30,2018 (8,869) — (6,158) (195) (15,222)
Net2019changes 164 — (733) (100) (669)
December29,2019 (8,705) — (6,891) (295) (15,891)
Net2020changes (233) 1 (66) 947 649
January3,2021 $(8,938) 1 (6,957) 652 (15,242)
(1) PertheadoptionofASU2016-01-FinancialInstruments
Amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpact.Foreigncurrency
translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiaries.For
additionaldetailsoncomprehensiveincomeseetheConsolidatedStatementsofComprehensiveIncome.
DetailsonreclassificationsoutofAccumulatedOtherComprehensiveIncome:
Gain/(Loss)OnSecurities—reclassificationsreleasedtoOther(income)expense,net.
EmployeeBenefitPlans—reclassificationsareincludedinnetperiodicbenefitcost.SeeNote10foradditionaldetails.
Gain/(Loss)OnDerivatives&Hedges—reclassificationstoearningsarerecordedinthesameaccountasthehedged
transaction.SeeNote6foradditionaldetails.
14. International Currency Translation
Fortranslationofitssubsidiariesoperatinginnon-U.S.Dollarcurrencies,theCompanyhasdeterminedthatthelocal
currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomies,which
aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationof100%ormoreduringthepastthreeyears,
orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency.ForthemajorityoftheCompany’ssubsidiaries
thelocalcurrencyisthefunctionalcurrency.
Inconsolidatinginternationalsubsidiaries,balancesheetcurrencyeffectsarerecordedasacomponentofaccumulated
othercomprehensiveincome.TheothercurrentandnoncurrentassetslinewithintheStatementofCashflowsincludes
theimpactofforeigncurrencytranslation.Thisequityaccountincludestheresultsoftranslatingcertainbalancesheet
assetsandliabilitiesatcurrentexchangeratesandsomeaccountsathistoricalrates,exceptforthoselocatedinhighly
inflationaryeconomies,(ArgentinaandVenezuela).Thetranslationofbalancesheetaccountsforhighlyinflationary
economiesarereflectedintheoperatingresults.
Arollforwardofthechangesduringfiscalyears2020,2019and2018forforeigncurrencytranslationadjustmentsis
includedinNote13.
72 • Johnson&Johnson2020AnnualReportNetcurrencytransactiongainsandlossesincludedinOther(income)expensewerelossesof$209million,$267million
and$265millioninfiscalyears2020,2019and2018,respectively.
15. Earnings Per Share
Thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended
January3,2021,December29,2019andDecember30,2018:
(InMillionsExceptPerShareAmounts) 2020 2019 2018
Basicnetearningspershare $5.59 5.72 5.70
Averagesharesoutstanding—basic 2,632.8 2,645.1 2,681.5
Potentialsharesexercisableunderstockoptionplans 118.3 136.3 139.0
Less:sharesrepurchasedundertreasurystockmethod (80.4) (97.8) (92.5)
Convertibledebtshares — 0.7 0.7
Adjustedaveragesharesoutstanding—diluted 2,670.7 2,684.3 2,728.7
Dilutednetearningspershare $5.51 5.63 5.61
Thedilutednetearningspersharecalculationforfiscalyear2020excluded18millionsharesrelatedtostockoptions,as
theexercisepriceoftheseoptionswasgreaterthantheiraveragemarketvalue.AsofJanuary3,2021,theCompanydid
nothaveconvertibledebt.
Thedilutednetearningspersharecalculationforfiscalyear2019excludedaninsignificantnumberofsharesrelatedto
stockoptions,astheexercisepriceoftheseoptionswasgreaterthantheaveragemarketvalueoftheCompany’sstock.
Thedilutednetearningspersharecalculationforfiscalyear2019includedthedilutiveeffectofconvertibledebtthatwas
offsetbytherelatedreductionininterestexpenseof$1millionafter-tax.
Thedilutednetearningspersharecalculationforfiscalyear2018includedallsharesrelatedtostockoptions,asthe
exercisepriceofalloptionswaslessthantheaveragemarketvalueoftheCompany’sstock.Thedilutednetearningsper
sharecalculationforfiscalyear2018includedthedilutiveeffectofconvertibledebtthatwasoffsetbytherelated
reductionininterestexpenseof$1millionafter-tax.
16. Common Stock, Stock Option Plans and Stock Compensation Agreements
AtJanuary3,2021,theCompanyhad2stock-basedcompensationplans.Thesharesoutstandingareforcontractsunder
theCompany’s2005Long-TermIncentivePlanandthe2012Long-TermIncentivePlan.The2005Long-TermIncentive
PlanexpiredApril26,2012.Alloptionsandrestrictedsharesgrantedsubsequenttothatdatewereunderthe2012Long-
TermIncentivePlan.Underthe2012Long-TermIncentivePlan,theCompanymayissueupto650millionsharesof
commonstock,plusanysharescanceled,expired,forfeited,ornotissuedfromthe2005Long-TermIncentivePlan
subsequenttoApril26,2012.Sharesavailableforfuturegrantsunderthe2012Long-TermIncentivePlanwere
277millionattheendoffiscalyear2020.
Thecompensationcostthathasbeenchargedagainstincomefortheseplanswas$1,005million,$977millionand
$978millionforfiscalyears2020,2019and2018,respectively.Thetotalincometaxbenefitrecognizedintheincome
statementforshare-basedcompensationcostswas$210million,$227millionand$192millionforfiscalyears2020,
2019and2018,respectively.TheCompanyalsorecognizedadditionalincometaxbenefitsof$248million,$209million
and$264millionforfiscalyears2020,2019and2018,respectively,forwhichoptionswereexercisedorrestrictedshares
werevested.Thetotalunrecognizedcompensationcostwas$804million,$823millionand$827millionforfiscalyears
2020,2019and2018,respectively.Theweightedaverageperiodforthiscosttoberecognizedwas1.76years,
1.71yearsand1.73yearsforfiscalyears2020,2019,and2018,respectively.Share-basedcompensationcosts
capitalizedaspartofinventorywereinsignificantinallperiods.
TheCompanysettlesemployeebenefitequityissuanceswithtreasuryshares.Treasurysharesarereplenishedthrough
marketpurchasesthroughouttheyearforthenumberofsharesusedtosettleemployeebenefitequityissuances.
StockOptions
Stockoptionsexpire10yearsfromthedateofgrantandvestoverserviceperiodsthatrangefrom6monthsto4years.All
optionsaregrantedattheaverageofthehighandlowpricesoftheCompany’sCommonStockontheNewYorkStock
Exchangeonthedateofgrant.
Johnson&Johnson2020AnnualReport • 73ThefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheBlack-Scholesoptionvaluationmodel
thatusestheassumptionsnotedinthefollowingtable.For2020,2019and2018grants,expectedvolatilityrepresentsa
blendedrateof10-yearweeklyhistoricaloverallvolatilityrate,anda5-weekaverageimpliedvolatilityratebasedon
at-the-moneytradedJohnson&Johnsonoptionswithalifeof2years.Forallgrants,historicaldataisusedtodetermine
theexpectedlifeoftheoption.Therisk-freeratewasbasedontheU.S.Treasuryyieldcurveineffectatthetimeofgrant.
Theaveragefairvalueofoptionsgrantedwas$16.42,$17.80and$17.98,infiscalyears2020,2019and2018,
respectively.Thefairvaluewasestimatedbasedontheweightedaverageassumptionsof:
2020 2019 2018
Risk-freerate 1.47% 2.56% 2.77%
Expectedvolatility 15.33% 16.27% 15.77%
Expectedlife(inyears) 7.0 7.0 7.0
Expecteddividendyield 2.60% 2.80% 2.70%
AsummaryofoptionactivityunderthePlanasofJanuary3,2021,December29,2019andDecember30,2018,and
changesduringtheyearsendingonthosedatesispresentedbelow:
Aggregate
Intrinsic
Weighted Value
Outstanding Average (Dollarsin
(SharesinThousands) Shares ExercisePrice Millions)
SharesatDecember31,2017 111,306 $90.48 $5,480
Optionsgranted 17,115 129.51
Optionsexercised (16,228) 75.44
Optionscanceled/forfeited (2,541) 112.90
SharesatDecember30,2018 109,652 98.29 3,214
Optionsgranted 19,745 131.94
Optionsexercised (14,785) 82.43
Optionscanceled/forfeited (2,975) 125.11
SharesatDecember29,2019 111,637 105.63 4,478
Optionsgranted 20,723 151.41
Optionsexercised (16,275) 86.05
Optionscanceled/forfeited (1,835) 137.62
SharesatJanuary3,2021 114,250 $116.22 $4,703
Thetotalintrinsicvalueofoptionsexercisedwas$1,021million,$807millionand$1,028millioninfiscalyears2020,
2019and2018,respectively.
ThefollowingtablesummarizesstockoptionsoutstandingandexercisableatJanuary3,2021:
(SharesinThousands) Outstanding Exercisable
Weighted Weighted
Average Average
Average Exercise Exercise
ExercisePriceRange Options Life(1) Price Options Price
$62.20-$72.54 11,111 1.8 $70.79 11,111 $70.79
$90.44-$100.06 22,304 3.6 $95.36 22,304 $95.36
$100.48-$115.67 28,180 5.6 $108.64 27,695 $108.51
$129.51-$131.94 32,553 7.6 $130.85 145 $130.53
$141.06-$151.41 20,102 9.1 $151.41 34 $151.41
114,250 6.0 $116.22 61,289 $96.97
(1) Averagecontractualliferemaininginyears.
74 • Johnson&Johnson2020AnnualReportStockoptionsoutstandingatDecember29,2019andDecember30,2018were111,637andanaveragelifeof6.0years
and109,652andanaveragelifeof6.2years,respectively.StockoptionsexercisableatDecember29,2019and
December30,2018were60,761atanaveragepriceof$88.88and54,862atanaveragepriceof$82.03,respectively.
RestrictedShareUnitsandPerformance ShareUnits
TheCompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrom6monthsto3years.The
Companyalsograntsperformanceshareunits,whicharepaidinsharesofJohnson&JohnsonCommonStockafterthe
endofathree-yearperformanceperiod.Whetheranyperformanceshareunitsvest,andtheamountthatdoesvest,istied
tothecompletionofserviceperiodsthatrangefrom6monthsto3yearsandtheachievement,overathree-yearperiod,of
threeequally-weightedgoalsthatdirectlyalignwithorhelpdrivelong-termtotalshareholderreturn:operationalsales,
adjustedoperationalearningspershare,andrelativetotalshareholderreturn.Beginninginfiscal2020,performance
sharesweregrantedwithtwoequally-weightedgoalsthatdirectlyalignwithorhelpdrivelong-termtotalshareholder
return:adjustedoperationalearningspershareandrelativetotalshareholderreturn.Thenumberofsharesactuallyearned
attheendofthethree-yearperiodwillvary,basedonlyonactualperformance,from0%to200%ofthetargetnumberof
performanceshareunitsgranted.
AsummaryoftherestrictedshareunitsandperformanceshareunitsactivityunderthePlansasofJanuary3,2021is
presentedbelow:
Outstanding Outstanding
Restricted Performance
(SharesinThousands) ShareUnits ShareUnits
SharesatDecember29,2019 16,769 2,174
Granted 5,051 816
Issued (6,042) (702)
Canceled/forfeited/adjusted (780) (52)
SharesatJanuary3,2021 14,998 2,236
Theaveragefairvalueoftherestrictedshareunitsgrantedwas$139.58,$121.31and$119.67infiscalyears2020,
2019and2018,respectively,usingthefairmarketvalueatthedateofgrant.Thefairvalueofrestrictedshareunitswas
discountedfordividends,whicharenotpaidontherestrictedshareunitsduringthevestingperiod.Thefairvalueof
restrictedshareunitsissuedwas$650million,$586millionand$614millionin2020,2019and2018,respectively.
Theweightedaveragefairvalueoftheperformanceshareunitsgrantedwas$160.54,$124.67and$120.64infiscal
years2020,2019and2018,calculatedusingtheweightedaveragefairmarketvalueforeachofthecomponentgoalsat
thedateofgrant.
Thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof
grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividends,whicharenotpaidonthe
performanceshareunitsduringthevestingperiod.Thefairvaluefortherelativetotalshareholderreturngoalofeach
performanceshareunitwasestimatedonthedateofgrantusingtheMonteCarlovaluationmodel.Thefairvalueof
performanceshareunitsissuedwas$91million,$119millionand$129millioninfiscalyears2020,2019and2018,
respectively.
Johnson&Johnson2020AnnualReport • 7517. Segments of Business* and Geographic Areas
SalestoCustomers %Change
(DollarsinMillions) 2020 2019 2018 ’20vs.’19 ’19vs.’18
ConsumerHealth(1)
OTC
U.S. $2,460 2,010 1,850 22.4% 8.6
International 2,364 2,434 2,484 (2.9) (2.0)
Worldwide 4,824 4,444 4,334 8.5 2.5
SkinHealth/Beauty(2)
U.S. 2,350 2,392 2,403 (1.7) (0.4)
International 2,100 2,201 1,979 (4.6) 11.2
Worldwide 4,450 4,593 4,382 (3.1) 4.8
OralCare
U.S. 683 621 637 9.9 (2.5)
International 958 906 918 5.7 (1.2)
Worldwide 1,641 1,528 1,555 7.4 (1.7)
BabyCare
U.S. 376 362 422 3.7 (14.2)
International 1,141 1,313 1,436 (13.1) (8.6)
Worldwide 1,517 1,675 1,858 (9.4) (9.9)
Women’sHealth
U.S. 13 12 13 8.2 (5.5)
International 888 974 1,036 (8.8) (6.0)
Worldwide 901 986 1,049 (8.6) (6.0)
WoundCare/Other
U.S. 480 441 436 8.9 1.2
International 240 230 239 4.1 (3.9)
Worldwide 720 671 675 7.2 (0.6)
TOTALCONSUMERHEALTH
U.S. 6,362 5,839 5,761 9.0 1.4
International 7,691 8,059 8,092 (4.6) (0.4)
Worldwide 14,053 13,898 13,853 1.1 0.3
(1) PreviouslyreferredtoasConsumer
(2) PreviouslyreferredtoasBeauty
76 • Johnson&Johnson2020AnnualReportSalestoCustomers %Change
(DollarsinMillions) 2020 2019 2018 ’20vs.’19 ’19vs.’18
PHARMACEUTICAL
Immunology
U.S. 10,175 9,641 9,073 5.5 6.3
International 4,880 4,309 4,047 13.2 6.5
Worldwide 15,055 13,950 13,120 7.9 6.3
REMICADE®
U.S. 2,508 3,079 3,664 (18.5) (16.0)
U.S.Exports 346 294 436 18.0 (32.7)
International 893 1,007 1,226 (11.4) (17.8)
Worldwide 3,747 4,380 5,326 (14.4) (17.8)
SIMPONI/SIMPONIARIA®
U.S. 1,155 1,159 1,051 (0.3) 10.2
International 1,088 1,029 1,033 5.8 (0.4)
Worldwide 2,243 2,188 2,084 2.6 5.0
STELARA®
U.S. 5,240 4,346 3,469 20.6 25.3
International 2,467 2,015 1,687 22.4 19.4
Worldwide 7,707 6,361 5,156 21.1 23.4
TREMFYA®
U.S. 926 764 453 21.3 68.5
International 421 248 91 69.9 **
Worldwide 1,347 1,012 544 33.2 85.9
OTHERIMMUNOLOGY
U.S. — — — — —
International 11 10 10 6.4 4.5
Worldwide 11 10 10 6.4 4.5
InfectiousDiseases
U.S. 1,735 1,597 1,378 8.6 15.9
International 1,839 1,815 1,926 1.3 (5.7)
Worldwide 3,574 3,413 3,304 4.7 3.3
EDURANT®/rilpivirine
U.S. 44 50 58 (11.2) (13.7)
International 920 812 758 13.3 7.1
Worldwide 964 861 816 11.9 5.6
PREZISTA®/PREZCOBIX®/REZOLSTA®/SYMTUZA®
U.S. 1,587 1,422 1,169 11.6 21.6
International 597 689 786 (13.4) (12.3)
Worldwide 2,184 2,110 1,955 3.5 8.0
OTHERINFECTIOUSDISEASES
U.S. 104 126 151 (17.6) (16.5)
International 323 315 382 2.6 (17.6)
Worldwide 427 441 533 (3.2) (17.3)
Johnson&Johnson2020AnnualReport • 77SalestoCustomers %Change
(DollarsinMillions) 2020 2019 2018 ’20vs.’19 ’19vs.’18
Neuroscience
U.S. 3,091 2,919 2,574 5.9 13.4
International 3,457 3,409 3,503 1.4 (2.7)
Worldwide 6,548 6,328 6,077 3.5 4.1
CONCERTA®/methylphenidate
U.S. 183 233 229 (21.4) 1.7
International 439 463 434 (5.1) 6.6
Worldwide 622 696 663 (10.6) 4.9
INVEGASUSTENNA®/XEPLION®/INVEGATRINZA®/TREVICTA®
U.S. 2,314 2,107 1,791 9.8 17.6
International 1,339 1,224 1,137 9.4 7.7
Worldwide 3,653 3,330 2,928 9.7 13.7
RISPERDALCONSTA®
U.S. 296 314 315 (5.9) (0.3)
International 346 374 422 (7.5) (11.4)
Worldwide 642 688 737 (6.8) (6.7)
OTHERNEUROSCIENCE
U.S. 298 266 239 12.4 11.4
International 1,334 1,349 1,510 (1.1) (10.7)
Worldwide 1,632 1,614 1,749 1.1 (7.7)
Oncology
U.S. 5,092 4,299 4,331 18.5 (0.7)
International 7,275 6,393 5,513 13.8 16.0
Worldwide 12,367 10,692 9,844 15.7 8.6
DARZALEX®
U.S. 2,232 1,567 1,203 42.4 30.3
International 1,958 1,430 822 36.9 73.9
Worldwide 4,190 2,998 2,025 39.8 48.0
ERLEADA®
U.S. 583 297 124 96.1 **
International 176 35 — ** **
Worldwide 760 332 124 ** **
IMBRUVICA®
U.S. 1,821 1,555 1,129 17.1 37.7
International 2,307 1,856 1,486 24.3 24.9
Worldwide 4,128 3,411 2,615 21.0 30.4
VELCADE®
U.S. — — — — —
International 408 751 1,116 (45.7) (32.7)
Worldwide 408 751 1,116 (45.7) (32.7)
ZYTIGA®/abirateroneacetate
U.S. 373 810 1,771 (54.0) (54.3)
International 2,097 1,985 1,727 5.6 15.0
Worldwide 2,470 2,795 3,498 (11.6) (20.1)
78 • Johnson&Johnson2020AnnualReportSalestoCustomers %Change
(DollarsinMillions) 2020 2019 2018 ’20vs.’19 ’19vs.’18
OTHERONCOLOGY
U.S. 83 70 104 19.2 (32.7)
International 330 336 362 (1.9) (7.2)
Worldwide 413 407 466 1.7 (12.7)
PulmonaryHypertension
U.S. 2,133 1,684 1,651 26.6 2.0
International 1,015 939 922 8.2 1.9
Worldwide 3,148 2,623 2,573 20.0 1.9
OPSUMIT®
U.S. 1,008 766 700 31.7 9.4
International 631 562 515 12.3 9.0
Worldwide 1,639 1,327 1,215 23.5 9.2
UPTRAVI®
U.S. 955 714 598 33.8 19.3
International 138 105 65 30.9 62.4
Worldwide 1,093 819 663 33.5 23.5
OTHER
U.S. 169 205 353 (17.6) (41.9)
International 247 272 342 (9.2) (20.5)
Worldwide 416 476 695 (12.8) (31.5)
Cardiovascular/Metabolism/Other
U.S. 3,509 3,734 4,279 (6.0) (12.7)
International 1,369 1,458 1,537 (6.1) (5.2)
Worldwide 4,878 5,192 5,816 (6.0) (10.7)
XARELTO®
U.S. 2,345 2,313 2,477 1.4 (6.6)
International — — — — —
Worldwide 2,345 2,313 2,477 1.4 (6.6)
INVOKANA®/INVOKAMET®
U.S. 564 536 711 5.2 (24.6)
International 231 199 170 16.3 17.3
Worldwide 795 735 881 8.2 (16.5)
PROCRIT®/EPREX®
U.S. 277 505 674 (45.1) (25.1)
International 274 285 314 (3.8) (9.2)
Worldwide 552 790 988 (30.2) (20.0)
OTHER
U.S. 323 380 417 (15.1) (9.1)
International 864 974 1,053 (11.3) (7.6)
Worldwide 1,186 1,353 1,470 (12.4) (8.0)
TOTALPHARMACEUTICAL
U.S. 25,735 23,874 23,286 7.8 2.5
International 19,837 18,324 17,448 8.3 5.0
Worldwide 45,572 42,198 40,734 8.0 3.6
Johnson&Johnson2020AnnualReport • 79SalestoCustomers %Change
(DollarsinMillions) 2020 2019 2018 ’20vs.’19 ’19vs.’18
MEDICALDEVICES
DiabetesCare
U.S. — — 371 — **
International — — 638 — **
Worldwide — — 1,009 — **
InterventionalSolutions
U.S. 1,452 1,443 1,283 0.6 12.5
International 1,594 1,554 1,363 2.6 14.0
Worldwide 3,046 2,997 2,646 1.6 13.3
Orthopaedics
U.S. 4,779 5,319 5,281 (10.2) 0.7
International 2,984 3,520 3,604 (15.2) (2.3)
Worldwide 7,763 8,839 8,885 (12.2) (0.5)
HIPS
U.S. 793 863 841 (8.2) 2.6
International 487 575 577 (15.3) (0.3)
Worldwide 1,280 1,438 1,418 (11.0) 1.4
KNEES
U.S. 743 889 911 (16.4) (2.4)
International 427 591 591 (27.8) 0.0
Worldwide 1,170 1,480 1,502 (21.0) (1.4)
TRAUMA
U.S. 1,648 1,652 1,599 (0.2) 3.3
International 966 1,068 1,100 (9.6) (2.9)
Worldwide 2,614 2,720 2,699 (3.9) 0.8
SPINE,SPORTS&OTHER(3)
U.S. 1,595 1,915 1,930 (16.7) (0.8)
International 1,104 1,286 1,336 (14.1) (3.8)
Worldwide 2,699 3,201 3,266 (15.7) (2.0)
Surgery
U.S. 3,249 3,828 4,125 (15.1) (7.2)
International 4,983 5,673 5,776 (12.2) (1.8)
Worldwide 8,232 9,501 9,901 (13.4) (4.0)
ADVANCED
U.S. 1,535 1,637 1,657 (6.2) (1.2)
International 2,304 2,458 2,345 (6.2) 4.8
Worldwide 3,839 4,095 4,002 (6.2) 2.3
GENERAL
U.S. 1,714 2,192 2,468 (21.8) (11.2)
International 2,679 3,215 3,431 (16.7) (6.3)
Worldwide 4,392 5,406 5,899 (18.8) (8.4)
Vision
U.S. 1,557 1,794 1,777 (13.2) 0.9
International 2,362 2,830 2,776 (16.5) 2.0
80 • Johnson&Johnson2020AnnualReportSalestoCustomers %Change
(DollarsinMillions) 2020 2019 2018 ’20vs.’19 ’19vs.’18
Worldwide 3,919 4,624 4,553 (15.2) 1.6
CONTACTLENSES/OTHER
U.S. 1,213 1,304 1,237 (7.0) 5.4
International 1,781 2,088 2,065 (14.7) 1.1
Worldwide 2,994 3,392 3,302 (11.7) 2.7
SURGICAL
U.S. 344 490 540 (29.7) (9.4)
International 581 742 711 (21.7) 4.4
Worldwide 925 1,232 1,251 (24.9) (1.6)
TOTALMEDICALDEVICES
U.S. 11,036 12,384 12,837 (10.9) (3.5)
International 11,923 13,579 14,157 (12.2) (4.1)
Worldwide 22,959 25,963 26,994 (11.6) (3.8)
WORLDWIDE
U.S. 43,133 42,097 41,884 2.5 0.5
International 39,451 39,962 39,697 (1.3) 0.7
Worldwide $82,584 82,059 81,581 0.6% 0.6
(3) PreviouslyreferredtoasSpine&Other
* Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
** Percentagegreaterthan100%ornotmeaningful
Income(Loss)BeforeTax IdentifiableAssets
(DollarsinMillions) 2020(3) 2019(4) 2018(5) 2020 2019
ConsumerHealth $(1,064) 2,061 2,320 $27,355 26,618
Pharmaceutical 15,462 8,816 12,568 66,158 56,292
MedicalDevices 3,044 7,286 4,397 49,578 49,462
Total 17,442 18,163 19,285 143,091 132,372
Less:Expensenotallocatedtosegments(1) 945 835 1,286
Generalcorporate(2) 31,803 25,356
Worldwidetotal $16,497 17,328 17,999 $174,894 157,728
AdditionstoProperty, Depreciationand
Plant&Equipment Amortization
(DollarsinMillions) 2020 2019 2018 2020 2019 2018
ConsumerHealth $248 328 438 $785 765 688
Pharmaceutical 863 950 1,012 4,006 3,910 3,802
MedicalDevices 1,980 1,912 1,843 2,140 2,014 2,103
Segmentstotal 3,091 3,190 3,293 6,931 6,689 6,593
Generalcorporate 256 308 377 300 320 336
Worldwidetotal $3,347 3,498 3,670 $7,231 7,009 6,929
Johnson&Johnson2020AnnualReport • 81SalestoCustomers Long-LivedAssets(6)
(DollarsinMillions) 2020 2019 2018 2020 2019
UnitedStates $43,133 42,097 41,884 $49,951 41,528
Europe 18,980 18,466 18,753 49,363 48,015
WesternHemisphereexcludingU.S. 5,335 5,941 6,113 2,734 2,862
Asia-Pacific,Africa 15,136 15,555 14,831 5,484 5,486
Segmentstotal 82,584 82,059 81,581 107,532 97,891
Generalcorporate 1,029 1,049
Othernonlong-livedassets 66,333 58,788
Worldwidetotal $82,584 82,059 81,581 $174,894 157,728
SeeNote1foradescriptionofthesegmentsinwhichtheCompanyoperates.
Exportsalesarenotsignificant.Infiscalyear2020,theCompanyutilizedthreewholesalersdistributingproductsforall
threesegmentsthatrepresentedapproximately16.0%,12.0%and12.0%ofthetotalconsolidatedrevenues.Infiscalyear
2019,theCompanyhadthreewholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately
15.0%,12.0%and11.0%ofthetotalconsolidatedrevenues.Infiscalyear2018,theCompanyhadthreewholesalers
distributingproductsforallthreesegmentsthatrepresentedapproximately14.0%,11.0%,and11.0%ofthetotal
consolidatedrevenues.
(1) Amountsnotallocatedtosegmentsincludeinterest(income)expenseandgeneralcorporate(income)expense.
(2) Generalcorporateincludescash,cashequivalentsandmarketablesecurities.
(3) ConsumerHealthincludes:
• Litigationexpenseof$3.9billion,primarilytalcrelatedreservesandcertainsettlements.
Pharmaceuticalincludes:
• Litigationexpenseof$0.8billion,primarilyrelatedtotheagreementinprincipletosettleopioidlitigation
• Anunrealizedgainonsecuritiesof$0.5billion
• Arestructuringrelatedchargeof$0.1billion
MedicalDevicesincludes:
• Acontingentconsiderationreversalof$1.1billionrelatedtothetimingofcertaindevelopmentalmilestones
associatedwiththeAurisHealthacquisition.
• Litigationexpenseof$0.3billion
• Arestructuringrelatedchargeof$0.3billion
• Anin-processresearchanddevelopmentexpenseof$0.2billion
• AMedicalDeviceRegulationchargeof$0.1billion
(4) ConsumerHealthincludes:
• Againof$0.3billionrelatedtotheCompany’spreviouslyheldequityinvestmentinDR.CI:LABO
• Litigationexpenseof$0.4billion
• Arestructuringrelatedchargeof$0.1billion
Pharmaceuticalincludes:
• Litigationexpenseof$4.3billionofwhich$4.0billionisrelatedtotheagreementinprincipletosettleopioidlitigation
• Anin-processresearchanddevelopmentexpenseof$0.9billionrelatedtotheAliosasset
• Aresearchanddevelopmentexpenseof$0.3billionforanupfrontpaymentrelatedtoargenx
• Anunrealizedgainonsecuritiesof$0.6billion
• Actelionacquisitionandintegrationrelatedcostsof$0.2billion
• Arestructuringchargeof$0.1billion
MedicalDevicesincludes:
• Againof$2.0billionfromthedivestitureoftheASPbusiness
• Arestructuringrelatedchargeof$0.4billion
82 • Johnson&Johnson2020AnnualReport• Litigationexpenseof$0.4billion
• AurisHealthacquisitionandintegrationrelatedcostsof$0.1billion
(5) ConsumerHealthincludes:
• Againof$0.3billionfromthedivestitureofNIZORAL®
• Litigationexpenseof$0.3billion
Pharmaceuticalincludes:
• Anin-processresearchanddevelopmentchargeof$1.1billionrelatedtotheAliosandXO1assetsandthe
correspondingXO1contingentliabilityreversalof$0.2billion
• Actelionacquisitionandintegrationrelatedcostsof$0.2billion
• Anunrealizedlossonsecuritiesof$0.2billion
• Againof$0.2billionfromthedivestitureofcertainnon-strategicPharmaceuticalproducts
MedicalDevicesincludes:
• Litigationexpenseof$1.7billion
• Arestructuringrelatedchargeof$0.6billion
• AMOacquisitionandintegrationrelatedcostsof$0.1billion
• Againof$0.5billionfromthedivestitureoftheLifeScanbusiness
(6) Long-livedassetsincludeproperty,plantandequipment,netforfiscalyears2020,and2019of$18,766and
$17,658,respectively,andintangibleassetsandgoodwill,netforfiscalyears2020and2019of$89,795and
$81,282,respectively.
18. Acquisitions and Divestitures
Certainbusinesseswereacquiredfor$7.3billionincashand$0.4billionofliabilitiesassumedduringfiscalyear2020.
Theseacquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeen
includedinthefinancialstatementsfromtheirrespectivedatesofacquisition.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$7.5billionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.
Thefiscalyear2020acquisitionsprimarilyincluded:allrightstotheinvestigationalcompoundbermekimab,whichhas
multipledermatologicalindications,alongwithcertainemployeesfromXBiotechInc.(XBiotech),Momenta
Pharmaceuticals,Inc.(Momenta),acompanythatdiscoversanddevelopsnoveltherapiesforimmune-mediateddiseases
andtheoutstandingsharesinVerbSurgicalInc.,acompanywithsignificantroboticsanddatasciencecapabilities.
Duringthefiscalfirstquarterof2020,theCompanycompletedtheacquisitionofallrightstotheinvestigationalcompound
bermekimab,whichhasmultipledermatologicalindications,alongwithcertainemployeesfromXBiotechInc.,fora
purchasepriceof$0.8billion.Thefairvalueoftheacquisitionwasallocatedprimarilytonon-amortizableintangibleassets,
primarilyIPR&D,for$0.8billionapplyingaprobabilityofsuccessfactorthatrangedfrom20%to60%toreflectinherent
development,regulatoryandcommercialriskforthedifferentindications.Thediscountrateappliedwasapproximately
16%.XBiotechmaybeeligibletoreceiveadditionalpaymentsuponthereceiptofcertaincommercializationauthorizations.
ThetransactionwasaccountedforasabusinesscombinationandincludedinthePharmaceuticalsegment.
Additionally,inthefiscalfirstquarterof2020,theCompanycompletedtheacquisitionofalloutstandingsharesinVerb
SurgicalInc.,acompanywithsignificantroboticsanddatasciencecapabilities,includingthosesharespreviouslyheldby
Verily.ThetransactionwasaccountedforasabusinesscombinationandincludedintheMedicalDevicessegment.The
fairvalueoftheacquisitionwasallocatedprimarilytonon-amortizableintangibleassets,primarilyIPR&D,for$0.4billion,
goodwillfor$0.2billion,otherassetsof$0.2billionandliabilitiesassumedof$0.3billion.ThefairvalueoftheCompany’s
previouslyheldequityinvestmentinVerbSurgicalInc.was$0.4billion.
OnOctober1,2020,theCompanycompletedtheacquisitionofMomentaforapurchasepriceofapproximately
$6.1billion,netofcashacquired.Thefairvalueoftheacquisitionwasallocatedprimarilytonon-amortizableintangible
assets(IPR&D)of$6.0billion,goodwillof$1.2billion,otherassetsof$0.5billionandliabilitiesof$1.6billion.Theassets
Johnson&Johnson2020AnnualReport • 83acquiredareintendedtoaddresssubstantialunmetmedicalneedinmaternal-fetaldisorders,neuro-inflammatory
disorders,rheumatology,dermatologyandautoimmunehematology.Dependingontheasset,probabilityofsuccess
factorsrangingfrom20%to77%wereusedinthefairvaluecalculationtoreflectinherentdevelopmentandregulatory
riskoftheIPR&D.Thediscountrateappliedwasapproximately13%.Thegoodwillisprimarilyattributabletosynergies
expectedtoarisefromthebusinessacquisitionandisnotexpectedtobedeductiblefortaxpurposes.Thetransactionwas
accountedforasabusinesscombinationandincludedinthePharmaceuticalsegment.
Duringfiscalyear2019certainbusinesseswereacquiredfor$5.8billionincashand$1.4billionofliabilitiesassumed.
Theseacquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeen
includedinthefinancialstatementsfromtheirrespectivedatesofacquisition.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$6.8billionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.
Thefiscalyear2019acquisitionsprimarilyincludedDR.CI:LABO,aJapanesecompanyfocusedonthemarketing,
developmentanddistributionofabroadrangeofdermocosmetic,cosmeticandskincareproductsandAurisHealth,Inc.a
privatelyhelddeveloperofrobotictechnologies,initiallyfocusedinlungcancer,withanFDA-clearedplatformcurrently
usedinbronchoscopicdiagnosticandtherapeuticprocedures.
OnJanuary17,2019,theCompanyacquiredDR.CI:LABO,aJapanesecompanyfocusedonthemarketing,development
anddistributionofabroadrangeofdermocosmetic,cosmeticandskincareproductsforatotalpurchasepriceof
approximately¥230billion,whichequatestoapproximately$2.1billion,usingtheexchangerateof109.06JapaneseYen
toeachU.S.DollaronJanuary16,2019.Additionally,inthefiscalfirstquarterof2019,theCompanyrecognizedapre-tax
gainrecordedinOther(income)expense,net,ofapproximately$0.3billionrelatedtotheCompany’spreviouslyheld
equityinvestmentinDR.CI:LABO.
TheCompanytreatedthistransactionasabusinesscombinationandincludeditintheConsumerHealthsegment.During
thefiscalfirstquarterof2020,theCompanyfinalizedthepurchasepriceallocation.Thefinalfairvalueoftheacquisition
wasallocatedprimarilytoamortizableintangibleassetsfor$1.5billion,goodwillfor$1.2billionandliabilitiesof
$0.4billion.Theamortizableintangibleassetswerecomprisedofbrand/trademarksandcustomerrelationshipswitha
weightedaveragelifeof15.3yearsThegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromthebusiness
acquisitionandisnotexpectedtobedeductiblefortaxpurposes.
OnApril1,2019theCompanycompletedtheacquisitionofAurisHealth,Inc.forapproximately$3.4billion,netofcash
acquired.Additionalcontingentpaymentsofupto$2.35billion,intheaggregate,maybepayableuponreachingcertain
predeterminedmilestones.AurisHealthwasaprivatelyhelddeveloperofrobotictechnologies,initiallyfocusedinlung
cancer,withanFDA-clearedplatformcurrentlyusedinbronchoscopicdiagnosticandtherapeuticprocedures.The
CompanytreatedthistransactionasabusinesscombinationandincludeditintheMedicalDevicessegment.Thefair
valueoftheacquisitionwasallocatedprimarilytoamortizableandnon-amortizableintangibleassets,primarilyIPR&Dfor
$3.0billion,goodwillfor$2.0billion,marketablesecuritiesof$0.2billionandliabilitiesassumedof$1.8billion,which
includesthefairvalueofthecontingentpaymentsmentionedabove.Duringthefiscalsecondquarterof2020,the
Companyfinalizedthepurchasepriceallocation.Duringfiscal2020,theCompanyrecordedOtherincomeof
approximately$1.1billionforthereversalofallofthecontingentconsiderationrelatedtothetimingofcertain
developmentalandcommercialmilestones,whicharenotexpectedtobemetbasedontheCompany’scurrenttimelines.
Duringthefiscalthirdquarterof2020,theCompanyrecordedapartialIPR&Dimpairmentchargeof$0.1billionrelatedto
timingandprogressionofthedigitalsurgeryplatforms.Aprobabilityofsuccessfactorrangingfrom55%to95%was
usedinthefairvaluecalculationtoreflectinherentregulatoryandcommercialriskofthecontingentpaymentsandIPR&D.
Thediscountrateappliedwasapproximately10%.Thegoodwillisprimarilyattributabletosynergiesexpectedtoarise
fromthebusinessacquisitionandisnotexpectedtobedeductiblefortaxpurposes.
Duringfiscalyear2018certainbusinesseswereacquiredfor$0.9billionincashand$0.1billionofliabilitiesassumed.
Theseacquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeen
includedinthefinancialstatementsfromtheirrespectivedatesofacquisition.Theexcessofpurchasepriceoverthe
estimatedfairvalueoftangibleassetsacquiredamountedto$1.0billionandhasbeenassignedtoidentifiableintangible
assets,withanyresidualrecordedtogoodwill.
InaccordancewithU.S.GAAPstandardsrelatedtobusinesscombinations,andgoodwillandotherintangibleassets,
supplementalproformainformationforfiscalyears2020,2019and2018isnotprovided,astheimpactofthe
aforementionedacquisitionsdidnothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancial
position.
84 • Johnson&Johnson2020AnnualReportDivestitures
Subsequenttofiscal2020,inseparatetransactions,theCompanydivestedtwobrandsoutsidetheU.S.withinthe
Pharmaceuticalsegmentandreceivedcombinedproceedsofapproximately$0.6billion.TheCompanywillreflectthese
branddivestituresinits2021financialresults.
Duringfiscalyear2020,theCompanysold11.8millionsharesofIdorsiaLTD(Idorsia),orits8.3%ownershipinthe
company.ThetransactionresultedingrossproceedsofapproximatelyCHF337million($357million)basedonasales
priceofCHF28.55/shareandanimmaterialnetloss.TheCompanycurrentlyhasrightstoatleastanadditional
38.7millionshares(orapproximately20%ofIdorsiaequity)throughaconvertibleloanwithaprincipalamountofCHF
445million(dueJune2027).IdorsiaalsohasaccesstoanapproximateCHF243millioncreditfacilitywiththeCompany.
AsofJanuary3,2021,Idorsiahasnotmadeanydraw-downsunderthecreditfacility.
Duringfiscalyear2019,theCompanydivesteditsASPbusinesstoFortiveCorporationforanaggregatevalueof
approximately$2.8billion,consistingof$2.7billionofcashproceedsand$0.1billionofretainednetreceivables.The
Companyrecognizedapre-taxgainrecordedinOther(income)expense,net,ofapproximately$2.0billion.
Duringfiscalyear2018,theCompanydivestedtheLifeScanIncbusinessforapproximately$2.1billionandretained
certainnetliabilities.Otherdivestituresinfiscalyear2018included:NIZORAL®,RoC®andcertainnon-strategic
Pharmaceuticalproducts.In2018,thepre-taxgainsonthedivestitureswereapproximately$1.2billion.
Infiscalyear2018,theCompanyacceptedabindingoffertoformastrategiccollaborationwithJabilInc.,oneofthe
world’sleadingmanufacturingservicesprovidersforhealthcareproductsandtechnologyproducts.TheCompanyis
expandinga12-yearrelationshipwithJabiltoproducearangeofproductswithintheEthiconEndo-SurgeryandDePuy
Synthesbusinesses.Thistransactionincludesthetransferofemployeesandmanufacturingsites.Thetransferswere
completedinfiscalyear2020.AsofJanuary3,2021,therewerenoassetsheldforsaleontheConsolidatedBalance
Sheet.AsofDecember29,2019,theassetsheldforsaleontheConsolidatedBalanceSheetwere$0.1billionof
inventoryandproperty,plantandequipment,net.ForadditionaldetailsontheglobalsupplychainrestructuringseeNote
20totheConsolidatedFinancialStatements.
19. Legal Proceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability;
intellectualproperty;commercial;supplierindemnificationandothermatters;governmentalinvestigations;andotherlegal
proceedingsthatarisefromtimetotimeintheordinarycourseoftheirbusiness.Duetotheongoingimpactsofthe
COVID-19pandemic,certaintrialshavebeenrescheduledordelayed.TheCompanycontinuestomonitoritslegal
proceedingsasthesituationevolves.
TheCompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata
liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimated.AsofJanuary3,2021,theCompanyhas
determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimated.The
Companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight
bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithASC450-20-25.Fortheseand
otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossible,theCompany
isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccrued.Amountsaccruedforlegal
contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon
estimatesandassumptionsincludingtimingofrelatedpayments.Theabilitytomakesuchestimatesandjudgmentscanbe
affectedbyvariousfactorsincluding,amongotherthings,whetherdamagessoughtintheproceedingsare
unsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnotcommencedorisnotcomplete;proceedingsarein
earlystages;matterspresentlegaluncertainties;therearesignificantfactsindispute;proceduralorjurisdictionalissues;
theuncertaintyandunpredictabilityofthenumberofpotentialclaims;abilitytoachievecomprehensivemulti-party
settlements;complexityofrelatedcross-claimsandcounterclaims;and/ortherearenumerouspartiesinvolved.Tothe
extentadverseverdictshavebeenrenderedagainsttheCompany,theCompanydoesnotrecordanaccrualuntilalossis
determinedtobeprobableandcanbereasonablyestimated.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutionof,orincreaseinaccrualsfor,
oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
Johnson&Johnson2020AnnualReport • 85PRODUCTLIABILITY
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving
multipleproducts.Claimantsinthesecasesseeksubstantialcompensatoryand,whereavailable,punitivedamages.While
theCompanybelievesithassubstantialdefenses,itisnotfeasibletopredicttheultimateoutcomeoflitigation.Fromtime
totime,evenifithassubstantialdefenses,theCompanyconsidersisolatedsettlementsbasedonavarietyof
circumstances.TheCompanyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewithASC
450-20basedoncurrentlyavailableinformation,whichinsomecasesmaybelimited.TheCompanyaccruesanestimate
ofthelegaldefensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonably
estimated.Forcertainofthesematters,theCompanyhasaccruedadditionalamountssuchasestimatedcostsassociated
withsettlements,damagesandotherlosses.Productliabilityaccrualscanrepresentprojectedproductliabilityfor
thousandsofclaimsaroundtheworld,eachindifferentlitigationenvironmentsandwithdifferentfactpatterns.Changesto
theaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable.
Themostsignificantofthesecasesinclude:theDePuyASR™XLAcetabularSystemandDePuyASR™HipResurfacing
System;thePINNACLE®AcetabularCupSystem;pelvicmeshes;RISPERDAL®;XARELTO®;bodypowderscontaining
talc,primarilyJOHNSONS®BabyPowder;INVOKANA®;andETHICONPHYSIOMESH®FlexibleCompositeMesh.Asof
January3,2021,intheUnitedStatestherewereapproximately560plaintiffswithdirectclaimsinpendinglawsuits
regardinginjuriesallegedlyduetotheDePuyASR™XLAcetabularSystemandDePuyASR™HipResurfacingSystem;
7,800withrespecttothePINNACLE®AcetabularCupSystem;14,900withrespecttopelvicmeshes;9,300with
respecttoRISPERDAL®;12,600withrespecttoXARELTO®;25,000withrespecttobodypowderscontainingtalc;300
withrespecttoINVOKANA®;and4,200withrespecttoETHICONPHYSIOMESH®FlexibleCompositeMesh.
InAugust2010,DePuyOrthopaedics,Inc.(DePuy)announcedaworldwidevoluntaryrecallofitsASR™XLAcetabular
SystemandDePuyASR™HipResurfacingSystemusedinhipreplacementsurgery.Claimsforpersonalinjuryhavebeen
madeagainstDePuyandJohnson&Johnson.Thenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuits
aresettledordismissedandadditionallawsuitsarefiled.CasesfiledinfederalcourtsintheUnitedStateshavebeen
organizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheNorthernDistrictofOhio.Litigationhas
alsobeenfiledincountriesoutsideoftheUnitedStates,primarilyintheUnitedKingdom,Canada,Australia,Ireland,
Germany,IndiaandItaly.InNovember2013,DePuyreachedanagreementwithaCourt-appointedcommitteeoflawyers
representingASRHipSystemplaintiffstoestablishaprogramtosettleclaimswitheligibleASRHippatientsintheUnited
StateswhohadsurgerytoreplacetheirASRHips,knownasrevisionsurgery,asofAugust31,2013.DePuyreached
additionalagreementsinFebruary2015andMarch2017,whichfurtherextendedthesettlementprogramtoincludeASR
HippatientswhohadrevisionsurgeriesafterAugust31,2013andpriortoFebruary15,2017.Thissettlementprogram
hasresolvedmorethan10,000claims,thereforebringingtoresolutionsignificantASRHiplitigationactivityintheUnited
States.However,lawsuitsintheUnitedStatesremain,andthesettlementprogramdoesnotaddresslitigationoutsideof
theUnitedStates.InAustralia,aclassactionsettlementwasreachedthatresolvedtheclaimsofthemajorityofASRHip
patientsinthatcountry.InCanada,theCompanyhasreachedagreementstosettletheclassactionsfiledinthatcountry.
TheCompanycontinuestoreceiveinformationwithrespecttopotentialadditionalcostsassociatedwiththisrecallona
worldwidebasis.TheCompanyhasestablishedaccrualsforthecostsassociatedwiththeUnitedStatessettlement
programandDePuyASR™Hip-relatedproductliabilitylitigation.
ClaimsforpersonalinjuryhavealsobeenmadeagainstDePuyOrthopaedics,Inc.andJohnson&Johnson(collectively,
DePuy)relatingtothePINNACLE®AcetabularCupSystemusedinhipreplacementsurgery.Productliabilitylawsuits
continuetobefiled,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipated
numberofcases.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-districtlitigationinthe
UnitedStatesDistrictCourtfortheNorthernDistrictofTexas.Litigationhasalsobeenfiledinsomestatecourtsandin
countriesoutsideoftheUnitedStates.SeveraladverseverdictshavebeenrenderedagainstDePuy,oneofwhichwas
reversedonappealandremandedforretrial.Duringthefirstquarterof2019,DePuyestablishedaUnitedStates
settlementprogramtoresolvethesecases.Aspartofthesettlementprogram,adverseverdictshavebeensettled.The
CompanyhasestablishedanaccrualforproductliabilitylitigationassociatedwiththePINNACLE®AcetabularCup
Systemandtherelatedsettlementprogram.
ClaimsforpersonalinjuryhavebeenmadeagainstEthicon,Inc.(Ethicon)andJohnson&JohnsonarisingoutofEthicon’s
pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapse.TheCompanycontinuesto
receiveinformationwithrespecttopotentialcostsandadditionalcases.CasesfiledinfederalcourtsintheUnitedStates
hadbeenorganizedasamulti-districtlitigation(MDL)intheUnitedStatesDistrictCourtfortheSouthernDistrictofWest
Virginia.TheMDLCourtisremandingcasesfortrialtothejurisdictionswherethecasewasoriginallyfiledandadditional
pelvicmeshlawsuitshavebeenfiled,andremain,outsideoftheMDL.TheCompanyhassettledorotherwiseresolveda
86 • Johnson&Johnson2020AnnualReportmajorityoftheUnitedStatescasesandtheestimatedcostsassociatedwiththesesettlementsandtheremainingcases
arereflectedintheCompany’saccruals.Inaddition,classactionsandindividualpersonalinjurycasesorclaimshavebeen
commencedinvariouscountriesoutsideoftheUnitedStates,includingclaimsandcasesintheUnitedKingdom,the
Netherlands,andclassactionsinIsrael,AustraliaandCanada,seekingdamagesforallegedinjuryresultingfromEthicon’s
pelvicmeshdevices.InNovember2019,theFederalCourtofAustraliaissuedajudgmentregardingitsfindingswith
respecttoliabilityinrelationtothethreeLeadApplicantsandgenerallyinrelationtothedesign,manufacture,preand
post-marketassessmentsandtesting,andsupplyandpromotionofthedevicesinAustraliausedtotreatstressurinary
incontinenceandpelvicorganprolapse.InMarch2020,theCourtentereddamagesawardstothethreeLeadApplicants.
TheCompanyisappealingthedecision.Withrespecttoothergroupmembers,therewillbeanindividualcase
assessmentprocesswhichwillrequireproofofuseandcausallyrelatedloss.Theformoftheindividualcaseassessment
processhasnotyetbeendeterminedbytheCourt.TheclassactionsinCanadawerediscontinuedin2020asaresultof
asettlementofagroupofcases.TheCompanyhasestablishedaccrualswithrespecttoproductliabilitylitigation
associatedwithEthicon’spelvicmeshproducts.
FollowingaJune2016worldwidemarketwithdrawalofETHICONPHYSIOMESH®FlexibleCompositeMesh,claimsfor
personalinjuryhavebeenmadeagainstEthicon,Inc.andJohnson&Johnsonallegingpersonalinjuryarisingoutoftheuse
ofthisherniameshdevice.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-district
litigation(MDL)intheUnitedStatesDistrictCourtfortheNorthernDistrictofGeorgia.Amulti-countylitigation(MCL)has
alsobeenformedinNewJerseystatecourtandassignedtoAtlanticCountyforcasespendinginNewJersey.Inaddition
tothemattersintheMDLandMCL,thereareadditionallawsuitspendingintheUnitedStatesDistrictCourtforthe
SouthernDistrictofOhio,whicharepartoftheMDLforpolypropylenemeshdevicesmanufacturedbyC.R.Bard,Inc.,and
lawsuitspendingoutsidetheUnitedStates.Discoveryisproceedinginthesecasesandcertainofthecasesarein
preparationfortrials.
ClaimshavealsobeenfiledagainstEthiconandJohnson&JohnsonallegingpersonalinjuriesarisingfromthePROCEED®
MeshandPROCEED®VentralPatchherniameshproducts.InMarch2019,theNewJerseySupremeCourtenteredan
orderconsolidatingthesecasespendinginNewJerseyasanMCLinAtlanticCountySuperiorCourt.Additionalcases
havebeenfiledinvariousfederalandstatecourtsintheUS,andinjurisdictionsoutsidetheUS.Discoveryisunderwayin
thesecases.
InSeptember2019,plaintiffs’attorneyfiledanapplicationwiththeNewJerseySupremeCourtseekingcentralized
managementof107PROLENE™PolypropyleneHerniaSystem(“PHS”)cases.TheNewJerseySupremeCourtgranted
plaintiffsapplicationinJanuary2020andthosecaseshavealsobeentransferredtoanMCLinAtlanticCountySuperior
Court.Discoveryisunderwayinthesecases.
TheCompanyhasestablishedaccrualswithrespecttoproductliabilitylitigationassociatedwithETHICON
PHYSIOMESH®FlexibleCompositeMesh,PROCEED®MeshandPROCEED®VentralPatch,andPROLENE™
PolypropyleneHerniaSystemproducts.
ClaimsforpersonalinjuryhavebeenmadeagainstJanssenPharmaceuticals,Inc.andJohnson&Johnsonarisingoutofthe
useofRISPERDAL®,andrelatedcompounds,indicatedforthetreatmentofschizophrenia,acutemanicormixedepisodes
associatedwithbipolarIdisorderandirritabilityassociatedwithautism.Lawsuitshavebeenprimarilyfiledinstatecourtsin
Pennsylvania,California,andMissouri.OtheractionsarependinginvariouscourtsintheUnitedStatesandCanada.
Productliabilitylawsuitscontinuetobefiled,andtheCompanycontinuestoreceiveinformationwithrespecttopotential
costsandtheanticipatednumberofcases.TheCompanyhassuccessfullydefendedanumberofthesecasesbutthere
havebeenverdictsagainsttheCompany,includingaverdictinOctober2019of$8.0billionofpunitivedamagesrelated
toonesingleplaintiffwhichwassubsequentlyreducedinJanuary2020to$6.8millionbythetrialjudge.TheCompany
andplaintiffareeachappealingthisjudgment.TheCompanyhassettledorotherwiseresolvedmanyoftheUnitedStates
casesandthecostsassociatedwiththesesettlementsarereflectedintheCompany’saccruals.
ClaimsforpersonalinjuryarisingoutoftheuseofXARELTO®,anoralanticoagulant,havebeenmadeagainstJanssen
Pharmaceuticals,Inc.(JPI);Johnson&Johnson(J&J);andJPI’scollaborationpartnerforXARELTO®,BayerAGandcertain
ofitsaffiliates.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-districtlitigationinthe
UnitedStatesDistrictCourtfortheEasternDistrictofLouisiana.Inaddition,caseshavebeenfiledinstatecourtsacrossthe
UnitedStates.ManyofthesecaseswereconsolidatedintoastatemasstortlitigationinPhiladelphia,Pennsylvaniaandina
coordinatedproceedinginLosAngeles,California.ClassactionlawsuitsalsohavebeenfiledinCanada.InMarch2019,JPI
andJ&JannouncedanagreementinprincipletothesettletheXARELTO®casesintheUnitedStates;thesettlement
agreementwasexecutedinMay2019,thesettlementbecamefinalinDecember2019,andthesettlementwasfundedin
January2020.ThisresolvedthemajorityofcasespendingintheUnitedStates.TheCompanyhasestablishedaccrualsfor
itscostsassociatedwiththeUnitedStatessettlementprogramandXARELTO®relatedproductliabilitylitigation.
Johnson&Johnson2020AnnualReport • 87PersonalinjuryclaimsallegingthattalccausescancerhavebeenmadeagainstJohnson&JohnsonConsumerInc.and
Johnson&Johnsonarisingoutoftheuseofbodypowderscontainingtalc,primarilyJOHNSON’S®BabyPowder.The
numberofpendingpersonalinjurylawsuitscontinuestoincrease,andtheCompanycontinuestoreceiveinformationwith
respecttopotentialcostsandtheanticipatednumberofcases.Lawsuitshavebeenprimarilyfiledinstatecourtsin
Missouri,NewJerseyandCalifornia,andsuitshavealsobeenfiledoutsidetheUnitedStates.Themajorityofcasesare
pendinginfederalcourt,organizedintoamulti-districtlitigation(MDL)intheUnitedStatesDistrictCourtfortheDistrictof
NewJersey.IntheMDL,thepartiessoughttoexcludeexpertsthroughDaubertmotions.InApril2020,theCourtissued
rulingsthatlimitthescopeoftestimony,includingsometheoriesandtestingmethods,forcertainplaintiffexpertwitnesses
anddeniedplaintiffs’attempttolimitthescopeoftestimonyofcertainoftheCompany’switnesses.Withthisrulingmade,
case-specificdiscoveryhasbegunpertheCourt’sdirective.
Intalccasesthathavepreviouslygonetotrial,theCompanyhasobtaineddefenseverdictsinanumberofthem,butthere
havealsobeenverdictsagainsttheCompany,manyofwhichhavebeenreversedonappeal.InJune2020,theMissouri
CourtofAppealsreversedinpartandaffirmedinpartaJuly2018verdictof$4.7billioninInghamv.Johnson&Johnson,et
al.,No.ED207476(Mo.App.),reducingtheoverallawardto$2.1billionand,withadditionalinterestasofJanuary3,
2021,astheCompanypursuesfurtherappeal,iscurrently$2.5billion(theInghamdecision).Anapplicationfortransferof
thecasetotheMissouriSupremeCourtwassubsequentlydenied,andtheCompanyiscurrentlyseekingreviewbythe
UnitedStatesSupremeCourt.TheCompanycontinuestobelievethatithasstronglegalgroundsfortheappealofthis
verdict,aswellasotherverdictsthatithasappealed.NotwithstandingtheCompany’sconfidenceinthesafetyofitstalc
products,incertaincircumstancestheCompanyhasandmaysettlecases.TheCompanyhasestablishedanaccrualfor
defensecostsandreservesfortheresolutionofcertaincasesandclaims,includingtheInghamdecisioncurrentlyon
appeal,inconnectionwithproductliabilitylitigationassociatedwithbodypowderscontainingtalc.
InFebruary2019,theCompany’stalcsupplier,ImerysTalcAmerica,Inc.andtwoofitsaffiliates,ImerysTalcVermont,Inc.
andImerysTalcCanada,Inc.(collectively,Imerys)filedavoluntarychapter11petitioncommencingareorganizationunder
theUnitedStatesBankruptcyCodeintheUnitedStatesBankruptcyCourtfortheDistrictofDelaware(Imerys
Bankruptcy).TheImerysBankruptcyrelatestoImerys’potentialliabilityforpersonalinjuryfromexposuretotalcumpowder
soldbyImerys(TalcClaims).Initsbankruptcyfiling,ImerysnotedcertainclaimsitallegesithasagainsttheCompanyfor
indemnificationandrightstojointinsuranceproceeds.TheCompanypreviouslyproposedtoresolveImerys’(andthe
Company’s)obligationsarisingoutoftheTalcClaimsbyagreeingtoassumethedefenseoflitigationofallTalcClaims
involvingtheCompany’sproducts,waivingtheCompany’sindemnificationclaimsagainstImerys,andliftingtheautomatic
staytoenabletheTalcClaimstoproceedoutsidethebankruptcyforumwiththeCompanyagreeingtosettleorpayany
judgmentagainstImerys.InMay2020,Imerysandtheasbestosclaimants’committee(PlanProponents)filedtheirPlanof
Reorganization(thePlan)andtheDisclosureStatementrelatedtheretoagreeingtoputitsNorthAmericanoperationsup
forauctionwhichwassubsequentlyamended.TheCompanyhasobjectedtotheDisclosureStatementandintendsto
objecttothePlanofReorganizationascurrentlystructured.Additionally,inJune2020,CyprusMinesCorporationandits
parent(Cyprus)filedanadversaryproceedingagainsttheCompanyaswellasImerysseekingadeclarationofindemnity
undercertaincontractualagreements.TheCompanydeniessuchindemnificationisowedandfiledamotiontodismissthe
adversarycomplaintarguing,amongotherthings,thattheCourtdoesnothavesubjectmatterjurisdictionoverCyprus’s
claimsagainsttheCompany.ThePlanProponentsfilednumerousamendmentstothePlanandDisclosureStatementto
whichtheCompanyobjected.AhearingonthePlanProponent’sDisclosureStatementwasheldinJanuary2021,andthe
CourtenteredanorderapprovingtheDisclosureStatementfortheNinthAmendedJointChapter11Planof
ReorganizationofImerysTalcAmerica,Inc.anditsDebtorAffiliatesallowingDebtorstoproceedwithsolicitingvoteson
thePlan.TheCompanyintendstocontinuetoobjecttothePlan.AhearingtoconsiderconfirmationofthePlanhasbeen
scheduledforJune2021.
InFebruary2018,asecuritiesclassactionlawsuitwasfiledagainstJohnson&Johnsonandcertainnamedofficersinthe
UnitedStatesDistrictCourtfortheDistrictofNewJersey,allegingthatJohnson&Johnsonviolatedthefederalsecurities
lawsbyfailingtodiscloseallegedasbestoscontaminationinbodypowderscontainingtalc,primarilyJOHNSON’S®Baby
Powder,andthatpurchasersofJohnson&Johnson’ssharessufferedlossesasaresult.Plaintiffisseekingdamages.In
April2019,theCompanymovedtodismissthecomplaintandbriefingonthemotionwascompleteasofAugust2019.In
December2019,theCourtdenied,inpart,themotiontodismiss.InMarch2020,Defendantsansweredthecomplaint.
Discoveryisunderway.
InJune2019,ashareholderfiledacomplaintinitiatingasummaryproceedinginNewJerseystatecourtforabooksand
recordsinspection.InAugust2019,Johnson&Johnsonrespondedtothebooksandrecordscomplaintandfiledacross
motiontodismiss.InSeptember2019,PlaintiffrepliedandtheCourtheardoralargument.TheCourthasnotyetruledin
thebooksandrecordsaction.InOctober2019,December2019,andJanuary2020,fourshareholdersfiledfourseparate
derivativelawsuitsagainstJohnson&Johnsonasthenominaldefendantanditscurrentdirectorsandcertainofficersas
88 • Johnson&Johnson2020AnnualReportdefendantsintheUnitedStatesDistrictCourtfortheDistrictofNewJersey,allegingabreachoffiduciarydutiesrelatedto
theallegedasbestoscontaminationinbodypowderscontainingtalc,primarilyJOHNSON’S®BabyPowder,andthat
Johnson&Johnsonhassuffereddamagesasaresultofthoseallegedbreaches.InFebruary2020,thefourcaseswere
consolidatedintoasingleactionunderthecaptionInreJohnson&JohnsonTalcStockholderDerivativeLitigation.
InJuly2020,areportwasdeliveredtotheCompany’sBoardofDirectorsbyindependentcounselretainedbytheBoard
toinvestigatetheallegationsinthederivativelawsuitsandinaseriesofshareholderlettersthattheBoardreceivedraising
similarissues.FouroftheshareholderswhosentdemandsareplaintiffsintheInreJohnson&JohnsonTalcStockholder
DerivativeLitigation.TheindependentcounselrecommendedthattheCompanyrejecttheshareholderdemandsandtake
thestepsthatarenecessaryorappropriatetosecuredismissalofthederivativelawsuits.TheBoardunanimouslyadopted
therecommendationsoftheindependentcounsel’sreport.InOctober2020,theshareholdersfiledaconsolidated
complaint,andinJanuary2021,Johnson&Johnsonmovedtodismisstheconsolidatedcomplaint.
InJanuary2019,twoERISAclassactionlawsuitswerefiledbyparticipantsintheJohnson&JohnsonSavingsPlan
againstJohnson&Johnson,itsPensionandBenefitsCommittee,andcertainnamedofficersintheUnitedStatesDistrict
CourtfortheDistrictofNewJersey,allegingthatthedefendantsbreachedtheirfiduciarydutiesbyofferingJohnson&
JohnsonstockasaJohnson&JohnsonSavingsPlaninvestmentoptionwhenitwasimprudenttodosobecauseof
failurestodiscloseallegedasbestoscontaminationinbodypowderscontainingtalc,primarilyJOHNSON’S®Baby
Powder.Plaintiffsareseekingdamagesandinjunctiverelief.InSeptember2019,Defendantsfiledamotiontodismiss.In
April2020,theCourtgrantedDefendants’motionbutgrantedleavetoamend.InJune2020,Plaintiffsfiledanamended
complaint,andinJuly2020,Defendantsmovedtodismisstheamendedcomplaint.AsofOctober2020,briefingon
Defendants’motionwascomplete.
AlawsuitpendingintheSuperiorCourtofCaliforniafortheCountyofSanDiegoallegingviolationsofCalifornia’s
ConsumerLegalRemediesActrelatingtoJOHNSON’S®BabyPowderhasbeenresolvedintheCompany’sfavor.Inthat
lawsuit,theplaintiffsallegethatJohnson&JohnsonviolatedtheCLRAbyfailingtoproviderequiredProposition65
warnings.InJuly2019,theCompanyfiledanoticeofremovaltotheUnitedStatesDistrictCourtfortheSouthernDistrict
ofCaliforniaandplaintiffsfiledasecondamendedcomplaintshortlythereafter.InOctober2019,theCompanymovedto
dismissthesecondamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybegranted.Inresponsetothose
motions,plaintiffsfiledathirdamendedcomplaint.InDecember2019,theCompanymovedtodismissthethirdamended
complaintforfailuretostateaclaimuponwhichreliefmaybegranted.InApril2020,theCourtgrantedthemotionto
dismissbutgrantedleavetoamend.InMay2020,plaintiffsfiledaFourthAmendedComplaintbutindicatedthatthey
wouldbefilingamotionforleavetofileafifthamendedcomplaint.PlaintiffsfiledaFifthAmendedComplaintinAugust
2020.TheCompanymovedtodismisstheFifthAmendedComplaintforfailuretostateaclaimuponwhichreliefmaybe
granted.InJanuary2021,theCourtissuedanOrderandopinionrulingintheCompany’sfavorandgrantingthemotionto
dismisswithprejudice.
InJanuary2020,theAbtahiLawGroupfiledanactionunderProposition65againstJohnson&JohnsonandJohnson&
JohnsonConsumerInc.aswellasanumberofotherallegedtalcumpowdermanufacturersanddistributors,includingone
Californiacompany.Inthataction,theplaintiffallegescontaminationoftalcumpowderproductswithunsafelevelsof
arsenic,hexavalentchromiumandlead.Theplaintiffseekscivilpenaltiesandinjunctiverelief.Defendantsfiledamotionfor
summaryjudgmentinJanuary2021,andahearinghasbeenscheduledforApril2021.Limitedinformaldiscoveryis
continuing.
Inaddition,theCompanyhasreceivedpreliminaryinquiriesandsubpoenastoproducedocumentsregardingthese
mattersfromSenatorMurray,amemberoftheSenateCommitteeonHealth,Education,LaborandPensions,the
DepartmentofJustice,theSecuritiesandExchangeCommission(SEC)andtheU.S.CongressionalSubcommitteeon
EconomicandConsumerPolicy.TheCompanyproduceddocumentsasrequiredinresponseandwillcontinueto
cooperatewithgovernmentinquiries.InNovember2020,theSECterminateditsinvestigation.
ClaimsforpersonalinjuryhavebeenmadeagainstanumberofJohnson&Johnsoncompanies,includingJanssen
Pharmaceuticals,Inc.andJohnson&Johnson,arisingoutoftheuseofINVOKANA®,aprescriptionmedicationindicated
toimproveglycemiccontrolinadultswithType2diabetes.InDecember2016,lawsuitsfiledinfederalcourtsintheUnited
Stateswereorganizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheDistrictofNewJersey.Cases
havealsobeenfiledinstatecourts.ClassactionlawsuitshavebeenfiledinCanada.Productliabilitylawsuitscontinueto
befiled,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof
cases.TheCompanyhassettledorotherwiseresolvedmanyofthecasesandclaimsintheUnitedStatesandthecosts
associatedwiththesesettlementsarereflectedintheCompany’saccruals.
Johnson&Johnson2020AnnualReport • 89ClaimsforpersonalinjuryhavebeenmadeagainstanumberofJohnson&Johnsoncompanies,includingJanssen
Pharmaceuticals,Inc.andJohnson&Johnson,arisingoutoftheuseofELMIRON®,aprescriptionmedicationindicatedfor
thereliefofbladderpainordiscomfortassociatedwithinterstitialcystitis.Theselawsuits,whichallegethatELMIRON®
contributestothedevelopmentofpermanentretinalinjuryandvisionloss,havebeenfiledinbothstateandfederalcourts
acrosstheUnitedStates.InDecember2020,thefederalcases,includingtwoputativeclassactioncasesseekingmedical
monitoring,wereorganizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheDistrictofNewJersey.In
addition,threeclassactionlawsuitshavebeenfiledinCanada.Productliabilitylawsuitscontinuetobefiled,andthe
Companycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcases.The
CompanyhasestablishedaccrualsfordefensecostsassociatedwithELMIRON®relatedproductliabilitylitigation.
INTELLECTUALPROPERTY
CertainsubsidiariesofJohnson&Johnsonaresubject,fromtimetotime,tolegalproceedingsandclaimsrelatedto
patent,trademarkandotherintellectualpropertymattersarisingoutoftheirbusinesses.Manyofthesemattersinvolve
challengestothecoverageand/orvalidityofthepatentsonvariousproductsandallegationsthatcertainoftheCompany’s
productsinfringethepatentsofthirdparties.Althoughthesesubsidiariesbelievethattheyhavesubstantialdefensesto
thesechallengesandallegationswithrespecttoallsignificantpatents,therecanbenoassuranceastotheoutcomeof
thesematters.Alossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproducts,
resultinlossofsalesduetolossofmarketexclusivity,requirethepaymentofpastdamagesandfutureroyalties,andmay
resultinanon-cashimpairmentchargeforanyassociatedintangibleasset.Significantmattersaredescribedbelow.
MedicalDevices
InNovember2016,MedIdea,L.L.C.(MedIdea)filedapatentinfringementlawsuitagainstDePuyOrthopaedics,Inc.inthe
UnitedStatesDistrictCourtfortheNorthernDistrictofIllinoisalleginginfringementbytheATTUNE®KneeSystem.In
April2017,MedIdeafiledanamendedcomplaintaddingDePuySynthesProducts,Inc.andDePuySynthesSales,Inc.as
nameddefendants(collectively,DePuy).MedIdeaallegedinfringementofUnitedStatesPatentNos.6,558,426(’426);
8,273,132(’132);8,721,730(’730)and9,492,280(’280)relatingtoposteriorstabilizedkneesystems.Specifically,
MedIdeaallegesthattheSOFCAMTMContactfeatureoftheATTUNE®posteriorstabilizedkneeproductsinfringesthe
patents-in-suit.MedIdeaisseekingmonetarydamagesandinjunctiverelief.InJune2017,thecasewastransferredtothe
UnitedStatesDistrictCourtfortheDistrictofMassachusetts.InNovember2019,judgmentwasenteredinfavorof
DePuy.InJanuary2021,theU.S.CourtofAppealsfortheFederalCircuitaffirmed.
InDecember2016,Dr.FordAlbrittonsuedAcclarent,Inc.(Acclarent)inUnitedStatesDistrictCourtfortheNorthern
DistrictofTexasallegingthatAcclarent’sRELIEVA®SpinandRELIEVEASpinPlus®productsinfringeU.S.Patent
No.9,011,412.Dr.Albrittonalsoallegesbreachofcontract,fraudandthatheisthetrueownerofAcclarent’sU.S.Patent
No.8,414,473.TrialisscheduledtobegininOctober2021.
InNovember2017,BoardofRegents,TheUniversityofTexasSystemandTissueGen,Inc.(collectively,UT)filedalawsuit
intheUnitedStatesDistrictCourtfortheWesternDistrictofTexasagainstEthicon,Inc.andEthiconUS,LLC
(collectively,Ethicon)allegingthemanufactureandsaleofVICRYL®PlusAntibacterialSutures,MONOCRYL®Plus
AntibacterialSutures,PDS®PlusAntibacterialSutures,STRATAFIX®PDS®AntibacterialSuturesandSTRATAFIX®
MONOCRYL®PlusAntibacterialSuturesinfringeplaintiffs’UnitedStatesPatentNos.6,596,296(’296)and7,033,603
(’603)directedtoimplantablepolymerdrugreleasingbiodegradablefiberscontainingatherapeuticagent.UTisseeking
damagesandaninjunction.InDecember2018,EthiconfiledpetitionswiththeUnitedStatesPatentandTrademarkOffice
(USPTO),seekingInterPartesReview(IPR)ofbothassertedpatents.InJune2020,theUSPTOdeniedinstitutionofthe
’296patentIPRandgrantedinstitutionofthe’603patentIPR.UTdismissedthe’603patentfromthesuitandnolonger
accusesPDS®PlusAntibacterialSuturesorSTRATAFIX®PDS®PlusAntibacterialSuturesofinfringement.The
previouslyscheduleddistrictcourttrialhasbeenpostponed.
InAugust2018,IntuitiveSurgical,Inc.andIntuitiveSurgicalOperations,Inc.(collectively,Intuitive)filedapatent
infringementsuitagainstAurisHealth,Inc.(Auris)inUnitedStatesDistrictCourtfortheDistrictofDelaware.Inthesuit,
IntuitiveallegeswillfulinfringementofU.S.PatentNos.6,246,200(’200);6,491,701(’701);6,522,906(’906);6,800,056
(’056);8,142,447(’447);8,620,473(’473);8,801,601(’601);and9,452,276(’276)basedonAuris’Monarch™Platform.
AurisfiledIPRPetitionswiththeUSPTOregardingthe’200,’056,’601’701,’447,’276and’906patents.Intuitive
subsequentlydroppedthe’200,’473and’701patentsfromthesuit.InDecember2019,theUSPTOinstitutedreviewof
the’601patentanddeniedreviewofthe’056patent.InFebruaryandMarch2020,theUSPTOinstitutedreviewofthe
’200,’447,’701and’906patentsanddeniedreviewofthe’276patent.InDecember2020,theUSPTOdeclaredallof
90 • Johnson&Johnson2020AnnualReportthechallengedclaimsinthe’601patenttobeinvalid.Intuitivehasappealedthatdecision.Thedistrictcourttrialis
scheduledtobegininJune2021.
InAugust2019,RSBSpineLLC(RSBSpine)filedapatentinfringementsuitagainstDePuySynthes,Inc.inUnitedStates
DistrictCourtfortheDistrictofDelaware.InOctober2019,RSBSpineamendedthecomplainttochangethenamed
defendantstoDePuySynthesSales,Inc.andDePuySynthesProducts,Inc.Inthesuit,RSBSpineallegeswillful
infringementofUnitedStatesPatentNos.6,984,234and9,713,537byoneormoreofthefollowingproducts:
ZERO-P-VA™Spacer,ZERO-P®Spacer,ZERO-PNATURAL™Plate,SYNFIX®LRSpacerandSYNFIX®Evolution
System.RSBSpineseeksmonetarydamagesandinjunctiverelief.InNovember2019,thesuitwasconsolidatedfor
pre-trialpurposeswithotherpatentinfringementsuitsbroughtbyRSBSpineintheUnitedStatesDistrictCourtforthe
DistrictofDelawareagainstLifeSpine,Inc.,MedactaUSA,Inc.,andPrecisionSpine,Inc.InJune2020,thecasewas
stayedpendingIPRproceedingsfiledbytheConsolidatedDefendantsinvolvingtheassertedpatents.
InMarch2020,Osteoplastics,LLCfiledapatentinfringementsuitagainstDePuySynthes,Inc.,DePuySynthesProducts,
Inc.,MedicalDeviceBusinessServices,Inc.,andSynthes,Inc.(collectively,DePuySynthes)intheUnitedStatesDistrict
CourtfortheDistrictofDelaware.Inthesuit,OsteoplasticsallegeswillfulinfringementofU.S.PatentNos.8,781,557;
9,929,920;9,330,206;9,626,756;9,672,617;9,672,302;and9,275,191basedonthePROPLANCMF®Virtual
SurgicalPlanningServicesandtheTruMatch®CMFPersonalizeSolutions.InApril2020,Osteoplasticsfiledanamended
complainttosubstituteU.S.PatentNo.9,292,920forU.S.PatentNo.9,929,920.Osteoplasticsseeksmonetarydamages
andinjunctiverelief.InJune2020,DePuySynthesfiledamotiontodismissthecomplaint.InOctober2020,theCourt
dismissedMedicalDeviceBusinessServices,Inc.fromthecasebutotherwisedeniedthemotion.Trialisscheduledfor
October2022.
Pharmaceutical
LitigationAgainstFilersofAbbreviatedNewDrugApplications(ANDAs)
ThefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledANDAswiththeFDAorundertaken
similarregulatoryprocessesoutsideoftheUnitedStates,seekingtomarketgenericformsofproductssoldbyvarious
subsidiariesofJohnson&Johnsonpriortoexpirationoftheapplicablepatentscoveringthoseproducts.TheseANDAs
typicallyincludeallegationsofnon-infringementandinvalidityoftheapplicablepatents.Intheeventthesubsidiariesare
notsuccessfulinanaction,ortheautomaticstatutorystayoftheANDAsexpiresbeforetheUnitedStatesDistrictCourt
rulingsareobtained,thethird-partycompaniesinvolvedwouldhavetheability,uponapprovaloftheFDA,tointroduce
genericversionsoftheirproductstothemarket,resultinginthepotentialforsubstantialmarketshareandrevenuelosses
fortheapplicableproducts,andwhichmayresultinanon-cashimpairmentchargeinanyassociatedintangibleasset.In
addition,fromtimetotime,subsidiariesmaysettlethesetypesofactionsandsuchsettlementscaninvolvetheintroduction
ofgenericversionsoftheproductsatissuetothemarketpriortotheexpirationoftherelevantpatents.TheInterPartes
Review(IPR)processwiththeUSPTO,createdunderthe2011AmericaInventsAct,isalsobeingusedattimesby
genericcompaniesinconjunctionwithANDAsandlawsuits,tochallengetheapplicablepatents.
ZYTIGA®
InNovember2017,JanssenInc.andJanssenOncologyInc.(collectively,Janssen)initiatedaNoticeofApplicationunder
Section6ofthePatentedMedicines(NoticeofCompliance)RegulationsagainstApotexInc.(Apotex)andtheMinisterof
HealthinCanadainresponsetoApotex’sfilingofanAbbreviatedNewDrugSubmission(ANDS)seekingapprovalto
marketagenericversionofZYTIGA®beforetheexpirationofCanadianPatentNo.2,661,422(’422).Thefinalhearing
concludedinMay2019.InOctober2019,theCourtissuedanorderprohibitingtheCanadianMinisterofHealthfrom
approvingApotex’sANDSuntiltheexpirationofthe’422patent.InNovember2019,Apotexfiledanappeal.
BeginninginJanuary2019,JansseninitiatedStatementsofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsinCanadaagainstApotex,PharmascienceInc.(Pharmascience)andDr.Reddy’sLaboratories
Ltd.andDr.Reddy’sLaboratories,Inc.(collectively,DRL)inresponsetothoseparties’filingofAbbreviatedNewDrug
Submissions(ANDS)seekingapprovaltomarketgenericversionsofZYTIGA®beforetheexpirationofthe’422patent.
ThefinalhearingintheseactionsconcludedinNovember2020,andtheCourtissuedadecisionholdingthe’422patent
invalidinJanuary2021.InFebruary2021,Janssenappealedthedecision.
InAugust2020,JansseninitiatedaStatementofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstJAMPPharmaCorporation(Jamp)inCanadainresponsetoJamp’sfilingofanANDS
seekingapprovaltomarketagenericversionofZYTIGA®beforetheexpirationofthe’422patent.Thefinalhearingis
scheduledtobegininMay2022.
Johnson&Johnson2020AnnualReport • 91IneachoftheseCanadianactions,Janssenisseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric
versionsofZYTIGA®beforetheexpirationofthe’422patent.
XARELTO®
InAugust2020,JanssenPharmaceuticals,Inc.(JPI)andBayerIntellectualPropertyGmbHandBayerAG(collectively,
Bayer)filedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainst
Dr.Reddy’sLaboratories,Inc.andDr.Reddy’sLaboratories,Ltd.(collectively,DRL)whichfiledanANDAseekingapproval
tomarketagenericversionofXARELTO®beforeexpirationofU.S.PatentNo.9,539,218(’218).Inthislawsuit,JPIand
BayerwereseekinganorderenjoiningDRLfrommarketingtheirgenericversionsofXARELTO®beforetheexpirationof
therelevantpatents.InNovember2020,JPIandBayerenteredintoaconfidentialsettlementagreementwithDRL,andthe
casewasvoluntarilydismissed.
INVOKANA®/INVOKAMET®/INVOKAMETXR®
BeginninginJuly2017,JanssenPharmaceuticals,Inc.,JanssenResearch&Development,LLC,CilagGmbHInternational
andJanssenPharmaceuticaNV(collectively,Janssen)andMitsubishiTanabePharmaCorporation(MTPC)filedpatent
infringementlawsuitsintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainstanumberofgeneric
companiesthatfiledANDAsseekingapprovaltomarketgenericversionsofINVOKANA®,INVOKAMET®and/or
INVOKAMET®XRbeforeexpirationofMTPC’sUnitedStatesPatentNos.7,943,582(’582)and/or8,513,202(’202)
relatingtoINVOKANA®,INVOKAMET®and/orINVOKAMET®XR.Janssenistheexclusivelicenseeoftheasserted
patents.NameddefendantsincludeMSNLaboratoriesPrivateLtd.andMSNPharmaceuticals,Inc.(MSN);Zydus
Pharmaceuticals(USA)Inc.(Zydus);Sandoz,Inc.(Sandoz);andLupinLtd.andLupinPharmaceuticals,Inc.(Lupin).These
caseswereconsolidatedintooneaction(PolymorphMainAction),whichhasbeenscheduledfortrialstartinginApril
2021.InDecember2020,JanssenandMTPCenteredintoaconfidentialsettlementwithSandozandinJanuary2021,
JanssenandMTPCenteredintoaconfidentialsettlementwithLupin.ThecasesagainstSandozandLupinwerevoluntarily
dismissed.
InJuly2017,JanssenandMTPCfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictof
NewJerseyagainstZyduswhichfiledANDAsseekingapprovaltomarketgenericversionsofINVOKANA®and
IVOKAMET®beforeexpirationofMTPC’sUnitedStatesPatentNo.7,943,788(’788),8,222,219(’219)and/or
8,785,403(’403)relatingtoINVOKANA®,INVOKAMET®and/orINVOKAMET®XR(CompoundsMainAction).Janssenis
theexclusivelicenseeoftheassertedpatents.TrialconcludedinOctober2020.
InJuly2019,JanssenandMTPCfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictof
NewJerseyagainstMSN,whichfiledanANDAseekingapprovaltomarketagenericversionofINVOKAMETXR®before
expirationofthe’582patentand’202patentrelatingtoINVOKAMETXR®.InOctober2019,JanssenandMTPCinitiated
apatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainstMSN,whichfiled
ANDAsseekingapprovaltomarketgenericversionsofINVOKANA®andINVOKAMETXR®beforeexpirationofthe’788
patent.InOctober2019,JanssenandMTPCinitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfor
theDistrictofNewJerseyagainstDr.Reddy’sLaboratories,Inc.andDr.Reddy’sLaboratoriesLtd(DRL),whofiledan
ANDAseekingapprovaltomarketagenericversionofINVOKAMET®beforeexpirationofthe’788patent.InJanuary
2021,JanssenandMTPCfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyagainstMacleodsPharmaceuticals,Ltd.andMacleodsPharmaUSA,Inc.(Macleods),whichfiledanANDAseeking
approvaltomarketagenericversionofINVOKAMETXR®beforeexpirationofthe’582patentand’202patentrelatingto
INVOKAMETXR®.InFebruary2021,JanssenfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtforthe
DistrictofNewJerseyagainstMacleodsPharmaceuticals,Ltd.andMacleodsPharmaUSA,Inc.(Macleods),whichfiledan
ANDAseekingapprovaltomarketagenericversionofINVOKANA®beforeexpirationofUnitedStatesPatent
No.10,617,668relatingtoINVOKANA®.TheselawsuitshavenotbeenconsolidatedwiththeMainActions.
IneachoftheseU.S.lawsuits,JanssenandMTPCareseekinganorderenjoiningthedefendantfrommarketingtheir
genericversionsofINVOKANA®,INVOKAMET®and/or,INVOKAMETXR®beforetheexpirationoftherelevantpatents.
InOctober2020,JanssenInc.,JanssenPharmaceuticaNVandMTPCinitiatedaStatementofClaimunderSection6of
thePatentedMedicines(NoticeofCompliance)RegulationsagainstSandozCanadaInc.(Sandoz)inCanadainresponse
toSandoz’sfilingofanANDSseekingapprovaltomarketagenericversionofINVOKANA®beforetheexpirationofthe
CanadianPatentNos.2,534,024and2,671,357.ThefinalhearingisscheduledtobegininAugust2022.
JanssenInc.,JanssenPharmaceuticaNVandMTPCareseekinganorderenjoiningSandozfrommarketingitsgeneric
versionofINVOKANA®beforetheexpirationoftherelevantpatents.
92 • Johnson&Johnson2020AnnualReportOPSUMIT®
InOctober2020,ActelionPharmaceuticalsLtd(Actelion)initiatedapatentinfringementlawsuitintheUnitedStates
DistrictCourtfortheDistrictofNewJerseyagainstLaurusLabsLimitedandPharmaQ,Inc.(collectively,Laurus),which
filedanANDAseekingapprovaltomarketgenericversionsofOPSUMIT®beforetheexpirationofU.S.Patent
No.7,094,781(’781).ActelionwasseekinganorderenjoiningLaurusfrommarketinggenericversionsofOPSUMIT®
beforetheexpirationofthe’781patent.InJanuary2021,ActelionenteredintoasettlementagreementwithLaurus.
InMay2020,JanssenInc.(Janssen)andActelioninitiatedaStatementofClaimunderSection6ofthePatented
Medicines(NoticeofCompliance)RegulationsagainstSandozCanadaInc.(Sandoz)inCanadainresponsetoSandoz’s
filingofanANDSseekingapprovaltomarketagenericversionofOPSUMIT®10mg,beforetheexpirationofCanadian
PatentNo.2,659,770(’770).TrialisscheduledtobegininJanuary2022.
InMay2020,JanssenandActelioninitiatedaStatementofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstApotexInc.(Apotex)inCanadainresponsetoApotex’sfilingofanANDSseeking
approvaltomarketagenericversionofOPSUMIT®10mg,beforetheexpirationofthe’770patent.Trialisscheduledto
begininFebruary2022.
InJuly2020,JanssenandActelioninitiatedaStatementofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstJAMPPharmaCorporation(JAMP)inCanadainresponsetoJAMP’sfilingofanANDS
seekingapprovaltomarketagenericversionofOPSUMIT®10mgbeforetheexpirationofthe’770patentandCanadian
PatentNo.2,621,273(’273).TrialisscheduledtobegininApril2022.
IneachoftheseCanadianactions,JanssenandActelionareseekinganorderenjoiningthedefendantsfrommarketing
theirgenericversionsofOPSUMIT®beforetheexpirationoftherelevantpatents.
INVEGASUSTENNA®
InJanuary2018,JanssenPharmaceuticaNVandJanssenPharmaceuticals,Inc.(collectively,Janssen)initiatedapatent
infringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainstTevaPharmaceuticalsUSA,
Inc.(Teva),whichfiledanANDAseekingapprovaltomarketagenericversionofINVEGASUSTENNA®beforethe
expirationofUnitedStatesPatentNo.9,439,906(’906).TrialconcludedinOctober2020.
InAugust2019,JansseninitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyagainstMylanLaboratoriesLimited(Mylan),whichfiledanANDAseekingapprovaltomarketagenericversionof
INVEGASUSTENNA®beforetheexpirationofthe’906patent.InFebruary2020,MylanfiledaPetitionforInterPartes
ReviewwiththeUSPTOseekingtoinvalidatethe’906patent.TheUSPTOdeniedthePetitioninSeptember2020,and
Mylanappealed.
InDecember2019,JansseninitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtsfortheDistrictsof
NewJerseyandDelawareagainstPharmascienceInc.,MallinckrodtPLCandSpecgxLLC(collectively,Pharmascience),
whichfiledanANDAseekingapprovaltomarketagenericversionofINVEGASUSTENNA®beforetheexpirationofthe
’906patent.
IneachoftheseU.S.lawsuits,Janssenisseekinganorderenjoiningthedefendantfrommarketingagenericversionof
INVEGASUSTENNA®beforetheexpirationoftherelevantpatents.
InFebruary2018,JanssenInc.andJanssenPharmaceuticaNV(collectively,JanssenCanada)initiatedaStatementofClaim
underSection6ofthePatentedMedicines(NoticeofCompliance)RegulationsagainstTevaCanadaLimited(Teva
Canada)inresponsetoTeva’sfilingofanANDSseekingapprovaltomarketagenericversionofINVEGASUSTENNA®
beforetheexpirationofCanadianPatentNos.2,309,629(’629)and2,655,335(’335).Janssensubsequentlydiscontinued
theportionofthelawsuitrelatingtothe’629patent.InMay2020,theCanadianFederalCourtissuedaPublicJudgment
andReasonsdeclaringthatTevaCanada’sgenericversionofINVEGASUSTENNA®,ifapproved,wouldinfringeclaimsof
the’335patentandthattheclaimsofthe’335patentarenotinvalidforobviousness.TevaCanadaappealed.
InNovember2020,JanssenCanadainitiatedaStatementofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstPharmascienceInc.inresponsetoPharmascienceInc.’sfilingofanANDSseeking
approvaltomarketagenericversionofINVEGASUSTENNA®beforetheexpirationofthe’335patent.TheFinalHearing
isscheduledtobegininJuly2022.
Johnson&Johnson2020AnnualReport • 93InJanuary2021,JanssenCanadainitiatedaStatementofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstApotexInc.(Apotex)inresponsetoApotex’sfilingofanANDSseekingapprovalto
marketagenericversionofINVEGASUSTENNA®beforetheexpirationofthe’335patent.TheFinalHearingisscheduled
tobegininSeptember2022.
IneachoftheseCanadianlawsuits,JanssenCanadaisseekinganorderenjoiningthedefendantfrommarketingageneric
versionofINVEGASUSTENNA®beforetheexpirationoftherelevantpatents.
IMBRUVICA®
BeginninginJanuary2018,PharmacyclicsLLC(Pharmacyclics)andJanssenBiotech,Inc.(JBI)filedpatentinfringement
lawsuitsintheUnitedStatesDistrictCourtfortheDistrictofDelawareagainstanumberofgenericcompaniesthatfiled
ANDAsseekingapprovaltomarketgenericversionsofIMBRUVICA®140mgcapsulesbeforeexpirationof
Pharmacyclics’UnitedStatesPatentNos.8,008,309,7,514,444,8,697,711,8,735,403,8,957,079,9,181,257,
8,754,091,8,497,277,8,925,015,8,476,284,8,754,090,8,999,999,9,125,889,9,801,881,9,801,883,9,814,721,
9,795,604,9,296,753,9,540,382,9,713,617and/or9,725,455relatingtoIMBRUVICA®.JBIistheexclusivelicenseeof
theassertedpatents.Thenameddefendantsincludethefollowinggenericcompanies:CiplaLimitedandCiplaUSAInc.
(collectively,Cipla);SandozInc.andLekPharmaceuticalsd.d.(collectively,Sandoz).
InJanuary2019,PharmacyclicsandJBIamendedtheircomplaintagainstSandoztoallegeinfringementofUnitedStates
PatentNos.10,125,140and10,106,548.
InFebruary2019,PharmacyclicsandJBIamendedtheircomplaintagainstCiplatoallegeinfringementofUnitedStates
PatentNos.10,106,548,and10,125,140.
InMarch2019,PharmacyclicsandJBIfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrict
ofDelawareagainstAlvogenPineBrookLLCandNatcoPharmaLtd.(collectively,Alvogen),whichfiledanANDAseeking
approvaltomarketgenericversionsofIMBRUVICA®tablets,assertinginfringementofUnitedStatesPatentNos.
7,514,444,8,003,309,8,476,284,8,497,277,8,697,711,8,753,403,8,754,090,8,754,091,8,952,015,8,957,079,
9,181,257,9,296,753,9,655,857,9,725,455,10,010,507,10,106,548,and10,125,140.
InMay2019,PharmacyclicsandJBIamendedtheircomplaintagainstCiplatofurtherallegeinfringementofUnitedStates
PatentNo.10,016,435.InJune2019,PharmacyclicsandJBIamendedtheircomplaintagainstAlvogentofurtherallege
infringementofUnitedStatesPatentNo.10,213,386.
InAugust2019,PharmacyclicsandJBIamendedtheircomplaintsagainstCiplaandSandoztofurtherallegeinfringement
ofU.S.PatentNos.10,294,231and10,294,232.InAugust2019,theCourtgrantedajointstipulationtostaythelitigation
againstCipla.
TrialintheactionsagainstSandozandAlvogentookplaceinOctober2020.
InMarch2019,SandozfiledanIPRPetitionwiththeUSPTO,seekingtoinvalidateUnitedStatesPatentNo.9,795,604.In
September2020,theUSPTOissuedafinaldecisionintheIPRinvalidatingcertainclaimsofthe’604patentand
upholdingthevalidityofcertainclaimsinthe’604patent.Thefinaldecisionwasnotappealedbytheparties.
InMarch2020,PharmacyclicsandJBIfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrict
ofDelawareagainstAlvogenandSandozassertinginfringementofUnitedStatesPatentNo.10,478,439.InApril2020,
PharmacyclicsandJBIamendedtheircomplaintagainstSandoztofurtherallegeinfringementofU.S.Patent
No.10,463,668.InOctober2020,PharmacyclicsandJBIamendedtheircomplaintagainstSandoztofurtherallege
infringementofU.S.PatentNos.10,752,634and10,695,350andamendedtheircomplaintagainstAlvogentofurther
allegeinfringementofU.S.PatentNo.10,653,696.InDecember2020theCourtenteredajointstipulationdismissingthe
complaintagainstSandoz.
InApril2020,PharmacyclicsandJBIfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrict
ofDelawareagainstZydusWorldwideDMCCandCadilaHealthcareLimited(collectively,Zydus),whichfiledanANDA
seekingapprovaltomarketgenericversionsofIMBRUVICA®tablets,assertinginfringementofUnitedStatesPatentNos.
7,514,444,8,008,309,8,476,284,8,497,277,8,697,711,8,753,403,8,754,090,8,754,091,8,952,015,8,957,079,
9,181,257,9,296,753,9,655,857,9,725,455,10,010,507,10,106,548,10,125,140,10,213,386and10,478,439.
TrialsintheactionsagainstAlvogenandZydusarescheduledtobegininMarch2022.
Ineachofthelawsuits,PharmacyclicsandJBIareseekinganorderenjoiningthedefendantsfrommarketinggeneric
versionsofIMBRUVICA®beforetheexpirationoftherelevantpatents.
94 • Johnson&Johnson2020AnnualReportUPTRAVI®
InApril2020,ActelionPharmaceuticalsLtd(Actelion)andNipponShinyakuCo.,Ltd.(NipponShinyaku)initiatedapatent
infringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainstanumberofgeneric
companiesthatfiledANDAsseekingapprovaltomarketgenericversionsofUPTRAVI®beforeexpirationofNippon
Shinyaku’sUnitedStatesPatentNos.7,205,302;8,791,122;and9,284,280relatingtoUPTRAVI®.Actelionisthe
exclusivelicenseeoftheassertedpatents.ThedefendantsincludeAlembicPharmaceuticalsLimitedandAlembic
PharmaceuticalsInc.(collectively,Alembic);MSNLaboratoriesPrivateLimitedandMSNPharmaceuticalsInc.(collectively,
MSN);VGYAANPharmaceuticalsLLC(VGYAAN);andZydusPharmaceuticals(USA),Inc.andZydusWorldwideDMCC
(collectively,Zydus).InJanuary2021,theCourtenteredjointstipulationsdismissingVGYAANandMSNfromsuit.
ActelionandNipponShinyakuareseekinganorderenjoiningthedefendantsfrommarketinggenericversionsof
UPTRAVI®beforetheexpirationoftherelevantpatents.
INVEGATRINZA®
InSeptember2020,JanssenPharmaceuticals,Inc.,JanssenPharmaceuticaNV,andJanssenResearch&Development,
LCC(collectively,Janssen)initiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyagainstMylanLaboratoriesLimited,MylanPharmaceuticalsInc.,andMylanInstitutionalLLC(collectively,Mylan).
MylanfiledanANDAseekingapprovaltomarketgenericversionsofINVEGATRINZA®beforeexpirationofUnitedStates
PatentNo.10,143,693relatingtoINVEGATRINZA®.JanssenisseekinganorderenjoiningMylanfrommarketinga
genericversionofINVEGATRINZA®beforetheexpirationoftherelevantpatent.
GOVERNMENTPROCEEDINGS
Likeothercompaniesinthepharmaceutical,consumerhealthandmedicaldevicesindustries,Johnson&Johnsonand
certainofitssubsidiariesaresubjecttoextensiveregulationbynational,stateandlocalgovernmentagenciesintheUnited
Statesandothercountriesinwhichtheyoperate.Suchregulationhasbeenthebasisofgovernmentinvestigationsand
litigations.Themostsignificantlitigationbroughtby,andinvestigationsconductedby,governmentagenciesarelisted
below.Itispossiblethatcriminalchargesandsubstantialfinesand/orcivilpenaltiesordamagescouldresultfrom
governmentinvestigationsorlitigation.
AverageWholesalePrice(AWP)Litigation
Johnson&Johnsonandseveralofitspharmaceuticalsubsidiaries(theJ&JAWPDefendants),alongwithnumerousother
pharmaceuticalcompanies,werenamedasdefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolving
allegationsthatthepricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwise
actionableconductbecause,amongotherthings,thecompaniesallegedlyreportedaninflatedAverageWholesalePrice
(AWP)forthedrugsatissue.PayorsallegedthattheyusedthoseAWPsincalculatingproviderreimbursementlevels.The
plaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseof
thedrugsatissuebasedonAWP,andstategovernmententitiesthatmadeMedicaidpaymentsforthedrugsatissue
basedonAWP.Manyofthesecases,bothfederalactionsandstateactionsremovedtofederalcourt,wereconsolidated
forpre-trialpurposesinamulti-districtlitigationintheUnitedStatesDistrictCourtfortheDistrictofMassachusetts,where
allclaimsagainsttheJ&JAWPDefendantswereultimatelydismissed.TheJ&JAWPDefendantsalsoprevailedinacase
broughtbytheCommonwealthofPennsylvania.OtherAWPcaseshavebeenresolvedthroughcourtorderorsettlement.
ThecasebroughtbyIllinoiswassettledaftertrial.InNewJersey,aputativeclassactionbaseduponAWPallegationsis
pendingagainstCentocor,Inc.andOrthoBiotechInc.(bothnowJanssenBiotech,Inc.),Johnson&JohnsonandALZA
Corporation.Allothercaseshavebeenresolved.
OpioidLitigation
Beginningin2014andcontinuingtothepresent,Johnson&JohnsonandJanssenPharmaceuticals,Inc.(JPI),alongwith
otherpharmaceuticalcompanies,havebeennamedinmorethan3,100lawsuitsrelatedtothemarketingofopioids,
includingDURAGESIC®,NUCYNTA®andNUCYNTA®ER.Thesuitsalsoraiseallegationsrelatedtopreviouslyowned
activepharmaceuticalingredientsuppliersubsidiaries,TasmanianAlkaloidsPty,Ltd.andNoramco,Inc.(bothsubsidiaries
weredivestedin2016).Themajorityofthecaseshavebeenfiledbystateandlocalgovernments.Similarlawsuitshavealso
beenfiledbyprivateplaintiffsandorganizations,includingbutnotlimitedtothefollowing:individualplaintiffsonbehalfof
childrensufferingfromNeonatalAbstinenceSyndrome;hospitals;andhealthinsurers/payors.Todate,complaintsagainst
pharmaceuticalcompanies,includingJohnson&JohnsonandJPI,havebeenfiledbythestateAttorneysGeneralin
Johnson&Johnson2020AnnualReport • 95Arkansas,Florida,Idaho,Illinois,Kentucky,Louisiana,Mississippi,Missouri,NewHampshire,NewJersey,NewMexico,New
York,Ohio,Oklahoma,SouthDakota,Texas,WashingtonandWestVirginia.Complaintsagainstthemanufacturersalso
havebeenfiledinstateorfederalcourtbycity,countyandlocalgovernmentagenciesinthefollowingstates:Alabama,
Arizona,Arkansas,California,Connecticut,Florida,Georgia,Illinois,Kentucky,Louisiana,Maine,Maryland,Massachusetts,
Mississippi,Missouri,Nevada,NewHampshire,NewJersey,NewMexico,NewYork,NorthCarolina;Ohio,Oklahoma,
Oregon,Pennsylvania,RhodeIsland,SouthCarolina,SouthDakota,Tennessee,Texas,Utah,Virginia,Washington,West
VirginiaandWisconsin.TheGovernmentofPuertoRicofiledsuitinSuperiorCourtofSanJuan.Therearemorethan370
casespendinginvariousstatecourts.Thereareover2,800federalcasescoordinatedinafederalMulti-DistrictLitigation
(MDL)pendingintheU.S.DistrictCourtfortheNorthernDistrictofOhio(MDLNo.2804).Inaddition,theProvinceof
BritishColumbiafiledsuitinCanada.InOctober2019,ananti-trustcomplaintwasfiledbyprivateplaintiffsinfederalcourt
inTennesseeandispendingtransfertotheMDL.Theseactionsallegeavarietyofclaimsrelatedtoopioidmarketing
practices,includingfalseadvertising,unfaircompetition,publicnuisance,consumerfraudviolations,deceptiveactsand
practices,falseclaimsandunjustenrichment.Thesuitsgenerallyseekpenaltiesand/orinjunctiveandmonetaryreliefand,in
someofthesuits,theplaintiffsareseekingjointandseveralliabilityamongthedefendants.Anadversejudgmentinanyof
theselawsuitscouldresultintheimpositionoflargemonetarypenaltiesandsignificantdamagesincluding,punitive
damages,costofabatement,substantialfines,equitableremediesandothersanctions.
ThetrialinthematterfiledbytheOklahomaAttorneyGeneralresultedinajudgmentagainstJohnson&JohnsonandJPIin
theamountof$572million,subjecttoafinalordertobeissuedbytheCourt.TheCourtissuedafinaljudgmentreducing
theamountto$465million.Johnson&JohnsonandJPIhaveappealedthejudgment.TheCompanybelievesthatithas
stronggroundstooverturnthisjudgment.InOctober2019Johnson&JohnsonandJPIannouncedasettlementofthefirst
casesetfortrialintheMDLwithtwocountiesinOhio.
Johnson&Johnson,JPIandotherpharmaceuticalcompanieshavealsoreceivedsubpoenasorrequestsforinformation
relatedtoopioidsmarketingpracticesfromthefollowingstateAttorneysGeneral:Alaska,Indiana,Montana,New
Hampshire,SouthCarolina,Tennessee,TexasandWashington.InSeptember2017,Johnson&JohnsonandJPIwere
contactedbytheTexasandColoradoAttorneyGeneral’sOfficesonbehalfofapproximately38statesregardingamulti-
stateAttorneyGeneralinvestigation.InOctober2019,theCompanyannouncedaproposedagreementinprinciplethat
wouldincludetheCompanypaying$4billionassettlementofthesematters.InOctober2020,theCompanyagreedto
contributeuptoanadditional$1billiontoanall-insettlementamountthatwouldresolveopioidlawsuitsfiledandfuture
claimsbystates,cities,countiesandtribalgovernments,foratotalof$5billionwhichhasbeenaccrued,subjectto
variousconditionsandanagreementbeingfinalized.Thisagreementinprincipleisnotanadmissionofliabilityorwrong-
doingandwouldresolveopioidlawsuitsfiledandfutureclaimsbystates,citiesandcounties.TheCompanycannotpredict
iforwhentheagreementwillbefinalizedandindividualcasesareongoing.
InAugust2019,Johnson&JohnsonreceivedagrandjurysubpoenafromtheUnitedStatesAttorney’sOfficeforthe
EasternDistrictofNewYorkfordocumentsrelatedtotheCompany’santi-diversionpoliciesandproceduresand
distributionofitsopioidmedications,inwhattheCompanyunderstandstobepartofabroaderinvestigationinto
manufacturers’anddistributors’monitoringprogramsandreportingundertheControlledSubstancesAct.InSeptember
2019,Johnson&JohnsonreceivedsubpoenasfromtheNewYorkStateDepartmentofFinancialServices(NYDFS)as
partofanindustry-wideinquiryintotheeffectofopioidprescriptionsonNewYorkhealthinsurancepremiums.In
September2020,theCompanylearnedthatNYDFSfiledastatementofchargesrelatedtothisinvestigation.
FromJune2017throughDecember2019,theCompany’sBoardofDirectorsreceivedaseriesofshareholderdemand
lettersallegingbreachesoffiduciarydutiesrelatedtothemarketingofopioids.TheBoardretainedindependentcounselto
investigatetheallegationsinthedemands,andinApril2020,independentcounseldeliveredareporttotheBoard
recommendingthattheCompanyrejecttheshareholderdemandsandtakethestepsthatarenecessaryorappropriateto
securedismissalofrelatedderivativelitigation.TheBoardunanimouslyadoptedtherecommendationsoftheindependent
counsel’sreport.
InNovember2019,oneoftheshareholderswhosentademandfiledaderivativecomplaintagainstJohnson&Johnsonas
thenominaldefendantandcertaincurrentandformerdirectorsandofficersasdefendantsintheSuperiorCourtofNew
Jersey.Thecomplaintallegesbreachesoffiduciarydutiesrelatedtothemarketingofopioids,andthatJohnson&Johnson
hassuffereddamagesasaresultofthoseallegedbreaches.InMay2020,theshareholderfiledanamendedcomplaint
challengingtheBoard’srejectionofhisdemand.InAugust2020,Johnson&Johnsonmovedtodismisstheamended
complaint,andasofDecember2020,thatmotionwasfullybriefed.InAugust2020,anothershareholderwhosenta
demandfiledaseparatederivativecomplaintinthesamecourtmakingsimilarallegations.InOctober2020,theCourt
granteddefendants’requesttoreassignthesecond-filedcasetothedivisionwherethefirst-filedcaseispending.
96 • Johnson&Johnson2020AnnualReportInDecember2019,twoadditionalshareholderswhosentdemandsfiledtwoseparatederivativecomplaintsmakingsimilar
allegationsagainstJohnson&Johnsonasthenominaldefendantandcertaincurrentandformerdirectorsandofficersas
defendantsintheUnitedStatesDistrictfortheDistrictofNewJersey.InApril2020,thetwofederalcaseswere
consolidatedintoasingleactioncaptionedInreJohnson&JohnsonOpioidStockholderDerivativeLitigation.InJuly2020,
theshareholdersfiledaconsolidatedcomplaint.InSeptember2020,Johnson&Johnsonmovedtodismissthe
consolidatedcomplaint,andinDecember2020,theshareholdersopposedJohnson&Johnson’smotion.Johnson&
JohnsonfileditsreplyinFebruary2021.InJuly2020,anadditionalshareholderwhosentademandfiledaderivative
complaintinthesamefederalcourtmakingsimilarallegationsagainstthesamedefendantsnamedintheconsolidated
action.InJanuary2021,pursuanttoanorderintheconsolidatedaction,thethirdcasewasconsolidatedintothe
consolidatedaction.InFebruary2021,theshareholdersintheconsolidatedactionfiledamotionforvoluntarydismissal.
Other
InAugust2012,DePuyOrthopaedics,Inc.,DePuy,Inc.(nowknownasDePuySynthes,Inc.),andJohnson&Johnson
Services,Inc.(collectivelyDePuy)receivedaninformalrequestfromtheUnitedStatesAttorney’sOfficefortheDistrictof
MassachusettsandtheCivilDivisionoftheUnitedStatesDepartmentofJustice(theUnitedStates)fortheproductionof
materialsrelatingtotheDePuyASR™XLHipdevice.InJuly2014,theUnitedStatesnotifiedtheUnitedStatesDistrict
CourtfortheDistrictofMassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttotheFalseClaims
Actagainstthecompanies.InFebruary2016,thedistrictcourtgrantedthecompanies’motiontodismisswithprejudice,
unsealedthequitamcomplaint,anddeniedthequitamrelators’requestforleavetofileafurtheramendedcomplaint.The
quitamrelatorsappealedthecasetotheUnitedStatesCourtofAppealsfortheFirstCircuit.InJuly2017,theFirstCircuit
affirmedthedistrictcourt’sdismissalinpart,reversedinpart,andaffirmedthedecisiontodenytherelators’requesttofile
athirdamendedcomplaint.Therelators’remainingclaimsarenowpendingbeforethedistrictcourt.InJuly2020,the
CourtorderedtherelatorstocompletediscoverybyAugust2020;theRelatorshaverequestedanextensionoftheAugust
2020deadlinethatDePuyopposedandadditionaldiscovery-relatedmotionshavebeenfiledbybothparties.Additionally,
DePuyhasrequestedascheduleforthefilingofamotiontostrikeandtodismisstherelators’secondamendedcomplaint.
InOctober2012,Johnson&JohnsonwascontactedbytheCaliforniaAttorneyGeneral’sofficeregardingamulti-state
AttorneyGeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby
Johnson&Johnson’ssubsidiary,Ethicon,Inc.(Ethicon).InMay2016,CaliforniaandWashingtonfiledcivilcomplaints
againstJohnson&Johnson,EthiconandEthiconUS,LLCallegingviolationsoftheirconsumerprotectionstatutes.Similar
complaintswerefiledagainstthecompaniesbythefollowingstates:Kentucky,Mississippi,WestVirginiaandOregon.In
April2019,Johnson&JohnsonandEthiconsettledtheWashingtoncase.TheCaliforniacasestartedtrialinJuly2019
andconcludedinSeptember2019.ThetrialdatefortheKentuckycasewasscheduledforSeptember2019buthasbeen
adjournedandnonewtrialdatehasbeenscheduled.InOctober2019,Johnson&JohnsonandEthiconsettledthemulti-
stateinvestigationwith41otherstatesandtheDistrictofColumbia.InJanuary2020,theCourtinCaliforniaissueda
statementofdecision,findinginfavoroftheStateofCalifornia,andawardedcivilpenaltiesintheamountof$344million.
InApril2020,theCourtinCaliforniadeniedtheCompany’smotionforanewtrial.InAugust2020,theCourtentered
judgmentwithrespecttothepenaltiesof$344million,butdeniedtheAttorneyGeneral’srequestforinjunctiverelief.The
Companyisappealingthepenaltyjudgment.InApril2020,theCompanysettledtheWestVirginia.InOctober2020,the
CompanysettledwiththeAttorneyGeneralofOregon.InNovember2020,theCompanysettledwiththeAttorney
GeneralofMississippi.
InDecember2012,Therakos,Inc.(Therakos),formerlyasubsidiaryofJohnson&JohnsonandpartoftheOrtho-Clinical
Diagnostics,Inc.(OCD)franchise,receivedaletterfromthecivildivisionoftheUnitedStatesAttorney’sOfficeforthe
EasternDistrictofPennsylvaniainformingTherakosthattheUnitedStatesAttorney’sOfficewasinvestigatingthesales
andmarketingofUvadex®(methoxsalen)andtheUvarXts®andCellex®Systemsduringtheperiod2000tothepresent.
TheUnitedStatesAttorney’sOfficerequestedthatOCDandJohnson&Johnsonpreservedocumentsthatcouldrelateto
theinvestigation.TherakoswassubsequentlyacquiredbyanaffiliateofGoresCapitalPartnersIII,L.P.inJanuary2013,
andOCDwasdivestedinJune2014.FollowingthedivestitureofOCD,Johnson&JohnsonretainedOCD’sportionofany
liabilityresultingfromtheinvestigationforactivitythatoccurredpriortothesaleofTherakos.Followingproductionof
documentstoandsettlementdiscussionswiththeU.S.Attorney’sOffice,J&JaffiliateMedicalDeviceBusinessServices,
Inc.agreedtoresolveclaimsunderthefederalFalseClaimsActandanalogousstatelawsinasettlementannouncedin
November2020.Inthesettlementagreement,MedicalDeviceBusinessServicesexpresslydeniedanywrongfulconduct.
Asaresultofthesettlement,aquitamcomplaintfiledbytworelatorspendingintheU.S.DistrictCourtfortheEastern
DistrictofPennsylvaniawillbedismissed.Separatesettlementagreementswiththestatesparticipatinginthesettlement
areintheprocessofbeingfinalized.
Johnson&Johnson2020AnnualReport • 97InJune2014,theMississippiAttorneyGeneralfiledacomplaintinChanceryCourtofTheFirstJudicialDistrictofHinds
County,MississippiagainstJohnson&JohnsonandJohnson&JohnsonConsumerCompanies,Inc.(nowknownas
Johnson&JohnsonConsumerInc.)(JJCI).ThecomplaintallegesthatdefendantsviolatedtheMississippiConsumer
ProtectionActbyfailingtodiscloseallegedhealthrisksassociatedwithfemaleconsumers’useoftalccontainedin
JOHNSON’S®BabyPowderandJOHNSON’S®ShowertoShower(aproductdivestedin2012)andseeksinjunctive
andmonetaryrelief.ThematterisstayedpendinginterlocutoryappealofaDecember2018denialofJohnson&Johnson
andJJCI’smotionforsummaryjudgment.TheMississippiSupremeCourtgrantedJ&JandJJCI’srequesttofilean
interlocutoryappealofthedenialofthemotionforsummaryjudgmentinlate2019.Briefingiscompleteandoralargument
washeldinFebruary2021.
InJanuary2020,theStateofNewMexicofiledaconsumerprotectioncaseallegingthattheCompanydeceptively
marketedandsolditstalcumpowderproductsbymakingmisrepresentationsaboutthesafetyoftheproductsandthe
presenceofcarcinogens,includingasbestos.TheStateofNewMexicofiledanAmendedComplaintinMarch2020.The
CompanymovedtodismisscertainoftheclaimsintheAmendedComplaint,whichwasgranted.TheCompanythenfiled
amotionforpartialjudgmentonthepleadingsinDecember2020.
Forty-onestateshavecommencedajointinvestigationintotheCompany’smarketingofitstalcumpowderproducts.At
thistime,themulti-stategrouphasnotassertedanyclaimsagainsttheCompany.SeveralstateshaveissuedCivil
InvestigativeDemandsseekingdocumentsandotherinformation.
InMarch2016,JanssenPharmaceuticals,Inc.(JPI)receivedaCivilInvestigativeDemandfromtheUnitedStates
Attorney’sOfficefortheSouthernDistrictofNewYorkrelatedtoJPI’scontractualrelationshipswithpharmacybenefit
managersovertheperiodfromJanuary1,2006tothepresentwithregardtocertainofJPI’spharmaceuticalproducts.The
demandwasissuedinconnectionwithaninvestigationundertheFalseClaimsAct.TheCompanyhasprovided
documentsinresponsetothedemand.
InJuly2016,Johnson&JohnsonandJanssenProductsLPwereservedwithaquitamcomplaintpursuanttotheFalse
ClaimsActfiledintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyallegingtheoff-labelpromotionoftwo
HIVproducts,PREZISTA®andINTELENCE®,andanti-kickbackviolationsinconnectionwiththepromotionofthese
products.ThecomplaintwasfiledundersealinDecember2012.Thefederalandstategovernmentshavedeclinedto
intervene,andthelawsuitisbeingprosecutedbytherelators.InFebruary2021,theCourtstayedthecaseandordered
mediation.
InMarch2017,JanssenBiotech,Inc.receivedaCivilInvestigativeDemandfromtheUnitedStatesDepartmentofJustice
regardingaFalseClaimsActinvestigationconcerningmanagementandadvisoryservicesprovidedtorheumatologyand
gastroenterologypracticesthatpurchasedREMICADE®orSIMPONIARIA®.InAugust2019,theUnitesStates
DepartmentofJusticenotifiedJanssenBiotech,Inc.thatitwasclosingtheinvestigation.Subsequently,theUnitedStates
DistrictCourtfortheDistrictofMassachusettsunsealedaquitamFalseClaimsActcomplaint,whichwasservedonthe
Company.TheDepartmentofJusticehaddeclinedtointerveneinthequitamlawsuitinAugust2019.TheCompanyfiled
amotiontodismiss,whichwasgrantedinpartanddeniedinpart.Discoveryisunderway.
InAprilandSeptember2017,Johnson&JohnsonreceivedsubpoenasfromtheUnitedStatesAttorneyfortheDistrictof
MassachusettsseekingdocumentsbroadlyrelatingtopharmaceuticalcopaymentsupportprogramsforDARZALEX®,
OLYSIO®,REMICADE®,SIMPONI®,STELARA®andZYTIGA®.ThesubpoenasalsoseekdocumentsrelatingtoAverage
ManufacturerPriceandBestPricereportingtotheCenterforMedicareandMedicaidServicesrelatedtothoseproducts,
aswellasrebatepaymentstostateMedicaidagencies.TheCompanyhasprovideddocumentsinresponsetothe
subpoenas.
InJune2017,Johnson&JohnsonreceivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
MassachusettsseekinginformationregardingpracticespertainingtothesterilizationofDePuySynthes,Inc.spinal
implantsatthreehospitalsinBostonaswellasinteractionsofemployeesofCompanysubsidiarieswithphysiciansat
thesehospitals.Johnson&JohnsonandDePuySynthes,Inc.haveproduceddocumentsinresponsetothesubpoenaand
arefullycooperatingwiththegovernment’sinvestigation.
InJuly2018thePublicProsecutionServiceinRiodeJaneiroandrepresentativesfromtheBrazilianantitrustauthority
CADEinspectedtheofficesofmorethan30companiesincludingJohnson&JohnsondoBrasilIndústriaeComérciode
ProdutosparaSaúdeLtda.Theauthoritiesappeartobeinvestigatingallegationsofpossibleanti-competitivebehaviorand
possibleimproperpaymentsinthemedicaldeviceindustry.Wecontinuetoactivelyrespondtoinquiriesregardingthe
ForeignCorruptPracticesActfromtheUnitedStatesDepartmentofJusticeandtheUnitedStatesSecuritiesand
ExchangeCommission.
98 • Johnson&Johnson2020AnnualReportFromtimetotime,theCompanyhasreceivedrequestsfromavarietyofUnitedStatesCongressionalCommitteesto
produceinformationrelevanttoongoingcongressionalinquiries.ItisthepolicyofJohnson&Johnsontocooperatewith
theseinquiriesbyproducingtherequestedinformation.
GENERALLITIGATION
InMarch2018,apurportedclassactionwasfiledintheCircuitCourtThirdJudicialDistrictMadisonCounty,Illinois
againstJohnson&JohnsonConsumer,Inc.(JJCI),allegingviolationsofstateconsumerfraudstatutesbasedon
nondisclosureofallegedhealthrisksassociatedwithtalccontainedinJOHNSON’S®BabyPowder.Thecomplaintseeks
damagesbutdoesnotallegepersonalinjury.InOctober2020,JJCImovedtodismissthecomplaint.
InAugust2014,UnitedStatesCustomsandBorderProtection(USCBP)issuedaPenaltyNoticeagainstJanssenOrtho
LLC(JanssenOrtho),assessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolate(theactive
pharmaceuticalingredientinPREZISTA®)inconnectionwithitsimportationintotheUnitedStates.InAugust2020,US
CBPformallyrejectedJanssen’sSupplementalPetitionchallengingthepenaltiesassessmentanddemandedpaymentof
themitigatedpenalty.InOctober2020,USCBPagreedtonotreferthemattertotheOfficeofChiefCounselatthistime,
pendingresolutionoftherelatedClassificationLitigation.InDecember2013,JanssenOrthosuedtheUnitedStatesinthe
UnitedStatesCourtofInternationalTrade(theClassificationLitigation)seekingadeterminationthatdarunavirethanolate
isexemptfromdutiesuponimportationintotheUnitedStates.InFebruary2020,theCourtruledthatdarunavirethanolate
iseligiblefordutyfreetreatment.InApril2020,theUnitedStatesappealedtotheUnitedStatesCourtofAppealsforthe
FederalCircuit.
InSeptember2020,GenmabA/SbroughtanarbitrationagainstJanssenBiotech,Inc.pursuanttoa2012License
Agreementbetweentheparties.ThearbitrationrelatestoroyaltiesforcertainJanssendaratumumabproducts.
InMarchandApril2015,over30putativeclassactioncomplaintswerefiledbycontactlenspatientsinanumberofcourts
aroundtheUnitedStatesagainstJohnson&JohnsonVisionCare,Inc.(JJVCI)andothercontactlensmanufacturers,
distributors,andretailers,allegingverticalandhorizontalconspiraciestofixtheretailpricesofcontactlenses.The
complaintsallegethatthemanufacturersreachedagreementswitheachotherandcertaindistributorsandretailers
concerningthepricesatwhichsomecontactlensescouldbesoldtoconsumers.Theplaintiffsareseekingdamagesand
injunctiverelief.AlloftheclassactioncasesweretransferredtotheUnitedStatesDistrictCourtfortheMiddleDistrictof
FloridainJune2015.TheplaintiffsfiledaconsolidatedclassactioncomplaintinNovember2015.Discoveryandpre-trial
motionpracticeiscomplete.Notrialdatehasbeenset.
InAugust2015,twothird-partypayorsfiledapurportedclassactionintheUnitedStatesDistrictCourtfortheEastern
DistrictofLouisianaagainstJanssenResearch&Development,LLC,JanssenOrthoLLC,JanssenPharmaceuticals,Inc.,
Ortho-McNeil-JanssenPharmaceuticals,Inc.andJohnson&Johnson(aswellascertainBayerentities),allegingthatthe
defendantsimproperlymarketedandpromotedXARELTO®assaferandmoreeffectivethanlessexpensivealternative
medicationswhilefailingtofullydiscloseitsrisks.Thecomplaintseeksdamages.InNovember2020,Defendantsmoved
todismissthecomplaint.
InSeptember2017,Pfizer,Inc.(Pfizer)filedanantitrustcomplaintagainstJohnson&JohnsonandJanssenBiotech,Inc.
(collectively,Janssen)inUnitedStatesDistrictCourtfortheEasternDistrictofPennsylvania.PfizerallegesthatJanssen
hasviolatedfederalantitrustlawsthroughitscontractingstrategiesforREMICADE®.Thecomplaintseeksdamagesand
injunctiverelief.Discoveryisongoing.
BeginninginSeptember2017,multiplepurportedclassactionswerefiledonbehalfofindirectpurchasersof
REMICADE®againstJohnson&JohnsonandJanssenBiotech,Inc.(collectively,Janssen)allegingthatJanssenhas
violatedfederalantitrustlawsthroughitscontractingstrategiesforREMICADE®.Thecaseswereconsolidatedforpre-trial
purposesasInreREMICADE®AntitrustLitigationinUnitedStatesDistrictCourtfortheEasternDistrictofPennsylvania.
Theconsolidatedcomplaintseeksdamagesandinjunctiverelief.Discoveryisongoing.
InJune2018,WalgreenCo.andKrogerCo,filedanantitrustcomplaintagainstJohnson&JohnsonandJanssenBiotech,
Inc.(collectively,Janssen)intheUnitedStatesDistrictCourtfortheEasternDistrictofPennsylvania.Thecomplaint
allegesthatJanssenhasviolatedfederalantitrustlawsthroughitscontractingstrategiesforREMICADE®.Thecomplaint
seeksdamagesandinjunctiverelief.InMarch2019,summaryjudgmentwasgrantedinfavorofJanssen.InFebruary
2020,theUnitedStatesCourtofAppealsfortheThirdCircuitreversedtheDistrictCourt’sdecision.Discoveryis
ongoing.
Johnson&Johnson2020AnnualReport • 99InJune2019,theUnitedStatesFederalTradeCommission(FTC)issuedaCivilInvestigativeDemandtoJohnson&
JohnsoninconnectionwithitsinvestigationofwhetherJanssen’sREMICADE®contractingpracticesviolatefederal
antitrustlaws.TheCompanyproduceddocumentsandinformationresponsivetotheCivilInvestigativeDemand.
InOctober2017,certainUnitedStatesservicemembersandtheirfamiliesbroughtacomplaintagainstanumberof
pharmaceuticalandmedicaldevicescompanies,includingJohnson&JohnsonandcertainofitssubsidiariesinUnited
StatesDistrictCourtfortheDistrictofColumbia,allegingthatthedefendantsviolatedtheUnitedStatesAnti-Terrorism
Act.Thecomplaintallegesthatthedefendantsprovidedfundingforterroristorganizationsthroughtheirsalespractices
pursuanttopharmaceuticalandmedicaldevicecontractswiththeIraqiMinistryofHealth.InJuly2020,theDistrictCourt
dismissedthecomplaint.InJanuary2021,plaintiffsappealedtheDistrictCourt’sdecisiontotheUnitedStatesCourtof
AppealsfortheDistrictofColumbiaCircuit.
InOctober2018,twoseparateputativeclassactionswerefiledagainstActelionPharmaceuticalLtd.,Actelion
PharmaceuticalsUS,Inc.,andActelionClinicalResearch,Inc.(collectivelyActelion)inUnitedStatesDistrictCourtforthe
DistrictofMarylandandUnitedStatesDistrictCourtfortheDistrictofColumbia.ThecomplaintsallegethatActelion
violatedstateandfederalantitrustandunfaircompetitionlawsbyallegedlyrefusingtosupplygenericpharmaceutical
manufacturerswithsamplesofTRACLEER®.TRACLEER®issubjecttoaRiskEvaluationandMitigationStrategyrequired
bytheFoodandDrugAdministration,whichimposesrestrictionsondistributionoftheproduct.InJanuary2019,the
plaintiffsdismissedtheDistrictofColumbiacaseandfiledaconsolidatedcomplaintintheUnitedStatesDistrictCourtfor
theDistrictofMaryland.InOctober2019,theCourtgrantedActelion’smotiontodismisstheamendedcomplaint.
PlaintiffshaveappealedthedecisiontotheUnitedStatesCourtofAppealsfortheFourthCircuit.
InDecember2018,JanssenBiotech,Inc.,JanssenOncology,Inc,JanssenResearch&Development,LLC,andJohnson&
Johnson(collectively,Janssen)wereservedwithaquitamcomplaintfiledonbehalfoftheUnitedStates,28states,and
theDistrictofColumbia.Thecomplaint,whichwasfiledinDecember2017inUnitedStatesDistrictCourtfortheNorthern
DistrictofCalifornia,allegesthatJanssenviolatedthefederalFalseClaimsActandstatelawwhenprovidingpricing
informationforZYTIGA®tothegovernmentinconnectionwithdirectgovernmentsalesandgovernment-fundeddrug
reimbursementprograms.Atthistime,thefederalandstategovernmentshavedeclinedtointervene.Thecasehasbeen
transferredtoUnitedStatesDistrictCourtfortheDistrictofNewJersey.InSeptember2019,Janssenmovedtodismiss
thecomplaint.
InApril2019,BlueCross&BlueShieldofLouisianaandHMOLouisiana,Inc.filedaclassactioncomplaintagainst
JanssenBiotech,Inc,JanssenOncology,Inc,JanssenResearch&Development,LLCandBTGInternationalLimitedinthe
UnitedStatesDistrictCourtfortheEasternDistrictofVirginiaonbehalfofindirectpurchasersofZYTIGA®.Several
additionalcomplaintswerefiledthereafterinVirginiaandNewJersey.Theindirectpurchasercomplaintsgenerallyallege
thatthedefendantsviolatedtheantitrustandconsumerprotectionslawsofseveralstatesandtheShermanActby
pursuingpatentlitigationrelatingtoZYTIGA®inordertodelaygenericentryandseekdamages.TheVirginiacaseshave
beentransferredtotheUnitedStatesDistrictCourtfortheDistrictofNewJerseyandconsolidatedwiththeNewJersey
caseforpretrialpurposes.InMay2020,aclassactioncomplaintwasfiledagainstJanssenBiotechInc.,Janssen
Oncology,Inc.,JanssenResearch&DevelopmentLLCandBTGInternationalLimitedintheUnitedStatesDistrictCourt
fortheDistrictofNewJersey,onbehalfofdirectpurchasersofZYTIGA®.Thedirectpurchasercomplaintallegesthat
defendantsviolatedtheShermanActbypursuingpatentlitigationrelatingtoZYTIGA®inordertodelaygenericentry,and
seekdamagesandinjunctiverelief.
InMay2019,aclassactionantitrustcomplaintwasfiledagainstJanssenR&DIreland(Janssen)andJohnson&Johnsonin
theUnitedStatesDistrictCourtfortheNorthernDistrictofCalifornia.ThecomplaintallegesthatJanssenviolatedfederal
andstateantitrustandconsumerprotectionlawsbyagreeingtoexclusivityprovisionsinitsagreementswithGilead
concerningthedevelopmentandmarketingofcombinationantiretroviraltherapies(cART)totreatHIV.Thecomplaintalso
allegesthatGileadenteredintosimilaragreementswithBristol-MyersSquibbandJapanTobacco.InMarch2020,the
Courtgrantedinpartanddeniedinpartdefendants’motionstodismiss.PlaintiffsfiledanamendedcomplaintinApril
2020.Defendantsmovedtodismisstheamendedcomplaint.InJuly2020,theCourtgrantedinpartanddeniedinpartthe
renewedmotiontodismiss.Discoveryisongoing.
InOctober2019,InnovativeHealth,LLCfiledacomplaintagainstBiosenseWebster,Inc.(BWI)intheUnitedStates
DistrictCourtfortheMiddleDistrictofCalifornia.ThecomplaintallegesthatcertainofBWI’sbusinesspracticesand
contractualtermsviolatetheantitrustlawsoftheUnitedStatesandtheStateofCaliforniabyrestrictingcompetitioninthe
saleofHighDensityMappingCathetersandUltrasoundCatheters.InJanuary2020,BWIfiledamotiontodismissthe
complaint.InAugust2020,theCourtgrantedinpartanddeniedinpartBWI’smotiontodismiss.Discoveryisongoing.
100 • Johnson&Johnson2020AnnualReportInNovember2019,Johnson&JohnsonreceivedademandforindemnificationfromPfizerInc.,pursuanttothe2006Stock
andAssetPurchaseAgreementbetweentheCompanyandPfizer.AlsoinNovember2019,Johnson&Johnson,Inc.
receivedademandforindemnificationfromSanofiConsumerHealth,Inc.,pursuanttothe2016AssetPurchase
AgreementbetweenJ&J,Inc.andSanofi.InJanuary2020,Johnson&Johnsonreceivedademandforindemnificationfrom
BoehringerIngelheimPharmaceuticals,Inc.,pursuanttothe2006AssetPurchaseAgreementamongtheCompany,
Pfizer,andBoehringerIngelheim.Thenoticesseekindemnificationforlegalclaimsrelatedtoover-the-counterZantac
(ranitidine)products.PlaintiffsintheunderlyingactionsallegethatZantacandotherover-the-counterranitidine
medicationscontainunsafelevelsofNDMA(N-nitrosodimethylamine)andcancauseand/orhavecausedvariouscancers
inpatientsusingtheproducts,andseekinjunctiveandmonetaryrelief.
InOctober2020,FortisAdvisorsLLC(Fortis),initscapacityasrepresentativeoftheformerstockholdersofAurisHealth
Inc.(Auris),filedacomplaintagainstJohnson&Johnson,EthiconInc.,andcertainnamedofficersandemployees
(collectively,Ethicon)intheCourtofChanceryoftheStateofDelaware.Thecomplaintallegesbreachofcontract,fraud,
andothercausesofactionagainstEthiconinconnectionwithEthicon’sacquisitionofAurisin2019.Thecomplaintseeks
damagesandotherrelief.InDecember2020,Ethiconmovedtodismisscertaincausesofactioninthecomplaint.
Johnson&JohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtundertheComprehensive
EnvironmentalResponse,Compensation,andLiabilityAct,commonlyknownasSuperfund,andcomparablestate,localor
foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastand/orfutureremediation.
Johnson&Johnson2020AnnualReport • 10120. Restructuring
Inthefiscalsecondquarterof2018,theCompanyannouncedplanstoimplementaseriesofactionsacrossitsGlobal
SupplyChainthatareintendedtofocusresourcesandincreaseinvestmentsinthecriticalcapabilities,technologiesand
solutionsnecessarytomanufactureandsupplyitsproductportfolio,enhanceagilityanddrivegrowth.TheGlobalSupply
Chainactionsincludeexpandingtheuseofstrategiccollaborationsandbolsteringinitiativestoreducecomplexity,improve
cost-competitiveness,enhancecapabilitiesandoptimizetheSupplyChainnetwork.ForadditionaldetailsontheGlobal
SupplyChainrestructuringstrategiccollaborationsseeNote18totheConsolidatedFinancialStatements.Infiscalyear
2020,theCompanyrecordedapre-taxchargeof$0.4billion,whichisincludedonthefollowinglinesoftheConsolidated
StatementofEarnings,$0.2billioninrestructuring,$0.1billioninother(income)expenseand$0.1billionincostof
productssold.Totalprojectcostsofapproximately$1.3billionhavebeenrecordedsincetherestructuringwas
announced.Seethefollowingtableforadditionaldetailsontherestructuringprogram.
Intotal,theCompanyexpectstheGlobalSupplyChainactionstogenerateapproximately$0.6billionto$0.8billionin
annualpre-taxcostsavingsthatwillbesubstantiallydeliveredby2022.TheCompanyexpectstorecordpre-tax
restructuringchargesofapproximately$1.9billionto$2.3billion,overthe4to5yearperiodofthisactivity.Thesecosts
areassociatedwithnetworkoptimizations,exitcostsandaccelerateddepreciationandamortization.
Thefollowingtablesummarizestheseverancechargesandtheassociatedspendingundertheseinitiativesthroughthe
fiscalyearended2020:
(DollarsinMillions) Severance AssetWrite-offs/Sales Other(2) Total
Reservebalance,December30,2018 $194 — 48 242
2019activity (30) — (32) (62)
Reservebalance,December29,2019 164 — 16 180
Currentyearactivity:
Charges — 43 405 448
Cashsettlements (29) 24(4) (399) (404)
Settlednoncash — (67) (13)(3) (80)
Reservebalance,January3,2021(1) $135 — 9 144
(1) Cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenext2yearsinaccordancewiththeCompany’splans
andlocallaws.
(2) Otherincludesprojectexpensesuchassalariesforemployeessupportingtheseinitiativesandconsultingexpenses.
(3) RelatestopensionrelatednetactuariallossesassociatedwiththetransferofemployeestoJabilInc.aspartofthestrategic
collaboration.
(4) Representsgainonsaleofanasset
TheCompanycontinuouslyreevaluatesitsseverancereservesrelatedtorestructuringandthetimingofpaymentsdueto
theplannedreleaseofassociatesregardingseverallonger-termprojects.TheCompanybelievesthattheexisting
severancereservesaresufficienttocovertheGlobalSupplyChainplansgiventheperiodoverwhichtheactionswilltake
place.TheCompanywillcontinuetoassessandmakeadjustmentsasnecessaryifadditionalamountsbecomeprobable
andestimable.
102 • Johnson&Johnson2020AnnualReportReport of Independent Registered Public
Accounting Firm
TotheBoardofDirectorsandShareholdersofJohnson&Johnson
OpinionsontheFinancialStatementsandInternalControloverFinancialReporting
WehaveauditedtheaccompanyingconsolidatedbalancesheetsofJohnson&Johnsonanditssubsidiaries(the
“Company”)asofJanuary3,2021andDecember29,2019,andtherelatedconsolidatedstatementsofearnings,of
comprehensiveincome,ofequityandofcashflowsforeachofthethreefiscalyearsintheperiodendedJanuary3,2021,
includingtherelatednotes(collectivelyreferredtoasthe“consolidatedfinancialstatements”).Wealsohaveauditedthe
Company’sinternalcontroloverfinancialreportingasofJanuary3,2021,basedoncriteriaestablishedinInternalControl
—IntegratedFramework(2013)issuedbytheCommitteeofSponsoringOrganizationsoftheTreadwayCommission
(COSO).
Inouropinion,theconsolidatedfinancialstatementsreferredtoabovepresentfairly,inallmaterialrespects,thefinancial
positionoftheCompanyasofJanuary3,2021andDecember29,2019,andtheresultsofitsoperationsanditscash
flowsforeachofthethreefiscalyearsintheperiodendedJanuary3,2021inconformitywithaccountingprinciples
generallyacceptedintheUnitedStatesofAmerica.Alsoinouropinion,theCompanymaintained,inallmaterialrespects,
effectiveinternalcontroloverfinancialreportingasofJanuary3,2021,basedoncriteriaestablishedinInternalControl—
IntegratedFramework(2013)issuedbytheCOSO.
BasisforOpinions
TheCompany’smanagementisresponsiblefortheseconsolidatedfinancialstatements,formaintainingeffectiveinternal
controloverfinancialreporting,andforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporting,
includedintheaccompanyingManagement’sReportonInternalControlOverFinancialReporting.Ourresponsibilityisto
expressopinionsontheCompany’sconsolidatedfinancialstatementsandontheCompany’sinternalcontroloverfinancial
reportingbasedonouraudits.WeareapublicaccountingfirmregisteredwiththePublicCompanyAccountingOversight
Board(UnitedStates)(PCAOB)andarerequiredtobeindependentwithrespecttotheCompanyinaccordancewiththe
U.S.federalsecuritieslawsandtheapplicablerulesandregulationsoftheSecuritiesandExchangeCommissionandthe
PCAOB.
WeconductedourauditsinaccordancewiththestandardsofthePCAOB.Thosestandardsrequirethatweplanand
performtheauditstoobtainreasonableassuranceaboutwhethertheconsolidatedfinancialstatementsarefreeofmaterial
misstatement,whetherduetoerrororfraud,andwhethereffectiveinternalcontroloverfinancialreportingwasmaintained
inallmaterialrespects.
Ourauditsoftheconsolidatedfinancialstatementsincludedperformingprocedurestoassesstherisksofmaterial
misstatementoftheconsolidatedfinancialstatements,whetherduetoerrororfraud,andperformingproceduresthat
respondtothoserisks.Suchproceduresincludedexamining,onatestbasis,evidenceregardingtheamountsand
disclosuresintheconsolidatedfinancialstatements.Ourauditsalsoincludedevaluatingtheaccountingprinciplesused
andsignificantestimatesmadebymanagement,aswellasevaluatingtheoverallpresentationoftheconsolidatedfinancial
statements.Ourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol
overfinancialreporting,assessingtheriskthatamaterialweaknessexists,andtestingandevaluatingthedesignand
operatingeffectivenessofinternalcontrolbasedontheassessedrisk.Ourauditsalsoincludedperformingsuchother
proceduresasweconsiderednecessaryinthecircumstances.Webelievethatourauditsprovideareasonablebasisfor
ouropinions.
DefinitionandLimitationsofInternalControloverFinancialReporting
Acompany’sinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe
reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith
generallyacceptedaccountingprinciples.Acompany’sinternalcontroloverfinancialreportingincludesthosepoliciesand
proceduresthat(i)pertaintothemaintenanceofrecordsthat,inreasonabledetail,accuratelyandfairlyreflectthe
transactionsanddispositionsoftheassetsofthecompany;(ii)providereasonableassurancethattransactionsare
Johnson&Johnson2020AnnualReport • 103recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting
principles,andthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof
managementanddirectorsofthecompany;and(iii)providereasonableassuranceregardingpreventionortimelydetection
ofunauthorizedacquisition,use,ordispositionofthecompany’sassetsthatcouldhaveamaterialeffectonthefinancial
statements.
Becauseofitsinherentlimitations,internalcontroloverfinancialreportingmaynotpreventordetectmisstatements.Also,
projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate
becauseofchangesinconditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
CriticalAuditMatters
Thecriticalauditmatterscommunicatedbelowaremattersarisingfromthecurrentperiodauditoftheconsolidated
financialstatementsthatwerecommunicatedorrequiredtobecommunicatedtotheauditcommitteeandthat(i)relateto
accountsordisclosuresthatarematerialtotheconsolidatedfinancialstatementsand(ii)involvedourespecially
challenging,subjective,orcomplexjudgments.Thecommunicationofcriticalauditmattersdoesnotalterinanywayour
opinionontheconsolidatedfinancialstatements,takenasawhole,andwearenot,bycommunicatingthecriticalaudit
mattersbelow,providingseparateopinionsonthecriticalauditmattersorontheaccountsordisclosurestowhichthey
relate.
U.S.PharmaceuticalRebateReserves-ManagedCare,MedicareandMedicaid
AsdescribedinNote1totheconsolidatedfinancialstatements,theCompanyrecognizesrevenuefromproductsales
whenobligationsunderthetermsofacontractwiththecustomeraresatisfied.Rebatesanddiscountsprovidedto
customersareaccountedforasvariableconsiderationandrecordedasareductioninsales.Theliabilityforsuchrebates
anddiscountsisrecognizedwithinAccruedRebates,Returns,andPromotionsontheconsolidatedbalancesheet.A
significantportionoftheliabilityrelatedtorebatesisfromthesaleofpharmaceuticalgoodswithintheU.S.,primarilythe
ManagedCare,MedicareandMedicaidprograms,whichamountedto$7.2billionasofJanuary3,2021.Forsignificant
rebateprograms,whichincludetheU.S.ManagedCare,MedicareandMedicaidrebateprograms,rebatesanddiscounts
estimatedbymanagementarebasedoncontractualterms,historicalexperience,patientoutcomes,trendanalysis,and
projectedmarketconditionsintheU.S.pharmaceuticalmarket.
TheprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtoU.S.pharmaceuticalrebate
reserves—ManagedCare,MedicareandMedicaidisacriticalauditmatterarethesignificantjudgmentbymanagement
duetothesignificantmeasurementuncertaintyinvolvedindevelopingthesereservesandthehighdegreeofauditor
judgment,subjectivityandauditeffortinperformingproceduresandevaluatingtheassumptionsrelatedtocontractual
terms,historicalexperience,patientoutcomes,trendanalysis,andprojectedmarketconditionsintheU.S.pharmaceutical
market.
Addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour
overallopinionontheconsolidatedfinancialstatements.Theseproceduresincludedtestingtheeffectivenessofcontrols
relatingtoU.S.pharmaceuticalrebatereserves—ManagedCare,MedicareandMedicaid,includingcontrolsoverthe
assumptionsusedtoestimatetheserebates.Theseproceduresalsoincluded,amongothers,(i)developingan
independentestimateoftherebatesbyutilizingthirdpartyinformationonpriceandmarketconditionsintheU.S.
pharmaceuticalmarket,thetermsofthespecificrebateprograms,andthehistoricalexperienceandtrendanalysisof
actualrebateclaimspaid;(ii)testingrebateclaimsprocessedbytheCompany,includingevaluatingthoseclaimsfor
consistencywiththecontractualandmandatedtermsoftheCompany’srebatearrangements;and(iii)comparingthe
independentestimatestomanagement’sestimates.
LitigationContingencies-Talc
AsdescribedinNotes1and19totheconsolidatedfinancialstatements,theCompanyrecordsaccrualsforloss
contingenciesassociatedwithlegalmatters,includingtalc,whenitisprobablethataliabilitywillbeincurredandthe
amountofthelosscanbereasonablyestimated.TotheextentadverseverdictshavebeenrenderedagainsttheCompany,
managementdoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated.For
thesematters,managementisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrued.
Amountsaccruedforlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsand
uncertaintiesthatrelyheavilyonestimatesandassumptionsincludingtimingofrelatedpayments.Theabilitytomakesuch
estimatesandjudgmentscanbeaffectedbyvariousfactors,including,amongotherthings,whetherdamagessoughtin
104 • Johnson&Johnson2020AnnualReporttheproceedingsareunsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnotcommencedorisnot
complete;proceedingsareinearlystages;matterspresentlegaluncertainties;therearesignificantfactsindispute;
proceduralorjurisdictionalissues;theuncertaintyandunpredictabilityofthenumberofpotentialclaims;abilitytoachieve
comprehensivemulti-partysettlements;complexityofrelatedcross-claimsandcounterclaims;and/ortherearenumerous
partiesinvolved.TherehavebeenverdictsagainsttheCompanyforthismatter,includingaverdictinJuly2018of
$4.7billion,whichwasreversedinpartandaffirmedinpartbytheMissouriCourtofAppealsinJune2020,reducingthe
overallawardto$2.1billionand,withadditionalinterestasofJanuary3,2021,astheCompanypursuesfurtherappeal,is
currently$2.5billion.AnapplicationfortransferofthecasetotheMissouriSupremeCourtwassubsequentlydenied,and
theCompanyiscurrentlyseekingreviewbytheUnitedStatesSupremeCourt.Asdescribedbymanagement,the
Companycontinuestobelievethatithasstronglegalgroundsfortheappealofthisverdict,aswellasotherverdictsithas
appealed.NotwithstandingtheCompany’sconfidenceinthesafetyofitstalcproducts,incertaincircumstancesthe
Companyhasandmaysettlecases.TheCompanyhasestablishedanaccrualfordefensecostsandreservesfor
settlementofcertaincasesandclaims,aswellasonecasecurrentlyonappeal,inconnectionwithproductliability
litigationassociatedwithbodypowderscontainingtalc.
Theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtothetalclitigationisacriticalaudit
matterarethesignificantjudgmentbymanagementwhenassessingthelikelihoodofalossbeingincurredandwhen
determiningwhetherareasonableestimateofthelossorrangeoflossforeachclaimcanbemade,whichinturnledtoa
highdegreeofauditorjudgment,subjectivityandeffortinperformingproceduresandevaluatingmanagement’s
assessmentofthelosscontingenciesassociatedwiththislitigation.
Addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour
overallopinionontheconsolidatedfinancialstatements.Theseproceduresincludedtestingtheeffectivenessofcontrols
relatingtomanagement’sevaluationofthetalclitigation,includingcontrolsoverdeterminingwhetheralossisprobable
andwhethertheamountoflosscanbereasonablyestimated,aswellasfinancialstatementdisclosures.These
proceduresalsoincluded,amongothers,(i)gaininganunderstandingoftheCompany’sprocessaroundtheaccounting
andreportingforthetalclitigation;(ii)discussingthestatusofsignificantknownactualandpotentiallitigationwiththe
Company’sin-houselegalcounsel,aswellasexternalcounselwhendeemednecessary;(iii)obtainingandevaluatingthe
lettersofauditinquirywithinternalandexternallegalcounselforsignificantlitigation;(iv)evaluatingthereasonablenessof
management’sassessmentregardingwhetheranunfavorableoutcomeisreasonablypossibleorprobableandreasonably
estimable;and(v)evaluatingthesufficiencyoftheCompany’slitigationcontingenciesdisclosures.
Litigation-Opioids
AsdescribedinNotes1and19totheconsolidatedfinancialstatements,theCompanyrecordsaccrualsforloss
contingenciesassociatedwithlegalmatters,includingopioids,whenitisprobablethataliabilitywillbeincurredandthe
amountofthelosscanbereasonablyestimated.TotheextentadverseverdictshavebeenrenderedagainsttheCompany,
managementdoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated.For
thesematters,managementisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrued.
Amountsaccruedforlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsand
uncertaintiesthatrelyheavilyonestimatesandassumptionsincludingtimingofrelatedpayments.Theabilitytomakesuch
estimatesandjudgmentscanbeaffectedbyvariousfactors,including,amongotherthings,whetherdamagessoughtin
theproceedingsareunsubstantiatedorindeterminate;matterspresentlegaluncertainties;therearesignificantfactsin
dispute;proceduralorjurisdictionalissues;theuncertaintyandunpredictabilityofthenumberofpotentialclaims;abilityto
achievecomprehensivemulti-partysettlements;complexityofrelatedcross-claimsandcounterclaims;and/orthereare
numerouspartiesinvolved.TheCompanyhasbeennamedinnumerouslawsuitsbroughtbycertainstateandlocal
governmentsrelatedtoopioidsmatters.ThetrialinthematterfiledbytheOklahomaAttorneyGeneralresultedina
judgmentagainsttheCompanyintheamountof$572millionwhichwassubsequentlyreducedto$465million.The
Companyhasappealedthejudgmentand,asdescribedbymanagement,believesthatithasstronggroundstooverturn
thisjudgment.SeparatelyinOctober2019,theCompanyannouncedaproposedagreementinprinciplethatwould
includetheCompanypaying$4billionassettlementofthelawsuits.InOctober2020,theCompanyagreedtocontribute
uptoanadditional$1billiontoanall-insettlementamountthatwouldresolveopioidlawsuitsfiledandfutureclaimsby
states,cities,countiesandtribalgovernments,foratotalof$5billionwhichhasbeenaccrued,subjecttovarious
conditionsandanagreementbeingfinalized.Asdescribedbymanagement,thisagreementinprincipleisnotanadmission
ofliabilityorwrong-doingandwouldresolveopioidlawsuitsfiledandfutureclaimsbystates,citiesandcounties.
Theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtotheopioidslitigationisacritical
auditmatterarethesignificantjudgmentbymanagementwhenassessingthelikelihoodofalossbeingincurredforthe
judgmentagainsttheCompanyinOklahomaandwhendeterminingwhetherareasonableestimateoftherangeoflossfor
Johnson&Johnson2020AnnualReport • 105theproposedagreementinprincipletosettleopioidslitigationcanbemade,whichinturnledtoahighdegreeofauditor
judgment,subjectivityandeffortinperformingproceduresandevaluatingmanagement’sassessmentoftheloss
contingenciesassociatedwiththislitigation.
Addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour
overallopinionontheconsolidatedfinancialstatements.Theseproceduresincludedtestingtheeffectivenessofcontrols
relatingtomanagement’sevaluationoftheopioidlitigation,includingcontrolsoverdeterminingwhetheralossisprobable
andwhethertheamountoflosscanbereasonablyestimated,aswellasfinancialstatementdisclosures.These
proceduresalsoincluded,amongothers,(i)gaininganunderstandingoftheCompany’sprocessaroundtheaccounting
andreportingfortheopioidslitigation;(ii)discussingthestatusofsignificantknownactualandpotentiallitigationand
ongoingsettlementnegotiationswiththeCompany’sin-houselegalcounsel,aswellasexternalcounselwhendeemed
necessary;(iii)obtainingandevaluatingthelettersofauditinquirywithinternalandexternallegalcounselforsignificant
litigation;(iv)evaluatingthereasonablenessofmanagement’sassessmentregardingwhetheranunfavorableoutcomeis
reasonablypossibleorprobableandreasonablyestimable;and(v)evaluatingthesufficiencyoftheCompany’slitigation
contingenciesdisclosures.
/s/PricewaterhouseCoopersLLP
FlorhamPark,NewJersey
February22,2021
WehaveservedastheCompany’sauditorsinceatleast1920.Wehavenotbeenabletodeterminethespecificyearwe
beganservingasauditoroftheCompany.
106 • Johnson&Johnson2020AnnualReportManagement’s Report on Internal Control Over
Financial Reporting
UnderSection404oftheSarbanes-OxleyActof2002,managementisrequiredtoassesstheeffectivenessofthe
Company’sinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreport,basedonthatassessment,
whethertheCompany’sinternalcontroloverfinancialreportingiseffective.
ManagementoftheCompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial
reporting.TheCompany’sinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe
reliabilityoftheCompany’sfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith
generallyacceptedaccountingprinciples.
Internalcontrolsoverfinancialreporting,nomatterhowwelldesigned,haveinherentlimitations.Therefore,internalcontrol
overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial
statementpreparationandmaynotpreventordetectallmisstatements.Moreover,projectionsofanyevaluationof
effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin
conditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
TheCompany’smanagementhasassessedtheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingas
ofJanuary3,2021.Inmakingthisassessment,theCompanyusedthecriteriaestablishedbytheCommitteeof
SponsoringOrganizationsoftheTreadwayCommission(COSO)in“InternalControl-IntegratedFramework(2013).”
Thesecriteriaareintheareasofcontrolenvironment,riskassessment,controlactivities,informationandcommunication,
andmonitoring.TheCompany’sassessmentincludedextensivedocumenting,evaluatingandtestingthedesignand
operatingeffectivenessofitsinternalcontrolsoverfinancialreporting.
BasedontheCompany’sprocessesandassessment,asdescribedabove,managementhasconcludedthat,asof
January3,2021,theCompany’sinternalcontroloverfinancialreportingwaseffective.
TheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingasofJanuary3,2021hasbeenauditedby
PricewaterhouseCoopersLLP,anindependentregisteredpublicaccountingfirm,asstatedintheirreport,whichappears
herein.
/s/AlexGorsky /s/JosephJ.Wolk
AlexGorsky JosephJ.Wolk
Chairman,BoardofDirectors ExecutiveVicePresident,
ChiefExecutiveOfficer ChiefFinancialOfficer
Johnson&Johnson2020AnnualReport • 107Shareholder Return Performance Graphs
SetforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnontheCompany’sCommonStockfor
periodsoffiveyearsandtenyearsendingJanuary3,2021,againstthecumulativetotalreturnoftheStandard&Poor’s
500StockIndex,theStandard&Poor’sPharmaceuticalIndexandtheStandard&Poor’sHealthCareEquipmentIndex.
Thegraphsandtablesassumethat$100wasinvestedonDecember31,2015andDecember31,2010ineachofthe
Company’sCommonStock,theStandard&Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexandthe
Standard&Poor’sHealthCareEquipmentIndexandthatalldividendswerereinvested.
5YearShareholderReturn
PerformanceJ&Jvs.Indices
$245
Johnson & Johnson
S&P 500 Index
$195
S&P Pharmaceu(cid:2)cal Index
S&P Healthcare Equipment
Index
$145
5-Year CAGR
J&J 11.9%
S&P 500 15.2%
S&P Pharm 8.2%
$95
S&P H/C Equip 19.8% 2015 2016 2017 2018 2019 2020
2015 2016 2017 2018 2019 2020
Johnson&Johnson $100.00 $115.32 $143.47 $136.10 $158.16 $175.32
S&P500Index $100.00 $111.95 $136.38 $130.39 $171.44 $202.96
S&PPharmaceuticalIndex $100.00 $98.44 $110.81 $119.78 $137.85 $148.23
S&PHealthcareEquipmentIndex $100.00 $106.48 $139.38 $162.02 $209.52 $246.47
10YearShareholderReturn
PerformanceJ&Jvs.Indices
$500
Johnson & Johnson
S&P 500 Index $400
S&P Pharmaceu(cid:2)cal Index
$300
S&P Healthcare Equipment
Index
10-Year CAGR $200
J&J 13.1%
S&P 500 13.9%
S&P Pharm 13.3%
$100
S&P H/C Equip 17.2% 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Johnson&Johnson $100.00 $109.89 $121.79 $163.95 $192.37 $194.59 $224.41 $279.18 $264.84 $307.77 $341.17
S&P500Index $100.00 $102.11 $118.44 $156.78 $178.22 $180.67 $202.27 $246.41 $235.59 $309.74 $366.70
S&PPharmaceuticalIndex $100.00 $117.76 $134.75 $182.22 $222.70 $235.59 $231.91 $261.06 $282.19 $324.76 $349.21
S&PHealthcareEquipmentIndex $100.00 $99.20 $116.33 $148.54 $187.58 $198.78 $211.67 $277.07 $322.07 $416.50 $489.94
108 • Johnson&Johnson2020AnnualReportItem 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE
Notapplicable.
Item 9A. CONTROLS AND PROCEDURES
DisclosureControlsandProcedures.AttheendoftheperiodcoveredbythisReport,theCompanyevaluatedthe
effectivenessofthedesignandoperationofitsdisclosurecontrolsandprocedures.TheCompany’sdisclosurecontrols
andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbytheCompanyinthereportsthatit
filesorsubmitsundertheExchangeActisrecorded,processed,summarizedandreportedwithinthetimeperiods
specifiedintheSEC’srulesandforms.Disclosurecontrolsandproceduresinclude,withoutlimitation,controlsand
proceduresdesignedtoensurethatinformationrequiredtobedisclosedbytheCompanyinthereportsthatitfilesor
submitsundertheExchangeActisaccumulatedandcommunicatedtotheCompany’smanagement,includingitsprincipal
executiveandprincipalfinancialofficers,orpersonsperformingsimilarfunctions,asappropriatetoallowtimelydecisions
regardingrequireddisclosure.AlexGorsky,ChairmanandChiefExecutiveOfficer,andJosephJ.Wolk,ExecutiveVice
President,ChiefFinancialOfficer,reviewedandparticipatedinthisevaluation.Basedonthisevaluation,Messrs.Gorsky
andWolkconcludedthat,asoftheendoftheperiodcoveredbythisReport,theCompany’sdisclosurecontrolsand
procedureswereeffective
ReportsonInternalControlOverFinancialReporting.Theinformationcalledforbythisitemisincorporatedhereinby
referenceto“Management’sReportonInternalControlOverFinancialReporting”,andtheattestationregardinginternal
controlsoverfinancialreportingincludedinthe“ReportofIndependentRegisteredPublicAccountingFirm”includedin
Item8ofthisReport.
ChangesinInternalControlOverFinancialReporting.DuringthefiscalquarterendedJanuary3,2021,therewereno
changesintheCompany’sinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequired
underRules13a-15and15d-15undertheExchangeActthathavemateriallyaffected,orarereasonablylikelyto
materiallyaffect,theCompany’sinternalcontroloverfinancialreporting.TheCompanyhasnotexperiencedanymaterial
impacttoitsinternalcontrolsoverfinancialreportingdespitethefactthatmostofitsemployeesareworkingremotelydue
totheCOVID-19pandemic.TheCompanyproactivelytookactionstore-evaluateandrefineitsfinancialreportingprocess
throughadditionalmonitoringcontrolstoprovidereasonableassurancethatthefinancialresultsarereportedaccurately
andtimely.TheCompanycontinuestomonitorandassesstheeffectivenessofthedesignandoperationofitsdisclosure
controlsandprocedures.
TheCompanyisimplementingamulti-year,enterprise-wideinitiativetointegrate,simplifyandstandardizeprocessesand
systemsforthehumanresources,informationtechnology,procurement,supplychainandfinancefunctions.Theseare
enhancementstosupportthegrowthoftheCompany’sfinancialsharedservicecapabilitiesandstandardizefinancial
systems.ThisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessintheCompany’sinternalcontrolover
financialreporting.Inresponsetothisinitiative,theCompanyhasandwillcontinuetoalignandstreamlinethedesignand
operationofitsfinancialcontrolenvironment.
Item 9B. OTHER INFORMATION
Notapplicable.
Johnson&Johnson2020AnnualReport • 109PART III
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheAuditCommitteeunder
thecaption“Item1.ElectionofDirectors—BoardCommittees”;andthematerialunderthecaptions“Item1.Electionof
Directors”and,ifapplicable,“StockOwnershipandSection16Compliance—DelinquentSection16(a)Reports”inthe
ProxyStatement;andthematerialunderthecaption“ExecutiveOfficersoftheRegistrant”inPartIofthisReport.
TheCompany’sCodeofBusinessConduct,whichcoversallemployees(includingtheChiefExecutiveOfficer,Chief
FinancialOfficerandController),meetstherequirementsoftheSECrulespromulgatedunderSection406ofthe
Sarbanes-OxleyActof2002.TheCodeofBusinessConductisavailableontheCompany’swebsiteatwww.jnj.com/
code-of-business-conduct,andcopiesareavailabletoshareholderswithoutchargeuponwrittenrequesttotheSecretary
attheCompany’sprincipalexecutiveoffices.AnysubstantiveamendmenttotheCodeofBusinessConductoranywaiver
oftheCodegrantedtotheChiefExecutiveOfficer,theChiefFinancialOfficerortheControllerwillbepostedonthe
Company’swebsiteatwww.investor.jnj.com/gov.cfmwithinfivebusinessdays(andretainedonthewebsiteforatleastone
year).
Inaddition,theCompanyhasadoptedaCodeofBusinessConduct&EthicsforMembersoftheBoardofDirectorsand
ExecutiveOfficers.TheCodeofBusinessConduct&EthicsforMembersoftheBoardofDirectorsandExecutiveOfficers
isavailableontheCompany’swebsiteatwww.investor.jnj.com/gov/boardconduct.cfm,andcopiesareavailableto
shareholderswithoutchargeuponwrittenrequesttotheSecretaryattheCompany’sprincipalexecutiveoffices.Any
substantiveamendmenttotheCodeoranywaiveroftheCodegrantedtoanymemberoftheBoardofDirectorsorany
executiveofficerwillbepostedontheCompany’swebsiteatwww.investor.jnj.com/gov.cfmwithinfivebusinessdays(and
retainedonthewebsiteforatleastoneyear).
Item 11. EXECUTIVE COMPENSATION
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptions“Item1.
ElectionofDirectors—DirectorCompensation,”and“Item2.CompensationCommitteeReport,”“Compensation
DiscussionandAnalysis”and“ExecutiveCompensationTables”intheProxyStatement.
Thematerialincorporatedhereinbyreferencetothematerialunderthecaption“CompensationCommitteeReport”inthe
ProxyStatementshallbedeemedfurnished,andnotfiled,inthisReportandshallnotbedeemedincorporatedby
referenceintoanyfilingundertheSecuritiesActof1933,asamended,ortheSecuritiesExchangeActof1934,as
amended,asaresultofthisfurnishing,excepttotheextentthattheCompanyspecificallyincorporatesitbyreference.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaption“Item1.Stock
OwnershipandSection16Compliance”intheProxyStatement;andNote16“CommonStock,StockOptionPlansand
StockCompensationAgreements”oftheNotestoConsolidatedFinancialStatementsinItem8ofthisReport.
110 • Johnson&Johnson2020AnnualReportEquity Compensation Plan Information
ThefollowingtableprovidescertaininformationasofJanuary3,2021concerningthesharesoftheCompany’sCommon
Stockthatmaybeissuedunderexistingequitycompensationplans.
Numberof
Securitiesto
beIssuedUpon WeightedAverage NumberofSecurities
Exerciseof ExercisePriceof RemainingAvailablefor
Outstanding Outstanding FutureIssuanceUnderEquity
PlanCategory OptionsandRights OptionsandRights CompensationPlans(2)(3)
EquityCompensationPlansApprovedbySecurity
Holders(1) 131,483,837 $100.98 276,949,737
EquityCompensationPlansNotApprovedbySecurity
Holders — — —
Total 131,483,837 $100.98 276,949,737
(1) IncludedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbytheCompany’sshareholders:
2005Long-TermIncentivePlanand2012Long-TermIncentivePlan.
(2) Thiscolumnexcludessharesreflectedunderthecolumn“NumberofSecuritiestobeIssuedUponExerciseofOutstandingOptions
andRights.”
(3) The2005Long-TermIncentivePlanexpiredApril26,2012.Alloptionsandrestrictedsharesgrantedsubsequenttothatdatewere
underthe2012Long-TermIncentivePlan.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptions“Item1.
ElectionofDirectors—DirectorIndependence”and“RelatedPersonTransactions”intheProxyStatement.
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaption“Item3.
RatificationofAppointmentofIndependentRegisteredPublicAccountingFirm”intheProxyStatement.
Johnson&Johnson2020AnnualReport • 111PART IV
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Thefollowingdocumentsarefiledaspartofthisreport:
1. FinancialStatements
ConsolidatedBalanceSheetsatendofFiscalYears2020and2019
ConsolidatedStatementsofEarningsforFiscalYears2020,2019and2018
ConsolidatedStatementsofComprehensiveIncomeforFiscalYears2020,2019and2018
ConsolidatedStatementsofEquityforFiscalYears2020,2019and2018
ConsolidatedStatementsofCashFlowsforFiscalYears2020,2019and2018
NotestoConsolidatedFinancialStatements
ReportofIndependentRegisteredPublicAccountingFirm
Allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial
statementsornotes.
2. ExhibitsRequiredtobeFiledbyItem60lofRegulationS-K
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetotheExhibitIndexinthisReport.
Item 16. FORM 10-K SUMMARY
RegistrantsmayvoluntarilyincludeasummaryofinformationrequiredbyForm10-KunderthisItem16.TheCompanyhas
electednottoincludesuchsummaryinformation.
112 • Johnson&Johnson2020AnnualReportSIGNATURES
PursuanttotherequirementsofSection13oftheSecuritiesExchangeActof1934,theregistranthasdulycausedthis
Reporttobesignedonitsbehalfbytheundersigned,thereuntodulyauthorized.
Date:February22,2021
JOHNSON&JOHNSON
(Registrant)
By /s/A.Gorsky
A.Gorsky,Chairman,BoardofDirectors,
andChiefExecutiveOfficer
PursuanttotherequirementsoftheSecuritiesExchangeActof1934,thisreporthasbeensignedbelowbythefollowing
personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicated.
Signature Title Date
/s/A.Gorsky Chairman,BoardofDirectors February22,2021
A.Gorsky ChiefExecutiveOfficer
(PrincipalExecutiveOfficer)
/s/J.J.Wolk
ChiefFinancialOfficer February22,2021
J.J.Wolk (PrincipalFinancialOfficer)
/s/R.J.DeckerJr. ControllerandChiefAccountingOfficer February22,2021
R.J.DeckerJr. (PrincipalAccountingOfficer)
/s/M.C.Beckerle Director February22,2021
M.C.Beckerle
/s/D.S.Davis Director February22,2021
D.S.Davis
/s/I.E.L.Davis Director February22,2021
I.E.L.Davis
/s/J.A.Doudna Director February22,2021
J.A.Doudna
/s/M.A.Hewson Director February22,2021
M.A.Hewson
/s/H.Joly Director February22,2021
H.Joly
/s/M.B.McClellan Director February22,2021
M.B.McClellan
/s/A.M.Mulcahy Director February22,2021
A.M.Mulcahy
Johnson&Johnson2020AnnualReport • 113Signature Title Date
/s/C.Prince Director February22,2021
C.Prince
/s/A.E.Washington
Director February22,2021
A.E.Washington
/s/M.A.Weinberger Director February22,2021
M.A.Weinberger
/s/N.Y.West Director February22,2021
N.Y.West
/s/R.A.Williams Director February22,2021
R.A.Williams
114 • Johnson&Johnson2020AnnualReportEXHIBIT INDEX
Reg.S-K
ExhibitTable
ItemNo. DescriptionofExhibit
3(i) RestatedCertificateofIncorporationeffectiveFebruary19,2016—IncorporatedhereinbyreferencetoExhibit3(i)ofthe
Registrant’sForm10-KAnnualReportforthefiscalyearendedJanuary3,2016.
3(ii) CertificateofAmendmenttotheCertificateofIncorporationofJohnson&JohnsoneffectiveApril30,2020—Incorporatedherein
byreferencetoExhibit3.1oftheRegistrant’sForm8-KCurrentReportfiledApril29,2020.
3(iii) By-LawsoftheCompany,asamendedeffectiveJune9,2020—IncorporatedhereinbyreferencetoExhibit3.1ofthe
Registrant’sForm8-KCurrentReportfiledJune10,2020.
4(a) UpontherequestoftheSecuritiesandExchangeCommission,theRegistrantwillfurnishacopyofallinstrumentsdefiningthe
rightsofholdersoflong-termdebtoftheRegistrant.
4(b) DescriptionofSecuritiesRegisteredPursuanttoSection12oftheSecuritiesExchangeActof1934—Incorporatedhereinby
referencetoExhibit4.1oftheRegistrant’sForm8-KCurrentReportfiledAugust12,2020.
10(a) 2005Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibit4oftheRegistrant’sS-8RegistrationStatement
filedonMay10,2005(fileno.333-124785).*
10(b) FormofStockOptionCertificateunderthe2005Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibit10.1of
theRegistrant’sForm8-KCurrentReportfiledJanuary13,2012.*
10(c) 2012Long-TermIncentivePlan—IncorporatedhereinbyreferencetoAppendixAoftheRegistrant’sProxyStatementfiledon
March15,2017.*
10(d) FormofStockOptionCertificate,RestrictedShareUnitCertificateandPerformanceShareUnitCertificateunderthe2012
Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibits10.2,10.3and10.4oftheRegistrant’sForm10-Q
QuarterlyReportforthequarterendedApril1,2012.*
10(e) GlobalNonQualifiedStockOptionAwardAgreement,GlobalRestrictedShareUnitAwardAgreementandGlobalPerformance
ShareUnitAwardAgreementunderthe2012Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibits10.1,
10.2and10.3oftheRegistrant’sForm10-QQuarterlyReportforthequarterendedApril1,2018.*
10(f) Johnson&JohnsonExecutiveIncentivePlan(AmendedasofNovember28,2018)—IncorporatedhereinbyreferencetoExhibit
10(a)oftheRegistrant’sForm10-QQuarterlyReportforthequarterendedMarch31,2019.*
10(g) DomesticDeferredCompensation(CertificateofExtraCompensation)Plan—IncorporatedhereinbyreferencetoExhibit10(g)
oftheRegistrant’sForm10-KAnnualReportfortheyearendedDecember28,2003.*
10(h) AmendmentstotheCertificateofExtraCompensationPlaneffectiveasofJanuary1,2009—Incorporatedhereinbyreferenceto
Exhibit10(j)oftheRegistrant’sForm10-KAnnualReportfortheyearendedDecember28,2008.*
10(i) 2009CertificatesofLong-TermPerformancePlan—IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm
10-QQuarterlyReportforthequarterendedSeptember27,2009.*
10(j) AmendedandRestatedDeferredFeePlanforDirectors(AmendedasofJanuary17,2012)—Incorporatedhereinbyreference
toExhibit10(k)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearendedJanuary1,2012.*
10(k) TheJohnson&JohnsonExecutiveIncomeDeferralPlanAmendedandRestatedEffectiveJanuary1,2010—Incorporatedherein
byreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReportforthequarterendedSeptember30,2012.*
10(l) ExcessSavingsPlan(EffectiveasofJanuary1,1996)—IncorporatedhereinbyreferencetoExhibit10(j)oftheRegistrant’s
Form10-KAnnualReportforthefiscalyearendedDecember29,1996.*
10(m) AmendmentstotheJohnson&JohnsonExcessSavingsPlaneffectiveasofJanuary1,2009—Incorporatedhereinbyreference
toExhibit10(p)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearendedDecember28,2008.*
10(n) AmendedandRestatedExcessBenefitPlanofJohnson&JohnsonandAffiliatedCompanies(Amendedandrestatedeffective
January1,2020,exceptasotherwiseprovided)—Filedwiththisdocument.*
10(o)** ExecutiveLifePlanAgreement—IncorporatedhereinbyreferencetoExhibit10(i)oftheRegistrant’sForm10-KAnnualReport
forthefiscalyearendedJanuary3,1993.*
10(p) ExecutiveLifePlanAgreementClosureLetter—IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-Q
QuarterlyReportforthequarterendedMarch29,2015.*
10(q) EmploymentAgreementforDr.PaulusStoffels-IncorporatedhereinbyreferencetoExhibit10.2oftheRegistrant’sForm10-Q
QuarterlyReportforthequarterendedSeptember30,2012.*
Johnson&Johnson2020AnnualReport • 11510(r) SeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies,AmendedandRestatedasofOctober1,2014—
IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReportforthequarterended
September28,2014.*
10(s) FirstAmendmenttotheSeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies(asamendedandrestated
effectiveOctober1,2014)—IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReport
forthequarterendedJune28,2015.*
10(t) SecondAmendmenttotheSeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies(asamendedandrestated
effectiveOctober1,2014)—IncorporatedhereinbyreferencetoExhibit10(x)oftheRegistrant’sForm10-KAnnualReportfor
thefiscalyearendedJanuary3,2016.*
21 Subsidiaries-Filedwiththisdocument.
23 ConsentofIndependentRegisteredPublicAccountingFirm—Filedwiththisdocument.
31.1 CertificationofChiefExecutiveOfficerPursuanttoSection302oftheSarbanes-OxleyAct—Filedwiththisdocument.
31.2 CertificationofChiefFinancialOfficerPursuanttoSection302oftheSarbanes-OxleyAct—Filedwiththisdocument.
32.1 CertificationofChiefExecutiveOfficerPursuanttoSection906oftheSarbanes-OxleyAct—Furnishedwiththisdocument.
32.2 CertificationofChiefFinancialOfficerPursuanttoSection906oftheSarbanes-OxleyAct—Furnishedwiththisdocument.
Exhibit101:
EX-101.INS InstanceDocument—theinstancedocumentdoesnotappearintheInteractiveDataFilebecauseitsXBRLtagsareembedded
withintheInlineXBRLdocument
EX-101.SCH InlineXBRLTaxonomyExtensionSchema
EX-101.CAL InlineXBRLTaxonomyExtensionCalculationLinkbase
EX-101.LAB InlineXBRLTaxonomyExtensionLabelLinkbase
EX-101.PRE InlineXBRLTaxonomyExtensionPresentationLinkbase
EX-101.DEF InlineXBRLTaxonomyExtensionDefinitionDocument
Exhibit104: CoverPageInteractiveDataFile—thecoverpageinteractivedatafiledoesnotappearintheInteractiveDataFilebecauseits
XBRLtagsareembeddedwithintheInlineXBRLdocument.
* Managementcontractorcompensatoryplan.
**Paperfiling.
AcopyofanyoftheExhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequest
specifyingthedesiredexhibit(s)totheSecretaryattheprincipalexecutiveofficesoftheCompany.PursuanttoItem
601(b)(4)(iii)(A)ofRegulationS-K,theCompanyhasnotfiledasexhibitstothisForm10-Kcertainlong-termdebt
instruments,includingindentures,underwhichthetotalamountofsecuritiesauthorizeddoesnotexceed10%ofthetotal
assetsoftheCompanyanditssubsidiariesonaconsolidatedbasis.TheCompanyherebyagreestofurnishacopyofany
suchinstrumenttotheSECuponrequest.
TheFollowingExhibits,indicatedasbeingfiledwiththisdocument,areomittedfromtheprintedversionofthis2020
AnnualReport.
Exhibit10(n)
Exhibit21
Exhibit23
116 • Johnson&Johnson2020AnnualReportExhibit31.1
CERTIFICATIONOFCHIEFEXECUTIVEOFFICER
PURSUANTTOSECTION302OFTHESARBANES-OXLEYACT
I,AlexGorsky,certifythat:
1.IhavereviewedthisAnnualReportonForm10-KforthefiscalyearendedJanuary3,2021(the“report”)of
Johnson&Johnson(the“Company”);
2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea
materialfactnecessarytomakethestatementsmade,inlightofthecircumstancesunderwhichsuchstatementswere
made,notmisleadingwithrespecttotheperiodcoveredbythisreport;
3.Basedonmyknowledge,thefinancialstatements,andotherfinancialinformationincludedinthisreport,fairly
presentinallmaterialrespectsthefinancialcondition,resultsofoperationsandcashflowsoftheCompanyasof,and
for,theperiodspresentedinthisreport;
4.TheCompany’sothercertifyingofficer(s)andIareresponsibleforestablishingandmaintainingdisclosurecontrols
andprocedures(asdefinedinExchangeActRules13a-15(e)and15d-15(e))andinternalcontroloverfinancial
reporting(asdefinedinExchangeActRules13a-15(f)and15d-15(f))fortheCompanyandhave:
(a)Designedsuchdisclosurecontrolsandprocedures,orcausedsuchdisclosurecontrolsandprocedures
tobedesignedunderoursupervision,toensurethatmaterialinformationrelatingtotheCompany,includingits
consolidatedsubsidiaries,ismadeknowntousbyotherswithinthoseentities,particularlyduringtheperiodin
whichthisreportisbeingprepared;
(b)Designedsuchinternalcontroloverfinancialreporting,orcausedsuchinternalcontroloverfinancial
reportingtobedesignedunderoursupervision,toprovidereasonableassuranceregardingthereliabilityof
financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally
acceptedaccountingprinciples;
(c)EvaluatedtheeffectivenessoftheCompany’sdisclosurecontrolsandproceduresandpresentedinthis
reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandprocedures,asoftheendofthe
periodcoveredbythisreportbasedonsuchevaluation;and
(d)DisclosedinthisreportanychangeintheCompany’sinternalcontroloverfinancialreportingthat
occurredduringtheCompany’smostrecentfiscalquarter(theCompany’sfourthfiscalquarterinthecaseofan
annualreport)thathasmateriallyaffected,orisreasonablylikelytomateriallyaffect,theCompany’sinternalcontrol
overfinancialreporting;and
5.TheCompany’sothercertifyingofficer(s)andIhavedisclosed,basedonourmostrecentevaluationofinternal
controloverfinancialreporting,totheCompany’sauditorsandtheauditcommitteeoftheCompany’sboardof
directors(orpersonsperformingtheequivalentfunctions):
(a)Allsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover
financialreportingwhicharereasonablylikelytoadverselyaffecttheCompany’sabilitytorecord,process,
summarizeandreportfinancialinformation;and
(b)Anyfraud,whetherornotmaterial,thatinvolvesmanagementorotheremployeeswhohaveasignificant
roleintheCompany’sinternalcontroloverfinancialreporting.
/s/AlexGorsky
AlexGorsky
ChiefExecutiveOfficer
Date:February22,2021
Johnson&Johnson2020AnnualReportExhibit31.2
CERTIFICATIONOFCHIEFFINANCIALOFFICER
PURSUANTTOSECTION302OFTHESARBANES-OXLEYACT
I,JosephJ.Wolkcertifythat:
1.IhavereviewedthisAnnualReportonForm10-KforthefiscalyearendedJanuary3,2021(the“report”)of
Johnson&Johnson(the“Company”);
2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea
materialfactnecessarytomakethestatementsmade,inlightofthecircumstancesunderwhichsuchstatementswere
made,notmisleadingwithrespecttotheperiodcoveredbythisreport;
3.Basedonmyknowledge,thefinancialstatements,andotherfinancialinformationincludedinthisreport,fairly
presentinallmaterialrespectsthefinancialcondition,resultsofoperationsandcashflowsoftheCompanyasof,and
for,theperiodspresentedinthisreport;
4.TheCompany’sothercertifyingofficer(s)andIareresponsibleforestablishingandmaintainingdisclosurecontrols
andprocedures(asdefinedinExchangeActRules13a-15(e)and15d-15(e))andinternalcontroloverfinancial
reporting(asdefinedinExchangeActRules13a-15(f)and15d-15(f))fortheCompanyandhave:
(a)Designedsuchdisclosurecontrolsandprocedures,orcausedsuchdisclosurecontrolsandprocedures
tobedesignedunderoursupervision,toensurethatmaterialinformationrelatingtotheCompany,includingits
consolidatedsubsidiaries,ismadeknowntousbyotherswithinthoseentities,particularlyduringtheperiodin
whichthisreportisbeingprepared;
(b)Designedsuchinternalcontroloverfinancialreporting,orcausedsuchinternalcontroloverfinancial
reportingtobedesignedunderoursupervision,toprovidereasonableassuranceregardingthereliabilityof
financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally
acceptedaccountingprinciples;
(c)EvaluatedtheeffectivenessoftheCompany’sdisclosurecontrolsandproceduresandpresentedinthis
reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandprocedures,asoftheendofthe
periodcoveredbythisreportbasedonsuchevaluation;and
(d)DisclosedinthisreportanychangeintheCompany’sinternalcontroloverfinancialreportingthat
occurredduringtheCompany’smostrecentfiscalquarter(theCompany’sfourthfiscalquarterinthecaseofan
annualreport)thathasmateriallyaffected,orisreasonablylikelytomateriallyaffect,theCompany’sinternalcontrol
overfinancialreporting;and
5.TheCompany’sothercertifyingofficer(s)andIhavedisclosed,basedonourmostrecentevaluationofinternal
controloverfinancialreporting,totheCompany’sauditorsandtheauditcommitteeoftheCompany’sboardof
directors(orpersonsperformingtheequivalentfunctions):
(a)Allsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover
financialreportingwhicharereasonablylikelytoadverselyaffecttheCompany’sabilitytorecord,process,
summarizeandreportfinancialinformation;and
(b)Anyfraud,whetherornotmaterial,thatinvolvesmanagementorotheremployeeswhohaveasignificant
roleintheCompany’sinternalcontroloverfinancialreporting.
/s/JosephJ.Wolk
JosephJ.Wolk
ChiefFinancialOfficer
Date:February22,2021
Johnson&Johnson2020AnnualReportExhibit32.1
CERTIFICATIONOFCHIEFEXECUTIVEOFFICER
PURSUANTTOSECTION906OFTHESARBANES-OXLEYACT
Theundersigned,AlexGorsky,theChiefExecutiveOfficerofJohnson&Johnson,aNewJerseycorporation(the
“Company”),pursuantto18U.S.C.1350,asadoptedpursuanttoSection906oftheSarbanes-OxleyActof2002,
herebycertifiesthat,tothebestofmyknowledge:
(1) theCompany’sAnnualReportonForm10-KforthefiscalyearendedJanuary3,2021(the“Report”)fully
complieswiththerequirementsofSection13(a)oftheSecuritiesExchangeActof1934;and
(2) theinformationcontainedintheReportfairlypresents,inallmaterialrespects,thefinancialconditionand
resultsofoperationsoftheCompany.
/s/AlexGorsky
AlexGorsky
ChiefExecutiveOfficer
Dated:February22,2021
ThiscertificationisbeingfurnishedtotheSECwiththisReportonForm10-KpursuanttoSection906ofthe
Sarbanes-OxleyActof2002andshallnot,excepttotheextentrequiredbysuchAct,bedeemedfiledbytheCompany
forpurposesofSection18oftheSecuritiesExchangeActof1934,asamended,orotherwisesubjecttotheliabilityof
thatsection.
Johnson&Johnson2020AnnualReportExhibit32.2
CERTIFICATIONOFCHIEFFINANCIALOFFICER
PURSUANTTOSECTION906OFTHESARBANES-OXLEYACT
Theundersigned,JosephJ.Wolk,theChiefFinancialOfficerofJohnson&Johnson,aNewJerseycorporation(the
“Company”),pursuantto18U.S.C.1350,asadoptedpursuanttoSection906oftheSarbanes-OxleyActof2002,
herebycertifiesthat,tothebestofmyknowledge:
(1) theCompany’sAnnualReportonForm10-KforthefiscalyearendedJanuary3,2021(the“Report”)fully
complieswiththerequirementsofSection13(a)oftheSecuritiesExchangeActof1934;and
(2) theinformationcontainedintheReportfairlypresents,inallmaterialrespects,thefinancialconditionand
resultsofoperationsoftheCompany.
/s/JosephJ.Wolk
JosephJ.Wolk
ChiefFinancialOfficer
Dated:February22,2021
ThiscertificationisbeingfurnishedtotheSECwiththisReportonForm10-KpursuanttoSection906ofthe
Sarbanes-OxleyActof2002andshallnot,excepttotheextentrequiredbysuchAct,bedeemedfiledbytheCompany
forpurposesofSection18oftheSecuritiesExchangeActof1934,asamended,orotherwisesubjecttotheliabilityof
thatsection.
Johnson&Johnson2020AnnualReport[THISPAGEINTENTIONALLYLEFTBLANK][THISPAGEINTENTIONALLYLEFTBLANK][THISPAGEINTENTIONALLYLEFTBLANK]Board of Directors Senior Management
ALEXGORSKY
Chairman,BoardofDirectors ALEXGORSKY*
ChiefExecutiveOfficer;
MARYC.BECKERLE
Chairman,ExecutiveCommittee
ChiefExecutiveOfficer,HuntsmanCancerInstitute
attheUniversityofUtah; JOAQUINDUATO*
DistinguishedProfessorofBiology, ViceChairman,ExecutiveCommittee
CollegeofScience,UniversityofUtah
PAULUSSTOFFELS*
D.SCOTTDAVIS
ViceChairman,ExecutiveCommittee;ChiefScientificOfficer
FormerChairmanandChiefExecutiveOfficer,
UnitedParcelService,Inc. ROBERTJ.DECKERJR.
IANE.L.DAVIS CorporateController;ChiefAccountingOfficer
Non-ExecutiveChairman,Rolls-RoyceHoldingsplc;
PETERM.FASOLO*
FormerChairmanandWorldwideManagingDirector,
ExecutiveVicePresident,ChiefHumanResourcesOfficer
McKinsey&Company
JENNIFERA.DOUDNA ASHLEYMcEVOY*
ProfessorofChemistry;ProfessorofBiochemistry& ExecutiveVicePresident,WorldwideChairman,
MolecularBiology; MedicalDevices
LiKaShingChancellor’sProfessorinBiomedical
andHealth,UniversityofCalifornia,Berkeley THIBAUTMONGON*
ExecutiveVicePresident,WorldwideChairman,
MARILLYNA.HEWSON
ConsumerHealth
ExecutiveChairman;FormerChairmanandChief
ExecutiveOfficer, MATTHEWORLANDO
LockheedMartinCorporation CorporateSecretary;
WorldwideVicePresident,CorporateGovernance
HUBERTJOLY
FormerChairmanandChiefExecutiveOfficer,Best
MICHELLER.RYAN
BuyCo.,Inc.
Treasurer
MARKB.McCLELLAN
Director,Duke-RobertJ.Margolis,MD, MICHAELE.SNEED*
CenterforHealthPolicy,DukeUniversity ExecutiveVicePresident,GlobalCorporateAffairs;
ChiefCommunicationsOfficer
ANNEM.MULCAHY
FormerChairmanandChiefExecutiveOfficer, JENNIFERTAUBERT*
XeroxCorporation ExecutiveVicePresident,WorldwideChairman,
Pharmaceuticals
CHARLESPRINCE
FormerChairmanandChiefExecutiveOfficer,
MICHAELH.ULLMANN*
CitigroupInc.
ExecutiveVicePresident,GeneralCounsel
A.EUGENEWASHINGTON
DukeUniversity’sChancellorforHealthAffairs; KATHRYNE.WENGEL*
PresidentandChiefExecutiveOfficer, ExecutiveVicePresident,ChiefGlobalSupplyChainOfficer
DukeUniversityHealthSystem
JOSEPHJ.WOLK*
MARKA.WEINBERGER ExecutiveVicePresident,ChiefFinancialOfficer
FormerChairmanandChiefExecutiveOfficer,EY
*Member,ExecutiveCommittee
NADJAY.WEST
FormerLieutenantGeneral,U.S.Army
RONALDA.WILLIAMS
FormerChairmanandChiefExecutiveOfficer,
AetnaInc.
Johnson&Johnson2020AnnualReportPRINCIPALOFFICE STOCKLISTING JOHNSON&JOHNSONONLINE
OneJohnson&JohnsonPlaza Johnson&JohnsonCommonStock
NewBrunswick,NewJersey08933 ListedonNewYorkStockExchange Ourwebsite:www.jnj.com
(732)524-0400 StockSymbol:JNJ
http://www.jnj.com/media-center
2021ANNUALMEETINGOFSHAREHOLDERS SHAREHOLDERRELATIONSCONTACT
Thursday,April22,2021 MatthewOrlando
CorporateSecretary www.facebook.com/jnj
10:00a.m.(Eastern)
(732)524-2455
Meetingwillbeheldvirtuallyat www.twitter.com/JNJNews
www.virtualshareholdermeeting.com/JNJ2021. INVESTORRELATIONSCONTACT
www.youtube.com/jnj
Allshareholdersasoftherecorddateof ChristopherDelOrefice
February23,2021areinvitedtoattend. VicePresident,InvestorRelations
(800)950-5089 http://www.linkedin.com/company/
AformalNoticeofAnnualMeetingand
(732)524-2955 johnson-&-johnson
ProxyStatementandproxycardhavebeen
madeavailabletoshareholders. InvestorRelationswebsite:
www.investor.jnj.com
TheJohnson&Johnson2020Yearin
2020ANNUALREPORTONFORM10-KAND
2021PROXYSTATEMENT STOCKTRANSFERAGENTANDREGISTRAR Reviewisavailableonourwebsiteat
Johnson&Johnson’sAnnualReportonForm10-K Questionsregardingstockholdings,
https://www.jnj.com/2020-year-in-review.
forthefiscalyearendedJanuary3,2021is certificatereplacement/transfer,dividends Theinformationonthesewebsitesshould
includedinthisAnnualReportinitsentirety,with andaddresschangesshouldbedirectedto notbedeemedtobepartofthisAnnual
theexceptionofcertainexhibits.TheForm10-K, ourstocktransferagentandregistrarat: Report.
completewithallofitsexhibits,isavailableonour ComputershareTrustCompany,N.A.
websiteatwww.investor.jnj.com/sec.cfm,andthe P.O.Box505000
SEC’swebsiteatwww.sec.gov. Louisville,KY40233
Shareholdersmayalsoobtaincopiesofthe Overnightmail:
ComputershareTrustCompany,N.A.
exhibits,our2020AnnualReporton
462South4thStreet,Suite1600
Form10-Kandour2021ProxyStatement
Louisville,KY40202
withoutcharge,uponwrittenrequesttothe
(800)328-9033or(781)575-2718
OfficeoftheCorporateSecretaryatour
principalofficeaddress,orbycalling Shareholderwebsite:
(800)950-5089. www.computershare.com/investor
ELECTRONICDELIVERYNOTIFICATION DividendReinvestmentPlan
The2021ProxyStatementandour2020Annual ThePlanallowsforfullorpartialdividend
Reportareavailableonourwebsiteat reinvestmentandadditionalweeklycash
www.investor.jnj.com/gov/ investmentsupto$50,000peryearin
annualmeetingmaterials.cfm.Shareholderswho Johnson&JohnsonCommonStockwithout
receivepapercopiesofourProxyStatementand pershareorservicechargesonstock C132107
AnnualReportbymailcanelecttoreceiveinstead purchases.Ifyouareinterestedin
ane-mailmessagewithalinktothosedocuments participatinginthePlanandneedan
ontheInternet.Registeredshareholdersmay enrollmentformand/ormoreinformation,
enrollinelectronicdeliveryat pleasecallthePlanadministrator, TheJohnson&Johnson2020AnnualReport
www.computershare-na.com/green.Beneficial ComputershareTrustCompany,N.A.at containsmanyofthevaluabletrademarks
shareholders(whoholdsharesofJohnson& (800)328-9033or(781)575-2718 andtradenamesownedandusedbythe
JohnsonCommonStockthroughabank,brokeror (outsidetheU.S.)oraccessonlineat Johnson&JohnsonFamilyofCompaniesin
otherholderofrecord)generallycanenrollfor www.computershare.com/investor. theUnitedStatesandinternationallyto
electronicdeliveryat:enroll.icsdelivery.com/jnj. distinguishproductsandservicesof
HearingImpaired
outstandingquality.
Shareholderswhohaveinquiriesregarding
©Johnson&Johnson2021
stock-relatedmatterscancommunicate
directlywithComputershareTrustCompany,
N.A.viaatelecommunicationsdevice(TDD).
Thetelephonenumberforthisserviceis
(800)952-9245or(781)575-2692
(outsidetheU.S.).